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Psychotic disorders represent a severe category of mental disorders affecting about one 
percent of the population. Individuals experience a loss or distortion of contact with reality 
alongside other symptoms, many of which are still not adequately managed using existing 
treatments. While animal models of these disorders could offer insights into these disorders 
and potential new treatments, translation of this knowledge has so far been poor in terms of 
informing clinical trials and practice. The aim of this project was to improve our 
understanding of these pre-clinical studies and identify potential weaknesses underlying 
translational failure. 
I carried out a systematic search of the literature to provide an unbiased summary of 
publications reporting animal models of schizophrenia and other psychotic disorders. From 
these publications, data were extracted to quantify aspects of the field including reported 
quality of studies, study characteristics and behavioural outcome data. The latter of these 
data were then used to calculate estimates of efficacy using random-effects meta-analysis.  
Having identified 3847 publications of relevance, including 852 different methods used to 
induce the model, over 359 different outcomes tested in them and almost 946 different 
treatments reported to be administered. I show that a large proportion of studies use simple 
pharmacological interventions to induce their models of these disorders, despite the 
availability of models using other interventions that are arguably of higher translational 
relevance. I also show that the reported quality of these studies is low, and only 22% of 
studies report taking measures to reduce the risk of biases such as randomisation and 
blinding, which has been shown to affect the reliability of results drawn. 
Through this work it becomes apparent that the literature is incredibly vast for studies looking 
at animal models of psychotic disorders and that some of the relevant work potentially 
overlaps with studies describing other conditions. This means that drawing reliable 
conclusions from these data is affected by what is made available in the literature, how it is 
reported and identified in a search and the time that it takes to reach these conclusions. I 
introduce the idea of using computer-assisted tools to overcome one of these problems in 
the long term. 
Translation of results from studies looking at animals modelling uniquely-human psychotic 
disorders to clinical successes might be improved by better reporting of studies including 
publishing of all work carried out, labelling of studies more uniformly so that it is identifiable, 
better reporting of study design including improving on reporting of measures taken to 





Psychotic disorders are a group of debilitating mental disorders affecting about one percent 
of the population. These disorders are characterized by symptoms where individuals 
experience a loss or distortion of contact with reality. Despite the availability of treatments for 
these individuals, symptoms are not uniformly managed across different individuals and a 
large proportion of people remain unresponsive to these medications. Experiments using 
animals to model these human conditions are informative and are carried out with the aim of 
improving our understanding of the underlying biology of these disorders, while also 
providing a platform from which new potential treatments can be tested before they are taken 
forward to clinical trials. Unfortunately these data collected pre-clinically have not led to 
significant changes in clinical practice. The aim of this work was to better understand this 
area of research and identify the reasons underlying their weaknesses in informing clinical 
research. 
I performed a search of the scientific literature to identify a set of publications that report 
experiments of animal models of all psychotic disorders including schizophrenia. Once all 
studies of relevance were identified, information reported within these publications was 
extracted. This included the reported quality of methodology, details about experimental 
design and finally results from these experiments. This information was then used to quantify 
the field and summarise some of these data to calculate overall effectiveness of a model or 
overall efficacy of certain treatments. 
The search performed identified almost 4000 publications of relevance, including over 800 
different methods used to create each animal model, over 300 different outcomes used to 
measure performance of these animals and almost 1000 different treatments tested in these 
animals. I show that about 40% of these studies use simple drug-induced methods to create 
their models of these disorders, despite the availability of models that are perhaps more 
relevant to the human condition. I also show that study quality is not well reported across 
studies, which has been shown previously by other research to negatively affect the 
reliability of results drawn. Overall, it is clear that the literature describing these experiments 
using animal models of psychotic disorders is very broad and that some experiments 
described are similar to experiments performed as part of research looking at other 
disorders. In order to be able to draw meaningful conclusions and use these to then inform 
clinical research and practise, we need to be able to identify all the relevant research that 
has been carried out pre-clinically, which is affected by cases where research is not 
published or not described in a manner expected. Moreover as there are a large number of 
these pre-clinical studies that have been and continue to be performed, summarising these 
data takes time and new tools need to be considered to be able to provide conclusions from 
these data faster and more up-to-date. 
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The potential of studies using animal models of psychotic disorders in informing clinical 
studies in future might be improved by better reporting of studies including publishing of all 
work carried out, labelling of studies more uniformly so that it is identifiable, better reporting 
of study quality and design and concentrating on research involving models that have more 

























"If I have seen further, it is by standing upon the shoulders of giants" 
Sir Isaac Newton 
From a letter written to a fellow scientist, Robert Hooke (1675) 
 
1 Introduction 
1.1 The Burden of Mental Health 
Mental Health is defined by the World Health Organization (WHO) as a “a 
state of well-being in which every individual realizes his or her own potential, can 
cope with the normal stresses of life, can work productively and fruitfully, and is able 
to make a contribution to her or his community” (World Health Organization, 2001). 
While good mental health is not simply the result of the absence of a defined mental 
disorder, mental disorders are becoming an exponentially increasing burden on our 
society with about 450 million people worldwide affected (World Health 
Organization, 2001).  
In the clinic, the diagnosis of mental health disorders is carried out using two 
universally established tools. These are the International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision (ICD-10) published by the 
WHO; and the Diagnostic and Statistical Manual of Mental Disorders, 5th Revision 
(DSM-5) distributed by the American Psychiatric Association (APA) (American 
Psychiatric Association, 2013; World Health Organization, 2016). These 
classification systems have some limitations due to their categorical approach to the 
classification of mental disorders, which fails to capture the individual differences in 
the severity of mental disorders (Brown and Barlow, 2005). Broadly speaking all the 
disorders described under mental and behavioural disorders are characterized by 
some mixture of atypical thoughts, emotions and behaviours and clinical profiles 
therefore overlap between many of these disorders so that diagnosis is often not 
clear-cut (Stern et al., 2008; World Health Organization, 2016). Results from 
scientific literature databases such as PubMed reveal that mental disorders at the 
cognitive–emotional interface over the last decade have received growing attention 
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in research. Psychotic disorders represent a severe category of these mental 
disorders. 
1.2 Psychosis and Psychotic Disorders  
Psychosis was introduced into the literature in 1841 by Canstatt and later used by 
Feuchtersleben from 1945 onwards to describe mental disorders that were 
“diseases of the personality” and therefore affected personality as a whole, eluding 
to “compound conditions” where the disorder was not exclusively limited to just the 
mind or the body (Beer, 1996; Burgy, 2008). The modern translation of the word 
means “any illness of the mind” (Beer, 1996) and today we recognise psychosis in 
itself not as a distinct medical diagnosis, but as a common feature of many mental 
disorders, which are characterised by a loss of contact with reality (Stern et al., 
2008). These disorders represent a group of incredibly mysterious mental disorders, 
which are marked by disorganized thinking and perceptions that manifest 
themselves most illustriously through delusions and hallucinations. The overall 
prevalence of psychotic disorders has been reported to be about 0.4% in the United 
Kingdom in adults aged 16 to 64 years (Great Britain Office for National Statistics, 
2002), with incidence rates being the highest for non-affective psychoses at 23 per 
100 000 person-years and schizophrenia accounting for about 15 per 100 000 
person-years (Kirkbride et al., 2012).  
1.2.1 Nosology 
Broadly speaking we can group psychotic disorders into four main diagnostic 
categories. These include: (1) non-affective psychotic disorders that are primarily 
considered to be psychotic disorders and include examples like schizophrenia and 
schizoaffective disorder; (2) affective psychotic disorders, or mood disorders that 
present with psychotic features, like bipolar disorder or major depressive disorder 
with psychotic features; (3) secondary psychotic disorders such as substance-
induced psychotic disorders; and (4) psychotic disorders due to a general medical 
condition (van Os and Kapur, 2009). 
Primary psychotic disorders including schizophrenia spectrum disorders are 
thought to occur along a spectrum, with schizoid disorder on the mild end and 
schizophrenia on the severe end of the spectrum (Arciniegas, 2015). Symptoms of 
psychosis are usually seen alongside other dimensions of neuropsychiatric 
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disturbances in these disorders. And therefore psychotic disorders are characterised 
by a diverse psychopathology and have to include abnormalities in at least one of 
the following domains (American Psychiatric Association, 2013):  
1) delusions, or false beliefs that are fixed even in the context of conflicting 
evidence; 2) hallucinations, defined as perceptions without corresponding 
external stimuli;  
3) cognitive deficits such as disorganized thinking and perception, including 
speech; 4) disorganized motor behaviour, including catatonia;  
and 5) negative symptoms, such as avolition and blunted emotional 
expression, which are more prominent in schizophrenia than other psychotic 
disorders.  
In the clinic, these psychotic disorders are heterogeneous in their symptomology. 
Diagnosis is made in the clinic based on history and examination of mental state, 
there are no diagnostic tests (Owen et al., 2016). Schizophrenia, the most common 
and debilitating of the psychotic disorders, is best characterized by a triad of 
symptoms including positive symptoms such as hallucinations and delusions; 
negative symptoms such as anhedonia and avolition; and cognitive deficits, 
especially in memory, attention, verbal fluency and executive function (Andreasen, 
1995; Savilla et al., 2008). These symptoms are required to be present for at least 6 
months. If the total duration of illness is less than 6 months then it is classed as 
schizophreniform disorder, and if it less than a month but more than a day it is 
classified as a brief psychotic disorder (American Psychiatric Association, 2013). 
Schizoaffective disorder is characterized by a mood disturbance in the form of major 
depressive or manic episode occurring with other active phase symptoms of 
schizophrenia. Making a differential diagnosis between schizophrenia, 
schizoaffective disorder and depressive or bipolar disorder with psychotic features is 
often difficult due to the large overlap in symptomology. Delusional disorder is 
characterized by delusions that persist for 1 month or longer and differs from 
schizophrenia and schizophreniform disorder in that other characteristic symptoms 
of schizophrenia are absent and the disorder usually has a much later onset 
(American Psychiatric Association, 2013; Marek and Merchant, 2005). Psychosis 
can also be secondary to certain medical conditions or substances of abuse. These 
are categorized by delusions and hallucinations developed during or after substance 
intoxication or during withdrawal from substance, or where these symptoms are the 
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direct consequence of another medical condition (American Psychiatric Association, 
2013). This syndromic approach of diagnostic criteria has been useful in 
categorizing disorders in the clinic, however, the assumption that these criteria map 
onto valid disease entities with specific causes and pathophysiology is believed to 
have hampered research progress over the years in these fields of research (Owen 
et al., 2016).   
Schizophrenia, being the most heterogeneous and least understood of the psychotic 
disorders has seen an incredible amount of research interest over the last century. It 
is difficult to summarise and make sense of all this research as several hundred 
thousand books and papers have been published on the topic of schizophrenia. A 
quick search of the literature in PubMed suggests that about 6000 publications 
relating to schizophrenia were published in the year 2017 alone. It is also predicted 
that this is an underestimate as it does not account for studies not indexed or those 
published in foreign languages and therefore not picked up during a search of the 
literature. Our overall understanding of this disorder is limited by abstracts of studies 
that do not report clear findings, those with methodological limitations not often 
obvious, and findings that are rarely replicable. This makes it difficult to identify 
important leads within the field (Tandon et al., 2008). As the majority of pre-clinical 
evidence identified and reviewed in this thesis refers to experimental conditions 
modelling schizophrenia, I will mainly focus on what we know about schizophrenia 
from here on. I will discuss some highlights in our understanding based on findings 
in the field that are thought to potentially play a role in the development of the 
disorder. Unfortunately, even in the context of these findings, our understanding of 
the disorder still remains limited in many ways, warranting further research in the 
area despite the slow progress. 
1.2.2 What we think we know about schizophrenia 
1.2.2.1 Clinical presentation 
In the clinic schizophrenia has a heterogeneous presentation with wide inter-
individual variation in terms of disease development, clinical course of the disorder, 
and symptoms appearing with varying levels of prominence throughout the course of 
the disorder (American Psychiatric Association, 2013; Rietschel et al., 2017). The 
positive symptoms of the disorder relapse and remit over time; however, some 
individuals can have long-term psychotic symptoms. Negative symptoms and 
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cognitive deficits on the other hand, may persist when positive symptoms are in 
remission and are therefore chronic and are associated with long-term burden on 
social function (Owen et al., 2016). Schizophrenia primarily has a peak of onset in 
young adulthood, and very rarely occurs before adolescence or after middle age 
(American Psychiatric Association, 2013). There also seem to be sex differences 
whereby men have a greater lifetime risk of developing the disorder, with an earlier 
age of onset (i.e. by about 3-5 years), more pronounced negative symptoms and 
higher deficits in social functioning (Rietschel et al., 2017). Women on the other 
hand, are reported to experience more depressive and paranoid symptoms and 
usually report better outcomes (Kelly, 2006). There is also a strong link to 
environmental influences, whereby schizophrenia appears to be more prevalent 
among lower socio-economic classes and migrant and minority ethnic populations 
(Morgan et al., 2010), as well as being associated with urbanicity (Vassos et al., 
2012). 
1.2.2.2 Genetic liability and susceptibility 
Most psychotic disorders have a strong genetic component as shown by a 
heritability rate of 81% for schizophrenia, and about 82-85% for other psychotic 
disorders (Cardno et al., 1999; Sullivan et al., 2003). This strong genetic component 
to the disorder is reiterated by the fact that biological relatives of individuals 
diagnosed with schizophrenia also show mild cognitive deficits (i.e. in attention, 
learning and memory) (Snitz et al., 2006), and are more often affected by psychiatric 
disorders themselves (Onstad et al., 1991).  
Our understanding of the genetics underlying schizophrenia is continuously 
evolving. Before genome-wide association studies (GWAS), genomic research in 
schizophrenia focused on candidate genes (Farrell et al., 2015). However, it is now 
thought that most past studies of these candidate gene associations had too low 
statistical power to detect a true association, and thus the idea of a particular gene 
being associated with schizophrenia has been challenged in recent years (Farrell et 
al., 2015). Nevertheless, many of these early genes identified and linked to the 
disorder converge functionally and seem to support the hypothesis that 
schizophrenia develops as a result of deficits in connectivity and synaptic signalling 
(Harrison and Weinberger, 2005). GWAS since then have identified more than 100 
distinct genome-wide significant loci linking schizophrenia to multiple common 
genetic variants, all with small effect sizes (Schizophrenia Working Group of the 
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Psychiatric Genomics Consortium et al., 2014), and they continue to find common 
genetic variants in individuals with schizophrenia to associate with the disorder. 
Many of these relate to the function and plasticity of certain neurotransmitter 
receptors and synapses, specifically those of N-methyl-D-aspartate receptors and 
glutamatergic synapses (Friston et al., 2016). Therefore, the genetic liability for 
schizophrenia is thought to be polygenic. Risk alleles have been identified in many 
different genes and many of these overlap with other psychiatric disorders (Rees et 
al., 2015), reiterating the limitations of  stratifying psychiatric disorders according to 
current diagnostic criteria (Owen et al., 2016). High heritability rate suggests that the 
risk is mainly inherited, however, de novo mutations (i.e. mutations arising for the 
first time in a family) also occur and rates are found to be higher in individuals with 
schizophrenia (i.e. 5% compared to 2% in control subjects) (Malhotra et al., 2011). 
Next-generation DNA sequencing techniques are also uncovering single nucleotide 
polymorphisms (SNPs, i.e. variations in the DNA sequence by a single nucleotide) 
and copy number variants (CNVs, i.e. large sections of the genome are repeated or 
deleted) that have been implicated in the disorder (Jia et al., 2017). Ultimately, it is 
thought that disease susceptibility is most likely a result of the interplay between a 
number of different genetic changes (Friston et al., 2016). However, despite this 
collection of knowledge, most of these genetic discoveries have not yet been 
applied to clinical use of genetic diagnoses for schizophrenia (Owen et al., 2016), 
suggesting we still have some way to go in our understanding of the contribution of 
these factors.  
1.2.2.3 Environmental risk factors 
Other non-genetic risk factors, such as environmental influences are also thought to 
play a role in the aetiology of schizophrenia. For example, evidence shows that 
common or shared environmental influences account for about 11% of liability to 
schizophrenia in twins (Sullivan et al., 2003). Twin studies also show that the 
concordance rates for these diagnoses between identical twins is just below 50% 
(Cardno et al., 1999), suggesting that genetics alone don’t explain the entirety of the 
story and do not necessarily predict the development of complex psychotic disorders 
like schizophrenia (Maynard et al., 2001). In fact, some research shows that 
environmental influences such as rearing environments can also have a strong 
effect on the development of symptoms of serious mental illnesses in children, 
contributing an additional risk to genetics (Tienari, 1991).  
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Environmental hits are varied and can be damaging at any time from conception to 
the onset of illness in early adulthood (Dean and Murray, 2005). Risk factors during 
early life include complications during birth, the season the birth occurs in, infections 
to the mother affecting the foetus in utero or the baby postnatally, malnutrition of the 
mother, stress to the mother and any other insults potentially affecting brain 
development (Dean and Murray, 2005). These observations are the main basis for 
the neurodevelopmental hypothesis of schizophrenia (Murray and Lewis, 1987), 
where abnormalities in neural development in utero starting as early as late first 
trimester, can lead to the activation of pathological changes in later life (Fatemi and 
Folsom, 2009). In childhood, factors such as early experiences of adverse 
upbringing, abuse or even head injury can affect the development of the brain and 
increase the risk of schizophrenia seen in later life. Triggers in later life might include 
drug abuse, chronic stress and other traumatic life events (Dean and Murray, 2005).  
While these factors are correlated with the development of the disorder, they don’t 
sufficiently predict the onset of the disorder and therefore it is thought that both 
genetics and environmental factors play a role in the development of the disorder 
(Maynard et al., 2001). Initially described as the “two-hit hypothesis” of the 
disorders, this theory implied that early disruptions to the central nervous system, 
such as an individual’s genetic makeup establishes a sort of predisposition to the 
disorder, making them more vulnerable to another insult from the environment 
leading to the development of symptoms (Maynard et al., 2001). More modern 
versions of this hypothesis recognise that genetic, environmental and other 
vulnerability factors are likely to be cumulative and interactive with each other in a 
more complex way then previously explained by the original binary two-hit model. It 
is thought that the development of schizophrenia is likely a result of a multi-hit 
threshold model where key neurodevelopmental milestones are affected (Davis et 
al., 2016).  
Our understanding of how these factors interact exactly are still limited. While there 
have been several theories on the possible mechanisms underlying the 
development and manifestation of the disorder, no single mechanism has been 
established that directly correlates with the onset of the disorder.  
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1.2.2.4 Structural and Functional abnormalities of the schizophrenic brain 
The nature of pathological abnormalities in the brain and their exact pathogenic 
mechanisms underlying schizophrenia are not yet completely understood, however, 
there have been a number of robust observations made based on post-mortem 
tissue studies, as well as neuroimaging and molecular biology studies. Overall, it is 
thought that a set of multiple, subtle changes arise affecting the neural circuitry in 
the brain (Harrison and Weinberger, 2005). 
Research shows that cerebral volume is reduced and total ventricular volume is 
greater in chronic schizophrenic individuals (Wright et al., 2000). For example, about 
80% of magnetic resonance imaging (MRI) studies show an enlargement of the 
lateral ventricles, and about 73% of studies show third ventricular enlargement in 
individuals diagnosed with schizophrenia. This enlargement of lateral ventricles is 
thought to imply tissue loss in surrounding brain regions or failures in normal 
development (Shenton et al., 2001).  
In addition, there seems to be a loss of cortical grey matter without cell death (Sekar 
et al., 2016), which has been found to be localized to mainly frontal and temporal 
areas of the brain (Kuperberg et al., 2003). These regions are involved in episodic 
memory, auditory information processing, short term memory acquisition and 
decision making (Karlsgodt et al., 2010). This abnormality is likely a result of 
abnormal thinning in cortical volume (Cannon et al., 2015) and reduced dendritic 
spine density in pyramidal neurons of the cortex (Garey et al., 1998). These are 
often targets of afferents from subcortical structures such as the thalamus, which 
has also been reported to be reduced in volume in schizophrenic individuals 
(Brickman et al., 2004). The thalamus connects multiple regions in the cortex and is 
thought to play a role in gating of sensory input to the cortex, which is negatively 
affected in schizophrenia (Rao et al., 2010). Ultimately, reductions in both grey 
matter volume and thalamus volume have been linked to more pronounced negative 
symptoms in schizophrenic individuals (Anderson et al., 2002; Rao et al., 2010).  
In addition to grey matter changes, there are also disruptions in white matter 
integrity within the brains of individuals with schizophrenia. White matter volume has 
been shown to be reduced in both first-episode and chronic schizophrenic 
individuals, and these abnormalities seem to be localized primarily to white matter in 
frontal and temporal regions (Kubicki et al., 2005). Greater disruptions in white 
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matter are associated with a greater severity in symptoms across the schizophrenia 
spectrum (Lener et al., 2015) 
Medial temporal lobe structures including the amygdala-hippocampal complex and 
parahippocampal gyrus are also reduced in volume, as observed in both first-
episode schizophrenia and chronic schizophrenia (Shenton et al., 2001). These 
structures are involved in associative and retrieval processes in memory, which are 
thought to underlie aberrant auditory and language processing functions seen in 
schizophrenia. Reductions in the volume of the hippocampus seem to correlate with 
a decline in reduced verbal and spatial memory performance (Allen et al., 2016), 
and an earlier onset of psychosis (Stefanis et al., 1999). Anatomically, hippocampal 
neurons in the pyramidal cell layer are normal in schizophrenia, however studies 
show that there is a reduction in the number of parvalbumin-positive interneurons in 
the CA1 and CA4 sectors and somatostatin-positive interneurons in all three 
hippocampal sectors. These changes are thought to be linked to psychotic 
symptoms and deficits in memory and other hippocampal functions (Konradi et al., 
2011). Changes in hippocampal volume seem especially influenced by 
environmental factors (Stefanis et al., 1999).  
Activation patterns in certain brain regions are also different in individuals with 
schizophrenia. For example, the dorsolateral prefrontal cortex has been shown to be 
activated to a lesser degree in schizophrenic individuals compared to healthy 
individuals during the performance of working memory and executive tasks (Glahn 
et al., 2005). This supports the theory of hypofrontality, or the reduced physiological 
activity in the prefrontal cortex (PFC) of the brain, seen in brain-imaging studies of 
the frontal and temporal lobes in schizophrenia (Davidson and Heinrichs, 2003). In 
comparison to this, imaging studies show an increase in activation of the anterior 
cingulate cortex and left frontal pole regions of the cortex (Glahn et al., 2005). This 
complex pattern of hypo- and hyper-activation of different brain areas supports the 
proposal that normal functional connectivity in the frontal and limbic structures is 
disturbed in schizophrenia, making it a syndrome of dysconnectivity (Glahn et al., 
2005). 
Despite robust evidence establishing associated structural abnormalities in the 
brains of schizophrenic individuals, it is sometimes unclear at what stage of disease 
development they occur and how they develop over time (Dietsche et al., 2017). 
Some  evidence shows that many structural changes such as lateral and third 
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ventricles enlargement, overall brain and hippocampal size reduction and white 
matter abnormalities are already seen at early stages of or stages leading up to the 
disorder (Dean et al., 2016; Vita et al., 2006). This implies that these features are 
not secondary to disease progression or seen as a result of anti-psychotic 
medication and that an aberrant course of brain development likely contributes to 
the onset of the disease (Karlsgodt et al., 2010). In comparison, however, there is 
no significant evidence to show that some other structural changes associated with 
schizophrenia such as a reduction in temporal lobe and amygdala volumes are 
present at these early stages of disease progression (Vita et al., 2006). Evidence 
shows that there is a significant reduction in the volume of the brain in schizophrenic 
individuals which occurs both before and after maximum brain volume attainment 
(Woods et al., 2005), implying that both aberrations in early development and at 
later developmental stages can negatively affect the brain.  
Despite these findings, no single functional or anatomical abnormalities have been 
identified that are specific to schizophrenia separating it from other disorders (Owen 
et al., 2016), limiting the applicability of these findings in the clinic. 
1.2.2.5 Neurochemical mechanisms 
Several influential hypotheses of schizophrenia exist regarding the neurobiology 
underpinning schizophrenia, implicating different neurotransmitter systems. The two 
most influential hypotheses involve a dysfunction of the dopaminergic and 
glutamatergic systems; however, serotonin and other neurotransmitters are also 
thought to be potentially involved. 
1.2.2.5.1 Dopamine 
The dopamine hypothesis initially came from observations that dopamine agonists 
like amphetamine which increase extracellular dopamine concentrations 
exacerbated psychotic symptoms in individuals with schizophrenia (Lieberman et al., 
1987) and were able to induce acute psychotic symptoms in healthy individuals 
(Bell, 1973). Moreover, most anti-psychotic medication block D2 dopamine 
receptors and their clinical efficacy in controlling hallucinations and delusions 
correlates with their affinity for the receptor (Seeman et al., 1976). Finally, drugs that 
deplete dopamine levels such as reserpine reduce psychotic symptoms (Howes and 
Kapur, 2009). Molecular imaging studies using radiotracers have found dopamine 
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release in schizophrenic individuals to be higher than in control subjects, which 
seems to directly relate to the degree of psychotic symptom severity seen in these 
individuals (Pogarell et al., 2012). More specifically, it is thought that increased 
release of dopamine in subcortical structures leads to increased dopamine D2 
receptor stimulation (Abi-Dargham et al., 2000), and in turn positive symptoms, 
which are thought to be mediated through a disturbed cortical pathway through the 
nucleus accumbens (Brisch et al., 2014). Not surprisingly, these symptoms respond 
better to current anti-psychotic medication, all of which as mentioned, show 
antagonistic activity at dopamine D2 receptors (Abi-Dargham et al., 2000). This 
dopamine circuit has been implicated in emotional and motivational processing and 
plays a role in encoding and expressing salient learning and memory formation 
(Laviolette, 2007).  
The negative symptoms of schizophrenia on the other hand, have been attributed to 
a reduction in dopamine D1 receptor activation in the PFC and nucleus (Abi-
Dargham et al., 2000; Brisch et al., 2014). The PFC is involved in executive 
functioning, which has been shown to be impaired in individuals diagnosed with 
schizophrenia (Weinberger and Gallhofer, 1997) and patients with dorsomedial PFC 
lesions show behaviours similar to negative symptoms seen in schizophrenic 
individuals (Orellana and Slachevsky, 2013). Dopamine D3 receptors are also 
thought to possibly be involved in these latter group of symptoms as overexpression 
of them in the striatum of mice disrupts motivation (Simpson et al., 2014). 
As a whole, the dopaminergic system is very vulnerable to outside factors such as 
disturbances during and around birth and development (Laviolette, 2007). Evidence 
shows that certain environmental factors can dysregulate the dopamine system to 
cause psychotic symptoms especially in individuals who already vulnerable (Stokes 
et al., 2013).  
Nevertheless, there are some limitations to the dopamine hypothesis. For example, 
psychosis-like symptoms can also be induced in healthy individuals and 
exacerbated in schizophrenic individuals by drugs that do not directly interact with 
dopaminergic receptors. These include glutamate antagonists, anti-cholinergics and 
agonists of the cannabinoid CB1 receptor system (Laviolette, 2007). Similarly, many 
individuals experiencing schizophrenic symptoms do not respond well to mainly 
dopaminergic antipsychotic drugs or any other manipulations that involve the 
depletion of presynaptic dopamine (Remington et al., 2012). Finally, drugs that 
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modulate dopaminergic pathways and affect the presentation of psychotic 
symptoms such as reserpine and amphetamine, also affect other monoamines in 
the brain (Howes et al., 2015).Therefore, dopaminergic dysfunction is not thought to 
be able to fully explain the abnormal neurobiology of schizophrenia.  
1.2.2.5.2 Glutamate and GABA 
Some research suggests that the dopamine system is in fact “normal” in its 
configuration, but something else is abnormally driving the dysregulation of it in the 
brains of individuals with schizophrenia (Grace, 2012). The glutamatergic system is 
another system that has attracted a lot of attention in recent years. Glutamate 
signalling is involved in synaptic plasticity and cortical processing (Steeds et al., 
2015), through the ability of glutamate receptors to stimulate neurite outgrowth, 
synaptogenesis and maturation of the synapse during development of the brain 
(Gaur et al., 2008). Evidence for the involvement of glutamate in schizophrenia 
pathophysiology comes from observations that drugs that manipulate glutamate 
transmission, especially N-methyl-d-aspartic acid (NMDA) receptor-interacting ones, 
like dissociative anaesthetics that block the receptor, are able to induce 
psychotomimetic states including negative symptoms and cognitive impairments that 
closely resemble schizophrenia (Javitt and Zukin, 1991). Moreover, a reduction in 
NMDA receptor binding has been shown in medication-free schizophrenia patients 
(Pilowsky et al., 2006), and enhancing NMDA receptor function has been shown to 
reduce negative symptoms and positively affect cognitive deficits in schizophrenic 
subjects (Goff and Coyle, 2001). This has led to the NMDA receptor hypofunction 
hypothesis if schizophrenia.  
In addition to glutamate, another key player of this hypothesis is the inhibitory 
neurotransmitter, gamma aminobutyric acid (GABA). Decreased GABAergic 
signalling in the PFC has been reported consistently in post-mortem schizophrenia 
compared to healthy individuals (Lodge et al., 2009). This seems to be restricted 
mainly to the calcium-binding protein parvalbumin-containing class of GABAergic 
interneurons (Lewis et al., 2005) and this dysfunction in the dorsolateral PFC has 
been linked to deficits in working memory (Lewis et al., 2004).  
It is thought that an excessive glutamate output in the glutamatergic pathway 
projecting from cortical pyramidal neurons through GABAergic inhibitory 
interneurons to dopaminergic neurons in the ventral tegmental area (VTA) leads to 
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overactivation of this communication pathway contributing to a hyperdopaminergic 
state in the mesolimbic area. This is thought to underlie the positive symptoms of 
schizophrenia (Homayoun and Moghaddam, 2007; Marsman et al., 2014; Stahl and 
Muntner, 2013). In support of this theory is the observation that administration of 
ketamine, an NMDA receptor antagonist, in healthy individuals leads to 
dopaminergic dysregulation, similar to that seen in schizophrenia (Kegeles et al., 
2000).  
Additionally, the mesolimbic area also gets input from the hippocampus, which can 
also similarly cause a hyperdopaminergic state in the mesolimbic area (Stahl and 
Muntner, 2013). In support of this, research has found evidence for a decreased 
density of parvalbumin-containing interneurons in the hippocampus (Zhang and 
Reynolds, 2002), as well as increased hippocampal activity, which in turn seems to 
correlate with psychotic symptoms, especially auditory hallucinations (Heckers, 
2001; Silbersweig et al., 1995). It has been proposed that hippocampal hyperactivity 
could drive the dopaminergic system to be hyper-responsive to stimuli and enter a 
state called aberrant salience (Kapur and Mamo, 2003), where all stimuli are treated 
similarly and given maximal attention and reaction (Grace, 2012). This impairment in 
information processing means that individuals affected have an inability to ignore 
irrelevant stimuli as often seen in schizophrenic individuals (Heckers, 2001). 
Evidence shows that stress, drug abuse and other environmental factors can also 
affect the hippocampus (Battistella et al., 2014; Grace, 2012; Jacobus and Tapert, 
2014; Mondelli et al., 2010).  
Negative symptoms and cognitive deficits characteristic of schizophrenia, can also 
be explained to a certain degree by glutamate. It is proposed that an overactivation 
of a different population of glutamate neurons negatively modulates dopamine 
neurons in the VTA which project to the PFC, leading to the hypoactive state in the 
mesocortical dopamine pathway (Stahl and Muntner, 2013). 
1.2.2.5.3 Serotonin 
Serotonin (or 5-hydroxytryptamine; 5-HT) has also been suggested to potentially 
play a role in the formation of psychotic symptoms (Steeds et al., 2015). 5-HT2A 
receptor agonists, like the hallucinogens D-lysergic acid diethylamide (LSD) and 
psilocybin, induce symptoms similar to those seen in first episode schizophrenic 
individuals, which include agitation, anxiety and hallucinations (Steeds et al., 2015). 
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These drugs are also able to disrupt pre-pulse inhibition (PPI) of the startle reflex 
response, which is a phenomenon observed in schizophrenic individuals and serves 
as an operational measure of sensorimotor gating (Halberstadt and Geyer, 2010). 
Moreover, many atypical anti-psychotics such as clozapine, risperidone and 
olanzapine also have additional modulating activity on the serotonergic system by 
antagonising 5-HT2A receptors (Ichikawa et al., 2001).  
Serotonergic hallucinogens enhance glutamatergic transmission, through the 
activation of 5-HT2A (i.e. subtype of the 5-HT2 serotonin receptor) stimulation in the 
PFC (Aghajanian and Marek, 2000). This and the fact that blockade of 5-HT2A 
receptors reverses the effects of NMDA receptor antagonists, suggests the 
involvement of serotonergic mechanisms in the NMDA receptor hypofunction model 
of psychosis (Steeds et al., 2015). It is thought that atypical anti-psychotics with 5-
HT2A and D2 receptor antagonistic activities lead to distal activation of the 
mesocortical pathway and thus increased dopamine release in the medial PFC, 
through the promotion of 5-HT1A stimulation (Celada et al., 2013). As a hypoactive 
dopaminergic system in the PFC has been implicated in the formation of negative 
symptoms and cognitive deficits, 5-HT2A receptor antagonists have been suggested 
to have therapeutic value for negative symptoms and cognitive deficits in individuals 
with schizophrenia (Ichikawa et al., 2001; Roth et al., 2004). Clozapine, an atypical 
anti-psychotic often suggested to be superior to other anti-psychotics and 
recommended for treatment-resistant schizophrenic individuals, displays agonistic 
properties at the 5-HT1A receptor and has in some cases been shown to have an 
effect on both positive and negative symptoms of schizophrenia (Celada et al., 
2013).  
1.2.2.5.4 Cholinergic system 
It is also hypothesized that misregulated, cortical cholinergic inputs play a role in the 
development and manifestation of attentional deficits seen during positive symptoms 
of schizophrenia. Its dysregulation is a correlate of the abnormal mesolimbic 
dopaminergic transmission underlying positive symptoms (Moore et al., 1999; Sarter 
et al., 2005). Dopamine agonists have been shown to increase acetylcholine outflow 
in the cortex (Day and Fibiger, 1993). Normally acetylcholine (ACh) release is vital in 
the PFC for normal cognitive functioning, and the cholinergic system plays a role in 
information processing and cognition (Steeds et al., 2015). Changes in markers for 
the ACh and levels of the ACh synthesizing enzyme, choline acetyltransferase 
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(ChAT) have been frequently reported in individuals with schizophrenia (Terry and 
Jr, 2008). Muscarinic M1 and M2 receptors that play a role in neuronal excitability, 
synaptic plasticity and learning and memory, seem to be especially affected. The 
literature also shows that administration of muscarinic antagonists like scopolamine 
and atropine can induce a psychotic state which is similar to the symptoms seen in 
schizophrenia (Steeds et al., 2015; Terry and Jr, 2008). In addition to this a 
reduction in the α7 subtype of nicotinic Ach receptors is also observed in many 
cases of schizophrenia and has been linked to sensory gating deficits (Freedman et 
al., 2005). Interestingly, abuse of anticholinergic drugs is widespread among 
schizophrenic individuals who report functional benefits, including improvements in 
negative symptoms and cognitive abilities as a result of taking these drugs (Koukouli 
et al., 2017; Wells et al., 1989).  
Ultimately, schizophrenia is thought to involve a disruption of neuronal connectivity 
in turn causing a deficit in the coordinated processing of information (Gaspar et al., 
2009). Our current understanding is that a set of processes at a functional level, 
including a number of subtly altered networks throughout the brain contribute to 
reductions in synaptic activity and integration, and thus a disruption in functional 
dysconnectivity and miscommunication between different brain areas (Cannon et al., 
2015; Pettersson-Yeo et al., 2011). A prevailing view is that de novo or inherited 
mutations in one or multiple genes cause a failure of neuromodulation, which arises 
as a result of aberrant interactions of neuromodulator systems involving 
neurotransmitters discussed above. Because of how closely neurotransmitter 
systems in the brain are connected with one another, it is difficult to tease out which 
changes seen in neurobiology are primary, secondary or even tertiary signs of the 
disorder and therefore the exact mechanisms behind schizophrenia remain unclear 
(Zink and Correll, 2015). With genes of low penetrance, environmental factors are 
likely to also play a role in the development of the disorder, whereas much rarer high 
penetrance genes might be able to cause manifestation of the disease early on 
leading to a more severe form of the illness (Ahn et al., 2014; Friston et al., 2016). 
This molecular pathology leads to an inability to process sensory evidence 
appropriately and can lead to false inferences in the form of hallucinations and 
delusions (Friston et al., 2016). Anatomical changes described above are thought to 
develop overtime (van Haren et al., 2011).  
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1.2.3 Clinical management 
1.2.3.1 Current treatment of psychotic disorders and weaknesses 
Pharmacological treatment is recognised as the foundation of the clinical 
management of individuals who experience psychotic symptoms; however, 
psychotherapies like cognitive behavioural therapy (CBT) have also been shown to 
be effective in some cases, especially when used in combination with 
pharmacological medication (Miyamoto et al., 2005). The serendipitous discovery of 
the psychotropic drug chlorpromazine in the 1950s paved the way for 
pharmacological treatment of psychosis and led to development of first generation 
or “typical” anti-psychotics; and later, in the 1990s, of second generation or 
“atypical” anti-psychotics (Geyer et al., 2012). Both groups of drugs bring a burden 
of serious side effects and those taking these medications are observed to have 
extrapyramidal symptoms with first-generation antipsychotics and weight gain and 
metabolic syndrome with second-generation antipsychotics (Leucht et al., 2009). 
Clinical observations suggest that in general second-generation antipsychotics have 
little additional value compared with first-generation antipsychotics (Gupta, 2010; 
Leucht et al., 2009). Current NICE guidelines suggest that selection of treatment 
should be based on assessment of the balance between benefits and adverse 
effects for each individual (National Collaborating Centre for Mental Health (Great 
Britain), 2014). Unfortunately, over 60 years on from the identification of the first 
anti-psychotic, chlorpromazine, successive pharmacotherapies since 
chlorpromazine have largely been modifications of early drugs and current 
antipsychotic treatments still converge on the same mechanism of dopamine D2 
blockade for the management of psychosis (Kapur and Mamo, 2003; Zink and 
Correll, 2015). Our limited understanding of the pathophysiology of these disorders 
has hindered the development of novel treatments for psychotic disorders with no 
real, major breakthroughs having been made in recent decades. 
Despite available treatment options, the management of psychotic disorders 
continues to be problematic, stemming from a number of seemingly unmet 
therapeutic needs. National statistics report that just two-thirds of people identified 
as having had a psychotic episode in 2007 in the UK received medication, 
counselling or any other form of treatment (Great Britain Department of Health, 
2007). Moreover, one of the biggest issues with current treatment options are that 
there are a great proportion of individuals experiencing psychosis who are 
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unresponsive to medication available (Kapur and Mamo, 2003). In fact, the James 
Lind Alliance has established treatment of those experiencing schizophrenia that are 
unresponsive to treatment as the number one research priority in terms of treatment 
uncertainty (Lloyd and White, 2011). Recent estimations report that about 30% of 
patients respond to anti-psychotic treatment well and meet full remission criteria, 
while another 30% only show partial response to the drugs available and about 20-
30% do not respond to medication at all (Steeds et al., 2015). It is widely accepted 
that current available medication only manages symptoms, and of these mainly 
positive symptoms, however, there is no evidence to show that these medications 
also correct the underlying biological problem (Kahn et al., 2015). In fact another 
central criticism of current medication is that there is little proof indicating that these 
anti-psychotics alleviate much other than the psychosis, which is especially 
problematic for individuals who also experience negative symptoms and cognitive 
deficits alongside the positive symptoms of psychosis, commonly seen in 
schizophrenia (Geyer et al., 2012). Moreover while initially it was thought second 
generation anti-psychotics could replace the burdensome extra-pyramidal side 
effects of first generation anti-psychotics, it soon became apparent that previous 
side effects had just been replaced with newer ones (Leucht et al., 2009). In fact, 
evidence from the UK Database of Uncertainties about the Effects of Treatments 
show that many patients worry about the side effects of current treatments 
especially in the long term (https://www.library.nhs.uk/duets/). Perhaps 
unsurprisingly, possibly partly due to some of these factors, it is estimated that 
around half of schizophrenia patients don’t adhere to treatment recommendations 
(Gibson et al., 2013). This data suggests that new treatments should be tested in 
consideration of what outcomes matter the most to the people that will ultimately 
end up receiving these treatments (Lloyd and White, 2011).  
1.2.4 Challenges in developing new treatments for psychotic disorders 
The odyssey of drug development typically involves a slow process of basic 
research and discovery, testing and development of promising therapeutic 
compounds in animal models of the human deficit, and assessment of the 
compound in three stringent phases of clinical trials. This is followed by an 
anticipative approval by the appropriate agency (i.e. US Food and Drug 
Administration (FDA) or regional regulatory bodies in the European Union) (DiMasi 
et al., 2003; Steinmetz and Spack, 2009). This is usually an incredibly lengthy and 
costly process that usually takes years, and costs billions of dollars (Morgan et al., 
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2011; Van Norman, 2016). A recent study estimated that the likelihood of approval 
by the FDA for a new drug entering its first phase of clinical trials is on average 
about 10.4% (Hay et al., 2014), or about one in nine interventions that make it 
through the development process and go on to be approved by European or US 
regulatory bodies (Kola and Landis, 2004). Most compounds fail at Phase II and 
Phase III of development, however, it has also been shown that about 30% of drugs 
designed for treatment of the central nervous system (CNS) fail at registration (Kola 
and Landis, 2004).  
As mentioned, there has been very little progress in terms of new drug development 
for schizophrenia in recent years and it is clear that this is somewhat as a result of 
our still limited understanding of the underlying mechanisms of schizophrenia. One 
major limitation of progress in the field is that many findings associated with the 
disorder are not specific to schizophrenia and any functional and chemical changes 
are also associated with other psychiatric disorders, making it very difficult to thus 
use these observations as predictors of the disorder (Maynard et al., 2001). 
Moreover, there is a large extent of variability and heterogeneity between the clinical 
profiles of different individuals diagnosed with schizophrenia. These issues make it 
difficult to predict outcome in any given individual and develop treatments effective 
for all (Harrison and Weinberger, 2005). Currently no biomarker exists for 
schizophrenia, but it is also highly unlikely in the context of this clinical heterogeneity 
of the disorder that a single biomarker will be able to account for the multiple 
underlying pathophysiological processes that are currently thought to play a role in 
the development of schizophrenia (Weickert et al., 2013). Individuals who 
experience psychotic disorders such as schizophrenia have been shown to have an 
8.5-fold higher risk of suicide than when compared to the general population (Harris 
and Barraclough, 1998). Moreover, symptoms of schizophrenia are usually 
associated with a general low quality of life which is not often significantly improved 
by newer anti-psychotic treatments (Bobes et al., 2007), therefore current 
management of these disorders is clearly suboptimal and this needs to change. 
1.2.5 Pre-clinical studies and the role of animal models 
Naturally one of the biggest concerns when releasing a new drug into the 
marketplace is that they are safe and effective for the purpose that they were 
intended for. Low attrition rates in clinical drug development can be mainly attributed 
to inadequate efficacy and clinical safety (Kola and Landis, 2004; Arrowsmith, 
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2011). These are both factors that rely on pre-clinical studies involving animal 
models, therefore suggesting that current animal model experiments lack predictive 
value (Kola and Landis, 2004) 
An animal model in science is considered to be an experimental preparation that 
has been developed for the purpose of studying a condition in the same or a 
different species (Geyer and Markou, 2000). Animal models are invaluable tools in 
neuropsychiatric research as they provide an environment where disease 
progression can be monitored at a much higher rate as opposed to humans. This 
allows researchers to evaluate underlying structural and neurochemical changes 
that lead to the brain abnormality causing the disorder (Jones et al., 2011). For the 
purposes of novel drug development, pre-clinical studies allow for the investigation 
of a proposed therapeutic compound’s safety, efficacy and its toxicity in animal 
models, before they are given to humans. These experiments can also aid the 
design of the first phase of clinical trials in humans, by providing information about 
dosage to be evaluated and for example what signs to look for in humans to 
evaluate safety of the drug (Lo et al., 2009). It is imperative to keep in mind that 
extrapolating evidence from animals to humans is rarely straightforward and there 
are a number of limitations, including poor design, conduct of experiments as well as 
the obvious issue of lack of generalisability between the two species (Bracken, 
2009; van der Worp et al., 2010) 
Two ways in which researchers have attempted to create models of validity for 
psychiatric disorders is by reiterating the behavioural and cognitive abnormalities 
that are seen in the clinical phenotype of the disorder or by replicating the relevant 
neural, neurochemical, molecular or anatomical aspects of the disorder in question 
(Fernando and Robbins, 2011). In neuropsychiatric research we can broadly cluster 
models into four different groups: pharmacological-, genetic-, developmental- and 
lesion-induced models (Jones et al., 2011). Modelling disorders in animals is 
especially difficult for psychotic disorders, as these are heterogeneous in their 
symptomology and often present with high levels of co-morbidity (Fernando and 
Robbins, 2011; Geyer and Moghaddam, 2002). For this reason, more often than not, 
emphasis tends to be put on modelling symptoms rather than a disorder per se 
(Fernando and Robbins, 2011). While it is not clear that a rodent can experience 
psychosis as we understand it in humans (Powell and Miyakawa, 2006), such 
models may provide useful tools to study these complex human disorders and their 
20 
 
underlying structural and neurochemical changes, while also providing an assay to 
screen novel therapeutics in (Jones et al., 2011).  
Animal models are thought to have translational relevance to the symptoms of the 
human disorder in question, if they have construct, face and predictive validity for 
the disorder being modelled (Jones et al., 2011). These criteria suggest that animal 
models should have etiologic validity (i.e. etiologic relevance of the methods by 
which a model is created), ethological validity (i.e. observable outcomes of 
relevance), and pharmacological validity (i.e. response to treatment predictive of 
effects in humans) for the disorder, respectively (Belzung and Lemoine, 2011; 
Nestler and Hyman, 2010). Of course, the validity of an animal model is often 
subjective and it is suggested that greater agreement on how to judge validators 
would improve research in the field (Nestler and Hyman, 2010). There is also some 
ambiguity to the definition of some of these validities and how they are used to judge 
animal models. Throughout this thesis, I will define etiologic, or construct validity, as 
the theoretical relevance and rationale of the methods used to construct the model 
to the disease; face or ethological validity as the measure of how well the model 
constructed manages to recapitulate the pathophysiology of the human disease; and 
predictive validity as the ability for an animal model to respond to treatments in the 
same way as humans would. By these definitions an animal model with high 
construct validity to a disorder would be created through the same etiologic 
processes as those that underlie the disorder, one with strong face validity would 
display anatomical, biochemical, neuropathological and behavioural features similar 
to those in humans, and finally one with good predictive validity would be able to 
predict the effect of a treatment in humans with the disorder (Belzung and Lemoine, 
2011; Nestler and Hyman, 2010; Varga et al., 2010). Overall, despite many great 
appraisals of pre-clinical models published over the last two decades in the 
literature, there has not been any sort of quantification of the animal research field.   
1.2.6 Translation of knowledge from basic science to the clinic and its failure 
Translational medicine is the process of using information obtained in one research 
domain to inform and guide research in a different research domain (Figure 1.1). 
This term has gained popularity in the last decade as we are now beginning to 
question more and more why the large expansion of basic biomedical research has 
not seemed to make a considerable benefit to medical practice. While animal 
studies are invaluable in terms of informing subsequent research domains and 
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eventually healthcare practice, evidence shows that only about a third of highly cited 
animal studies (i.e. with more than 500 citations) are subsequently carried forward 
and translated to human randomized trials, and an estimated 11% of these 
interventions replicated in humans go on to be approved for the clinic (Hackam and 
Redelmeier, 2006). Across a number of different research fields, there seems to be 
an obvious breakdown in the drug development process between research done in 
animal models and successful drug candidates that are carried forward into clinical 
trials to be approved for the treatment of human patients. Many candidate 
treatments developed for schizophrenia have also turned out to be false positives 




This raises the fundamental question: what can we blame for this apparent attrition 
rate between bench and bedside in CNS disorders research? One perspective is 
that results from both domains of research are accurate, but human physiology and 
disease are not sufficiently exemplified by animal models and therefore animal 
models fail to replicate human disease with sufficient fidelity to predict efficacy of 
treatments in humans (van der Staay et al., 2009). Alternatively, the animal literature 
is affected by biases in the design, conduct and reporting of experiments so that 
they provide an incomplete picture of the overall physiology (Ioannidis, 2012; van 
der Worp et al., 2010). Previous analyses of pre-clinical studies from a number of 
neurological diseases suggest that the value of research using animal models is 
Figure 1.1 Translation of research from basic science to health 
and practice requires us to build on building blocks of knowledge 
from previous domains of research 
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marred by issues with inadequate methodological quality of studies, limited 
construct validity of models used, and by limited external validity of experimental 
design applied (van der Worp et al., 2010). Overall, research is considered to be 
informative and of high-quality, when experiments are well-designed in advance, 
when they are rigorously carried out during, and results obtained are analysed 
correctly afterwards (Samuel et al., 2016). How valid a study is, is determined firstly, 
by whether the question a study is asking is answered ‘correctly’ and how confident 
we can be in the data presented. This eludes to the quality of the methodology and 
whether it is in general free from bias (i.e. termed “internal validity”) (Krauth et al., 
2013). Secondly, we need to consider whether the research question being asked is 
appropriate to begin with. This is termed as “external validity” and looks at whether 
the study is fit for the purpose it has been designed (Higgins and Green, 2008), and 
whether we are able to make reasonable extrapolations to humans (Geyer and 
Markou, 2000). Even if studies are without the possibility of bias, translation of 
results from animal studies may still fail if there are differences between the animal 
model paradigm and either the clinical picture of the disorder or clinical trials testing 
the proposed treatment (van der Worp et al., 2010). 
These are both importantly recognized dimensions of validity for clinical studies and 
therefore are also of relevance to in vivo research. Weaknesses in these measures 
could lead to translational failure between research at the bench and bedside as 
they can lead to false interpretations of the data (Higgins and Green, 2008). 
Moreover, for research to be informative, the “completeness of reporting” (Moher et 
al., 2015) should also be of a high standard. This is essential in science if we are to 
build on previous observations and drive scientific progress (Landis et al., 2012).  
1.2.7 Systematic reviews and their utility 
To elucidate what might be to blame for this translational failure between 
pre-clinical and clinical research, it is clear we need a more systematic approach to 
evaluating animal research. A systematic review is a review that allows for the 
identification, synthesis and analysis of all available research in the literature in 
relation to a given research question (de Vries et al., 2014). It allows for the 
synthesis of the state of current knowledge so that it can guide future research in a 
more objective way than narrative reviews could, by putting any future research in 
the context of existing knowledge (Higgins and Green, 2008). 
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Single studies can rarely offer the opportunity to see the entire biological picture. By 
combining information from individual studies through a meta-analysis, if 
appropriate, power and precision of results can be increased (Noordzij et al., 2009). 
Systematic reviews are thought to be transparent and comprehensive and can 
generally offer a less biased picture than narrative reviews, for example, as they can 
minimise subjective selection bias of evidence. As a result, they have the potential 
to maximise the research that has been so far carried out in order to reduce the 
number of resources wasted, and replace and refine experiments so that they have 
higher informative value. This in turn better aids the bridging of knowledge from 
basic to clinical sciences. 
While systematic reviews are promising and clearly useful, at current the process of 
distillation of knowledge using this tool is confounded by a number of both 
uncontrollable and controllable factors. Essentially a review can only take into 
account the literature that is available and reported and the part of the literature that 
it manages to capture. This includes important and often uncontrollable confounding 
factors in the review process such as poor or incomplete reporting of experimental 
designs, and exclusion of relevant data from a review due to data from a research 
study remaining unpublished or indexed in a way, which makes it unidentifiable 
using a certain set of search terms. Moreover it is possible to introduce systematic 
flaws and potential biases into the systematic review process through limitations in 
design and conduct of these reviews. Novel, emerging tools such as the ROBIS tool 
will allow us to assess these risks of bias in systematic reviews more efficiently in 
future (Whiting et al., 2016). Ultimately, all of these limitations can lead to a 
distortion of the true biological picture when summarising evidence, even when 
summarised in a systematic way (Rosenthal, 1979; Sena et al., 2010).  
Nevertheless, by reviewing the literature on in vivo experiments, we can assess and 
critically appraise studies in the literature, to shed light on potential weaknesses in 
the pre-clinical field and where design and conduct of future experiments can be 
improved upon (de Vries et al., 2014). This is only possible if we have a bird’s eye 
view of what is out there already. This overview then has the potential to inform what 
we think we know; both about how these disorders are modelled in animals, and 
about how they support clinical drug development.  
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1.3 Aim and Objectives 
In order to begin to explore and unravel potential reasons for the limited progress in 
translation of research from animal studies of psychotic disorders to clinical research 
and practise, I wanted to initially improve our understanding of the preclinical 
research field and the role that animal models play in the drug discovery process. 
The work presented here was carried out with the aim of providing a transparent and 
comprehensive summary of the use of animal models of psychosis in the research 
field.  
This thesis reports the results of a systematic review of the preclinical literature of 
psychotic disorders wherein studies that test animal models of psychotic disorders 
against naïve, control animals have been identified to help our understanding of the 
underlying pathophysiology of these conditions in humans. In addition, I also include 
studies that investigate the therapeutic potential of certain treatment drugs. I review 
the literature in the context of four themes. I explore whether limited translation 
might be explained by a) a disorganized field whereby the identification of patterns 
in information becomes difficult, b) experiments carried out and published being of 
limited relevance to the clinical condition, c) studies published and methodological 
designs of experiments being of limited quality, and d) the data that can be captured 
from the literature being skewed or misrepresentative of the field. 
Chapter 2 describes the methodology I have used for this review, including 
explanations of calculations for meta-analyses carried out. Results of the search and 
the characterization of studies identified is presented and discussed in Chapter 3. 
Here I include a summary of models most commonly used, outcomes most widely 
measured and a list of treatment compounds that are tested in the literature 
identified. In Chapter 4 I take a subset of this data forward to explore four forms of 
validity – external, face, construct and predictive – in order to assess the relevance 
of animal models and experimental paradigms describing these have for the clinical 
condition. In Chapter 5 I introduce a novel technique for the categorisation of 
publications according to the reporting of a list of risk of bias and other 
methodological quality criteria. This is an automated tool that was developed while 
spending time at Óbuda University in Budapest, Hungary and uses text mining to 
speed up the process of reading and extracting data from publications. In Chapter 6 
I demonstrate the use for this tool, while reviewing the reporting of risk of bias items 
and other methodological quality criteria across the entire field. In Chapter 7 I 
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explore the difficulty in capturing all of the relevant data in relation to my research 
question and thus review the robustness of my obtained data. Finally, Chapter 8 
summarizes my results and thoughts on the field, discussing any trends identified 
and consequent suggestions I believe might help advance our understanding further 
of the use of animal models of psychotic disorders. 
The thesis will focus mainly on schizophrenia as this is the most commonly 
described psychotic disorder in the field of preclinical research. Nevertheless, as 
psychotic symptoms are shared by all of the psychotic disorders, any data reporting 
outcomes measured in animals thought to be of relevance to human psychosis is 
likely to improve our understanding of all these disorders and I try to make 
inferences to all psychotic disorders where possible. As a result this review includes 
all outcomes described in the context of psychotic disorders including negative 
symptoms and cognitive deficits. 
I believe that the data collected here is beneficial to the field because it is becoming 
more and more apparent that there is no panacea for all individuals who experience 
psychotic symptoms. It is imperative that we create a well-structured system of 
preclinical research that is continuously informed by and built on existing knowledge. 
For this, research needs to be comprehensive and informative, exploring different 
methodological designs to define the best dose, route and frequency to take forward 
to clinical trials; complete, so that all research endeavours are made public; and 
readily translatable so that animal models more closely model human pathogenesis 
and thus have maximised value in the drug discovery process for human psychotic 
disorders. The field of pre-clinical psychotic research has evolved over the years 
with our ever-increasing knowledge, and this knowledge has thus increased the 
breadth of research that is currently being carried out. There is a risk, however, that 
this will also potentially lead to a large number of false positive if research is not 
sufficiently guided by theories of aetiology, pathogenesis and cognition in the 
context of human psychosis (Moore, 2010). A more detailed and structured roadmap 
of the current field, would allow future studies to identify which models work best for 
modelling different clusters of signs resembling human symptoms of psychosis and 
therefore identify treatment drugs that might give equally promising results in the 










In this chapter, I discuss the general methodology that I used to conduct my 
systematic search of the research field and how I extracted the data I used for meta-
analysis at later stages of the project. Any other methods used throughout my 
project, more specific, are described within the corresponding chapter. I have also 
developed a new methodological technique to trial the use of text mining in order to 
speed up the process of reviewing the studies I included in my review, and this is 
discussed in Chapter 5. As a recognition of the importance of transparency and in 
light of the importance of specifying your methodology at the start of a project to 
avoid the introduction of bias, a detailed outline of the methods used for the main 
systematic review and meta-analysis part of the project has been published in a 
protocol format (Bahor et al., 2016). The contribution of other individuals to my work 
is acknowledged in more detail at the beginning of each specific chapter. Within this 
chapter I refer to Cristina Nunes-Fonseca (CF) and Hannah Vesterinen (HV) for 
their work. 
2.1 Systematic Review 
 
Studies that characterise animal models of psychotic disorders and/or test 
interventions in these animal models were identified from the literature using the 
electronic database PubMed. I chose to search a single database to perform a 
shallow, but broad review of the field, and thus get an exploratory snapshot of the 
research that was out there. This of course could have introduced a certain extent of 
selection bias into my overall findings and affected the robustness of my overall 
results (Higgins and Green, 2008), which is a limitation of the current work. While 
much of the literature on clinical systematic reviews recommends performing 
systematic review searches using multiple electronic databases (Higgins and Green, 
2008; Stevinson and Lawlor, 2004), there is also some evidence that has found 
performing these additional searches only has a modest impact on overall results 
(Halladay et al., 2015), with little change to overall statistical significance of results 
(Hartling et al., 2016). Guidance for systematic reviews of animal models has so far 
been less clear-cut and certainly the effect of how many and which databases are 
searched seems highly dependent on the topic being explored even for human 
studies (Hartling et al., 2016). 
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I defined psychotic disorders as a group of psychiatric disorders including non-
affective psychotic disorders, affective psychotic disorders, substance-induced 
psychotic disorders and psychotic disorders due to a general medical condition. 
Studies were identified using search terms synonymous to the word “psychosis” and 
a list of psychotic mental disorders. These disorders were primarily decided on using 
the classification list of mental disorders outlined in Chapter V of the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10) (World Health Organization, 2016). Information from the DSM-5 
Schizophrenia Spectrum and Other Psychotic Disorders chapter (American 
Psychiatric Association, 2013) was also used, to include only those that I considered 




   
Figure 2.1. Venn Diagram of Disorder Classifications based on ICD-10 and DSM-5 for three major groups of disorders –psychotic, 
mood and anxiety disorders. 
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Using ICD-10, psychotic disorders were identified under Chapter 5 of Mental and 
Behavioural Disorders, which included disorders of psychological development. 
More specifically, I chose to include the following items in the list of classifications: 
Schizophrenia, schizotypal and delusional disorders (F20-29), which covered 
schizophrenia, schizotypal disorder, persistent delusional disorders, induced 
delusional disorders, schizoaffective disorders, acute and transient psychotic 
disorders, other nonorganic psychotic disorders and unspecified nonorganic 
psychosis. This list was supplemented using the chapter Schizophrenia Spectrum 
and Other Psychotic Disorders from the DSM-5 to also include catatonia, substance- 
or medication-induced psychotic disorder and psychotic disorders due to another 
medical condition. I also considered affective disorders with psychotic features to be 
relevant in this review. Based on my list of disorders identified through the two 
classification systems used, and associated synonyms of these disorders I 
performed the search using the terms: 
((((((((((((((((((((((((psychot*) OR psychosis) OR psychoses) OR paranoia) OR 
paraphrenia) OR sensitive beziehungswahn) OR involutional paranoid state) OR 
folie deux) OR cataton*) OR delusion*) OR hallucinat*) OR schizotyp*) OR 
psychoactive) OR oneirophrenia) OR psychogen*) OR bouffee delirante) OR 
hebephrenia) OR schizophren*) OR schizoaffect*) OR manic stupor)) NOT 
comment*[Publication Type]) NOT case report*[Publication Type]) NOT 
letter*[Publication Type]) NOT review*[Publication Type]; 
In light of the project’s exploratory nature, I tried to keep search terms as broad as 
possible to maximise the number of relevant publications captured. For this same 
reason, I did not include any outcome measure terms in the search criteria. Other 
than including exclusions for certain publication types within the search terms, the 
search was also limited by an animal filter published previously in the literature by 
Hooijmans et al. (Hooijmans et al., 2010b), claiming to a be an improved alternative 
to the default animal filter available on PubMed already. The search was completed 
on January 2013. No limits were imposed on this identified set of studies in terms of 
date published or language published in. A more detailed and expanded list of 
search terms can be found in the Appendix. 
The results of the search were exported into EndNote 6.0, which was used to also 
import any available PDFs through the University’s subscription system. Then using 
Reference Manager 12, studies were imported into an MS Access database I built to 
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be able to review studies in more detail during the study selection stages. The 
architecture of this database was simple, in that all the data were held within one 
table where each record corresponded to a single study identified within my search 
and held bibliographic information about that study.  I then designed forms for each 
of the selection phases of the review process, which was essentially a user-friendly 
interface that filtered the relevant fields of each record to display only those that 
were required for that phase of the project. 
 
2.1.1 Stages of study selection and data extraction 
 
Study selection of relevant studies for this review was divided into three main 
phases that coincided with two levels of data extraction:  
(1) Pre-screening of studies based on title and abstract to identify relevant studies 
and exclude non-primary animal studies;  
(2) Full text screening: involving categorizing publications according to model used, 
treatment tested and outcome measured; and the recording of reporting of 
experimental risk of bias; and  
(3) Screening at the level of data extraction for papers looking at behavioural 
outcome measures. 
The extraction of information regarding the reporting of experimental risk of bias items 
was simply to obtain an overall picture of the extent that these measures are reported 
in the literature and I did not use this as a variable to exclude papers from further 
analysis. 
 
2.1.2 Phase I: Pre-screening based on title and abstract 
After identification of studies, the first shallow level of inclusion and exclusion of 
studies was performed, based on the title and abstracts of all identified papers 
(Figure 2.2). Studies were screened by two independent reviewers (myself and CF) 
against a pre-defined inclusion and exclusion criteria, and a third independent 
investigator (HV) resolved any disagreements. During this first phase of the 
screening process we categorized publications by the human condition they claimed 
to model. Categories were schizophrenia, substance-induced psychosis, medical 
condition-induced psychosis, postpartum psychosis and unspecified psychosis.  
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2.1.2.1 Inclusion/Exclusion criteria 
This criteria demanded the inclusion of studies that reported experiments describing 
an in vivo model of a psychotic disorder and measuring an anatomical, 
electrophysiological, neurochemical, or psychosis-related behavioural outcome, 
and/or tested the effect of therapeutic interventions on the same outcomes in these 
models. This meant that studies characterising an animal model where these 
animals were compared to healthy animals; and those testing the effect of a drug in 
some of these models and comparing them to untreated animals, were included. 
Overall, studies were retained if they were primary research articles involving whole, 
non-human animal models of psychotic disorders that intended to model any human 
symptom related to psychotic disorders specified above, including transgenic animal 
models. This meant that any studies that were case reports, human studies, letters 
or comments, reviews, conference and seminar abstracts without data were 
excluded. Only studies looking at non-human animals were retained and all other 
experiments including those performed on in vitro samples were excluded. Abstracts 
were assessed for the reporting of an induction of any psychosis-related or other 
schizophrenia-associated behaviours or structural changes in the animal described. 
At this stage studies that did not report any of the outcome measures deemed 
appropriate for this review (behavioural, anatomical, electrophysiological and 
neurochemical) were also excluded from further analysis. Experiments considered 
to be of relevance were not limited in any way to animals of a specific age, sex or 
species; or interventions of a specific dosage, duration or frequency of 
administration. Studies of in vivo experiments where no disease model had been 
induced before treatment administration (i.e. drugs were not given to alleviate 
phenotype of model, such as toxicity studies examining side-effects of anti-psychotic 
drugs) were excluded as these experiments were not recognised to represent 
animal models of psychotic disorders. Moreover experiments investigating drug 
withdrawal, drug discrimination and any other drug addiction investigation models in 
animals, were excluded. All publications that had not been excluded at this stage by 
this pre-defined inclusion and exclusion criteria went on to the next phase of the 
project (Figure 2.2). 
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Figure 2.2. Screenshot of the form used in MS Access in order to screen studies 
identified in search against inclusion/exclusion criteria. There was a separate form for 
screeners 1 and 2 that looked identical. 
 
2.1.2.2 Disagreements between reviewers 
After phase I screening of abstracts by two screeners, a query was created to filter 
out and identify studies where there were differences in the screening classifications 
made by these screeners. These were reconciled by a third investigator, using 
separate forms created especially to display these results where studies could also 
be categorized based on full-text screening (Figure 2.3). As this was going on at the 




Figure 2.3. Form used for reconciliation of studies not agreed upon by screeners 1 
and 2 regarding inclusion/exclusion as well as simultaneous categorization.  
 
2.1.3 Phase II. Full text screening, categorization and assessment of 
reporting of experimental risk of bias 
The second phase of study selection was the first stage in the review process where 
studies were screened on a full-text basis (Figure 4). This phase of the screening 
process involved a detailed categorization process and was also the stage at which 
the reporting of measures taken within these experiments to reduce the risk of bias 
was assessed for. Unfortunately, where I was unable to obtain the PDF for a full-text 
article, the publication had to be excluded from further analysis as an abstract was 
simply not considered reliable enough to be able to categorise and ascertain 
reported study quality from. 
2.1.3.1 Inclusion/Exclusion criteria 
Here those studies that did not report the induction of a whole animal model of a 
psychotic disorder, including studies where a drug considered to be therapeutic for 
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psychotic disorders was administered without model induction, were excluded. 
Reviews or otherwise studies with no quantitative data were also excluded from 
further analysis. Where an experiment measured outcomes in animal models not 
thought to be of relevance to psychotic disorders (i.e. positive symptoms, negative 
symptoms or cognitive deficits), it was not considered to be relevant for the current 
review and was not included in any further stages of the review. Studies only 
reporting metabolic activity or modelling drug addiction were also excluded at this 
stage of the review. 
Publications that did not report behavioural measures were included still at this 
phase of the review, but were excluded from any further stages of the review due to 
time constraints. No studies were excluded based on their level of reporting of 
measures taken to reduce the risk of bias. Any studies that had to be excluded at 
this point due to inclusion/exclusion criteria were labelled with a reason for 
exclusion. 
 
Figure 2.4. Phase II categorization form for studies that had been included by both 
screeners allowing the input of fields concerning reported study quality, disease 
model induction details, details of any treatments tested in these models and 







Studies were categorized according to certain aspects of experimental design 
reported. Here details about the exact method used to create the animal model, the 
names of any treatments tested in these models and finally the type of outcome 
measure recorded during experimentation were logged. More specifically, I recorded 
information about the method used within a study to induce the experimental 
condition used to model the disorder of interest in a model animal. Where more than 
one model was used, I recorded each relevant model mentioned. Where an animal 
was given two different hits to model a condition, this was recorded as an example 
of a combination model. Where comparisons for both single and combination 
models could be identified, both were recorded (Figure 2.5).  
 
 
Experimental designs where treatments were administered to animal models, were 
also recorded in a separate field. Where studies were only looking at characterising 
the model and were given no therapeutic interventions this field was left blank. I 
recorded all treatments tested in relevant models even if they were reported to not 
have any significant effect on the model.  
Figure 2.5 Screenshot of drop-down options for studies where more than one model was 
reported within the same study 
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In a similar way, I recorded the outcome measures that were reported within each 
study. Specific detail such as the exact name of outcome measure and what it 
measured was only recorded for behavioural outcome measures as these were the 
ones data was extracted for in the next phase of the project. 
Categorization of studies was not only done to get a better overview of the field, but 
also in order to allow for the filtering of studies at a later time point for specific 
models. For studies that needed to be reconciled from disagreements at phase I of 
the review, studies were categorised in a similar way. This was carried out jointly by 
myself and HV. 
 
2.1.3.3 Extraction of details about reported methodological quality and 
reported risk of bias 
 
During this phase of categorization, studies were also scored against an 8-item 
study design checklist. This was to assess for both the extent to which bias might 
have been introduced during experimentation as reported within a study, as well as 
a possible reduction in imprecision and quality due to the lack of reporting of certain 
methodological aspects. 
 
This built on a checklist used by our group in previous projects (Macleod et al., 
2004), and was adapted to include the following items: (1) Randomisation; (2) 
Blinded conduction of experiment; (3) Blinded assessment of outcome; (4) 
Statement of Inclusion and Exclusion Criteria; (5) Sample Size Calculation; (6) 
Statement of possible Conflict of Interest; (7) Statement of compliance with Animal 
Welfare Regulations; and (8) Availability of a study protocol.  
 
I was interested in the prevalence of reporting of each item and study characteristics 
that might be related to these results (Figure 2.6). Two independent investigators 
normally carry out this phase of a systematic review project, however, resources 
only allowed for screening by a single investigator for each study here. An 
automated technique was developed (see Chapter 5) to address difficulties with the 
screening of so many studies. I did not exclude any studies from my final analysis, 
based on their overall study quality score as I wanted to assess the impact of these 





Figure 2.6. Screenshot from the database used to record details about the reporting of 
items from our list of study quality items. 
 
2.1.4 Phase III: Collection and Extraction of Data from Publications 
 
The final phase of screening was the final inclusion for data extraction and meta-
analysis and involved the screening of studies on a full-article level. At this phase of 
screening an in-depth level of data extraction was performed, where further details 
about the experiments performed and outcome data reported within each paper 
were recorded and extracted. 
2.1.4.1 Inclusion/Exclusion criteria 
As mentioned before, this was the stage I excluded studies not reporting a 
behavioural outcome from further analysis. I also excluded studies where data being 
referred to was not clear from a publication or were missing appropriate control 
groups. For meta-analysis three important pieces of data (n numbers, mean, 
SD/SEM) are required, therefore I could not include studies were this was not clearly 
reported in any further stages of this review. Any studies not meeting these criteria 
were excluded from the meta-analysis, but were retained for an overall review of the 
field (i.e. results from Phase II of the project) that describes this particular research 
field of interest. 
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2.1.4.2 Extraction of details about publication and model used 
 
Study characteristics that were extracted included further details specific to each 
study: name of first and corresponding authors, year of publication, title of article 
and name of journal. I was also interested in recording the type of journal article 
data were extracted from, to see whether this could have an effect on the reporting 
of certain kinds of data (Figure 2.7). 
 
 
Figure 2.7. Screenshot from the database used to record study identification details. 
 
Details about the animal model used within an experiment were also collected and 
recorded to include species, strain and sex, labelled as „unknown” if otherwise not 
specified. Age at the time of testing and weight of animals used was also recorded if 
it was reported, if not these fields were left blank. I also chose to record specific 
details about the method of model induction including type of model the model could 
be categorized as – this would be one of the following: pharmacological, 
developmental, lesion, genetic or a combination model. Other data that were 
extracted in this section were: details about the specific method used to induce the 
model; the site of this induction or injury; the dose or severity of the damage, where 
appropriate; details of the time and duration of administration, damage or exposure 





Figure 2.8. Screenshot from database detailing fields where data about animal model 
characteristics were entered. 
 
For developmental studies only (i.e. such as those inducing the animal model using 
isolation rearing), where other details such as husbandry and housing were 
important, additional fields were used to extract these data. Data were taken, where 
reported, detailing the conditions that experimental animals were placed in, such as 
diet, food availability, details about housing and conditions of laboratory used to 
keep animals as well as handling of animals (Figure 2.9). These were items that 
were based on a previous systematic review of animal models of neuropathic pain, 





Figure 2.9. Screenshot of database showing fields used to extract data about animal 
husbandry and housing for specific studies 
 
Multiple entries were created for studies where more than one model or more than 
one treatment drug had been tested. Data for each of these experiments were 
entered on different pages, but linked by the publication’s unique identifier. 
2.1.4.3 Extraction of outcome data 
All relevant comparisons of behavioural outcomes meeting the pre-specified 
inclusion and exclusion criteria were identified within each study. This meant that 
data were extracted separately for comparisons where variables such as age, sex 
and species of animals differed in the groups of animals being tested in an 
experiment. Data were also extracted separately for outcomes measured as a result 
of different treatment regimes. As many of the outcomes reported were measured 
over a period of time, where data were reported at multiple time points within the 
same group of animals over time, every single time point was taken, which would 
later be used to combine and calculate overall performance. 
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Characteristics of therapeutic interventions tested were extracted for studies that 
had looked at the effect of a treatment drug. These included the dose of the drug 
given, mode and time of delivery, frequency of administrations and the length of the 
treatment regimen. Details about the time taken between the recording of outcome 
measurements and treatment administration as well as time of outcome assessment 
relative to time of model induction, were also recorded (Figure 2.10). For studies 
characterising the model and not testing the effect of a treatment drug these fields 
were left blank. 
 
Figure 2.10. Screenshot of database where details about treatment tested and time of 
outcome assessment were recorded. 
 
In terms of outcome measurement details, the exact name of the outcome being 
measured, the method used to do this, or in other words the tools and way of 
measurement (e.g. count of beam breaks for locomotor activity), the units of 
measurement and whether the larger the numerical data recorded would indicate a 
better or worse outcome, were recorded. For later analysis, a note was also made of 
the number of experimental groups that were compared to the same cohort of 
control animals within an experiment, and for multiple measurements taken within 
the same experiment from the same cohort of animals, letters of the alphabet were 
used to identify different cohorts of animals (Figure 2.11). These data were 
important in order to avoid counting the same group of animals more than once at 




Figure 2.11. Screenshot of database showing fields where details of outcome 
measures would be recorded. 
 
For outcome measures of behaviour that required further information, this was 
extracted as additional information into a ‘user defined field’ (Figure 2.10). This was 
utilised mainly for experiments where pre-pulse inhibition (PPI) was measured, and 
we recorded details such as the strength of pre-pulse stimulus used, that were not 
otherwise a variable for other behavioural outcome measures. 
Within each of these comparisons for each outcome measure a mean, standard 
deviation or standard error of the mean and number of animals contributing to that 
mean (n) were extracted for both experimental and control groups. Where n 






Figure 2.12. Screenshot of database showing fields where specific outcome data 
measures from experiments were recorded. 
 
Preferably, these numerical data were extracted from the text of each publication, 
including cases where this was presented in a tabular format. In most cases, 
however, as results were presented graphically, Adobe Reader Measuring Tool in 
Adobe Acrobat XI was used to obtain numerical data needed for each comparison. It 
was decided early on that comparisons where data were unclear from graphs, 
authors would be contacted to clarify values and obtain correct data. In the absence 
of a response from these authors, data were excluded from further analysis. 
Unfortunately, where any of these data (mean, SD or SEM, n) were absent in a 
paper, that specific comparison had to be excluded from further analysis as it could 
not be included in the meta-analysis, however, these papers were retained in the 








I describe my methodological approach to the meta-analysis part of the project, 
based on the stages that normally follow the process of a meta-analysis. First, for 
each comparison, I calculated an effect size, which were then weighted and used to 
calculate a summary effect size. Finally, heterogeneity present in the data were 
calculated, to explore the impact of pre-defined study characteristics and how much 
of the heterogeneity can be attributed to any of these variables (Vesterinen et al., 
2014). 
 
2.2.1 Identification and definition of comparisons 
 
Studies characterising the model and those testing the effect of a drug in these 
models, were chosen to be analysed separately. Based on this a comparison was 
defined as a measure of neurobehavioural outcome in a group of animals that had 
been exposed to an intervention believed to induce an animal model of a human 
psychotic disorder, compared with a group of animals that had not been exposed to 
this intervention. Suitable controls in these comparisons were considered to be 
naïve animals for developmental and genetic studies, those that had been given 
sham surgery in the place of the lesion for lesion studies, and the administration of 
saline or another vehicle for pharmacological studies. Comparisons for studies 
testing the efficacy of a therapeutic intervention, were defined as a comparison of 
neurobehavioural outcomes measured in two different groups of animals that had 
been exposed to the same intervention to induce the model, but one had also been 
given a treatment drug to ameliorate behaviours, while the control group had not. 
Suitable control groups in this case for pharmacological studies included both those 
animals that had been given a vehicle as a treatment and non-treated animals. 
For analysis where data were reported from separate groups of animals, data 
collected from these groups were treated as independent comparisons and were 
included separately within the meta-analysis. Where more than one outcome 
measure was measured and reported for the same group of animals within a study, 
data were nested using the fixed effects model. This was considered separately for 
model-characterising comparisons and therapeutic drug comparisons. Where a 
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control group served multiple experimental groups within a study, the number of 
animals contributing to the meta-analysis was corrected for by dividing the number 
of animals that was reported by the number of experimental groups it had served.  
 
2.2.2 Individual comparison effect size estimate 
 
The data being extracted from publications included in the review were continuous 
data. These data required the extraction of a mean outcome of all animals in each 
group and its variance. Using these data it would have been possible to calculate an 
absolute difference in means, a normalised difference in means, or a standardised 
difference in means.  
An absolute difference in means (MD) allows for the simple calculation of the 
difference between the reported means of the two groups (control and treatment) 
within a comparison and its corresponding variance (equations 2.1,2.2, and 2.3) 
𝑀𝐷  = −     2.1 
Where 
 = sample mean of control group animals 
 = sample mean of treatment group animals 
 With Standard error calculated as: 
𝑆𝐸 =  
×
 𝑆      2.2   
Where  
𝑛  = number of animals in treatment group 
 𝑛  = true number of control animals (corrected for number of 
treatment  groups served by same control) 
𝑆 = the pooled standard deviation calculated 







With 𝑆  calculated as:  
𝑆 =  
( ) ( )
         2.3 
Where 
 𝑆𝐷  =reported standard deviations for control group (convert from 
standard error if necessary) 
𝑆𝐷  = reported standard deviations for treatment group (convert 
from standard error if necessary) 
I decided against using this method to estimate effect size for each comparison, 
because this method would have required my data being analysed to have come 
from the same outcome measure and be reported on the same scale across all my 
included studies. Considering the large differences in outcomes measured and the 
method used to do this across different studies, this would not have given a reliable 
effect size estimate. 
Normalised mean difference (NMD), an alternative method, is appropriate for data 
where the score of a normal, untreated or “sham” animal is already known or can be 
derived and therefore we can use this to express an absolute difference in means as 
a proportion of the mean in the control group (equations 2.4, 2.5 and 2.6)  
         
𝑁𝑀𝐷 =  
(  ) (  )
(   )
𝑥 100%    2.4 
Where 
  = sample mean of control group animals 
 = sample mean of treatment group animals 
 = sample mean of sham group 
 
 







Standard error calculated as: 
𝑆𝐸 =  ∗ + ∗     2.5 
Where  
𝑆𝐷 ∗= standard deviation of control group expressed as a 
percentage of the control group and normalised to the sham group 
value  
𝑆𝐷 ∗= standard deviation of treatment group expressed as a 
percentage of the control group and normalised to the sham group 
value (see below) 
Normalised standard deviations calculated as: 
𝑆𝐷 ∗ = 100% ×
  




𝑆𝐷  = reported standard deviation for control group 
𝑆𝐷  = reported standard deviation for treatment group 
It was decided right at the start of the project that where the performance of a naïve, 
unlesioned or wild-type animal could be inferred or was already known in at least 
80% of the experiments, NMD would be used to calculate individual effect size 
estimates as the primary outcome and standardised mean difference as a sensitivity 
analysis. If the performance of these animals was not known for more than 80% of 
the experiments then it was decided I would use NMD only as a sensitivity analysis 
and instead would use standardised mean difference meta-analysis as the primary 
outcome. 
Standardised mean difference (SMD) is mostly used where we do not know or 
cannot infer how a naïve animal would perform. This is especially relevant for some 
of our data where spontaneous locomotor activity would be measured in a group of 
animals as a neurobehavioural outcome. This method calculates a difference 
between the means of each group and divides this by a pooled variance. This allows 
x x x x
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for all outcome measures to be changed so they now are on a standardised scale 
with units given in standard deviations (SDs)(equations 2.7 and 2.8).  
𝑆𝑀𝐷 =  
( )
× 1 − × 𝑑𝑖𝑟𝑒𝑐𝑡𝑖𝑜𝑛   2.7 
Where 
 𝑆 = the pooled standard deviation calculated as before 
Direction = correction factor used to define the direction of the 
effect size 
 





                2.8 
 
This approach is helpful for analysis of data where performance for the same 
outcome reported are on different measurement scales. This is especially important 
for experiments where locomotor activity is being assessed as this can be recorded 
by counting number of beam breaks, analysing distance travelled over a period of 
time or number of runs, etc. 
Hedge’s G was used to calculate standardised mean difference, where appropriate. 
The reason for using this method was because this equation corrects for bias 
introduced by small sample sizes. This is especially relevant as animal studies in 
general and thus many experiments included in this review include small samples of 
animals in each of their groups (“small sample” defined here as less than 10 animals 
per group). Importantly though, here we had to take into account the direction of the 
effect (whether a higher score represents a better or worse outcome) and so this 
direction of effect was recorded at time of data extraction and later used to adjust 





2.2.3 Weighted and pooling of effect sizes to give summary effect size 
 
Since this review combined multiple studies of various precision, a weighted mean 
was calculated for each comparison, before all the data could be pooled. This was 
essential for the estimation of the overall effect size as this would allow for the 
studies that were more precise to carry more weight in their contribution to the final 
estimated combined effect, than those that were less precise and thus carried less 
information. The calculation of the distribution of effect sizes from individual 
comparisons had an estimated summary estimate (the weighted mean), an estimate 
of heterogeneity (the weighted sum of the deviations from this mean squared) and 
finally a measurement called tau-squared to represent the estimate of the variation 
between observed effects across different studies beyond that which we would 
expect to be explainable by random sampling error. 
For computing a pooled effect size there are two models available in meta-analysis 
– the fixed effects model and the random effects model.  
Using the fixed effect model we assume that there is a single true effect size where 
different studies give an estimate of the same effect. This makes the combined 
effect an estimate of the common effect size, where individual observed effect sizes 
deviate from this true effect simply as a result of random sampling error. Here I 
would have calculated the weight of each comparison using the inverse variance 
method, where each individual effect size would be multiplied by the inverse of their 
standard error (SE) squared (equation 2.9).  
Weight of each study under the fixed effects model: 
𝑊 =                                2.9 
Therefore weighted effect size under fixed effects model is: 
𝑊 𝐸𝑆 =  𝐸𝑆 ×    2.10 
Then individual effect sizes are multiplied by their attributed weight (equation 2.10, 
above), and the sum of these calculations is divided by the sum of the weights 
alone, to give us a summary effect estimate (equations 2.11, 2.12, and 2.13). 
𝐸𝑆 =  
∑ ∗
∑ ∗
    2.11 
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Where 𝐸𝑆  = effect size estimate for each individual study 
 𝑊∗ = calculated weight for each study, so that 
𝑊∗𝐸𝑆  = weighted effect size estimate for each individual 
study 
With standard error calculated as: 
𝑆𝐸 =  
∑ ∗
    2.12 
And 95% Confidence intervals as: 
95% 𝐶𝐼 =  𝐸𝑆  ± 1.95996 × 𝑆𝐸    2.13 
Under the random effects model we expect the true effect to vary between different 
studies as a consequence of varying study characteristics used in different 
experiments (i.e. an array of different drug doses, animal species, or methods of 
model induction used). Therefore, the combined effect will represent the mean of the 
population of true effects and will take into consideration both the sampling error we 
consider in the fixed-effects meta-analysis (within study variance), as well as 
differences in true effect sizes between studies (between-study variance). For this 
reason when weighing studies under this model, the inverse of the sum of within 
study variance has to be used (inverse variance calculation as before) and also Tau-
squared (τ2), which is a measure of excess-between study variation (equations 2.14, 
2.15, 2.16, 2.17, 2.18 and 2.19). τ2 is estimated using the method of moments 
(DerSimonian and Laird, 1986).  
Weight of each study under random effects model: 
𝑊∗ =  
( )
     2.14 
Where tau is estimated using the equation: 
𝜏 =       2.15 
Where  𝜏  = estimation of between-study variance 
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𝑄 = sum of the squared differences in effect sizes between 
studies and the pooled effect size (see equation 2.20 further 
below) 
𝑑𝑓 = degrees of freedom calculated by taking number of 
components in the strata and detracting 1 
𝐶 = measure used to convert the heterogeneity value into an 
average and put the value back into original units 
 
Therefore, weighted effect size under the random effects model: 
𝐸𝑆∗ =  𝐸𝑆 × 𝑊∗                  2.16 
Once studies have been weighted, I could calculate a random effects estimate of the 
combined effect (equation 2.13, 2.14, 2.15) 
𝐸𝑆 =  
∑ ∗
∑ ∗
      2.17 
With standard error calculated as: 
𝑆𝐸 =  
∑ ∗
       2.18 
And 95% Confidence intervals same as before: 
95% 𝐶𝐼 =  𝐸𝑆  ± 1.95996 × 𝑆𝐸        2.19 
I used the fixed-effects meta-analysis to combine multiple outcomes from the same 
experimental cohorts as here performance would be obtained from the same 
population of animals. For the overall statistical model of analysis when it came to 
estimating the combined effect, I used the random-effects model of analysis as there 






2.2.4 Assessing for heterogeneity 
 
Considering the large amount of heterogeneity across studies included in my review 
with respect to experimental design, I thought it would be interesting to know 
whether any differences between groups such as certain study characteristics 
influenced reported outcome. To assess heterogeneity Cochran’s Q and I2 was 
calculated.  
Cochran’s 𝑄 is the estimate of between study heterogeneity and is calculated as the 
weighted sum of differences between individual effect sizes and the pooled effect 
across studies under the fixed effects model squared (equation 2.20).  
𝑄 =  ∑ 𝑊∗ × (𝐸𝑆 − 𝐸𝑆 )2   2.20  
Where 𝑊∗ = calculated as before in equation 2.9 
The values of 𝑄 follow a chi-squared distribution under the assumption that if studies 
come from the same population of studies measuring the same thing, then any 
heterogeneity we see is a result of sampling error and 𝑄 will equal the degrees of 
freedom. 𝑄 is sensitive to the number of comparisons, so that it has a low power of 
test of heterogeneity when the number of comparisons is small, and too much power 
when there are a large number of comparisons. 
I also calculated I2, a statistic that estimates what proportion of the variation across 
different studies can be attributable to heterogeneity (i.e. true differences in effect 
sizes) and not chance (equation 2.21). This value is not sensitive to the number of 
comparisons used within a meta-analysis. The estimate of this value can help to 
decide whether fixed or random effects model of meta-analysis should be used. 
While this is subjective, it was decided based on a previous review (Vesterinen et 
al., 2015) that the random effects model of meta-analysis would be used where I2 
values were above 50% and thus interpreted as moderate or high heterogeneity. 





2.2.5 Exploring sources of heterogeneity 
 
Stratified meta-analysis builds on the assumption that studies which share certain 
characteristics will be similar in terms of outcome than those which do not share 
these characteristics. So heterogeneity is partitioned into these groups of studies 
that are similar and between groups of studies. For each strata I would calculate a 
random effects size and Cochran’s Q, which denotes the heterogeneity. These 
heterogeneity statistics are then summed and deducted from the total heterogeneity 
to give an estimate of the remaining heterogeneity that we assume comes from the 
differences between groups. We can test the significance of differences between Q 
and the variation we would have expected to see if the studies were from the same 
population of studies using the chi squared distribution (equation 2.22). 
𝑝 = 𝐶𝐻𝐼𝐷𝐼𝑆𝑇 𝑄 − 𝑠𝑢𝑚(𝑄 ) , 𝑑𝑓)  2.22 
Where 𝑄  = amount of heterogeneity for the global estimate of 
effect size 
𝑄  = amount of heterogeneity within components of the 
strata 
𝑑𝑓 = degrees of freedom calculated by taking number of 
components in the strata and detracting 1 
Meta-regression, takes this approach further and allows the effects of continuous 
and categorical characteristics to be investigated, where also more than one study 
characteristic can be taken into account at a time (i.e. multi-variate analysis). This 
method can tell us more about the data than stratified meta-analysis as it takes into 
account both within- and between- study variance. The only limitation is that this 
method requires a large number of studies for the analysis to be meaningful. Meta-
regression is a form of weighted linear regression, where we measure the 
relationship between a dependent outcome variable (our effect estimate) and one or 
more independent explanatory variable (study characteristics). Therefore, we need 





 If we can presume that the explanatory variable we are interested in is attributable 
for all the heterogeneity observed between studies, then a fixed-effects meta-
regression is appropriate, as this model does not allow for between study variation. 
Usually, however, it is more suitable to use random effects meta-regression, which 
allows for extra heterogeneity among the effects that cannot be explained by 
covariates and therefore both within study and between study variation. 
Where appropriate and data were sufficient (i.e. over 25 comparisons included in the 
meta-analysis), univariate meta-regression was performed to investigate potential 
sources of heterogeneity. This was decided on in the context that recent research 
shows that both univariate and multivariate regression are more reliable at detecting 
an effect of a variable of interest than stratified meta-analysis – which is shown to 
have substantial false positive rate with NMD estimates and low statistical power 
with SMD estimates of effect size (Wang et al., 2018). In the current review I 
describe heterogeneity using tau2 (estimation of excess between-study variance), 
residual I2 (the percentage of residual variation explained by between-study 
heterogeneity) and adjusted R2 (adj R2; the proportion of between-study variance 
explained by the model). Statistical analyses were performed using code written in R 
for combining data and Shiny Meta-analysis application 
(https://qianying.shinyapps.io/Multi/) for meta-analysis and meta-regression. I use 
meta-regression to investigate possible sources of heterogeneity including 
components of study quality and methodological criteria checklist and study design 
characteristics. I examined different study characteristic subgroups as potential 
sources of heterogeneity for model-characterising and treatment exploring studies 




Table 2.1 Variables of interest in exploring sources of heterogeneity for model-
characterising and treatment exploring studies 
MODEL-CHARACTERISING STUDIES TREATMENT EXPLORING STUDIES 
Species of animals used Species of animals used 
Gender of animals used Gender of animals used 
Specific intervention used to induce model Specific intervention used to induce model 
For schizophrenia models: Method of model 
induction (i.e. developmental, genetic, 
pharmacological, lesion or combination) 
For schizophrenia models: Method of model 
induction (i.e. developmental, genetic, 
pharmacological, lesion or combination) 
Extent of lesion/dose of drug used to induce 
model 
Extent of lesion/dose of drug used to induce 
model 
Outcome being measured Outcome being measured 
Exact methods used to assess outcome 
measure 
Exact methods used to assess outcome 
measure 
Time of outcome measurement (in relation 
to model induction) 
Time of outcome measurement (in relation 
to model induction and/or treatment 
administration) 
 Treatment given 
 Dose of treatment given 
 Time of administration 
 
2.2.6 Bonferroni correction 
 
The Holm-Bonferroni method was used to adjust significant values of p. This was 
necessary, because there were multiple comparisons when assessing differences 
between subgroups during the partitioning of studies according to certain study 
characteristics. Study characteristics were grouped separately for those that could 
be classed as experimental quality items and those that explored study design 




2.3 Publication Bias 
 
To see whether the potential unavailability of some research results could have 
skewed our perception of the research field, three different analyses were performed 
to assess for publication bias. This would appraise the extent to which the published 
literature used for the basis of my conclusions, was representative of the population 
of completed studies. This issue of publication bias widely affects all areas of 
research including pre-clinical studies (ter Riet et al., 2012), where these issues can 
lead to an overstatement of effects within studies (Sena et al., 2010). 
Risk of publication bias was evaluated using funnel plot assessment and Egger’s 
regression. I then used trim-and-fill analysis using STATA to identify possible 
missing studies in the literature. These evaluations were conducted independently 
for each outcome measure using non-nested data, to avoid suppressing any studies 
during analysis that might have contributed comparisons where different outcome 
measures were reported from the same cohort of animals. I was aware at the time of 
performance, that these analyses rarely take into account reasons for asymmetry 
seen in the literature other than publication bias and can be affected heavily by 
increasing between-study heterogeneity. 
2.3.1 Funnel plotting 
 
Funnel plotting uses a simple scatter plot of the relationship between calculated 
effect sizes plotted on the X-axis against a study’s precision on the Y-axis, to allow 
visual assessment of the potential presence of publication bias. While in systematic 
reviews it has been common practice to calculate precision as the inverse of the 
variance for a study (Vesterinen et al., 2014), in light of recent research that has 
been published I chose to use 1/√n to calculate precision. It has been shown that 
with the use of SMD when an effect is present within a meta-analysis there is a risk 
for substantial distortion in the estimation of asymmetry when plotting SMD against 
standard error. It is suggested that for estimation of publication bias for studies of 
small sizes such as preclinical studies, a sample size-based precision estimate is 
more suitable (Zwetsloot et al., 2017). 
 
Funnel plots build on the idea that precision of a study increases as the size of the 
study increases and as a result we see the smaller studies scattered widely on the 
bottom of the graph, with the larger studies less widely dispersed towards the top of 
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the graph. If there is no sign of publication bias a symmetrical, inverted funnel shape 
is expected to be created by the data points centred on the global estimate of overall 
estimate. If the graph is asymmetrical it can be concluded that publication bias was 
likely and the more notable this asymmetry, the more likely that I could expect a 
significant extent of publication bias (Higgins and Green, 2008). 
2.3.2 Egger regression 
 
Egger regression builds on the expectation that publication bias is more likely to 
affect small studies and these are likely to be of lower quality and show larger 
intervention effects. If this is not true then the effect sizes in a meta-analysis should 
vary due to random error more for small studies and less so with bigger studies 
(Egger et al., 1997). For this approach, I plotted a linear regression of normalized 
effect estimates (effect sizes divided by their standard error) on the Y-axis against 
precision (1/√n) on the X-axis. Whether the regression line crossed the origin was 
then visually assessed. Presence of publication bias was concluded if it did not. 
Results were reviewed with the knowledge that this method has a low power for 
detecting bias in studies of a small sample size, something that is common in pre-
clinical studies (Vesterinen et al., 2014).  
2.3.3 Trim and fill 
 
The trim and fill method was used to both identify and to correct for potentially 
missing studies in the literature, using funnel plot asymmetry arising from publication 
bias. The method first ‘trims’ small studies from the funnel plot that cause the 
asymmetry. Secondly, using the funnel plot of remaining studies, it estimates a ‘true’ 
centre of the funnel. Finally it replaces the trimmed studies and fills in areas around 
the centre where potential studies could be missing. This therefore not only gave me 
an estimate of the number of potentially missing studies, but it also gave me an 
adjusted effect size estimate, by including filled in studies in a meta-analysis. 
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3 Systematic Search Results and Characterization of the 
Literature 
3.1 Introduction 
Before we can begin to improve something, there needs to be some level of clarity 
over what that something is and what it is aiming to do. It is very difficult to solve a 
problem if you do not understand what the problem is in the first place. In order to 
see whether changes are making a difference we have to quantify the field 
somehow.  
The motivation behind performing a systematic search was the desire to summarise 
the field of pre-clinical psychosis research in a way that allows for an unbiased, 
categorized and complete collection of the published literature. The search 
performed was a shallow, but broad overview aiming to quantify animal studies 
related to psychosis and psychotic conditions.  
First, I wanted to categorise studies according to the experimental design used to 
investigate these conditions in animals by looking at the way they induced their 
models, how they quantified these models and if they had tried to ameliorate the 
effects created in these models at all using an additional intervention. This catalogue 
of the literature in theory would give us a snapshot of the literature as it stands. I 
then wanted to explore this catalogue further to see how variables changed in 
relation to one another and whether there were any obvious gaps in this picture. 
In this chapter, I describe the results of phase I and II of the project, corresponding 
to results of the screening and categorization phases, respectively. Here I describe 
both the results of this systematic search and comment on observations that I had 
made during the recording of these variables. 
3.2 Methods 
I would like to acknowledge the following people for helping with screening of 
studies: Cristina Nunes-Fonseca (CF) for being my second screener and Hanna 
Vesterinen (HV) for third screening any disagreements. I would also like to 
acknowledge Angus Sinclair (AS) and Alexandra Bannach-Brown (ABB) for their 
help with categorization of a subset of the studies included. 
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Methods are described in detail in the previous chapter, Chapter 2. Results are 
described here primarily from Phase I of the project, which involved performing an 
electronic search of the literature and having two independent investigators screen 
these identified studies for relevance based on their title and abstract. I also include 
data collected as part of Phase II of the project, where included studies from Phase I 
were screened for a second time at full-text level for categorisation according to 
methods used for model induction, outcomes measures within experimental designs 
and treatment administered, if any given.  
3.3 Results 
3.3.1 Phase I. Search of the literature 
The search performed in PubMed identified 14,721 publications (Figure 3.13.2, all 
data is available through request at https://doi.org/10.5281/zenodo.1209832). Two 
independent investigators double screened all publications. Using phase I inclusion 
and exclusion criteria 3461 publications were agreed to have potential relevance by 
both screeners. A remaining 9625 studies were agreed to be excluded by both 
investigators at this stage of the project. 1436 studies had to be refereed by a third 
investigator due to disagreements between screener 1 and 2. Of this, 874 were 
concluded to be of relevance. 199 search results were excluded from any further 
stages of the project, as no abstracts could be obtained. 4335 publications 
advanced further into phase II of the project.  
Categorization of studies at an abstract level identified 89% of studies included in 
this initial phase of the project reporting to be modelling schizophrenia in their 
animal experimental paradigms (Figure 3.23.1). Other publications referred to the 
modelling of substance-induced psychotic disorders or psychotic disorders due to a 
medical condition in the literature. 4% of publications did not specify a condition their 






Figure 3.13.2Flow diagram of publication inclusion 
Figure 3.23.1Phase I categorisation of studies at abstract level 
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3.3.2 Phase II. Categorisation of studies of relevance 
3.3.2.1 Summary of experimental design after categorisation of literature 
During phase II of the project, a further 451 publications were excluded for not 
meeting the inclusions criteria that were pre-specified. 37 publications were 
categorised as potentially being of relevance, however, in a foreign language, which 
could not be translated and therefore were excluded from further stages of the 
project. 3847 studies were included in phase II of the project and fully categorised. 
Categorisation of each of these studies included recording information about 
experimental approaches used to establish the model of interest, outcomes 
measured and used to assess animal models with, and treatment, if any, 
administered in an effort to alleviate the model. I describe these in more detail 
below. In addition, studies were also categorised according to the reporting of a list 
of criteria describing risk of bias and other methodological quality items. The results 
of this categorization are presented in Chapter 6. 
3.3.2.1.1 Experimental approaches to modelling 
Experiments describing animal models of psychotic disorders were broadly 
clustered into the four different groups mentioned in the literature: pharmacological-, 
genetic-, developmental- and lesion-induced models (Jones et al., 2011). Studies 
reported using one or a combination of these methods for model induction. The 
lesion group encapsulated models using high frequency stimulation, temporary 
inactivation and full lesions. For methods used, which did not quite fit into any of 
these four categories, I created additional categories. I created a category labelled 
„Environmental” to describe interventions that I considered environmental triggers in 
humans, as opposed to pathologic risk factors. This category mainly involved 
various forms of inducing stress in mature animals. As predominantly it is thought 
that schizophrenia is an early neurodevelopmental disorder (Corcoran et al., 2002), I 
considered environmental influences in later life as being different to those applied 
during early development of the animal. Examples of this latter method were 
categorised as developmental animal models instead. I only considered 
‘environmental’ inductions to be a valid animal model if they had been combined 
with another method of model induction. Similar to this, ’Adjunctive’ models included 
interventions that by themselves would not be sufficient to induce an animal model 
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of psychosis, however, when given supplementary to another intervention such as a 
pharmacological intervention, it could be considered a valid model. 
Further additional categories were modelled on classifications presented in ICD-10 
and DSM-5, namely substance-induced psychotic disorder, medication-induced 
psychotic disorder and psychotic disorder due to another medical condition. Those 
initially categorised as animal models of substance-induced psychotic disorder were 
eventually combined with other pharmacological models as many pharmacological 
models of schizophrenia are also considered to be substances of abuse in humans 
(Steeds et al., 2015). The final two categories were labelled as ’puerperal psychosis’ 
and ’menstrual psychosis’, neither of which are officially recognised by current 
psychiatric nosology, however, these were described in the literature as separate 
entities and therefore categorised here as such. Of course, publications often 
reported on more than one of these models within the same study, and therefore all 
possible reports of a model were recorded. 762 studies (20% of all included studies) 
reported combining some of these models to measure their effects in animals, and 
these I regarded as combination models in later stages of the project. 
Through this broad grouping of induction methods it is very clear that the models 
most often reported in the literature were pharmacologically induced (Table 3.1). 
The most common method of inducing a model was through the administration of a 
pharmacological agent. There were 4517 reports of pharmacological intervention 
Induction category
Number of times 
reported in the 
literature







Observational or Trained 68 1.0%
Psychotic Disorder Due to 
Another Medical Condition 29 0.4%




Puerperal psychosis 1 0.01%
Table 3.1 Prevalence of model induction method used to induce 
animal model of psychosis reported in the literature 
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used in the literature, accounting for  67.4% of all methods reported in the literature. 
Lesion studies were the least widely reported animal models of schizophrenia in the 
literature out of the original main four categories for models of schizophrenia.  
I wondered if these observations might be explained by these models having been 
used for longer than other model induction methods. When looking at changes in 
reporting over time, data indicates that pharmacological models have predominated 
the pre-clinical research field of psychotic disorders (Figure 3.3). While in recent 
years the use of genetic and developmental models has increased, pharmacological 
manipulations have continued to be at the forefront of research ahead of all of the 
other models reported in the literature. 
Overall, through categorisation of the literature I found 852 different ways reported 
to induce or potentiate animal models of psychotic disorders (see Appendix II. 
Results of categorisation of the literature: Complete list of model induction methods 
used, behavioural outcomes measured, and treatment compounds tested). 
Pharmacological models accounted for the largest proportion of these models 
(Table 3.2). In total 309 different pharmacological models were recorded to be 
reported in the literature. This was followed by 292 different genetic interventions 
and 129 different ways of inducing developmental animal models of schizophrenia. 
Many of the individual methods used to create these models were reported in the 








Figure 3.3 Prevalence of types of model induction methods reported in the literature over time 
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Due to Another 









Puerperal psychosis 1 0.1%
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As mentioned, many pharmacologically induced animal models of psychosis used 
substances of abuse and therefore could also be classed as substance-induced 
psychotic disorder (Figure 3.4). 
Figure 3.4 Top 15 interventions used to induce an animal model of psychosis 
pharmacologically  
Numbers in brackets show the number of publications reporting these models in the 
collated literature. 
Genetic models were the second most widely reported group of methods used to 
induce animal models of psychosis in the literature. The number of different genetic 
manipulations to create these animal models was high and accounted for about a 
third of all models in the final list (Figure 3.5).  
Figure 3.5 Top 15 genetic manipulations used to induce an animal model of psychosis 





Developmental models were almost as widely reported as genetic models in the 
literature, however, the number of actual models within this group was much less. 
This group mainly involved pre- and postnatal infections of pups as well other early 
disruptions to development, including obstetric complications and early damage to 
the brain (Figure 3.6). 
Figure 3.6 Top 15 interventions used to induce a developmental animal model of 
psychosis 











Lesion models were far less widely reported in the literature compared to the other 
main groups of induction methods. Lesions in this category were mostly introduced 
in adulthood, as any lesions given at a young age were categorised as 
developmental animal models. 
Figure 3.7 15 most widely reported lesion models in the preclinical psychosis field 
Numbers in brackets show the number of publications reporting these models in the 
collated literature. 
 
3.3.3 Outcome measures reported in the literature 
Categorising studies according to type of outcome they were measuring revealed 
that most studies reported behavioural outcomes. In total, 2951 studies (77%) 
reported measuring effects on behaviour, 358 studies (9%) reported anatomical 
outcomes, 476 studies (12%) reported electrophysiological and 1601 studies (42%) 
reported neurochemical outcomes.  
Behavioural measurements were further classed according to the test that was 
being used, the corresponding behaviour this test was thought to measure in the 
animals and the human behaviours that these animal behaviours are thought to 





The most common human symptoms to be modelled in animals were psychomotor 
agitation, anxiety and sensorimotor gating. Psychomotor agitation was based on 
measurements of animal behaviours such as locomotor performance and 
stereotyped behaviour and was reported in 2488 publications (84% of all studies) 
(Table 3.3). Other widely reported measures included measures relevant to negative 
symptoms such as anxiety-like behaviour in animals, and behaviours of relevance to 
cognitive deficits such as learning and memory and, in some ways, sensorimotor 
gating. 




Category of Human Behaviour thought to 
be measured





Psychomotor agitation Motor performance, Stereotyped behaviour 2488
Anxiety Anxiety-like behaviour 1455
Sensorimotor gating Latent inhibition, Sensory gating 1227
Learning and Memory
Affective learning, Associative learning, Attention and Memory, 
Avoidance Learning,  Discrimination learning and memory, Latent 
learning, Long-term memory, Reference Memory, Working 
memory, State-dependent retention, Relational memory
1165
Social behaviour Social behaviour 451
Depression Behavioural despair 148
Attention Attention 120
Executive functioning Cognitive flexibility, Problem-solving 91
Motor Co-ordination Motor co-ordination 88
Pain sensitivity Nociception 77
Avolition Motivation, Reward-seeking behaviour 59
Anhedonia Hedonic reaction to reward, Reward sensitivity 35
Impulsivity Avoidance behaviour, Decision-making, Impulsivity, Risk taking 33
Hallucination Hallucinatory-like behaviour 32
Other general abnormal behaviours Natural behaviours 27
Aggression Aggression 19
Olfactory dysfunction Odour discrimination, Olfaction 17
Brain lateralization Functional brain asymmetry 16
Psychotic polydipsia Polydipsia 15
Empathy (evolutionary precursor) D2 receptor priming 11
Interval timing Timing 11
Tardive dyskinesia Spontaneous orofacial movements 10
Insomnia Sleep-wake pattern 7
Mother-infant interaction Mother-infant interaction 6
Central nervous system and dopaminergic 
activity
Central nervous system and dopaminergic activity 3
Communication deficits Communication 3
Epileptic-like outcome Epileptic-like outcome 3
Human laughter Positive affect 3
Discriminative stimulus properties of drugs Discriminative stimulus properties of drugs 2
Sensitivity to cannabinoids Sensitivity to cannabinoids 2
Taste sensitivity Taste sensitivity 2
Activation of the opioid receptor system Activation of the opioid receptor system 1
Catatonia Catatonia 1
Perseveration Perseverative behavior 1
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Furthermore, data shows that this measure of behaviour has continuously 
dominated the pre-clinical research field among all other measures of behaviour in 
animal models of psychotic disorder over the years (Figure 3.8). 
 
In total 336 different behavioural outcome tests were recorded to be reported in the 
literature. Figure 3.9 shows the 10 most commonly reported tests in the literature to 
measure psychomotor agitation (for the full list of behaviours, see Appendix II. 
Results of categorisation of the literature: Complete list of model induction methods 
used, behavioural outcomes measured, and treatment compounds tested). These 




Figure 3.8 Prevalence of human behaviours of relevance to outcomes being 




Figure 3.9 10 most commonly reported measures of animal behaviour of relevance to 
psychomotor agitation 
Numbers in brackets show the number of publications reporting these measures in 
the collated literature. 
Anxiety-like behaviour was the second most widely reported measure in the 
literature.   
Figure 3.10 shows the 10 most commonly reported tests in the literature to measure 
this form of behaviour.  
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Figure 3.10 10 most commonly reported anxiety-like behaviours in the preclinical 
literature 
Numbers in brackets show the number of publications reporting these measures in 
the collated literature. 
Deficits in sensorimotor gating was mainly measured through pre-pulse inhibition, 
but also some other tests. Figure 3.11 shows the 10 most commonly reported tests 
in the literature to measure this form of behaviour. 
Figure 3.11 10 most commonly reported behavioural measures in animal models of 
psychosis of relevance to sensorimotor gating 
Numbers in brackets show the number of publications reporting these measures in 
the collated literature. 
Finally, disrupted learning and memory in animal models of psychosis was 
measured using a wide variety of different tests. Figure 3.12 shows the 10 most 
commonly reported tests in the literature to measure this form of behaviour. Many of 
these tests were described in different ways, however, could have been otherwise 
different versions of the same test.  
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Figure 3.12 10 most commonly reported behavioural measurements in animal models 
of psychosis of relevance to deficits in learning and memory 
Numbers in brackets show the number of publications reporting these measures in 
the collated literature. 
 
3.3.4 Treatments reported in the literature 
I also included experiments in my review that looked at the effects of treatment 
drugs in these animal models. In total 1796 studies (47% of all studies) were 
categorized to have reported testing the effects of a drug in an animal model of a 
psychotic disorder. This identified a total of 946 different compounds in the literature 
as having been tested in animal models of schizophrenia. 
The most commonly reported therapeutic agents in the literature are mainly 
understood to exert their effect on dopaminergic pathways in the brain and included 
many currently licensed antipsychotics (Table 3.4- showing top 25, for a full list of 
treatments see Appendix II. Results of categorisation of the literature: Complete list 
of model induction methods used, behavioural outcomes measured, and treatment 
compounds teste). Other pathways often targeted in the brain included modulations 




Table 3.4 25 most commonly reported treatments tested in animal models of 
psychosis in the literature 
Drugs thought to modulate the dopamine system were most commonly reported in 
the literature. Figure 3.13 shows the 15 most commonly reported drugs acting on 
this neurotransmitter. 
Figure 3.13 15 most widely reported dopaminergic treatment drugs in the literature 
Numbers in brackets show the number of publications reporting these treatments in 
the collated literature. 
Drug Mechanism of action System affected
Number of 
publications
Haloperidol Dopamine D2 receptor antagonist Dopamine 586
Clozapine Serotonin 5-HT2A/2C receptor antagonist and dopamine D2/D4 receptor antagonist Dopamine and Serotonin 464
Risperidone Dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist Dopamine and Serotonin 168
Olanzapine
Dopamine D2/D3/D4 receptor antagonist, serotonin 5-HT2A/5-HT2B/5-HT2C/5-HT6 




SCH23390 Dopamine D1 receptor antagonist Dopamine 69
Chlorpromazine Dopamine D2 receptor antagonist Dopamine 64
Sulpiride Dopamine D2 and D3 receptor antagonist Dopamine 48
Raclopride Dopamine D2/3 antagonist Dopamine 44
MDL 100907/M100907 Serotonin 5-HT2A receptor antagonist Serotonin 44
Nicotine Nicotinic acetylcholine receptor agonist Cholinergic 42
Aripiprazole
Serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist and 
dopamine D2/D3 receptor agonist
Dopamine and Serotonin 42
Quetiapine
Serotonin 5-HT1A /5-HT2 receptor antagonist, dopamine D1/D2 receptor antagonist, 
also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors
Dopamine and Serotonin 39
Diazepam GABA A receptor antagonist GABA 39
SR141716/Rimonabant Cannabinoid CB1 receptor antagonist Cannabinoid 30
LY379268 Glutamate mGluR 2/3 receptor agonist Glutamate 27
D-Serine Co-agonist of glutamate NMDA receptor Glutamate 26
Ritanserin Serotonin 5-HT2 receptor antagonist Serotonin 25
Ketanserin Serotonin 5-HT2 receptor antagonist Serotonin 25
WAY 100635 Serotonin 5-HT1A receptor antagonist Serotonin 25
Prazosin Adrenergic alpha-1 adrenoceptor antagonist Noradrenaline 22
8-OH-DPAT Serotonin 5-HT1A receptor agonist Serotonin 21
Ziprasidone Dopamine D2 receptor agonist and serotonin 5-HT2 receptor antagonist Dopamine and Serotonin 21
Fluoxetine Selective serotonin reuptake inhibitor Serotonin 21
LY354740 Glutamate mGlu2/3 receptor agonist Glutamate 20
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Modulation of serotonin was also popular in the field as a number of drugs 
administered as therapeutic compounds are thought to exert their action on 
serotonin receptors. Figure 3.14 shows the 15 most commonly reported drugs acting 
on this neurotransmitter. 
Finally, glutamate is another widely studied pathway in animal models of psychosis 
and Figure 3.15 shows the 15 most commonly reported drugs acting on this 
neurotransmitter. 
Figure 3.15 15 most widely reported glutamatergic treatment drugs in the literature 
Numbers in brackets show the number of publications reporting these treatments in 
the collated literature. 
Figure 3.14 15 most widely reported serotonergic drugs treatment drugs in the 
literature 
Numbers in brackets show the number of publications reporting these treatments in 
the collated literature. 
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In total 734 treatments (76%) were categorized as having been reported a twice or 
less, with 587 of these reported only once (62% of total treatments reported).  
3.4 Discussion 
A broad search of the literature identified a substantial amount of studies of potential 
relevance to animal models of psychosis and psychotic disorders. The 29% of 
publications included to be of relevance after the second phase of full-text screening 
was higher than initially expected, however, likely a result of the broad 
inclusion/exclusion criteria. On this initial screening of identified studies at an 
abstract level we categorised publications to be overwhelmingly reporting animal 
experiments of relevance to schizophrenia. Very few studies could be classed as 
anything other than this. 
3.4.1 Methods used to induce the model 
Through categorization of publications in phase II of the project, over 800 different 
inductions were recorded to be reported as of relevance to psychosis or more 
specifically schizophrenia. This number is volumes bigger than what is normally 
referenced in the literature in reviews of animal models of schizophrenia. A 
summary resource published by the Schizophrenia Research forum that aims to 
provide a comprehensive list of animal models used for research in schizophrenia, 
referenced 149 different models (Koenig, 2014).  
This substantial difference might be explained by the approach of this review when 
categorizing models. As a broad review I wanted to capture the field as it is and 
portray it without any subjective selection bias on my part. As a result the 
compilation presented here is a list of all animal interventions that have been 
reported in the literature to bear relevance to a psychotic disorder (in most cases 
schizophrenia) in the clinic. Arguably perhaps some of the models identified here 
would not be classed as classical models of schizophrenia per se, but of course this 
interpretation is subjective and there are no pre-defined criteria on this (Nestler and 
Hyman, 2010). Of course animal modelling for psychiatric disorders is especially 
challenging because the boundaries between different disorders especially their 
clinical profiles are often hazy and subjective (Hyman, 2010). Moreover, due to our 
limited understanding of these disorders in terms of pathophysiology, a lack of valid 
biomarkers and objective diagnostic tests, it is difficult to create true models of these 
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human disorders. Nevertheless, in the literature it is a common acceptance that 
animal models of schizophrenia are unlikely to and therefore are not required to 
model the entire spectrum of symptoms associated with the disorder to be classed 
as a valid animal model of schizophrenia (Fernando and Robbins, 2011). As a result 
authors often refer to their animals as models of schizophrenia even when they are 
simply assessing for signs believed to be representative of the positive symptoms in 
schizophrenia.  In fact it is recognised in the literature that an animal model of 
schizophrenia can be used for the purpose of further understanding a specific 
aspect of the disease, further exploring the validity of risk factors or for testing the 
efficacy of potential therapeutic drugs (Moore, 2010). For these reasons I did not 
exclude any models reported to be of relevance in the field. Unfortunately this 
relaxed approach to modelling also means that some animal models identified here 
might not be specific to schizophrenia and experimental setups might have 
relevance to other psychiatric disorders of similar etiology, genetic risk or clinical 
profiles (Doherty and Owen, 2014). This supports the belief held by some 
researchers in the field that a lack of progress in psychiatric research thus far can 
likely be attributed, at least in part, to current polythetic – categorical classification 
systems (Hengartner and Lehmann, 2017).  In fact, it was often observed that a 
publication would report an experimental model setup as being of relevance to 
multiple psychiatric disorders, one of them being a psychotic one. How differential 
labelling of studies being of relevance to multiple disorders affects the field and 
conclusions drawn in reviews as this one, I discuss later in Chapter 7. 
3.4.1.1 Pharmacological models 
Overall, most models recorded could be classed as pharmacological interventions 
and these were also the most widely reported group of models in the literature. A lot 
of models of substance-induced psychosis fell into this category as many stimulant 
drugs are used to induce animal models of relevance to schizophrenia (Steeds et 
al., 2015). Data collected here shows that these models have predominated the 
preclinical research field since the 1950s. The popularity of pharmacological 
methods to induce animal models of schizophrenia stems from early observations 
by Young and Scoville in 1938 that psychostimulants like amphetamines can induce 
a psychotic-like disorder in humans (Potvin et al., 2005). These animal models are 
based on our understanding of how different neurotransmitter systems may be 
affected in schizophrenia and therefore are thought to have good construct validity 
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for the disorder (Marcotte et al., 2001), despite the fact our understanding of the 
underlying biology is still very much limited. Due to the schizophrenic-like symptoms 
these drugs are able to create or exacerbate when administered in humans, these 
models are thought to also have good predictive validity for schizophrenia (Marcotte 
et al., 2001). Although it is important to note that in the clinic in some cases 
psychotic symptoms only arise after chronic administration of these drugs (e.g. 
amphetamine) (Steeds et al., 2015), whereas animal models often employ acute 
experimental paradigms using the same drugs. One major limitation of these models 
is their lack of etiological validity – in that they are unable to induce changes across 
multiple different neural systems, which is thought to be part of the complex 
pathophysiology of the disorder (Nestler and Hyman, 2010). Importantly, any 
treatment compounds discovered through the reversal of the effects of these 
psychotic pharmacological agents are constrained by the pharmacology of these 
agents to the specific mechanisms they are acting on (Moore, 2010). This means 
that novel treatments found to work in these models are compounds that are simply 
able to attenuate or reverse the specific effects of the manipulation itself (Wilson et 
al., 2010). This has limited the utility of these models in finding treatments with novel 
routes of action and treatments for negative and cognitive deficits, and as a result, 
novel therapeutics developed in these models have led to a large number of false 
positive compounds that show little or no efficacy in clinical trials (Moore, 2010). 
Another major limitation of these models is that they often fail to recapitulate the 
clinical nature of schizophrenia, which is a chronic, neurodevelopmental disorder, 
marked by transient combinations of different symptoms predominating at different 
stages (Steeds et al., 2015). Nevertheless, these models have been popular 
because they are easy and quick to perform and have been influential in forming the 
three most well-established theories of schizophrenia: the dopamine, the serotonin 
and the glutamate hypotheses (Geyer and Moghaddam, 2002).  
3.4.1.2 Genetic models 
As our understanding of the underlying biology of schizophrenia has increased over 
recent years in terms of what pathophysiological, genetic and environmental risk 
factors are associated with the disorder, models using lesion, genetic and 
developmental methods of ‘schizophrenia’ induction have also been introduced. We 
see from the data here that these models only really became more popular in the 
literature from 1990s onwards. Genetic and developmental models are mostly 
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examples of “risk factor models” whereby methods used to induce the model are 
based on our knowledge of susceptibility genes for schizophrenia or early 
environmental risk factors such as increasing paternal age, prenatal immune 
activation or stress of the mothers and other adverse early life experiences (Moore, 
2010). 
Genetic models have included complete knockouts, heterozygotes or conditional 
knockouts of genes of relevance, as well as transgenic overexpression of some 
genes, which tend to be based on post-mortem observations of genes upregulated 
in schizophrenic individuals. Limitations of these approaches are that the functional 
effects of genetic variants associated with schizophrenia are not always well 
understood. The association between the gene manipulated in a model and the risk 
for schizophrenia is not robust and therefore a knockdown or knockout of the gene 
in an animal is not necessarily homologous to the variation seen in humans with 
schizophrenia (Moore, 2010; Powell and Miyakawa, 2006). A recent GWAS study of 
schizophrenia did not find any common genetic variants that contributed a 
meaningful effect at genome-wide levels of significance (Ripke et al., 2013). While 
about 8,300 independent SNPs have been estimated to contribute to the aetiology 
of schizophrenia collectively through the same study, individually these alleles have 
a weak effect on schizophrenia risk. Exome sequencing studies have also not found 
significant support for any individual genes (Purcell et al., 2014) and early 
discoveries of candidate genes related to schizophrenia have also not been 
supported by these larger studies (Nutt and Need, 2014). Any possible candidate 
genes confirmed to be of relevance in future, will likely only be relevant to a small 
proportion of individuals with schizophrenia (Nutt and Need, 2014). As 
schizophrenia is thought to involve a large number of different genes, models 
focusing on single genes are unlikely to faithfully model the disorder in the 
laboratory. Nevertheless, genetic models can still be informative, but arguably only 
to a certain extent.  
3.4.1.3 Developmental models 
Developmental models were equally as prevalent in the literature as genetic models. 
Given the limited translational relevance of animal models of schizophrenia using 
pharmacological or genetic interventions, and the amount of evidence supporting 
the neurodevelopmental hypothesis, developmentally impaired animal models seem 
like a promising approach to improving understanding of underlying pathophysiology 
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and translating these insights into the clinic. These models are based on evidence 
that suggests that adverse environmental hits, especially during early life  increases 
the risk of the development of schizophrenia (Dean and Murray, 2005).The 
observations that symptoms usually arise in adolescence or early adulthood further 
support the belief that the underlying pathology begins in early brain development 
(Powell, 2010). Advantages of these models include the absence of any 
confounding drug or surgical interventions when testing novel compounds of 
therapeutic value, so that therapeutic compounds, which act of multiple 
pharmacological mechanisms can still be detected. This would allow for the 
discovery of treatment drugs which work differently to established medication and 
would potentially treat symptoms not being managed adequately by current 
medication (Jones et al., 2011). Moreover, developmental models offer a unique 
condition for the investigation of schizophrenia during early life and the prodromal 
phase of the disorder before symptoms arise, potentially leading to the identification 
of disease-modifying agents (Geyer et al., 2012). One major downside to these 
models is their lack of specificity to schizophrenia or any other psychiatric disorder 
for that matter (Nestler and Hyman, 2010). For example, early life stress is a risk 
factor for a multitude of psychiatric conditions in later life (Carr et al., 2013). As 
previously mentioned, where stress was not administered in early life I classed 
these interventions under the “environmental models” category. I believe these 
disturbances do not necessarily cause the disorder and in many cases do not lead 
to the manifestation of  psychotic symptoms, however, they can trigger existing 
vulnerabilities and so if coupled with these then they too can contribute to the 
manifestation of the disorder (Corcoran et al., 2002). The face, construct and 
predictive validity of three commonly used developmental animal models are 
explored in further detail in Chapter 4. 
3.4.1.4 Lesion models 
The fourth major group of animal models of schizophrenia are lesion models, which 
have been far less frequently reported in the literature compared to the other models 
mentioned above. Lesion models are usually created to try to recapitulate the 
neurodevelopmental and neurodegenerative theories of schizophrenia and involve 
targeted lesioning of brain tissue in animals using electrolytic, aspiration lesions or 
chemically induced lesions through the use of excitotoxic agents (Marcotte et al., 
2001). Research implicating the prefrontal cortex, hippocampus and thalamus in 
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schizophrenia has meant that many lesion models have focused on these areas of 
the brain in preclinical schizophrenia research (Marcotte et al., 2001). In this 
category I mainly classed lesions induced in adulthood, as I believe any lesions in 
the brain created during early development is likely to affect early maturation of the 
brain and should therefore instead be classed as a developmental model. This 
includes the widely reported animal model using neonatal lesioning of the ventral 
hippocampus. This is not always categorised the same in the literature (Jones et al., 
2011). An important distinction between lesions created during early development 
and in adulthood is that early lesions like other developmental models of 
schizophrenia are able to show a delayed onset of behaviours thought to be of 
relevance to human symptoms (Marcotte et al., 2001). Lesion models are thought to 
be of limited relevance to schizophrenia. Primarily because while anatomical 
abnormalities are observed in the brains of schizophrenic individuals (Karlsgodt et 
al., 2010), there is no evidence to suggest that these cause the psychotic disorder in 
question (Nestler and Hyman, 2010). Moreover these models show much more 
extensive damage than what is normally seen in human brains affected by 
schizophrenia (Marcotte et al., 2001). 
3.4.1.5 Combination models 
Administration of psychotomimetic agents is often combined with other models to 
create a multi-hit model thought to have more construct validity for complex 
psychotic disorders such as schizophrenia (Mattei et al., 2015). In the literature a 
mere 20% of publications reported combination models, however, showing that 
future studies could focus more on these experimental paradigms. There is a lot of 
discussion in the field about whether we need to move away from using simple 
models to study schizophrenia in animals. This has seen the increase in the use of 
combination models that combine more than one method of induction to try to 
recapitulate the complexity of the neurodegenerative schizophrenia phenotype that 
arises from an interplay of multiple altered genes, abnormal neurotransmission 
systems and environmental factors (Sarnyai et al., 2015). To account for these 
factors and the late adolescent onset of schizophrenia, a “multi-hit” model of 
schizophrenia has been proposed, where there is an early disruption to the 
development of the central nervous system, which produces a long-term 
vulnerability to other hits that will cause the manifestation of symptoms associated 
with the disorder. It is thought that the development of schizophrenia is a result of 
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the convergence and interaction of genetic, environmental and other vulnerability 
risk factors in a cumulative manner during critical periods of neurodevelopment 
(Davis et al., 2016). Therefore, these kinds of combination models are thought to be 
a reliable way of integrating these developmental, genetic and environmental factors 
that are thought to cause the pathogenesis of schizophrenia in humans and be able 
to produce more valid animal models of the disorder (Maynard et al., 2001; Sarnyai 
et al., 2015). These models are also beneficial in broadening our research targets to 
include more opportunities to study other symptoms of schizophrenia, potentially 
improving the clinical relevance of data collected in animal studies. For example, it is 
said that the cognitive deficits of schizophrenia precede symptoms of psychosis in 
many cases, by an average of 9 years (van Oel et al., 2002), and their treatment is 
usually associated with a better therapeutic outcome (Mintz and Kopelowicz, 2007). 
Despite these arguments for the possible superiority of combination models, simple 
models are still believed to have utility in research without fully recapitulating the 
disease (Pratt et al., 2012). Importantly, however, the predictive value of any of our 
current models is still not clear as they have not yet led to the development of any 
clinically approved therapeutics (Geyer et al., 2012). 
3.4.2 Outcome measures reported 
As with models, I attempted to capture the field as it was reported. While outcomes 
have been categorised according to what is commonly claimed in the literature in 
terms of what a behavioural outcome measure in these animals is measuring, this 
can vary from study to study. I also attempted to group behavioural tasks and 
measures according to what they were suggested to measure. Often it was very 
difficult to class some of these behavioural outcome measures because many 
studies would report the apparatus that they had used to measure behaviour with 
and not the actual behaviour that was being analysed (e.g. T-maze as opposed to a 
measure of spontaneous alternation). Moreover, I found that many studies would 
report the same outcome measures using different names and experimental setups, 
or reporting it as measurements of different concepts making comparisons between 
different experiments and drawing conclusions from a group of similar experiments 
difficult. It is imperative that future studies make it clear exactly what aspect of a 




3.4.2.1 Measures of relevance to positive symptoms 
Positive symptoms, which include hallucinations and delusions in humans, are 
difficult to recapitulate in animals as in humans they are diagnosed through verbal 
reporting and therefore it is not clear how effectively animal model-based 
biomarkers are able to model these symptoms (Steeds et al., 2015). Some studies 
refer to hallucinatory-like behaviour, however, of course this is a highly subjective 
measure of behaviour. Other animal behaviours thought to be analogous to positive 
symptoms include a measure of locomotion (i.e. usually a measure of hyperactivity) 
and stereotyped behaviour. While this behaviour does not correspond to any 
cardinal symptoms of schizophrenia (Nestler and Hyman, 2010)it is thought to be of 
relevance to psychomotor agitation in human schizophrenic individuals (Powell and 
Miyakawa, 2006). Changes in this domain of behaviour in animals is often measured 
in response to psychostimulants, NMDA receptor antagonists or novelty. Data 
collected here shows that this is the most widely reported measure of behaviour in 
the preclinical field of psychotic disorders. The advantages of this measure of 
behaviour are that it is easily carried out and shows sensitivity to antipsychotic 
drugs. Therefore, while this measure of behaviour is thought to have good predictive 
validity for antipsychotic efficacy in humans, it also has a number of limitations. First, 
in the clinic psychomotor agitation in schizophrenia is not overly common in 
individuals with only about 20% of all those experiencing schizophrenia presenting 
with episodes of agitation during their lifetime (Garriga et al., 2016). Moreover, 
locomotion is not a behavioural measure which is specific to the schizophrenia 
research field and is also widely used in other preclinical fields of research (Bailey 
and Crawley, 2009; Mchedlidze et al., 2011; Tatem et al., 2014). Moreover, as 
enhanced dopaminergic activity is thought to underlie the behaviour (van den 
Buuse, 2010), any treatment drugs that show response using this measure of 
behaviour are likely to only lead to the identification and development of more 
dopaminergic drugs.  
3.4.2.2 Measures of relevance to negative symptoms 
Negative symptoms are deficits in normal function and include symptoms of blunted 
effect, asocial behaviour, lack of motivation and impoverished speech (Nestler and 
Hyman, 2010). In the clinic negative symptoms are often diagnosed through 
interview-based approaches or through self-reporting (Barnes et al., 2014), which is 
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not something that is easily modelled in animal studies of course. Intrinsically human 
symptoms such as poverty of speech and blunted affect are especially difficult to 
model in animals (Sahin et al., 2016). However, research looking at ultrasonic 
vocalizations as shown here and discussed elsewhere, might be an experimental 
procedure in animals of some relevance to even unique behaviours like 
communication (Ferhat, Torquet, Le Sourd, 2016). Data collected here also shows 
that social behaviour and anxiety-like behaviour is widely reported in the literature, 
however, measures of affective state are far less prevalent. Measures of affective 
state and emotional regulation are important in human social interaction and 
communication (Sahin et al., 2016), therefore the strength of the inferences that can 
be made from animal social behaviour to human symptoms of social withdrawal are 
questionable. Current antipsychotics do little for improving negative symptoms 
associated with psychotic disorders, and development of new drugs is limited by our 
poor understanding of the underlying mechanisms mediating many of the symptoms 
in this domain (Young and Markou, 2015). Cognitive Neuroscience Treatment 
Research to Improve Cognition in Schizophrenia (CNTRICS) and Cambridge 
Neuropsychological Test Automated Battery (CANTAB) are two initiatives, which 
have been developed in recent years to aid the development of cross-species 
tests that can be used to study specific domains of schizophrenia symptoms (See 
www.cntrics.ucdavis.edu and www.cambridgecognition.com/cantab). So far, it has 
been recognised that studies trying to understand the neural mechanisms 
underlying behaviours of relevance to negative symptoms in animals have mainly 
used non-operant tasks (Young and Markou, 2015). It is believed that these 
neuromechanisms might be better understood by using more objective behavioural 
tests in preclinical studies that are similar to behavioural tests used in humans 
(Young and Markou, 2015). Finally, behavioural tests for negative symptoms are 
limited by the knowledge that specific negative symptoms may develop through 
varied mechanisms as they are not specific to schizophrenia and are implicated in 
other disorders like depression, autism and anxiety (Nestler and Hyman, 2010). 
3.4.2.3 Measures of relevance to cognitive deficits 
Cognitive deficits are described as core disturbances in psychotic disorders (Barch 
and Sheffield, 2014), and are associated with many other psychiatric disorders 
(Millan et al., 2012). They include impairments in attention and vigilance, working 
memory, reasoning and problem solving, processing speed, visual and verbal 
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learning and memory and social cognition (Nuechterlein et al., 2004). This domain of 
symptoms is also an important determinant of functional impairment and quality of 
life (Savilla et al., 2008). They precede all other symptoms and are relatively 
unresponsive to current antipsychotics available (Davidson et al., 2009). In 
recognition of this unmet clinical need and the need for the development of novel 
therapeutic compounds which address these symptoms in the clinic, initiatives such 
as the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS), CNTRICS and Treatment Units for Research on 
Neurocognition and Schizophrenia (TURNS) programs were set up. These initiatives 
aim to identify important domains of cognitive impairment in schizophrenia and how 
to best measure and thus treat these in the clinic (Pratt et al., 2012 and see 
www.MATRICS.ucla.edu). In animals it is extremely difficult to assess concepts 
such as thought or verbal learning and memory (Powell and Miyakawa, 2006) and 
therefore preclinical studies index certain cognitive function-related behaviours 
rather than be able to directly quantify it (Jones et al., 2011). There are no clear 
outlines for preclinical studies on cognitive test batteries, and therefore preclinical 
studies can often use behavioural paradigms, which have limited ability to measure 
the cognitive domains of interest accurately (Young et al., 2009). Animal behaviours 
thought to be of relevance to these symptoms collected from the literature here 
include various measures of learning and memory, which is the fourth most widely 
reported measure in the literature, along with measures of executive function and 
attention. While these are thought to have some extent of face validity for cognitive 
deficits seen in schizophrenia in humans, it is not always clear whether a cognitive 
task used in animals is measuring the same construct as is affected in humans 
(Pratt et al., 2012). Another major limitation of measures of cognitive deficits in 
animal models of psychotic disorders is that as with other measures of behaviours 
discussed above, they are not specific to schizophrenia. They are also seen in other 
neurological and psychiatric disorders; however, whether the disruptions in 
underlying neurobiological mechanisms are similar is not clear (Pratt et al., 2012). 
Cognitive tasks are also said to be confounded in animals by other factors such as 
low motivation or sedation reducing translational relevance of any results seen in 
these tests (Pratt et al., 2012). Developing and using tests, which are directly 
analogous to tasks that are used to measure the same constructs in 
neuropsychiatric test batteries in humans might improve this problem (Powell and 
Miyakawa, 2006). For example, a task normally used in humans for measuring 
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impulse control, namely the stop signal task has been recreated for use in preclinical 
experiments (Eagle and Robbins, 2003). Vice versa examples of tasks usually 
measured in animals, such as the Morris Water maze used for the assessment of 
spatial working memory has been modelled in a virtual version of this task in clinical 
research (Shipman and Astur, 2008). More similarities between the two research 
domains are likely to improve translation of knowledge from both sides.  
3.4.2.4 Other measures of relevance 
Additional abnormalities common in individuals diagnosed with schizophrenia such 
as deficits in sensorimotor gating have also been identified.  A deficit in an 
operational measure of sensorimotor gating, namely pre-pulse inhibition (PPI), has 
been observed in many individuals in the clinic with schizophrenia (Braff et al., 
2001).. Data collected here shows that sensorimotor gating is the third most widely 
described measure of behaviour in the preclinical literature. PPI has been proposed 
in recent years as a biomarker for schizophrenia (Mena et al., 2016). It is suggested 
that PPI is one of two neurophysiological measures, which fulfil all of the 
MATRICS/CNTRICS criteria and are suitable for use in clinical studies (Light and 
Swerdlow, 2014). This criterion expects that a neurophysiological biomarker is 
practical and stable over time, has utility as a repeated measure, is associated with 
functional outcome, has potential to show sensitivity to therapeutic agents, which is 
in line with observations in animals models and has clear links to neural circuits and 
behavioural mechanisms involved in the disease (Light and Swerdlow, 2014). 
PPI is thought to be strongly driven by genetics in both animals and humans (Light 
and Swerdlow, 2014). Evidence shows that there is increased heritability in the 
decline of PPI measures in families with higher genetic vulnerability for 
schizophrenia (Greenwood et al., 2016). Relatives of individuals with schizophrenia 
and subjects with schizotypal personality disorder show deficits in PPI, similarly to 
schizophrenic individuals. These deficits are otherwise not seen in control subjects 
(Cadenhead, 2011; Cadenhead et al., 2000). Alongside recent studies in the 
literature suggesting that PPI levels in schizophrenia show long term stability (Light 
et al., 2012; Mena et al., 2016), this supports the idea that PPI deficits are a trait or a 
vulnerability marker of psychotic disorders. There is also some evidence to show 
that PPI levels correlate with deficits in neurocognition as well as global functional 
status (Swerdlow et al., 2006), and vary within individuals based on symptom state, 
whereby PPI levels improve with improvements in symptoms (Meincke et al., 2004; 
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Minassian et al., 2007). The literature also shows that PPI deficits are responsive to 
medication and are improved especially by atypical antipsychotics in schizophrenic 
individuals (Mackeprang et al., 2002; Oranje et al., 2002). This suggests that PPI 
deficits may also be a state marker of psychotic disorders. Therefore, disturbances 
in mechanisms that underlie PPI and information-processing, may both make an 
individual susceptible to developing psychosis and vary in relation to acute 
symptoms (Meincke et al., 2004). 
This measure of behaviour has advantages over many other behavioural measures, 
as it is a phenomenon, which can be studied in animals and therefore holds good 
face and predictive validity for schizophrenia. It can be measured similarly in both 
rodents and humans, with similar results (Powell and Miyakawa, 2006), meaning 
this measure is able to increase our understanding of the neural and cellular 
substrates that underlie its translatability (Light and Swerdlow, 2014). Despite its 
suggested utility for predicting the likelihood of recovery in response to different 
types of therapies for cognitive interventions for schizophrenia (Light and Swerdlow, 
2014), we must keep in mind its limitations. This measure of behaviour is not 
specific either to schizophrenia. It has been documented to occur in many other 
conditions including bipolar disorder, obsessive-compulsive disorder and Lewy body 
dementia (Geyer et al., 2001; Perriol et al., 2005; Perry et al., 2001), which limits its 
applicability as a biomarker specifically for schizophrenia or other psychotic 
disorders. 
3.4.3 Therapeutic compounds reported to be tested 
Overall, just under half of all studies identified to be of relevance in the literature 
reported studying potential therapeutic compounds in animal models of psychotic 
disorders. Overall, data collected here shows that the majority of treatments tested 
previously target the dopaminergic and serotonergic pathways. In fact, the top nine 
therapeutic compounds reported in the literature have all been established to have 
some affinity for dopamine receptors. Most of the drugs at the top of the list of most 
widely reported drugs are also currently established antipsychotics. Due to their 
serendipitous discovery, most targets of current anti-psychotic treatments and their 
mechanisms of action were discovered post hoc (Nestler and Hyman, 2010).  
Therefore older studies have used „back-translational psychopharmacology” in order 
to learn more about these drugs (Moore, 2010), while also some newer studies use 
these established drugs as reference treatments when testing the effect of novel 
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treatment options. This is based on the principle that we know these drugs work in 
humans therefore if we can find drugs that show similar effects in animals then they 
are likely to also do well in humans. Of course, this arguably only identifies more 
compounds that work in similar ways to these drugs and doesn’t introduce drugs 
with novel mechanisms of action. Based on our knowledge of psychosis at this 
stage, we think that one out of the possible six dopamine pathways in the brain is 
affected in psychosis. Blocking of other dopaminergic pathways are what underlie 
other effects of dopaminergic drugs such as extrapyramidal side effects, secondary 
negative or cognitive deficits and hyperprolactinemia (Correll and Kane, 2014; 
Sesack and Carr, 2002). Unfortunately, a dopaminergic drug is unable to selectively 
target a single dopamine pathway and therefore targeting of other neurotransmitters 
are required to balance dopaminergic modulation in the other five dopaminergic 
pathways in the brain (Correll and Kane, 2014). Drugs of alternative mechanisms of 
action explored in the literature since these early drugs have included compounds 
acting on other pathways in the brain thought to be implicated in schizophrenia 
including cholinergic, glutamatergic, GABAergic, adrenergic, histaminergic or opioid 
pathways, as shown by data collated here. Many compounds interact with more 
than one of these pathways and therefore might be better candidates for treatment 
in the clinic as opposed to drugs, which target a single neurotransmitter system in 
the brain (Li et al., 2016).  
Despite these alternate psychotropic drugs developed for treatment of psychotic 
disorders, the approval of these drugs has not been successful. Many drugs have 
shown efficacy in animal models, but have not gone on to show this same efficacy in 
humans (Moore, 2010).The United States Food and Drug Administration (FDA), only 
licensed drugs for a long time if they showed efficacy in positive symptoms of 
schizophrenia. This prevented the identification and development of drugs effective 
for other symptoms of the disorder such as negative symptoms and cognitive 
deficits as mentioned above (Geyer, 2006). So perhaps with increased focus from 
initiatives in recent years (Pratt et al., 2012) on the treatment of symptoms of 
psychotic disorders unmet by current medication and those which arguably affects 
quality of life the most in patients, novel drugs will be introduced. It has been 
highlighted that the main unmet needs in schizophrenia treatment currently include 
medications that can treat negative symptoms and improve cognition, can help 
treatment-resistant patients and those that will increase compliance (Fellner, 2017). 
It is thought that manipulation of the appropriate dopaminergic, serotonergic and 
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glutamatergic targets can help to manage a range of different symptoms including 
negative symptoms and cognitive deficits. Improving tolerability and safety of drugs 
by moving away from high dopamine D2 receptor occupancy and limiting off-target 
neurotransmitter interactions causing adverse side-effects is likely to increase 
compliance (Li et al., 2016). There are a number of compounds in clinical trials at 
the moment for these unmet needs in schizophrenia treatment. Many of these drugs 
primarily act on serotonergic receptors and are aimed at either improving negative 
symptoms, treating cognitive impairments or addressing treatment-resistance 
associated with psychotic disorders (Fellner, 2017; Li et al., 2016). It remains to be 
seen whether these drugs will go on to be approved for clinical use. 
Data collected here show that there has been a vast number of different 
pharmacological agents and other interventions tested in animal models of 
psychosis for the improvement of symptoms. One of the most obvious observations 
based on these data is that there is a substantial lack of replicability. Many of the 
compounds in the list collated were reported only a handful of times. In fact 62% of 
compounds were found to be reported only once in the literature. A lack of 
replicability has continued to be a major issue in all preclinical research fields. Good 
scientific practise that improves credibility and robustness of results is based heavily 
on replication of studies (Ioannidis, 2014). Faulty conclusions can impede further 
understanding of a concept and are wasteful in research. It is thought that one 
reason behind high rates of candidate drug failure in clinical trials is that they have 
not been based on robust experimental data to begin with (Steward, 2016). Not only 
is research which is not replicated not robust, but it is also arguably wasteful. With 
the high rate of false positive drugs identified to show efficacy in animal models, but 
not in later clinical trials (Moore, 2010), it seems that a lack of replication might play 
a role in translational failure of therapeutic targets from animal model studies to 
clinical trials in humans. It has been shown in recent years that multiple efforts to 
replicate findings in the literature have shown that many studies can’t be replicated 
to the same extent as the original study (Ioannidis et al., 2014a), questioning the 
credibility of those initial findings. This is a major rate-limiting step in further 
understanding and the drug development process and I go on to explore further 
potential reasons behind this in the following chapters of this project. 
During categorization, all effort was made to only record compounds thought to be 
given with the aim of reversing or attenuating the effects of a model induced. 
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However, the role of some compounds in experimental designs was not always 
clear. Results show that some pharmacological compounds can appear on both the 
list of interventions to induce a model and the list of treatment drugs tested in animal 
models of schizophrenia. For example, recent evidence shows that ketamine, a non-
competitive NMDA glutamatergic receptor antagonist has been shown to have 
therapeutic efficacy as an antidepressant in the treatment of depression and bipolar 
disorder (Grady et al., 2017). It has also been found efficacious in patients who 
experience depressive symptoms in the context of psychotic symptoms (da Frota 
Ribeiro et al., 2016) or have a history of psychotic symptoms (Pennybaker et al., 
2017). This is despite its wide use in the preclinical literature for the modelling of 
schizophrenia in animals as seen here, and its adverse effects when abused in 
humans (Li et al., 2011). It is thought that the time course of response after 
administration can produce differential effects, with psychotomimetic effects being 
seen first, followed by antidepressant effects of the drug (Duman et al., 2012). 
Similarly, nicotine is often used by schizophrenic individuals as a form of ‘self-
medication’ due to its suggested ability of reducing psychiatric symptoms including 
cognitive deficits (Sacco et al., 2005)and side effects associated with antipsychotic 
treatment (Goff et al., 1992). However, nicotine is also a drug of abuse, which has 
been shown to increase dopamine release directly, similarly to other drugs of 
misuse (Brody et al., 2004). It has also been shown to be associated with an 
increased risk of psychosis and daily smokers have shown to have an earlier age of 
onset of psychotic disorder (Gurillo et al., 2015).  
Ultimately, the development of novel antipsychotics in the field is made difficult not 
just by the limitations of animal models available, but also by the lack of a “gold 
standard” medication that is available in the clinic for the complete treatment of 
schizophrenia that could be used as a positive control for novel compounds (Jones 
et al., 2011). Of course, before we can consider the full therapeutic potential of 
some of these drugs, things such as dose required for efficacy should be considered 
as evidence shows that while these drugs may improve one domain of symptoms, it 
might also make another worse (Zajaczkowski et al., 2003). Moreover, external 
validity of experimental setups used is extremely important when it comes to finding 
treatment compounds that show efficacy in animals and also humans. Evidence 
shows that current antipsychotics have a small therapeutic window of efficacy before 
they produce unwanted behaviours that might affect overall performance of an 
individual in a behavioural test (Jones et al., 2011). External validity is a concept 
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further discussed in the context of developmental models of schizophrenia in 
Chapter 4. 
3.4.4  Limitations 
The search performed was a shallow, but broad overview meaning that search 
terms used were not specific and this means that studies could have been missed 
that would otherwise have been of relevance if they did not specifically mention 
“psychosis” or any other psychotic disorders as classified in DSM-5 or ICD-10 
classification systems. This is further explored in Chapter 7. 
The lists of models, treatments and outcomes were broadly validated based on 
information from the wider literature when compiling tables and checked overall by 
myself. Nevertheless, a small proportion of publications were outsourced for 
categorization to students working with our group at the time of performance and 
therefore there might be some discrepancy between what is considered a model, a 
treatment and a valid outcome to one investigator compared to another. Publications 
were also categorized by a single reviewer, potentially leading to some errors in 
categorization of publications due to human error or misinterpretation of a 
publication. For many publications it was often not clear what would be considered a 
model and what would be considered a treatment due to poor reporting of study 
intentions. I also found on many occasions that a study would be described to be of 
relevance to schizophrenia as well as multiple other psychiatric disorders, but there 
would be little further explanation to this association. In reflection of the 
heterogeneity seen in the reporting of model induction, outcome measurement and 
testing of compounds of potentially therapeutic value in models, I agree with 
previous calls in the literature for authors to “state the goals of their model” (Nestler 
and Hyman, 2010). It is recommended that authors more explicitly state the nature 
of their models and what specific symptoms they are modelling in order to provide 
more conceptual clarity and easier assessment of validity and utility of models by 
reviewers and readers in general (Nestler and Hyman, 2010). I would argue that in 
many cases the message of why a model was created, what it was expected to 
show and why certain outcome measures were used including what they were 
intended to measure and the purpose of testing the specific compounds reported 
was not always clear. I believe that this can make it often difficult to put a publication 
into context with other work going on, which could also be an issue behind limited 






4 Construct, Face, Predictive and External Validity: 
Developmental Animal Models of Schizophrenia 
 
4.1 Introduction 
The validity of animal models for a human condition is judged by the extent to which 
the features of the model and the condition it is expected to model are similar (Varga 
et al., 2010). The use of animal models in the research fields of uniquely human 
disorders, such as psychiatric disorders, has been a particularly difficult challenge 
(Powell and Miyakawa, 2006). In the previous chapter I discussed how vast the 
literature on animal models of schizophrenia is and reviewed different models 
reported to have relevance to the disorder. While there is no formal validation of 
models, the three validities most often discussed in the context of animal models of 
human conditions are construct, face and predictive validity. In the literature these 
validities are often variably defined, however here I will use definitions used in 
recent literature of animal models of psychiatric disorders (Belzung and Lemoine, 
2011; Nestler and Hyman, 2010). 
According to this, construct validity describes the degree of relevance a method 
used to construct a model has to the condition being modelled (Nestler and Hyman, 
2010). In theory, to achieve construct validity we would create animal models of 
schizophrenia by mimicking the aetiology of the human disorder so that the animal 
would model, for example, neural or behavioural features of the disorder (Chadman 
et al., 2009). As the underlying pathophysiology and the exact aetiology has not 
been precisely established in the field of schizophrenia research, it is difficult to 
argue that animal models have high construct validity. This is especially because 
models based on “risk factors” are likely to also be of relevance to many other 
neurodevelopmental psychiatric disorders (Nestler and Hyman, 2010).  
Face validity is the observed similarity between the pathophysiology of the animal 
modelling the human, and the human condition in question. This can include 
similarity in anatomical, biochemical, neuropathological and behavioural features 
between animal model and human disorder (Nestler and Hyman, 2010). This can be 
a very misleading measure of how valid an animal model is, especially as most 
models are different species to the one they are designed to model. It is therefore 
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rare for two species to exhibit the same behaviours even when the underlying 
biology is similar. In turn, similarities in behaviours do not translate to similar 
underlying causes in two different species (Geyer and Markou, 2000). Of course, it 
is also important to note that the validation of any animal model can only be as good 
as the information that is available from the clinical side of psychosis research 
(Geyer and Moghaddam, 2002). Face validity is therefore a very subjective measure 
of validity, and is a difficult concept to defend because many of the symptoms that 
define the human disorder being modelled are defined subjectively and diagnostic 
categories are continuously re-defined and changed (Geyer and Markou, 2000). For 
example, using guidelines such as the DSM, the same disorder can be 
characterized by opposite symptoms and many symptoms are not distinct from 
those of other psychiatric disorders (Donaldson and Hen, 2015; Weinberger, 2013). 
These limitations make it very difficult to create animals that are representative of 
the disorder in question.  
Predictive validity is the extent to which a model is able to give accurate predictions 
about the efficacy of treatments in humans (Nestler and Hyman, 2010). In other 
words, to what degree does an animal model respond the same, as those with the 
human condition, to the same manipulation (Feifel and Shilling, 2010). As current 
antipsychotics are largely based on serendipitous clinical discoveries in the last 
century, the full predictive validity of animal models of psychotic disorders is not yet 
understood as they have not led to the development of any clinically approved 
treatment options for schizophrenia (Geyer et al., 2012). Geyer and Markou (2000) 
argue that because animal models exist solely for the purpose of bettering 
knowledge about a certain phenomenon, the only truly important criteria for 
evaluating an animal model of a human condition is it’s ability to have predictive 
validity (Geyer and Markou, 2000).  
Of course, it is not only important for a model to be valid in terms of being able to 
recreate specific signs or psychological constructs of a disorder. In order to inform 
clinical trials for novel treatment development, treatment strategies have to be 
clinically relevant as well as similarly applied in humans as they have been in 
animals (van der Worp et al., 2010). Threats to external validity can include aspects 
such as a lack of generalisability – where, for example, animals tested do not 
represent the patient population being modelled. Differences in experimental design 
that make translation to the clinic unrealistic, such as unrealistic doses, timing of 
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administration, and timing of outcome assessment, can also affect the translation of 
results from animal models to clinical studies (van der Worp et al., 2010). 
As mentioned, it is not thought that any one animal model is able to reiterate the 
complexity of the underlying biology of schizophrenia. Instead, many models model 
specific animal behaviours thought to be of relevance to human symptoms (Geyer 
and Moghaddam, 2002; Jones et al., 2011). It is very unlikely that animals will ever 
be able to model human-specific symptoms of schizophrenia such as altered 
perception, aberrant language or suicidal thoughts. However, not only do the 
measures taken from an animal model need to be reliable, but clinical measures 
must also be developed alongside these models that make it possible to produce 
meaningful inferences between the two (Geyer and Markou, 2000).  
As seen in Chapter 3, one of the most prevalent and promising groups of animal 
models of schizophrenia involves the administration of environmental insults during 
development in animals to model etiological factors thought to play a role in the 
development of the disorder (Jones et al., 2011). As mentioned in the previous 
chapter these models are based on the neurodevelopmental hypothesis of 
schizophrenia, whereby early environmental insults during development are thought 
to interact with genetic predispositions to induce dysfunctions in neural systems that 
become apparent in later life (Fatemi and Folsom, 2009). As a result, these models 
are thought to be more promising than pharmacological models and in many cases 
genetic models too as they are able to provide more etiological validity for the 
human condition. They are able to recapitulate the delayed onset of symptoms seen 
in the clinic as well as create a biological abnormality that spans multiple neural 
systems thought to play a role in schizophrenia (Wilson et al., 2010). 
Here I review this group of models and discuss their value to clinical research and 
novel drug development in the context of contrast, face and predictive validity. I also 







Part of this work was carried out as part of a BSc Biological Sciences Honours 
dissertation project on isolation rearing and maternal separation models for which I 
would like to acknowledge Monica Dingwall (MD) for her work. I would also like to 
acknowledge our research assistants, Kaitlyn Hair (KH) and Paula Grill (PG), for 
their hard work on data extraction from other included studies. Inclusion and 
categorization of publications was carried out by myself. Final extracted data were 
checked and meta-analyses were run by myself.  
4.2.1 Search strategy 
Publications of relevance were filtered from the 3847 studies that had been 
screened for inclusion within this systematic review of animal models of psychotic 
disorders. They were filtered based on results from Phase II of the review, so that 
studies categorized as reporting either a developmental or a combination of a 
developmental and another type of model were considered to be of relevance. In 
light of the large corpus of data categorized as examples of developmental models, I 
only focused on three widely reported developmental models: animals infected 
prenatally in the womb, animals infected postnatally in early life and adversely 
reared animals.  
4.2.2 Inclusion criteria 
Inclusion and exclusion of publications occurred at full-text level in line with data 
extraction using inclusion/exclusion criteria specific for Phase III of the project in 
Chapter 2. To reiterate, publications were excluded from further analysis if they did 
not report 1) behavioural outcome measures, 2) an appropriate control, 3) data 
required for meta-analysis (i.e. number of animals used or SD/SEM).  
4.2.3 Data extraction 
Data extraction was carried out by a single reviewer (MD, PG, KH or myself). Only 
comparisons of developmental models or combination models where one of the 
models was considered a developmental model were extracted. Comparisons 
comparing control animals with model animals (termed model-characterising 
experiments) and those where model animals given a treatment to reverse the effect 
of the model were compared with animals of the same morbidity given no treatment 
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were included (treatment-exploring experiments), were both extracted, but analysed 
separately. Details of study characteristics extracted are specified in Chapter 2. 
Where the same outcome was reported in multiple ways within the same group of 
animals (e.g. locomotor activity reported in distance travelled and time spent 
moving), all outcome measures were extracted and nested before analyses. 
4.2.4 Analysis 
All methods used for analysis are described in detail in Chapter 2. Where the same 
outcome was reported in multiple ways, these measures were nested to give a 
single comparison within an experimental group for that outcome measure. Model-
characterising comparisons and treatment-testing comparisons (see below for 
further detail) were meta-analysed separately. For specific models, treatments and 
outcome measures, and when appropriate and data sufficient (i.e. over 25 
comparisons included in the meta-analysis), univariate meta-regression was 
performed to investigate potential sources of heterogeneity. This was done focusing 
on different components of study design characteristics, and a significance level of 
p<0.05 was set for each test. To correct for multiplicity of testing, a Holm-Bonferroni 
adjusted critical p value was calculated to account for the number of variables tested 
within subgroup analyses. For most datasets, the adjusted critical p value was set at 
p<0.009 for looking at the effect of 6 variables, with the exception of pre-pulse 
inhibition, where the effect of 7 variables was, explored making the adjusted critical 
p value to be set at p<0.007. Heterogeneity is described using tau2 (estimation of 
excess between-study variance), residual I2 (the percentage of residual variation 
explained by between-study heterogeneity) and adjusted R2 (adj R2; the proportion 
of between-study variance explained by the model). Statistical analyses were 
performed using code written in R for combining data and Shiny Meta-analysis 
application (https://qianying.shinyapps.io/Multi/) for meta-analysis and univariate 
meta-regression.  
For reference, a worse or improved behavioural outcome is used to describe how 
groups of animals perform on a behavioural measure compared to their control. For 
model characterising studies, we are comparing model animals to control, sham 
animals and therefore a worsening in outcome means the animal model of the 




For treatment testing studies, comparisons are made between two identical groups 
of animal models, where one is given a therapeutic intervention to improve their 
performance, while the other, control group, is not. Here, we would expect to see an 
improvement in outcome using a behavioural measure in animal models, which 
have been given the treatment, when compared to those animals, which have not 
been given the same treatment. 
4.3 Results 
4.3.1 Overview of the field and external validity of model studies 
191 publications were identified from Phase II screening to include developmental 
manipulations, which induce behaviours thought to model human symptoms in 
schizophrenia as a result of prenatal or postnatal viral infection and adverse child 
rearing. During the data extraction process, 21 publications were excluded from this 
subset due to lack of data required for meta-analysis. 
In total, 84 publications reporting 974 comparisons reported characterising animal 
models of schizophrenia by comparing developmentally disturbed animals to healthy 
control animals.  
In total, model-characterising studies used a total of 21984 animals. Most 
experiments used rats (561 experiments, 12202 animals), with others using mice 
(371 experiments, 9241 animals) and monkeys (42 experiments, 541 animals). All of 
the monkeys used were rhesus macaques. The most commonly used strains of 
mouse were C57BL/6, of which most were specified to be a subline from the 
Jackson laboratory (124 comparisons, 3023 animals) and the rest were not further 
specified (61 comparisons, 1619 animals), and Balbc/c (40 comparisons, 1538 
animals). 69 experiments did not state the strain of mouse used (1148 animals). The 
most commonly used rats were Wistar rats (292 comparisons, 4784 animals), 
Sprague Dawley rats (170 comparisons, 4330 animals), Fischer rats (49 
comparisons, 910 animals) and Long-Evans rats (28 comparisons, 1359 animals).  
Most experiments reported using male animals (579 comparisons, 11346 animals), 
with only 85 experiments using female animals (1909 animals). 288 experiments 
reported using both (7986 animals). 12 experiments were not clear on the sex of 
animals used in their experimental design, leaving 403 animals unaccounted for. 
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In addition, 17 publications reported 143 comparisons looked at testing the effect of 
various treatments in model animals by comparing treated to non-treated animals.  
Treatment-testing studies used a total of 2483 animals. Most experiments used rats 
(84 experiments, 1222 animals), with others using mice (59 experiments, 1262 
animals). The most commonly used strain of mouse was C57BL/6 (47 comparisons, 
80% of all mice, 1047 animals). Rats used were most commonly Wistar rats (67 
comparisons, 997 animals), and others were of the Sprague Dawley strain (17 
comparisons, 225 animals). Most experiments reported using male animals (65 
comparisons, 878 animals), with only 22 experiments exclusively using female 
animals (360 animals). Only 56 experiments reported using both sexes, however, 
these experiments reported using the largest number of animals (1246 animals).  
The global estimate of effect of model-characterising studies was -0.68 SD units 
(95% CI -1.00- -0.36), meaning animal models of schizophrenia performed worse 
than control animals on behavioural measures by 0.68 SD units. The global estimate 
of efficacy of treatments administered in treatment-testing-studies was 1.01 SD units 
(95% CI 0.63-1.39), meaning treatments were able to improve behavioural 
outcomes in developmental models of schizophrenia by 1.01 SD units. 
As development plays a key factor in schizophrenia and symptoms in humans arise 
at different stages, time of assessment was used to calculate stage of life of animal 
at measurement (Table 4.1).  
 
Table 4.1 Developmental stages of life for mice, rats and rhesus macaques 
Put together using the following sources: Sengupta (2013); Casey, Glatt & Lee (2015);  
https://www.nc3rs.org.uk/macaques/macaques/life-history-and-diet/. 
  Mice Rats Rhesus Macaques 
Infant 0-28 days 0-21 days 0-12 months 
Juvenile 28-42 days 21-35 days 12-36 months 
Adolescent 42-56 days 35-50 days 3-8 years 






In studies characterising the animal model induced, 13 groups of animals were 
measured as infants, 37 as juveniles, 20 as adolescents, and 186 as adults. When 
data were stratified according to these stages, we see that experiments measuring 
animals at the juvenile phase report a greater worsening in behaviour in comparison 
to animals being measured at all other stages of life (Table 4.2). 
 
Combining infant, juvenile and adolescent animals into one group to include all 
measurements taken in young animals before puberty still shows that overall 
behaviour is worse in younger animals than in animals measured at a later stage in 
life (Table 4.3). Even so, it is obvious that most studies measure behaviour in adult 
animals. 
 
Treatments are also mainly tested in adults, with only two groups of animals being 
measured at the juvenile phase of their life. For this reason, it is difficult to analyse 
how well treatments work at different stages of an animal model’s life. 
Table 4.2 Global estimates of effect of model on behaviour at specific stages of life 
Estimates reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 
Table 4.3 Global estimates of effect of model on behaviour in young and adult 
animals 
Estimates reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 
Table 4.4 Global estimates of efficacy for treatments in young and adult animals 
Estimates reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 
calculation, nested where appropriate. 
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4.3.2 Exploring construct validity 
Construct validity describes the degree of similarity between an animal model and 
the human condition it is intended to model in terms of underlying neurobiological 
mechanisms (van der Staay et al., 2009). In order to explore the construct validity of 
developmentally induced animal models of schizophrenia further, I looked at the way 
in which models were induced and what effect these different experimental setups 
had on behaviour in these animals. Overall, model-characterising studies reported 
using 37 different methods to induce animal models of schizophrenia (Figure 4.1). 
12 of these induction methods were combination models where the main model was 
an insult to the animal’s development through prenatal or postnatal disturbance to 
normal development, combined with a second hit usually in later life involving some 
form of stress to the animal or pharmacological hit to exacerbate the underlying 
condition. The most common methods used to induce the model were by infection of 
mothers during pregnancy with the virus polyinosinic:polycytidylic acid (poly I:C) 
(433 comparisons, 11658 animals), the neurotoxin methylazoxymethanol acetate 
(MAM) (164 comparisons, 2646 animals) and lipopolysaccharide (LPS), a toxic 
component in gram-negative bacteria (98 comparisons, 2246  animals). 
 
 
Figure 4.1 Developmental methods used to induce psychosis under models of 
infection and adverse rearing conditions 
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In further analysis, for the sake of simplicity and clarity these models were grouped 
according to the type of method used to induce the model: prenatal insult, postnatal 
insult, adverse rearing condition, and combination model. These methods are now 
reviewed here in more detail. 
4.3.2.1 Prenatal infection 
896 experiments induced their model by affecting development before birth. This 
included the following classic maternal immune activation models: injections of LPS, 
TURP, poly I:C, MAM, ICLC (i.e. modified form of poly I:C), kainic acid, cytosine 
arabinoside (Ara-C), or various strains of influenza virus. Some of these 
interventions were combined with each other as well as with other maternal insults 
such as maternal iron deficiency. Many of these prenatal models were also 
combined with a second hit of pharmacological interventions administered later in 
the life of the pups including amphetamine, methamphetamine, apomorphine, and 
NMDA antagonists such as SDZ 220,581, ketamine, phencyclidine, or dizocilpine. 
Developmental models were also combined with genetic models, for example, poly 
I:C injection was given to IL-6 KO mice or Nurr1 (+/-) animals. Some animal models 
also combined a developmental intervention with an environmental stressor later in 
life such as juvenile restraint stress or postnatal cross fostering.  
Most of the animals reported to be subjected to this method of model induction were 
mice (356 experiments, 8992 animals) or rats (498 experiments, 11282 animals), 
with 42 comparisons carried out in monkeys (42 experiments, 541 animals). All 
monkeys were rhesus monkeys. The most commonly used strains were C57BL6/J 
for mice (124 experiments, 3023 animals) and Sprague Dawley for rats (147 
experiments, 3966 animals). Studies using these methods of model induction 
reported an overwhelming number of comparisons carried out in male animals (509 
experiments, 10275 animals), but many comparisons were also found to be among 
groups of animals of both sexes (287 experiments, 7969 animals). 78 comparisons 
were reported in only female animals (8.7% of all prenatal infection experiments, 
1827 animals). After birth, animals were measured at a number of different stages of 
life, including 30 measurements taken from infant animals (623 animals), 219 
measurements taken from juvenile animals (3301 animals), 76 measurements taken 
from adolescent animals (3076 animals) and 571 measurements taken from adult 
animals (13815 animals). Other details about experimental design are shown in 
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Overall, behaviour in animals where the model was induced through adverse rearing 
conditions worsened outcome by 0.74 SD units (95% CI -1.15--0.34) in model 
animals, compared to healthy, control animals (p<0.0001, n = 242 comparisons). 
Substantial heterogeneity was observed in the data (tau2 = 2.4092, I² = 97.5%), 
which was in part explained by the number of times intervention was administered 
prenatally in the mother (p = 0.0006, tau2 = 2.156, I² = 99.75%, adj R2 = 10.53%, 
Figure 4.2). Heterogeneity was not significantly explained by any of the other study 
characteristic variables investigated with univariate meta-regression, namely: 
animal, strain and sex of animals, method used to induce animal model, stage of life 
behaviour was measured at, time of outcome assessment, dose administered in 
mother to induce the model and time of administration during gestation. 
Figure 4.2 Relationship between the number of administrations of prenatal infection 
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Prenatal methylazoxymethanol acetate (MAM)
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4.3.2.2 Postnatal infection 
31 experiments using 501 animals induced their model by affecting development 
soon after birth. This included the following induction methods: neonatal kynurenic 
acid, neonatal kynurenic acid and amphetamine, neonatal viral infection using the 
influenza A/WSN/33 virus, and the poly I:C virus. Early in development meant 
administering these interventions at any time from postnatal day 2 up until postnatal 
day 14. 
Animals subjected to this method of model induction were rats (16 experiments, 
using 252 animals) or mice (15 experiments, using 249 animals). The rats were of 
the strains Sprague Dawley (4 experiments, using 60 animals) or Wistar (12 
experiments, using 192 animals). The mice used were C57BL/6 mice (6 
experiments, using 109 animals) or ICR mice (9 experiments, using 140 animals). 
Experiments overwhelmingly reported exclusively using male animals in their design 
(26 experiments, 84% of all experiments using postnatal models, 424 animals). One 
experiment reported using both male and female animals (17 animals), and 4 
reported using only female animals within their study design (60 animals). Once 
models were established, outcome was usually measured in adulthood (27 
experiments, 437 animals), with only a few studies measuring outcome in 
adolescence (4 experiments, 64 animals). Models using simple neonatal kynurenic 
acid treatment administered 20 repeated dosages of 200 mg/kg during development 
(2 experiments, 48 animals). When this was combined with amphetamine, an 
injection was only given once during development (1 experiment, 8 animals). 
Neonatal infection using a strain of the influenza virus was either administered once 
at 2400 plaque forming units (1 experiment, 17 animals) or repeatedly during 
development at a dosage of 200 mg/kg (2 experiments, 36 animals). Experiments 
reporting early postnatal infection using the Poly I:C virus to create their model (25 
experiments) used a variety of experimental paradigms. In four experiments the 
virus was administered once during development (60 animals), in 12 experiments it 
was administered three times during development (192 animals) and in 9 
experiments it was administered repeatedly 5 times during development (140 
animals). The dosage of the virus varied from 2-5 mg/kg.  
Overall, behaviour in animals where the model was induced through postnatal 
infection worsened outcome by 1.07 SD units (95% CI -1.52--0.61) in these animals, 
compared to healthy, control animals (p<0.0001, n = 12 comparisons). Substantial 
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heterogeneity was observed in the data (tau2 = 0.45, I² = 94.2%), however, due to 
low sample size after nesting of data, I was unfortunately unable to further explore 
sources of this heterogeneity. 
4.3.2.3 Adverse rearing 
48 experiments, using a total of 678 animals induced their model by affecting 
development during rearing of animals. This included the following induction 
methods: isolation rearing and phencyclidine, isolation rearing and MK-801, 
maternal deprivation and corticosterone treatment, maternal deprivation and 
apomorphine, maternal deprivation and ketamine, isolation rearing and poly I:C 
infection, and maternal poly I:C injection and postnatal cross fostering. 
Overall most of the animals subjected to this method of model induction were rats, 
with all but one experiment using rats in their experimental design (47 experiments, 
669 animals). One experiment reported using mice of the strain C57BL6/J (9 
animals). The rats used were of a variety of different strains, including Fischer rats 
(2 experiments, 32 animals), Hooded Lister rats (3 experiments, 23 animals), Lewis 
rats (2 experiments, 28 animals), Sprague Dawley rats (19 experiments, 305 
animals) and Wistar rats (21 experiments, 282 animals), with the latter two strains 
being used most widely across experiments. The sex of the animals was mostly 
male (44 experiments, 646 animals), with 3 experiments reporting the use of female 
animals (23 animals) and one experiment reportedly using both sexes (9 animals). 
Those experiments utilising isolation rearing as a model reported isolating animals 
for 5 to just over 12 weeks, always starting at 3 weeks of age. Animals were most 
commonly isolated for either  8 (12 experiments, 38% of all isolation rearing 
experiments, 183 animals) or 12 weeks (10 experiments, 31 % of all isolation 
rearing experiments, 120 animals). Experimental designs where the pup was 
deprived from the mother and separated from her were reported to always last for 
24 hours. Behaviour in animals was usually measured at the adult phase of life (43 
experiments, 638 animals), but 5 experiments also measured behaviours at the 
juvenile stage of life (40 animals). Where pharmacological agents were administered 





Overall, behaviour in animals where the model was induced through adverse rearing 
conditions worsened outcome by 0.37 SD units (95% CI -0.63--0.11, compared to 
other models: Table 4.6) in these animals, compared to healthy, control animals 
(p<0.0001, n = 20 comparisons). Substantial heterogeneity was observed in the 
data (tau2 = 0.2766, I² = 91.9%), however, due to low sample size after nesting of 
data, I was unfortunately unable to further explore sources of this heterogeneity. 
Table 4.6 Global estimates of efficacy for methods used to induce the animal model 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 
calculation, nested where appropriate. 
 
4.3.2.4 Combined or Simple Models 
853 experimental comparisons involved using simple animal models of 
schizophrenia to characterise the model. Combined models were less prevalent with 
only 121 experiments using an experimental design where a second-hit was used to 
create the model. When stratifying the dataset by whether experiments used simple 
or combined models as part of their experimental design, there was little difference 
between the two types of studies and their effect on behaviour in animal models of 
schizophrenia when compared to control animals. Overall, simple models worsened 
behavioural outcome by 0.70 SD units (95% CI -1.08—0.31) in model animals when 
compared to control animals (p<0.0001, n = 225 comparisons). On the other hand, 
combined models worsened behavioural outcome by 0.68 SD units (95% CI -1.00—
0.36) in model animals when compared to control animals (p<0.0001, n = 48 
comparisons). 
Table 4.7 Global estimates of effect for simple or combined model induction methods 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the calculation, 
nested where appropriate. 
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4.3.3 Exploring predictive validity 
Predictive validity of an animal model is the extent to which phenotypic effects in the 
model are similar to those in humans in response to the same therapeutic 
intervention (Kumar et al., 2016). Therefore, predictive validity expects the model to 
be able to predict behaviour in the disorder that it has been designed to model. This 
is especially important in novel treatment development (van der Staay et al., 2009). 
For example, if an animal model is able to correctly predict the efficacy of a 
treatment drug in the human condition, then we can say that it has high predictive 
validity. In order to explore the potential predictive validity of developmental animal 
models of schizophrenia, I looked at the effect of different treatments administered 
in studies reporting these animals. 
 
142 comparisons of treatment-testing experiments were identified that compare a 
group of model animals with another group of model animals who have been given a 
potential therapeutic intervention to reverse or alleviate outcome in behaviour. 12 
different interventions were tested in this subset of the literature (Figure 4.3). The 
most common of these were the already clinically established anti-psychotics 
clozapine, haloperidol and chlorpromazine.  
 
Figure 4.3 Treatments recorded to be tested in the literature. Number show number of 
experiments exploring these treatments. 
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It would have been interesting to compare experiments using established treatments 
with those using potential treatments, however, these newer compounds were 
reported in a few experiments and it was therefore not possible to make accurate 
comparisons. Here, I review the three most common treatments administered in the 
literature reviewed in further detail to explore the possible predictive validity of the 
models discussed in this chapter. 
4.3.3.1 Clozapine 
46 experiments using 815 animals tested the effects of clozapine in an animal model 
of developmentally-induced schizophrenia. Clozapine was administered to animal 
models of prenatal LPS or poly I:C infection, or was given to animals infected with 
poly I:C at an early stage of postnatal development.  
The animals used to test the effects of the drug were a mixture of rats (30 
experiments, 454 animals) and mice (16 experiments, 361 animals). The rats used 
were all of the Wistar strain. The mice used were Balb/c mice (2 experiments, 36 
animals) or C57BL6 mice (14 experiments, 325 animals). Experiments mostly used 
male animals (24 experiments, 352 animals), with 13 comparisons including animals 
of both sexes (307 animals) and 9 using only female animals (156 animals). Dosage 
of the drug administered varied from 1 mg/kg to 25 mg/kg. Most experiments 
reported administering clozapine at a dose somewhere in the middle of this range at 
doses of 5 mg/kg (12 experiments, 230 animals), 10 mg/kg (16 experiments, 216 
animals) or 15 mg/kg (9 experiments, 232 animals). The effect of all treatments were 
measured in adulthood after either a single treatment of clozapine or after 3-30 
repeated administrations of the drug. Most experiments either administered the drug 
once (17 experiments) or 8 times (16 experiments) before behavioural assessment.  
Overall, clozapine improved behaviour in animal models of schizophrenia by 1.29 
SD units (95% CI -0.61-1.98), when compared to untreated model animals 
(p<0.001, n = 23 comparisons). Substantial heterogeneity was observed in the data 
(tau2 = 2.39, I² = 98.6%), but due to the low sample size once comparisons in the 




28 experiments using 656 animals tested the effects of haloperidol in an animal 
model of developmentally-induced schizophrenia. Treatment was tested in animal 
models induced using prenatal infection with LPS or the poly I:C virus. 
Haloperidol was reported in studies to be tested mostly in mice (21 experiments, 
505 animals), with a few studies testing the effects of the drug in rats (7 
experiments, 152 animals). All rats used were of the Wistar strain and the mice used 
were mainly of the C57BL/6 strain (19 experiments, 469 animals), with two 
comparisons being reported in Balb/c mice (36 animals). Interestingly most 
treatments were tested in groups of animals that included both male and female 
animals (21 experiments, 512 animals), with only three comparisons being reported 
in only male animals (72 animals), and 3 reported in only female animals (72 
animals). The effect of treatment was always measured in adulthood in response to 
either 0.1 mg/kg (7 experiments), 3 mg/kg (19 experiments), or 5 mg/kg (2 
experiments) of the drug. Usually haloperidol was given to animals only once before 
testing its effect (20 experiments), however, two experiments reported measuring 
behaviour after six repeated administrations of the drug and 6 experiments reported 
measuring behaviour after 11 repeated administrations of the drug. 
Overall, administration of haloperidol led to an improvement in behaviour in animal 
models of schizophrenia by 0.80 SD units (95% CI -0.65-2.25) when compared to 
untreated model animals (p<0.001, n = 10 comparisons). Substantial heterogeneity 
was observed in the data (tau2 = 4.04, I² = 99.3%), but due to low sample size once 
comparisons in the same group had been nested, I was not able to explore this any 
further. 
4.3.3.3 Chlorpromazine 
16 experiments using 200 animals tested the effects of chlorpromazine in an animal 
model of prenatal infection with LPS. As all experiments came from the same lab, 
there was little variability in study design. All of the animals used to test the effects 
of the drug were Wistar rats (16 experiments, 252 animals). 10 of the comparisons 
reported in the literature used male animals (124 animals) and six used female 
animals (76 animals). Treatments were always tested in adulthood and behaviour 
was analysed in response to 8 repeated treatments of 10mg/kg of the drug. 
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Overall, behaviour in animal models of schizophrenia was improved by 
chlorpromazine by 1.17 SD units (95% CI -0.24-2.58, compared to other treatment 
drugs: Table 4.8), when compared to untreated model animals (p<0.001, n = 7 
comparisons). Substantial heterogeneity was observed in the data (tau2 = 2.24, I² = 
96.8%), but due to low sample size I was not able to explore this any further. 
 
4.3.4  Exploring face validity  
Face validity of an animal model looks at the degree to which we can see a 
descriptive similarity between the model and those that are being modelled. For 
example, do we see a behavioural dysfunction in the animal model in question 
similar to that in the human who is affected by the disorder we are attempting to 
model (van der Staay et al., 2009). To explore the face validity of developmental 
models of schizophrenia, I looked at different outcome measures that were used to 
measure behaviour in these animals.  
4.3.4.1 Model-characterising studies 
Altogether 32 different outcome measures were tested in the developmental models 
of schizophrenia reviwed here (Figure 4.4). The same outcomes performed in the 
same group of animals were nested for meta-analysis. The most commonly reported 
outcomes were pre-pulse  inhibition (357 comparisons, 9141 animals), social 
interaction (153 comparisons, 2405 animals) and locomotor activity (107 
comparisons, 2269 animals). These are further explored below. 
Table 4.8 Global estimates of treatment efficacy in developmentally-induced animal 
models of schizophrenia 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of 
this estimate and N correspond to the number of comparisons contributing to the 
calculation, nested where appropriate. 
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4.3.4.1.1 Pre-pulse inhibition 
Pre-pulse inhibition (PPI) is a neurological phenomenon where the protective 
response to a startling stimulus is weakened when it is preceded by a weaker 
stimulus that is non-startling (Valsamis and Schmid, 2011). Here the pulse is the 
starting stimulus and the weaker pre-stimulus is referred to as the pre-pulse. 
357 comparisons of PPI were identified within the model-characterising studies 
included in this analysis. Most of these measurements were performed on rats (246 
comparisons, 5423 animals) and mice (174 comparisons, 4267 animals), with only 
six comparisons being measured in monkeys (72 animals). The rats used were most 
Figure 4.4 Prevalence of behavioural outcome measures reported model-





commonly Sprague Dawley rats (102 comparisons, 2076 animals) and Wistar rats 
(122 comparisons, 2588 animals). The strain of mouse used was much less 
consistent across different studies, but a large proportion of studies used either 
C57BL/6 mice (40 comparisons, 1216 animals) or C57BL/6J mice (47 comparisons, 
1025 animals). Most studies used either only male animals (241 comparisons, 4601 
animals) or both male and female animals within the same experiment (110 
comparisons, 3366 animals). Only 55 experiments reported using only female 
animals (1117 animals) and for 10 experiments it was unclear which sex of animals 
was used (339 animals). Most experiments measured pre-pulse inhibition when the 
animal was an adult (323 comparisons, using 7089 animals). Seven experiments 
measured pre-pulse inhibition when the animal was an infant (168 animals), 52 
experiments when the animal was a juvenile (961), and 44 experiments did so 
during adolescence (1544 animals). Background noise used during experiments 
ranged from 45-72 decibels (dB), with the most common levels of white noise used 
being 65 Db (179 comparisons, 42% of all PPI experiments, 3900 animals) and 46 
Db (32 comparisons, 8% of all PPI experiments, 852 animals). Startling pulses 
reported by studies ranged from 65 Db to 120 Db, with most experiments using 
either 120 Db (187 experiments, 4157 animals) or 100 Db (59 experiments, 1277 
animals). The pre-pulse used ranged from 1-67 Db above background noise. Most 
commonly, pre-pulse was reported as being 12 Db (46 comparisons, 914 animals), 
10 Db (30 comparisons, 778 animals) or six Db (41 comparisons, 819 animals) 
above the background noise. Ten experiments used a visual stimulus as a pre-
pulse. Overall, most studies measured PPI at a range of different conditions. 
Unfortunately, 15 experiments did not specify the background noise level used, 99 
experiments did not specify the startling pulse strength used, and 154 experiments 
were unclear about what type of pre-pulse was used before the startling stimulus. 
Overall, behaviour measured using PPI was worse by 0.65 SD units (95% CI -0.54--
0.76) in model animals compared to healthy control animals (p<0.0001, n = 268 
comparisons). Substantial heterogeneity was observed in the data (tau2 = 0.7589, I² 
= 97.9%), which was in part explained by the stage of life at which animals were 
measured (p = 0.0015, tau2 = 0.7178, I² = 99.07%, adj R2 = 5.41%, Figure 4.5) and, 
stemming from this, the time of outcome assessment (p = 0.0003, tau2 = 0.7170, I² = 
99.08%, adj R2 = 5.52%, Figure 4.6). Heterogeneity was not explained by any of the 
other study characteristic variables investigated with univariate meta-regression, 
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namely: animal, strain and sex of animals, method used to induce animal model and 
pulse strength above background noise. 
 
Figure 4.5 Relationship between stage of life at which behaviour is 
measured in animals and reported effect size in model-characterising 
Figure 4.6 Relationship between time of outcome assessment and reported effect 
size in model-characterising experiments 
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4.3.4.1.2 Social interaction 
Social interaction is measured in animals by quantifying behaviours that are 
observed during the interaction of two or more individuals of the same species, and 
can be measured by a variety of different measures (Wilson and Koenig, 2014). 
These behavioural measures include playful and aggressive acts of interaction in a 
normal environment. They are thought to show relevance to sociability in humans, 
and thus can be of relevance to negative symptoms in schizophrenia such as 
asociality. 
I identified 153 individual comparisons measuring social interaction between model 
and control animals in the included dataset, using 2405 animals. Most of the animals 
used were rats (120 experiments, 1913 animals) or monkeys (28 experiments, 336 
animals). Only 5 experiments used mice (156 animals). All of the monkeys used 
were Rhesus macaques, while rats were either Wistar (91 experiments, 1235 
animals), Sprague Dawley (9 experiments, 338 animals), or Fischer (20 
experiments, 340 animals) rats. The mice used were either of the strains Balb/c (2 
experiments, 76 animals), C57BL/6 (2 experiments, 64 animals) or ICR (1 
experiment, 16 animals). Animals used within experiments were either exclusively 
male (116 experiments, 1759 animals) or a combination of male and female (32 
experiments, 476 animals). Five experiments did not state the sex of the animals 
used. Social interaction, unlike other outcome measures, was usually assessed in 
juveniles (113 experiments, 1323 animals). 30 experiments measured social 
interaction in adult animals (746 animals), 8 measured this behaviour in 
adolescence (312 animals) and two measured it in infancy (24 animals). 
Overall, measuring social interaction in developmental animal models of 
schizophrenia showed a worsening in behaviour by 0.61 SD units (95% CI -0.86-
0.36) when compared to healthy, control animals (p<0.0001, n = 19 comparisons). 
Substantial heterogeneity was observed in the data (tau2 = 0.2508, I² = 97.6%), 
however, due to low sample size after nesting of data, I was unable to further 
explore sources of this heterogeneity. 
4.3.4.1.3 Locomotor activity 
I identified 107 individual comparisons measuring locomotor activity in model-
characterising studies, using 2269 animals. These experiments mainly reported 
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using rats (70 experiments, 1484 animals) and mice (26 experiments, 767 animals) 
to measure locomotor activity, with only one experiment measuring the behaviour in 
monkeys (19 animals). As with studies measuring PPI, the strains most commonly 
used were Sprague Dawley (26 experiments, 551 animals) and Wistar (24 
experiments, 349 animals) for rats and C57BL/6J for mice (19 experiments, 343 
animals). Most experiments either used male animals (63 experiments, 1267 
animals) or reported using a combination of both male and female animals (33 
experiments, 768 animals). Ten experiments reported using female animals (10 
experiments, 187 animals) and one experiment did not specify the sex of animals 
used in its experimental design, leaving 48 animals unaccounted for. Locomotor 
activity was usually assessed in adulthood of the animals (74 comparisons, 1546 
animals), but was also frequently measured at the juvenile phase (22 experiments, 
301 animals). Much fewer experiments reported measuring locomotor activity during 
infancy (3 experiments, 93 animals) or during adolescence (8 experiments, 330 
animals).  
Overall, measuring locomotor activity in developmental animal models of 
schizophrenia showed a worsening in behaviour by 7.97 SD units (95% CI -16.41-
0.47, compared to other outcome measures:  
Table 4.9) when compared to healthy, control animals (p<0.0001, n = 68 
comparisons). Substantial heterogeneity was observed in the data (tau2 = 891.28, I² 
= 98.5%). Heterogeneity was not explained by any of the other study characteristic 
variables investigated with univariate meta-regression, namely: animal, strain and 
sex of animals, method used to induce animal model, stage of life at measurement 
and time of assessment. 
 
Table 4.9 Global estimates of effect for the three most widely reported measures 
of behaviour in developmentally-induced animal models of schizophrenia 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 




4.3.4.2 Treatment-testing studies 
Altogether 11 different outcome measures were tested in the treatment-testing 
studies of developmental models of schizophrenia reviewed here (Figure 4.7). Same 
outcomes performed in the same group of animals were nested for meta-analysis. 
The most commonly reported outcomes were PPI (52 comparisons, 955 animals), 
locomotor activity (20 comparisons, 256 animals) and startle reactivity (18 
comparisons, 405 animals). 
4.3.4.2.1 Pre-pulse inhibition 
I identified 52 individual comparisons measuring PPI in treatment-testing studies, 
using 955 animals. These experiments mainly reported using rats to measure PPI 
(40 experiments, 643 animals), with 12 comparisons being reported in mice (312 
animals). 
The rats used were most commonly Wistar rats (37 experiments, 598 animals), with 
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mice used were all of the C57BL/6 strain, three of which were specified to be of the 
substrain C57BL/6J (3 experiments, 63 animals). The sex of animals used was 
mainly male (23 experiments, 361 animals). Much fewer experiments used female 
animals (14 experiments, 237 animals), or both sexes within the same experiment 
(15 experiments, 357 animals). The effect of treatment drugs on PPI was 
predominantly assessed in adulthood (44 experiments, 827 animals), with eight 
measurements being taken during the juvenile life of the animals tested (128 
animals). Background noise used during experiment ranged from 45 Db to 70 Db, 
with most experiments using background noise at 65 Db (30 experiments, 58% of all 
experiments). Three experiments did not state the level of background noise used. 
The pre-pulse used ranged from 2-18 Db above background noise. The main test 
pulse was always 120 Db. 
Overall, treatments improved the performance of animals on the PPI test by 1.33 SD 
units (95% CI 0.65-2.00) when compared to untreated animals (p <0.0001, n = 19 
comparisons). Substantial heterogeneity was observed in the data (tau2 = 1.95, I² = 
99.1%), but I was not able to explore this any further due to low sample size. 
4.3.4.2.2 Locomotor activity 
Treatment studies reported measuring locomotor activity in 20 individual 
comparisons, using 256 animals. Treatments were tested in animal models induced 
in rats (11 experiments, 136 animals) and mice (9 experiments, 120 animals). The 
rats used in the experiments were mainly Wistar rats (10 experiments, 114 animals), 
with one experiment reporting the effect of a treatment in Sprague Dawley rats (22 
animals). The mice used were mainly of the C57BL/6 strain (8 experiment, 104 
animals), with one experiment measuring locomotor activity in CD-1 mice (16 
animals). All treatment assessing studies measuring locomotor activity as an 
outcome did so in adulthood.  
Overall, treatments improved model effects on locomotor activity by 1.40 SD units 
(95% CI 0.58-2.22), when compared to untreated animals (p <0.0001, n = 19 
comparisons). Substantial heterogeneity was observed in the data (tau2 = 2.73, I² = 
96.5%), but I was not able to explore this any further due to low sample size. 
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4.3.4.2.3 Startle reactivity 
I identified 22 individual comparisons measuring startle reactivity in treatment-testing 
studies, using 509 animals. These behavioural measures are often measured 
alongside PPI and assess the animal’s fear and anxiety (Hoffman, 2016). For 
example, it has been reported that increased startle reactivity in rodents might be 
relevant to early childhood trauma (Jovanovic et al., 2009), which is an 
environmental risk factor for psychosis (Dean and Murray, 2005).  
Experiments reporting this outcome as an effect of treatment did so using animal 
models created in Wistar rats (10 experiments, 177 animals) or C57BL/6 mice (12 
experiments, 332 animals). Startle reactivity was mostly measured in groups of 
animals that included both male and female animals (12 experiments, 332 animals). 
Six experiments used exclusively male animals (100 animals) and four used 
exclusively female animals (76 animals). The effect of treatments was always 
assessed in adulthood. Startle was measured in response to a pulse at a level of 
100 or 120 Db. 
Overall, treatments did not seem to substantially improve effects in startle reactivity 
in animal models of schizophrenia. Overall effects of treatments showed a 
worsening in behaviour by 0.12 SD units (95% CI -0.70-0.46, compared to other 
outcome measures: Table 4.10), when compared to untreated animals (p <0.0001, n 
= 14 comparisons). Substantial heterogeneity was observed in the data (tau2 = 0.98, 
I² = 98.0%), but I was not able to explore this any further due to low sample size. 
Table 4.10 Global estimates of effect of behavioural outcome measures in model-
characterising experiments 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of this 
estimate and N correspond to the number of comparisons contributing to the 




4.3.4.3 Outcomes grouped by aspect of behaviour test is intending to 
measure 
Behavioural outcome measures in animal models were also grouped according to 
human behaviours that these animal behaviours are believed to have relevance to. 
4.3.4.3.1 Model-characterising studies 
I found that 10 different aspects of human behaviour were measured in model 
characterising experiments (Figure 4.8). The most common of these behavioural 
measures measured in developmental models of animals were sensorimotor gating 
(357 comparisons, 9141 animals), social behaviour (162 comparisons, 2554 
animals), anxiety (129 comparisons, 3460 animals), psychomotor agitation (127 
comparisons, 2526 animals), and learning and memory (125 comparisons, 2772 
animals). 
 
Figure 4.8 Prevalence of human behaviours being modelled through animal 
outcome measures of behaviour in model-characterising experiments 
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When data were stratified according to these behaviours the overall effects seen in 
these measurements in animal models of schizophrenia compared to healthy 
animals are shown below (Table 4.11). 
 
4.3.4.3.2 Treatment-testing studies 
In experiments looking at the effect of a treatment, I found that six different aspects 
of human behaviour were measured (Figure 4.9). The most common of these 
human behaviours were sensorimotor gating (52 comparisons, using 955 animals), 
learning and memory (28 comparisons, 366 animals), anxiety (22 comparisons, 509 
animals) and psychomotor agitation (20 comparisons, 256 animals). 
 
Figure 4.9 Prevalence of human behaviours being modelled through animal outcome 
measures of behaviour in treatment-testing experiments 
Table 4.11 Global estimates of effect when stratifying data according to human 
behaviours being modelled in model-characterising experiments 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of 
this estimate and N correspond to the number of comparisons contributing to the 
calculation, nested where appropriate. 
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When data were stratified according to these behaviours, the overall effects of 
treatments seen in these measurements in animal models of schizophrenia 
compared to untreated animals, is shown below (Table 4.12). 
Table 4.12 Global estimates of effect when stratifying data according to human 
behaviours being modelled in treatment-testing experiments 
Estimates are reported in SMD units, brackets contain 95% confidence intervals of 
this estimate and N correspond to the number of comparisons contributing to the 
calculation, nested where appropriate. 
 
4.4 Discussion 
Reviewing three widely used developmentally-induced animal models of psychotic 
disorders, it is clear that these methods of model induction are able to cause an 
overall negative effect in the behaviours of these animals compared to control 
animals. 
In order to explore their validity further to increase our knowledge about 
schizophrenia and how to treat it clinically, I looked at how these models were 
reported, the details of their experimental design, the outcome measures that were 
measured and the treatments that were reported to have been tested to ameliorate 
the effects of these models in animals. Moreover, in order to allow for robust 
translation of knowledge from preclinical to clinical studies we need to measure 
external validity, which describes the extent to which findings in an animal model 
can be generalized across populations, environments and species. 
I use data extracted in the context of studies describing one or more of three 
developmental animal models of schizophrenia, to discuss these four levels of 
validity. Any interpretations made here using these data are done so and should be 
done so with caution due to often small sample sizes contributing to the overall 
observed effect.  
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4.4.1 External validity 
In order for pre-clinical studies to be useful for predicting outcome in humans, 
results in animal studies of psychotic disorders have to be generalizable to humans 
who present with these psychotic disorders. 
Here we see that a large majority of studies use male animals for their animal 
models. This is a common issue in many pre-clinical research fields (Beery and 
Zucker, 2011), and can have substantial effects on the generalizability of results 
gained in the pre-clinical field for other domains of research. While there have been 
rules in place since 1993 about including women in clinical trials, no such 
regulations exist in pre-clinical research. Even though some studies report using 
both male and female animals, results are not always presented and interpreted 
separately and therefore differences in outcomes are not clear between the sexes. 
In the clinic, a number of sex differences have been observed among schizophrenic 
individuals. While males have been shown to have an overall relative risk ratio of 1.6 
compared to females, incidence of schizophrenia in males and females varies 
across different age groups, with incidence of schizophrenia increasing to similar 
levels in women as in men by late middle age in women (Kleinhaus et al., 2011). 
Men tend to have an earlier onset of symptoms than women by about 3-4 years 
(Häfner, 2003), which reinforces the importance of age of model assessment in 
animals as well as age at which a potential treatment should be tested in these 
models. Data in this subset of the literature show that while model-characterising 
studies measure the behaviour of animals at various stages of life, most 
measurements are still taken in more mature animals and the effects of potential 
treatments are mainly only tested in adulthood. Schizophrenia has an onset peak in 
young adulthood, with men generally presenting with symptoms between 18-25, and 
women usually developing the disorder between 25-35. Women also seem to have 
a second onset peak after the age of 40, which is likely explained by hormonal 
changes (Kleinhaus et al., 2011). Moreover, some individuals present with the 
disorder much earlier or much later outside of this risk period in early adulthood and 
are potentially different in terms of psychopathology (Sato et al., 2004), something 
which has not been explored to a great extent in developmentally-induced animal 
models. Other differences between the sexes that could affect translatibility include 
differences in symptomology. Men and women don’t seem to differ significantly on 
positive symptoms (Ring et al., 1991), but men are observed to have more severe 
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negative symptoms than women in the form of worse social functioning, blunted 
affect and avolition. Women on the other hand more commonly show affective 
symptoms and are observed to respond better to treatments in the clinic (Leung and 
Chue, 2000). Furthermore, neuroimaging has shown differences between boys and 
girls in brain maturation during adolescence (Lenroot et al., 2007).  
It has also been noted in preclinical studies that males and females of animal 
models of psychotic disorders respond differently in experiments. For example, 
females have been shown to show enhanced responses to NMDA antagonists such 
as MK-801 and phencyclidine in terms of increased locomotion and stereotyped 
behaviours over their male counterparts. Females also experience less anxiety in 
response to these drugs compared to male animals (Kokras and Dalla, 2014). 
Animals also perform differently in some behavioural outcomes, with some evidence 
showing that female mice show reduced latent inhibition compared to male mice, 
whereas female rats show greater latent inhibition than male rats (Kokras and Dalla, 
2014). While meta-regression did not identify sex of animals as a variable that 
significantly explains observed heterogeneity in any of the above analyses, focusing 
research on a single sex is unlikely to give a complete picture of the underlying 
mechanisms involved in these disorders. As some behavioural measures are 
sensitive to hormonal fluctuations, these differences should be investigated, and 
models, outcome measures, and treatments should be validated in both sexes. If we 
know that there are profound differences between males and females in the clinic, 
then investigating this variation in detail might increase our understanding of the 
underlying biological differences. The studies reporting animal models using 
developmental induction methods reviewed here seem to account for little of this 
variability in the clinical population of schizophrenia, which potentially affect the 
external validity of results obtained in these preclinical studies. These variabilities 
are also seen in different strains and should therefore also be considered when 
generalizing results gained from mice or rats of the same strain. 
Moreover, the experimental design of treatment-assessing studies in animals is 
often too simplistic compared to its equivalent clinical treatment paradigms. For 
example, in humans treatments are expected to be taken continuously and 
discontinuation of treatment is associated with relapse of symptoms (Remington and 
Kapur, 2010). Simple acute administrations of therapeutic agents in animals do not 
reflect this treatment paradigm and, as a result, we do not observe the treatment 
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resistance and side-effects commonly associated with long-term treatment in human 
schizophrenics. 
Findings show that there is large variability in terms of the test used to measure 
changes in behaviours, the times at which model is induced, and the dose and 
frequency at which this is done. While variation in study design is widespread across 
the field and is likely to increase the external validity of findings, many conditions are 
only reported a handful of times, often within the same study. It is difficult to assess 
the robustness of findings if results are not replicated across different laboratories. I 
did not extract information here about certain study characteristics, but as we know 
the environment is a key player in the development of animals and schizophrenia in 
humans, it would be interesting to compare differences in the husbandry of animals, 
especially housing conditions, in models that are primarily based on this factor such 
as isolation rearing. Of course, this is very much limited by the extent to which these 
measures are reported within studies and evidence shows that reporting of these 
variables is incomplete in the literature (Prager et al., 2011). 
4.4.2 Construct validity 
The construct validity of developmentally-induced animal models of schizophrenia is 
thought to be high. As mentioned in Chapter 3, one of the supposed advantages of 
these models is that they are able to recapitulate the clinical picture of schizophrenia 
being a delayed onset of symptoms, whereby perturbations in early development do 
not manifest themselves behaviourally till adulthood (Marcotte et al., 2001). While 
most experiments measured behaviour during the adult phase of animals’ lives, 
measurements taken in young animals showed much larger effects in changes in 
behaviour between model and control animals. This variable, however, did not 
explain any of the observed heterogeneity.  
While most experiments measured behaviour in animal models created through 
prenatal disturbances to development, these did not seem to produce as large an 
effect on behaviour as, for example, infections administered after birth. In humans, 
prenatal infection has been established as a strong risk factor for schizophrenia, as 
microbial pathogens have been shown to lead to brain abnormalities, deficits in 
central nervous system development and associated behavioural disorders in later 
childhood (Brown and Patterson, 2011). Infections after birth have also been shown 
to possibly contribute to the aetiology of psychotic disorders like schizophrenia, 
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although perhaps not as strongly as prenatal infections (Dean and Murray, 2005). 
Nevertheless, both of these models are likely to be relevant especially as genome-
wide association studies (GWAS) show that some genetic vulnerabilities to 
schizophrenia might be explained as genetic vulnerabilities to infection (Stefansson 
et al., 2009). 
There was a large variety in terms of the experimental design used to induce the 
model. Animals were prenatally infected at all stages of pregnancy and the time of 
administration of infectious substances did not significantly explain any of the 
observed heterogeneity seen in the model. In humans, links between mental 
disorders and maternal infection have been shown at different stages of pregnancy 
for different types of infections (Brown and Deskits, 2010). Early to mid-pregnancy is 
most often implicated (Flinkkilä et al., 2016), however, it remains difficult to tell how 
this aspect of study design affects construct validity in animal models. Other 
research suggests that different times of infection in rodents can lead to the 
appearance of very different results in behaviour. For example, infection at early 
gestation is linked to sensorimotor deficits in adult offspring, which is thought to be 
of relevance to clinical positive symptoms, while infection at later stages of gestation 
is thought to be more closely linked with the development of behaviours related to 
negative symptoms and cognitive deficits (Macêdo et al., 2012).  
Interestingly, the dose of substance administered also did not account for any of the 
observed heterogeneity in the dataset. The impact of this variable on prenatal 
infection is also unclear in the clinic. For example, population studies of influenza 
infections have reported positive correlations between severity of infectious 
epidemics and number of children born who are later admitted to psychiatric 
hospitals. However, individual studies do not imply that exposure to an increased 
dose of prenatal influenza makes it more likely for an individual to then go on to 
develop the disorder in later life (McGrath et al., 1995). It is clear that in order to fully 
ascertain the construct validity of an animal model of prenatal infection given at a 
specific time and of a specific dose, we need to understand more about the clinical 
impact of these variables.  
Adverse rearing seemed to have the least amount of effect in producing a 
substantial deficit in behaviour in animal models. While adverse child-rearing 
experiences are considered to be an environmental risk factor for schizophrenia in 
humans, the correlation between these experiences and actual development of 
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schizophrenia is not as strong. The relationship becomes stronger when it is 
combined with a genetic predisposition for the disorder (Schiffman et al., 2001). 
While I did not review data on anatomical or neurochemical changes in these 
animals, other studies have shown brain abnormalities in these animals in the 
hippocampus and prefrontal cortex as well as affecting the microtubular 
cytoskeleton (Ratajczak et al., 2013). Therefore, this model may still have some 
construct validity to the human condition. In fact, this model may be more useful 
over than other models due to the fact that its induction involves no administration of 
a drug or compound of any kind. Therefore, any treatments that are able to reverse 
behavioural deficits in these models are likely to not simply be an antagonist to the 
agonist, or an antibiotic for the specific infection that was used to induce the model 
in the first place (Geyer and Moghaddam, 2002). 
Overall, most experiments described animal models of schizophrenia induced using 
simple techniques. While the overall effect on behaviour was similar between these 
experiments and those that induced the model using a combination of approaches, it 
is arguable that the latter may have more construct validity for the human condition. 
It is thought that schizophrenia develops as the result of a multi-hit threshold model. 
Events during a number of key neurodevelopmental milestones give rise to 
vulnerability factors that individually have a weak effect, but in unison are able to 
lead to the development and manifestation of symptoms of the disorder in 
individuals who are already genetically vulnerable (Davis et al., 2016). More studies 
reporting experimental paradigms of multiple-hit models should be carried out in 
order to ascertain whether these models might hold more relevance for clinical 
manifestations of schizophrenia than simple developmentally-induced animal 
models.  
4.4.3 Predictive validity 
The number of studies testing a treatment compound in developmental animal 
models of schizophrenia was substantially less than the number of studies reporting 
characterising these models. Moreover, most comparisons identified in the literature 
reported on the effects of already established antipsychotics in clinical use since at 
least the early 1970s. Many novel or different drugs working via different 
mechanisms were only reported in small numbers. This was disappointing as it 
meant I was not able to compare the overall effect of these drugs to the overall 
effect of the already established drugs.  
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Clozapine was the most widely tested treatment drug in this subset of the literature, 
followed by haloperidol and chlorpromazine. Clozapine was also the treatment that 
showed the largest efficacy in reducing deficits in behaviour when administered to 
developmentally-induced animal models of schizophrenia. Chlorpromazine showed 
the second largest effect, although all experiments were carried out in the same 
laboratory. Haloperidol was the least effective of the three at alleviating behavioural 
deficits in these animals. In the clinical literature, clozapine is reported to have 
superior efficacy over other antipsychotics and is especially utilised for the treatment 
of patients who are resistant to other forms of treatment (Mcilwain et al., 2011). 
Therefore, these results in animal studies seem to be in line with the findings of 
clinical trials, which show that clozapine performs better than haloperidol and 
chlorpromazine in chronic schizophrenics (Ravanic et al., 2009), and also better 
than all other typical antipsychotics (Essali et al., 2009) and atypical antipsychotics 
(Asenjo Lobos et al., 2010) in general.  
In animals, treatments were mostly tested in only male animals. In the clinic, it is not 
uncommon for men and women to require different treatments at different dosages 
(Barajas et al., 2015). For example, women require less medication to obtain a 
similar outcome as men, but they are also more vulnerable to antipsychotic-related 
side-effects (Smith, 2010). Figures collected in Scotland as part of National Services 
Scotland for medicines used in mental health show that 54% of patients receiving 
medication for the treatment of psychoses in 2016/2017 were female and 46% were 
male (NHS National Services Scotland, 2017). In addition to differential responses 
to behavioural measures in prenatally infected animal models of schizophrenia 
documented in the literature, previous studies also show that there are important 
differences between the sexes neurochemically. For example, it was shown that 
reductions in glutamate, aspartate and taurine in the prefrontal cortex were more 
pronounced in male than female animals exposed to Poly I:C infection during 
gestation (Bitanihirwe et al., 2010). These differences between models induced in 
different sexes can impact the extent to which they can predict the therapeutic 
efficacy of a treatment and might explain a large number of antipsychotics that prove 
efficacious in these animal models, but then go on to fail in clinical trials. While the 
functional mechanisms underlying sex differences remain unclear, what is clear is 
that in order to increase the predictive validity of any animal model of schizophrenia, 
treatments need to be tested on animals of both sexes to account for differences, 
such as fluctuations in hormones (Kokras and Dalla, 2014).   
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Furthermore, treatments were mostly tested in adulthood. While symptoms of 
psychosis arise in adolescence and early adulthood, statistics in the literature imply 
that treatment of these symptoms is often delayed in the clinic. The access of young 
people to mental health services has been shown to be poor, despite this group of 
individuals having the highest incidence and prevalence of mental health across the 
lifespan (McGorry et al., 2013). In fact, data collected in Scotland as part of National 
Services Scotland shows that the number of patients prescribed antipsychotics is 
highest for those in middle adulthood (NHS National Services Scotland, 2017). 
Aside from the issue of ambiguity around how different stages of adulthood in 
humans actually translate to “adult” animals (Semple et al., 2013), preclinical studies 
should also focus on testing treatments in younger animals as there has been a lot 
of interest in the prevention of psychiatric illnesses in the last few years. It is 
believed that the onset of psychotic symptoms is preceded by psychological or 
behavioural irregularities. Some researchers believe that the use of preventative 
treatments may reduce the likelihood of early clinical stages of the disorder 
progressing to a full-blown psychotic episode (Piontkewitz et al., 2012). In fact, 
evidence suggests that low doses of second-generation antipsychotics alongside 
psychosocial treatments may postpone the onset of psychotic symptoms in some 
individuals (Larson et al., 2010). Furthermore, it has also been shown in the clinical 
literature that those requiring treatment for the disorder at much earlier (i.e. juvenile 
and adolescent) and much later (i.e. elderly) stages of their lives are especially 
vulnerable to showing adverse side-effects in response to antipsychotic treatment 
(Smith, 2010). This heterogeneity in the clinical population of those requiring 
antipsychotic treatments, in terms of both age and sex, is not accounted for to a 
sufficient degree in the preclinical literature reviewed here, making true inferences 
about the predictive validity of these animal models limited.  
Differences in treatment regimens reported in experiments here and the way these 
drugs are used in the clinic by patients can also affect the predictive validity of the 
experiments described in the preclinical literature. In the clinic, especially those 
individuals with more severe symptoms often take antipsychotics long-term (Lally 
and MacCabe, 2015). Long-term treatment also means that these drugs in the clinic 
are given using multiple-dosing conditions. From the evidence here, we can see that 
for the three antipsychotics reviewed, the effect of haloperidol and clozapine was 
assessed in a large proportion of studies after a single administration of the 
treatment. It is difficult to assess the long-term efficacy of new drugs this way and it 
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is not representative of the clinical situation. To further complicate the predictive 
validity of these animal models of schizophrenia, there can be substantial 
pharmacokinetic differences between different species as well as strains. For 
example, the half-life of antipsychotics in rodents is much shorter than in humans, 
and therefore antipsychotics in animals show very high acute dopamine D2 receptor 
occupancy levels and very low D2 occupancy levels between doses (Kapur et al., 
2003). This can be potentially leading to conclusions not representative of the 
clinical picture even when drugs are administered repeatedly. This is shown by the 
evidence that a chronic regimen of single injections of haloperidol does not create 
the same pharmacokinetic profile as the same regimen in humans does (Kapur et 
al., 2000). Therefore, not only do further studies using developmental animal models 
need to use experimental designs to test novel therapeutics that more closely 
resemble the treatment regimens used in the clinic, but they also need to account 
for neurochemical differences between species. This also introduces the issue of 
side-effects that are commonly seen in the clinic after prolonged use of an 
antipsychotic (Leucht et al., 2017). The evidence reviewed here shows that 
treatment-testing studies generally measure far fewer behavioural endpoints than 
model-characterising studies and none of these behavioural endpoints included 
measures that are of relevance to side-effects in schizophrenic individuals. To be 
able to fully ascertain the predictive validity of an animal model, we have to be 
aware of both the positive and negative effects of a treatment drug during its 
development and testing in animals.  
Some other drugs tested in the literature included antidepressants, however, I was 
unable to look at the effect of these due to the small sample of experiments 
reporting them. Antidepressants have been tested in clinical trials as an adjunctive 
treatment for schizophrenia aimed at alleviating the negative symptoms of the 
disorder, however, significant improvement in these symptoms has not been shown 
(Barnes et al., 2006). More studies would be required both pre-clinically and 
clinically to assess the utility of these compounds for treatment. Furthermore, no 
treatments were tested in combined models, which as mentioned before could be a 
better representation of the clinical picture of schizophrenia. If a treatment drug 
works in a simple animal model that, has limited relevance to a clinical disorder, it is 
potentially more likely to fail in later clinical trials. This is a big issue in clinical 
research as many therapeutic drugs make it to late-stage clinical trials, but don’t 
advance any further (Moore, 2010).  
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4.4.4 Face validity  
In model-characterising studies, behavioural outcomes were measured using a wide 
variety of different tasks in animals. These tasks were reported to most commonly 
measure changes in behaviours of relevance to human phenomena and behaviours 
such as sensorimotor gating and psychomotor agitation, thought to be mainly of 
relevance to positive symptoms in schizophrenia; social behaviour and anxiety, 
thought to be of relevance to negative symptoms; and learning and memory, thought 
to represent cognitive deficits. The face validity of some of these measures of 
behaviour in animals is of course higher than others, as discussed in Chapter 3. It is 
not expected that animal models of schizophrenia should try to fully model the 
entirety of the disorder, especially as in the clinic this is complex and there is a large 
amount of variability concerning the combination of symptoms experienced by 
different individuals (Marcotte et al., 2001). Nevertheless, the face validity of those 
models that are only measured by one domain of behaviour, especially when this is 
judged based on a single test, is limited for a complex disorder such as 
schizophrenia, and will certainly not be specific to the disorder. Many of these 
behavioural endpoints are often measured as part of experiments looking at animal 
models of other psychiatric disorders. For example, locomotor activity is widely 
used, but also widely criticised in the preclinical literature for its lack of face validity 
to clinical behaviours (Powell and Miyakawa, 2006). Increased locomotor activity 
can also be of relevance to attention deficit disorder or mania, and clinical evidence 
in fact implies that hyperactivity in the clinic is actually of more relevance to bipolar 
disorder than schizophrenia (Perry et al., 2010). The lack of specificity of these 
measures can be a major issue in translation of results as an interpretation of the 
same measure of increase in locomotion can vary from “hyperactivity” to “agitation” 
to “increased motivation” based on condition of interest (Moore, 2010).  
The most popular outcome measure reported in the literature was pre-pulse 
inhibition, which measures a phenomenon called sensorimotor gating in humans, 
which as mentioned previously, is thought to be negatively affected in schizophrenic 
individuals. As already reviewed briefly in Chapter 3, this has been thought to be a 
behavioural outcome measure with good face validity as this same phenomenon 
can be measured in humans using similar stimulus parameters, and response 
characteristics seem to be similar across different species (Geyer, 2006). Many 
clinical studies suggest that PPI deficits improve in response to especially atypical 
132 
 
antipsychotic medication in schizophrenic individuals (Leumann et al., 2002), and 
that clozapine is superior in normalizing PPI compared to other atypical 
antipsychotics (Oranje et al., 2002). Furthermore, these improvements in PPI have 
been shown to correlate well with improvements in symptoms, including negative 
symptoms (Minassian et al., 2007). Face validity of this behavioural measure in 
animal models is further strengthened by observations here and elsewhere in the 
literature (Hadar et al., 2015). Data show that deficits in PPI seem to emerge 
postpubertally, which is an observation also corroborated by clinical evidence 
(Takahashi et al., 2011), however, human studies in schizophrenia don’t imply that 
this deficit worsens with age (Mena et al., 2016). Furthermore, studies in 
adolescents at risk for psychosis show that deficits in PPI are present before the 
onset of psychosis (Quednow et al., 2008; Ziermans et al., 2011), and this 
behavioural measure in animals might therefore be applicable in the study of 
preventative approaches to schizophrenia. However, it is also reported that PPI 
scores of prodromal subjects who go on to develop psychosis are comparable to 
those subjects who do not (Quednow et al., 2008), although the proportion of those 
that do is highly dependent on the term of observation. Nevertheless, this reiterates 
why early treatment of high-risk individuals remains controversial. Furthermore, the 
face validity of this measure is unfortunately further limited by the fact that a deficit in 
sensorimotor gating repsonse is not unique to schizophrenia and has been shown to 
be a neurobiological marker in many other psychatric conditions including bipolar 
disorder, Huntington’s disease, obsessive-compulsive disorder and attention-deficit 
disorder (Sánchez-Morla et al., 2016). Moreover, it is also a measure affected by 
sex as the relationship between impaired PPI and functional affliction is strongest in 
male schizophrenic individuals in the clinic and therefore is possibly less of a useful 
predictor of pscyhopathology in females. While sex did not account for any of the 
observed heterogeneity in behavioural measurements of PPI here, most 
experiments did report using male animals. Strain also did not significantly account 
for any of the observed heterogeneity in behavioural measurements of PPI reviewed 
here, however, elsewhere in the literature it has been suggested that some strains 
of rodents exhibit no or only transient PPI deficits after isolation rearing (Geyer et al., 
2001). Other factors that should be more closely looked at in future experiments are 
the role that variables such as pre-pulse intensity, pulse intensity, and background 
noise can play in variability of outcome. We see from the studies here that these can 
vary quite substantially between different experiments, and variations in these 
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variables have been shown in the literature to affect reported outcome (Swerdlow et 
al., 2000). Nevertheless PPI is considered to be a robust neurophysiologic 
biomarker for schizophrenia, as agreed by panels of experts, namely MATRICS 
(Green et al., 2004), and CNTRICS (Carter et al., 2008) (Light and Swerdlow, 2014).   
Despite PPI being the most commonly reported outcome in the subset of the 
literature reviewed here, measuring locomotor activity in animal models of psychosis 
proved to be a much more sensitive measure of an affected phenotype. This might 
partly be explained by a few experiments reporting very large differences in this 
behaviour between model and control animals. Nevertheless, locomotor activity 
appeared to also be a superior measure of behavioural outcome compared to other 
measures of behaviour in treatment-testing studies where there were no such 
outliers in the dataset. Animal hyperactivity as seen in Chapter 3 is a common 
measure of outcome in animal models of psychotic disorders, despite the fact that it 
is not a symptom commonly associated with schizophrenia. It is thought that an 
increase in locomotion in animals in response to novel environments or 
psychotomimetic drugs is a result of increased dopaminergic activity in mesolimbic 
and nigrostriatal dopamine pathways (van den Buuse, 2010). Locomotor activity is 
therefore used to assess for changes in the dopaminergic system in animals and is 
widely used in the pre-clinical literature as a marker of stereotypical behaviours in 
the clinic such as psychotic agitation. Where locomotor activity is measured in 
response to psychotomimetic drugs in developmental animal models, an increased 
sensitivity to the effects of these agents in these models is thought to model the 
increased sensitivity of schizophrenic individuals to these same psychotomimetic 
drugs in the clinic (Powell and Miyakawa, 2006). However, the face validity of this 
measure of behaviour has recently been questioned as it has been shown that 
individuals diagnosed with schizophrenia show increased presynaptic dopamine 
functions in the associative striatum, whereas animal models of amphetamine-
induced hyperactivity are mainly driven by dopamine release in the limbic striatum 
(Kesby et al., 2018). While these models have been shown to be predictive for 
antipsychotic efficacy, it is argued that this is simply due to a general increase in 
dopamine function across the striatum when psychotomimetic drugs are 
administered systematically, and systematic administrations of antipsychotics will 
therefore have an effect on dopaminergic receptors throughout the brain (Kesby et 
al., 2018).  
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More translationally relevant tests for the underlying pathophysiology of psychosis 
are thought to be cognitive behavioural tasks that can be measured to a similar 
degree in both humans and animals, and are potentially able to increase our 
knowledge about associative striatal function in animal models (Kesby et al., 2018).  
While many studies report measuring locomotor activity or pre-pulse inhibition, far 
fewer studies report looking at behaviours thought to be of relevance to cognitive 
deficits or negative symptoms in general. In humans, symptoms associated with 
deterioration in personal functioning typically arise before psychotic symptoms 
during a ’prodromal’ phase and include deficits in learning and memory, attention, 
social behaviour, communication and affect (Larson et al., 2010). In fact, 
neurocognitive deficits at these early stages are thought to be potentially useful in 
identifying individuals who are at higher risk of developing full-blown schizophrenia 
(Jahshan et al., 2010). Moreover, some psychiatrists believe that intervention at 
these early stages is able to prevent psychosis from developing (McGorry, 2015). In 
humans, cognitive deficits are severe in schizophrenic individuals, averaging about 
1-2 standard deviations below the rest of the population (Hurford et al., 2011). The 
results presented here show that animal models of developmental inductions only 
show small effects in behaviours measuring learning and memory. Moreover, 
measures of negative symptoms in the form of anxiety through tests such as startle 
reactivity and social interaction show small effects in behaviour for both model-
characterising and treatment-testing studies. At the moment, current antipsychotics 
show little impact on these symptoms, and evidence in support of specific 
treatments for either of negative symptoms or cognitive deficits within the context of 
schizophrenia is insufficient (Aquila and Citrome, 2015; Remington et al., 2016). It is 
true that it is often more difficult to model cognitive endophenotypes to the same 
level of cross-species homology as we are able to do with PPI for example, as in the 
clinic cognition is often tested through verbal communication (Feifel and Shilling, 
2010). Moreover, startle reactivity as a measure of relevance to negative symptoms 
is also measured differently in animals and humans, which makes the face validity of 
this measure hard to fully ascertain. Similar to other measures described here, these 
behaviours are also not specific to schizophrenia. This limits the face validity of 
animal models for schizophrenia that are only characterized by these deficits in 
behaviour. Therefore, quantification of models should employ a battery of 
behavioural tests relevant to schizophrenic behaviours across multiple cognitive and 
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affective domains to ascertain the full extent of face validity of a model and make 
results generalizable to subjects in the clinic (Moore, 2010).  
4.4.5 Limitations 
Unfortunately, as mentioned, resources only allowed for single data extraction. As 
has been pointed out before, double-data extraction is the gold standard, and 
therefore some human errors are naturally expected. Data extractors were given 
continuous guidance throughout the extraction process with any issues discussed 
with a second investigator (myself). All data extractors followed a pre-defined 
protocol and I checked 15% of both datasets in detail as the second screener. No 
substantial and recurring errors were encountered during this process and the data 
were therefore deemed robust. Unfortunately, due to time constraints, the rest of the 
data was only ‘sense checked’ during analysis, where any missing data or any 
obvious outliers were double-checked and re-extracted if necessary. Clearly, issues 
like this call for more robust quality control, and advocate for double-data extraction.  
While I have reviewed here three widely used and reported developmentally-
induced animal models of schizophrenia, the data collected here is not necessarily 
representative of the rest of the developmental research field and experiments using 
other methods of model induction. Moreover, data were only extracted for 
behavioural outcomes and face validity could therefore not be reviewed from a 
neurological point of view, even though it would be interesting to explore whether 
these results agreed with data seen in behavioural outcomes about the face validity 
of these animal models.  
We must also remember that conclusions based on the data presented here are 
affected by the small sample size of experiments for many of the variables 
measured, which affected my ability to perform multivariable meta-regression and 
assess for any co-linearity of variables. Finally, non-human animals and humans are 
different and behavioural changes in one might therefore not necessarily correlate 
with behavioural changes in the other. Underlying physiological responses to similar 
insults might not be the same in humans as it is in rodents or even monkeys. And 
lastly, there are some clear issues over differences in the developmental timeframe 








5 Text Mining as a Tool to Aid Systematic Reviews: A New 
Methodological Approach 
 
This work was performed in collaboration with researchers at the John von 
Neumann Faculty of Informatics, Óbuda University in Budapest, Hungary. As the 
development of this work was a computational challenge, rather than a biomedical 
hypothesis testing experiment, the reporting of the work will not be in the style of 
traditional biomedical reporting. I have instead based the structure of this chapter on 
that specified for dissertation projects at the School of Informatics of the University 
of Edinburgh (http://www.inf.ed.ac.uk/teaching/courses/diss/guide.html).  
5.1 Introduction  
As a result of advances in technology, the speed of inception of primary evidence is 
bypassing the speed at which we are able to summarize this data. This is a real 
limiting factor when it comes to making evidence-based decisions in medical 
biology, a problem that has been highlighted in the field of clinical trials (Bastian et 
al., 2010), but is an equally big issue in animal studies.  
The process of manual data extraction and analysis, is in itself a slow and subjective 
process, but these issues are magnified when it comes to the manual analysis of 
large volumes of data (Fayyad et al., 1996). This is especially the case in larger 
systematic reviews, which aim to incorporate all of the literature available for a given 
research topic and take as much information from these sources as possible. This 
contributes to the increase in the amount of data needing to be processed: 1) the 
number of records needing to be reviewed (i.e. studies in the review) and 2) the 
number of fields of interest that we are attributing to each of these records (i.e. study 
characteristics) (Fayyad et al., 1996). As a result, the benefit of systematic reviews 
is diminished by the time taken to perform them, so that findings of these reviews 
are generally out of date by the time of publishing. Adding to this time lag, is the 
concept that in systematic reviews it is encouraged that studies are reviewed by two 
independent investigators to account for human error and increase reliability.  
5.1.1 Motivation behind work 
I found reviewing and annotating publications a time-consuming task for the number 
of studies included within my review. This was an underlying issue throughout my 
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project, I realised that large, and broad projects would always have this limitation, 
unless alternative approaches were considered to enhance the speed of the review 
process. I hypothesised that automating part of the review process might make a 
difference to the speed at which you could complete a specific stage of the process. 
Such a computer aided approach would not only help a reviewer make more 
efficient use of their time, but also in turn maximise the potential of results gained 
from these reviews and let available evidence inform subsequent stages of the 
clinical drug development process faster. 
5.1.2 Objective of work undertaken 
My aim was to design a program that would not only reduce the aspect of reading 
and analysing publications for reporting of risk of bias items, but also reduce the 
impact of naturally occurring human error when doing this for a large number of 
studies.  
My two main objectives in order to achieve this: 1) develop a set of term identifiers 
that would allow for automatic phrase recognition, and 2) create a program that I 
could easily use to assess these words within multiple files at once and update a 
database storing data on these files accordingly. Primarily, I wanted to find a 
solution for increasing the efficiency of my own work, but if successful, also produce 
a tool, which could be of use to other systematic reviewers faced with similar 
problems when processing a large number of publications.  
This project was a subsidiary investigation to my overall systematic review of the 
field, but in this chapter,  I describe my reason for developing this methodology, 
discuss the utility of the approach taken and the potential of incorporating computer-
based approaches such as this one in the field of systematic reviews in pre-clinical 
biomedical sciences. While the key aspect of this work was the actual success of 
predicting risk of bias items within a number of large pieces of text reliably, I also 
describe the design of the project that we created to allow us to test this. 
5.2 Background 
Fayyad et al. (1996) suggested some time ago that volumes of this magnitude of 
work should be automated at least partially, instead of humans carrying out this 
process. They introduced the idea of knowledge discovery in databases to tackle 
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this problem of increasing difficulty in digesting the extensive volume of information 
that the digital age has made available (Fayyad et al., 1996). 
This involves the use of various computational tools to aid the process of humans 
acquiring useful knowledge from large volumes of digital data. A major step in this 
process is the use of data mining (Fayyad et al., 1996). This is the use of 
computational algorithms for the identification and extraction of patterns from large 
pieces of data, which are then often used for interpretation of the data and in aid of 
decision-making and derivation of useful knowledge from these data (Fayyad et al., 
1996; Hearst, 1999).  
A potential area where data mining can be used is in the mining of free-form text 
(i.e. text that is unstructured, for example those in a word processor). This is a form 
of natural language processing (NLP), where it is possible to automate annotation 
and thus classification of this text (Fayyad et al., 1996) by discovering information 
within data through the establishment of patterns across datasets and separating 
out signal from noise (Hearst, 1999). This is precisely what we do when we analyse 
a publication, we try to filter the relevant information from the background noise.  
Most NLP applications to systematic reviews seem to focus on the screening and 
inclusion/exclusion of relevant articles into a dataset. While there has been a 
number of attempts to utilise natural language processing techniques in the 
automating of data extraction in systematic reviews, these have been mainly 
exploratory, and few have been so far utilised in actual reviews for a full or even 
partial automation of the data extraction process. Moreover, the extent to the 
number of potentially extractable data elements that have been investigated is far 
from complete, and notably few automated natural language processing techniques 
focus on automating the assessment of the internal validity of publications 
(Jonnalagadda et al., 2015). 
5.2.1 Work carried out so far and possibilities for improvements 
In light of the size of my dataset and the need for a second screener during phase 2 
of the project, the motivation for this project was to develop a more efficient tool to 
aid my work by reducing the time taken to review full-text publications and provide a 
secondary form of review.  
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Based on this, I recognised that annotation and categorization was a stage of the 
systematic review process where text mining could potentially contribute. More 
specifically, I knew that one of the most uniform variables that could be extracted 
from a publication is the evidence for the reporting of measures taken to reduce the 
risk of bias and other methodological criteria. This was mainly based on personal 
experience of searching documents for specific words while usually performing this 
stage of the review. As there are generally only a limited number of ways in which 
certain risk of bias and methodological quality criteria can be described, by creating 
a list of search words we could search PDF’s of publications to help classify whether 
they had reported or not reported some of these list items.  
A solution that standardized and generalized the approach to this process would 
have the opportunity to overcome and minimise these issues within this seemingly 
simple stage of the review. 
5.2.1.1 Current method of reporting of risk of bias assessment 
The instruments used to assess the reporting of internal validity can vary 
considerably in the field of pre-clinical research (Krauth et al., 2013). Fundamentally 
though, they all use the same basic approach to assessment: scoring for the 
presence or absence of the clear description of a risk of bias or study quality item 
within a publication (Horn et al., 2001). As mentioned before, I use a modified 
CAMARADES checklist in my own review (Macleod et al., 2004). 
Once key words are identified within the active document of focus, I read the 
surrounding word environment and make a judgment call about whether there is 
sufficient evidence for the correct reporting of measures taken to reduce each risk of 
bias item and other methodological criteria on my checklist. I do this at a full-text 
level and while these measures are usually described within the Methods or Results, 
I am still required to find the right phrase or lack of thereof within each piece of text.  
As the analysis of this data element is a simple ‘Yes’ or ‘No’ interpretation of 
whether each item of interest has been reported or not, this should be a stage of the 
review where annotations should be consistent across different investigators. In 
practice, discrepancies often arise even at this stage of the review process. It is 
possible for a reviewer to miss the key piece of text required to interpret reporting of 
criteria. Secondly, subjectivity is introduced during interpretation of information. 
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For example, methods of randomisation are rarely described (van der Worp et al., 
2010), therefore a reviewer has to take reports of these items at face value and 
judge whether wording explains a generally correct method of randomisation or not. 
Finally, repetition of the process for large number of publications increases the 
chances of human error arising and the impact of subjectivity.  
By pre-defining which expressions should be classed as valid examples of the 
reporting of items on my checklist and which ones should not, a tool could 
potentially be created which automates this stage of the review. A solution of this 
kind would take out the above-mentioned subjectivity of text interpretation, and 
reduce the impact of the small percentage of human error that inevitably occurs 
when processing large amounts of data. A tool like this would have the potential to 
eliminate the need for a second screener, which is a common method used to try 
and reduce the likelihood of introducing errors into the dataset (Barchard and Pace, 
2011). In addition, the tool could be used as a way of validating the work of a 
human. This was a key requirement for my project, as I was not able to have a 
second data extractor for this part of my project. 
5.2.2 Previous work in similar fields 
Automation of risk of bias item reporting assessment in data identification and 
extraction from clinical trials has been explored so far by two different research 
groups (Marshall et al., 2015; Millard et al., 2016). Marshall et al.(2015) for example 
used machine learning to automatically judge the risk of bias within a trial in the 
COCHRANE Database of Systematic Reviews as well as extract text fragments 
supporting these conclusions (Marshall et al., 2015). This approach was similar to 
those used by researchers at the University of Bristol, who used machine learning to 
find relevant sentences within a piece of text and use this to rank both sentences 
and articles according to risk of bias (Millard et al., 2016). Both groups used 
supervised machine learning, with mean precision scores ranging from 0.53 to 0.87 
for items in both studies combined (Marshall et al., 2015; Millard et al., 2016). 
Unfortunately, both of these solutions have only been developed for the assessment 
of human trials. Both mainly focus on randomisation, allocation concealment and 
blinding at full-text level (although Marshall et al. also include inclusion/exclusion 
reporting), which are all risk of bias elements that are transferable to the pre-clinical 
research field. Despite this, some key aspects in the reporting of these risk of bias 
items differ between clinical trials and animal studies (Krauth et al., 2013). For this 
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reason, I wanted to see if I could develop a similar tool to automate the assessment 
of the reporting of risk of bias for studies reporting pre-clinical studies as opposed to 
clinical trials.  
Firstly, the approach taken for the evaluation of measures taken to reduce risk of 
bias is different for clinical trials, and the one that many systematic reviews use 
when assessing risk of bias in animal experimental publications. The approach for 
risk of bias prediction for clinical trials, and incidentally the tool used by both groups 
to develop their algorithm, is based on the COCHRANE Risk of Bias tool (Higgins et 
al., 2011). This tool does not class articles based on a simple checklist, but rather 
gives studies a “high”, “low”, or “unclear” risk of bias based on the amount of detail 
given within a published trial or mixture of sources for the same trial (Higgins et al., 
2011). In comparison, many systematic reviews of pre-clinical studies, including this 
current work, have used checklists to assess the likelihood of risk of bias or low 
methodology (Macleod et al., 2004; Sena et al., 2007).  Methodology is evolving and 
newer tools, such as SYRCLE’s risk of bias tool (SYRCLE’s RoB tool) for animal 
studies, which have been developed based on the Cochrane RoB tool, offer a more 
consistent and similar approach to the assessment of risk of bias to those used for 
human studies (Hooijmans et al., 2014). As it makes an important differentiation 
between assessment and interpretation, it is possible to class evidence of not 
randomising separately from those that did not give enough information to determine 
whether randomisation took place or not. This is not something current checklists, 
like the one used here, usually account for. While the applicability of this tool will still 
depend on the current detail of reporting within pre-clinical studies, moving towards 
this level of reporting of risk of bias assessment has the potential to yield a more 
accurate critical appraisal of the methodological quality of animal studies than a 
simple checklist method. While the content of description used still matters within 
these animal studies when it comes to interpretation of risk of bias within a study 
(Kilkenny et al., 2009), a number of challenges remain in analysing risk of bias in 
animal studies and why we analyse clinical trials differently to animal studies.  
Most importantly, reporting of risk of bias has improved in clinical trials (Plint et al., 
2006), while there has been little improvement seen in animal studies (Macleod et 
al., 2015). This is possibly due to more advanced awareness around the topic of 
methodological quality in clinical trial designs, and how inadequate studies can 
erroneously estimate treatment effects (Schulz et al., 1995); as well as the 
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introduction of guidelines adopted by journals (Schulz et al., 2010). The literature on 
how to evaluate risk of bias in a randomized clinical trial is also more extensive, 
whereas there was little in terms of guidance for the animal research community 
before the introduction of the ARRIVE guidelines in 2010 (Kilkenny et al., 2010b).  
This lack of universal standards and concurrent unfamiliarity with the rationale of 
these certain aspects of experimental design (Festing, 2013), mean that pre-clinical 
evidence reviewers come across a wide range of different expressions used to 
report risk of bias items, where sometimes these explanations don’t actually qualify 
for the true definition of the items (Hooijmans et al., 2014). Moreover, in animal 
studies we have greater flexibility in terms of experimental design including multiple 
species and models to recapitulate human behaviours, as well as a large range of 
outcomes measured. This is often due to animal experiments being exploratory 
(Ioannidis, 2012). While the COCHRANE risk of bias tool, encourages the 
assessment of risk of bias for each main outcome or class of outcomes (Higgins et 
al., 2011), many systematic reviews of animal studies perform reporting of risk of 
bias assessment on a publication level (Sena et al., 2007). While some forms of 
assessment suggest doing this for individual outcomes within studies (Hooijmans et 
al., 2014), this can sometimes be difficult as these risk of bias items are rarely stated 
separately for different outcome measures. These are all differences that can make 
the automation of pre-clinical studies compared to clinical studies different, and 
perhaps more difficult. 
In addition, in a systematic review of pre-clinical studies, we disregard human data if 
there is any within the same publication. This is something that needs to be taken 
into account when developing a tool for the identification of specific terms within a 
publication, so as to try and not pick up on risk of bias reporting for human studies 
within the same publication. 
5.2.3 The relevance of this work to our systematic review process 
CAMARADES has been working on creating a fully integrated online platform, which 
aims to act as a hub for systematic reviewers of preclinical studies to carry out 
different stages of their review using practical web-based tools and applications 
(www.syrf.org.uk). I wanted to create a solution that could potentially be further 
developed and incorporated into this framework if proven successful. This would 
add an additional step to the already present online systematic review process that 
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includes a web-assisted tool for screening and annotating your dataset. This 
approach of applying text mining to reporting of risk of bias assessment is in line 
with work by the SLIM (Systematic Living Information Machine) consortium, a multi-
centre collaborative pilot project that aims to automate various stages of the 
systematic review process with the motivation that someday automatic “living” 
systematic reviews will be achievable. 
5.3 Work undertaken 
5.3.1 Approach to design 
The main concept of the work I undertook was to use natural language processing 
to review a collection of publications describing pre-clinical studies of biomedical 
disorders, by identifying and predicting risk of bias assessment for each study.  
There were two components to the solution designed: the search terms used to 
capture the relevant information within a piece of text, and the program that ran 
these terms in a given set of files.  
5.3.1.1 Objective 1. Creation of a set of term identifiers 
The application of natural language processing to data extraction in systematic 
reviews is dependent on term identification, which is the main limiting factor in the 
processing of useful information in the literature (Krauthammer and Nenadic, 2004). 
My first objective was to develop a set of expressions that would allow for automatic 
term recognition within a text. There are a number of different approaches to this 
(Ananiadou and McNaught, 2006), including the ones used by the studies 
mentioned above where the machine learning approach has been used to identify 
relevant sentences within a large piece of text (Marshall et al., 2015; Millard et al., 
2016). Because our interpretation of a study’s risk of bias in animal studies requires 
a simpler approach of assessing for a positive or negative reporting of a checklist 
item, we took two different approaches and compared the results of these for their 
ability to recognise terms within a large piece of text. 
 
The first approach to term recognition, the dictionary-based approach, works by 
using existing terminology in order to find the occurrence of a term (Ananiadou and 
McNaught, 2006). The system is given a list of terms (i.e. could be a string) and if 
that term is matched within the text of interest, then it is recognised by the computer 
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as an instance of that term and its related concept (Caporaso, 2009). The accuracy 
of this approach to term recognition is most affected by term ambiguity, and 
deviation from the original terms specified (Ananiadou and McNaught, 2006). In 
comparison, the rule-based approach uses patterns of term formation, where rules 
are used to characterize a common structure for terms (Ananiadou and McNaught, 
2006). Here a string of defined characters is matched within a text of interest against 
a rule or rules that are given to the system. This is often achieved by way of regular 
expressions (Caporaso, 2009). 
I developed a set of key phrases for three widely applicable approaches, which can 
reduce the risk of bias in experimental design and provide more precise results. 
These were random allocation to treatment group, blinded assessment of outcome, 
and sample size calculation (SSC). I chose these risk of bias and methodological 
quality items because they were all included in the minimum core set of items 
authors should report in their grant applications and scientific publications (Landis et 
al., 2012).  
As I did not have structured data (i.e. quotations taken from actual publications) 
available for randomisation, blinding and SSC (i.e. specific quotes within the 
publication to justify risk of bias assessment), I had to first distinguish useful terms of 
the subject from non-related noise. From previous experience working on other 
systematic reviews, I realised that simple search words would not be specific 
enough for the computer to be able to always make a correct prediction for an item. 
For this reason, I decided to assess the phrase environment of words commonly 
associated with my items of interest. This was then used to develop a set of key 
phrases that would be designed to predict reporting.  
For randomisation and blinding, I used the library of PDFs I had available from my 
systematic search of animal models of psychotic disorders as my training set. I 
initially made a list of keywords that are commonly used to describe each of these 
items. The idea was to use the program PDF Xchange Viewer, find phrases 
containing those keywords and score them as “yes” or “no” for the reporting of that 
study quality item. I used “random” for randomisation and the terms “blind”, “aware” 
and “naïve” for blinded assessment of outcome. I made a record of every word 
environment I had identified these terms in in my set of .pdf files and used it to 
create a list of phrases that I would always class in a paper as having reported that 
risk of bias or methodological quality item in question. I used the definition of 
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randomisation as a random allocation of animals used to control and intervention 
groups. Blinding was defined as the reporting of investigators being blinded to the 
knowledge of which intervention had been given to which group of animals during 
the experiment (Hooijmans et al., 2014). This means that a sentence that said 
“animals were tested in a random order”, I would not class as having randomised 
during experimental design, but a sentence such as “animals were randomly 
assigned to groups” I would class as an example of reporting of randomisation. 
Similarly for blinded assessment of outcome “whole-cell blind patch clamp 
technique” should not be an example of reporting of blinding, however, “tests were 
carried out by a blind investigator” should be classed as a true example of the 
reporting of blinding, in my opinion.  
Due to the fact that SSC is a methodological quality criterion that is seldom reported 
in pre-clinical research fields (van der Worp et al., 2010), my approach for search 
term development was slightly different here. I used data extracted in our 
CAMARADES database as part of other systematic reviews to identify publications 
that had been classed as reporting SSC. Publications included here described pre-
clinical models of stroke, Parkinson’s disease and multiple sclerosis. While I relied 
on other investigator’s classification of this methodological criterion within a study, 
when identifying relevant publications, I made my own interpretations of each 
publication I reviewed. Much like before, I made a list of expressions that were used 
by authors within publications to say they had performed SSC. 
I extracted the shortest possible textual span that led me to determine reporting of 
risk of bias, even if these were not full sentences. It was essential that I obtained as 
many examples of descriptions as possible, so I extracted all possible standalone 
phrases that led me to my conclusion, even if this meant extracting multiple 
instances from the same publication. 
5.3.1.1.1 Dictionary-based approach 
Using my final list of differentiated word environments, I narrowed these down to a 
list of phrases that would pick up as many of these examples as possible while 
trying to avoid picking up any of the examples where risk of bias items would not be 
scored as having been reported. These phrases were then used as our term 
recognition set to parse files with. 
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5.3.1.1.2 Rule-based approach 
Regular expressions are a sequence of symbols and characters that declare a string 
or a pattern to search for in a longer piece of text. I thought that the use of regular 
expressions would provide more flexibility over simple phrase searching in terms of 
picking up on expressions that vary slightly from the list of expressions specified. It 
would also exclude instances where these expressions are used to explain 
something that was not done (i.e. experiment A was not randomised). I created a list 
of regular expressions that would serve the same function as my original term 
recognition set of words above, but without the limitation of having words appear in 
the specific order, case and tense given. 
5.3.1.2 Objective 2. Creation of program to run and record results of term 
recognition 
My second objective was to design an application that was able to perform and 
automate a series of steps that mimicked the human reviewing process (Figure 5.1) 
for multiple studies at once. This could then “read” a PDF, using our developed set 
of term recognizers, identify any potential useful snippets of text, predict risk of bias 
items of interest for that study, and finally record this information within a database 
containing data for a multitude of studies. 
To achieve this, we needed the program to have the following three functionalities: 
(1) read a given file; (2) search for words or phrases in this file; (3) interpret results 
of search and record this in a database accordingly.  






Primarily, I was the user, but it is a possibility that systematic reviewers in other 
fields of pre-clinical research could use the solution one day. I had to take into 
account certain basic characteristics about these potential users: variability in 
familiarity and ease of working with computer applications, varying levels of 
knowledge and experience of systematic reviews and reporting of risk of bias items, 
as well as different locations of users and resources including computer platforms 
preferred and available to them. 
5.3.1.2.1.2 Input and Output 
While it has been stated that there are numerous instruments available to assess 
risk of bias in pre-clinical studies (Krauth et al., 2013), systematic reviews performed 
by the team at CAMARADES and collaborators, tend to centralize around existing, 
previously published study quality lists of assessment (Macleod et al., 2004; Sena et 
al., 2007). These are then often adapted to the research area of interest studies that 
review is being conducted in and can assess a variable number of different risk of 
bias items (Krauth et al., 2013). Therefore, this part of the application would be 
different for different investigators and I wanted to make the input of this information 
open to different sorts of options.  
 
In terms of the information output that would be beneficial to the user, the aim of this 
application was primarily to show the search results for each individual publication 
(i.e. phrase identified and final ‘call’). This was so I could assess the overall 
effectiveness of our solution, but also in order to further develop the program by 
knowing which phrases had been identified within each publication and be able to 
look at those in more detail where disagreements arose between the computer and 
the human screener. In contrast, other users might only be interested in a summary 
of the prevalence of a certain risk of bias item, therefore, this sort of output was also 
important. I wanted the output to be communicated to the user through the user 
interface and give the user the option of storing the results in a database. As my 
project uses MS Access to record information about studies within my dataset, I 





CAMARADES has been working on creating a fully integrated online platform as 
mentioned earlier; therefore, I wanted to create a solution that could be incorporated 
into this framework if needed in the future. 
5.3.1.2.1.4 Summary of software requirements 
Based on these criteria with the help of a programmer I created an application that 
would ideally meet the following requirements to be considered successful: 
- User-friendly interface 
- Allow the investigation of the reporting of risk of bias item of choice 
- Search a number of different files at once 
- Facilitate the storage of these results in a database, if necessary 
- Possibility of integration into existing web-based platform 
5.3.1.3 External software  
One of the biggest considerations before starting the development of the project, 
involved thinking about how articles in a systematic search dataset might be “read” 
by the program. Usually scientific publications are published in PDF (Portable 
Document Format) (Adobe Systems Incorporated, 2006).  This file format can 
present elements of a printed document as an electronic image that is independent 
of software, hardware and operating system. PDF is based on PostScript, a page 
description language that runs in an interpreter to generate an image. This image is 
coded using separate objects, meaning text and images are stored in a special 
format that is fixed and not easily modifiable. This creates an obstacle when it 
comes to analysing these files, as the text that we see is not encoded in a plain text 
format. For this reason, in order to be able to edit or use this text of interest, it needs 
to be converted to an alternative format before it could be analysed.  
PDF documents were converted to plain text format using an external software. We 
trialled multiple converters available on the web and chose the “best option” 
(https://bytescout.com/). This software was chosen as it was able to convert as 
many of the given PDF files as possible (including secured PDFs in some cases) 
and gave an output that was meaningful and therefore could be easily searched 




5.3.1.4 Proposed Validation of Solution 
I tested the effectiveness of the program and validated my search terms developed 
for risk of bias items by comparing it to previous scoring of risk of bias by a human 
investigator (i.e. the current “gold standard”).  For this, I used a separate dataset of 
1359 of other in vivo studies from another project carried out by our group (Macleod 
et al., 2015), where risks of bias had been previously ascertained by two 
independent human reviewers. Results of the human screening process were stored 
within an independent MS Access database, where the application could update the 
appropriate fields based on the results of the search. Once the results of the 
application were known, I could simply run a query in order to look at the number of 
studies in agreement and those where the computer did not give the right prediction 
for risk of bias. 
In order to evaluate the performance of the search terms developed I compared the 
predictions made by the computer to the values given by the human screeners and 










Figure 5.2 Confusion matrix showing how performance of computer 
tool is evaluated against human screener 
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Using values from this table, I was able to calculate sensitivity (i.e. also termed 
recall). This is the number of positive publications correctly predicted by a computer, 
as a proportion of all the positively classed publications by a human screener 
(Equation 5.1);    
           5.1 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
 
Alongside specificity, which is the number of correctly predicted negative 
publications by a computer, as a proportion of all the actually negatively classed 
publications by a human screener (Equation 5.2); 
5.2 
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 
And Precision, which is the number of correctly predicted positive publications by a 
computer, as a proportion of all the positive predictions it has made (Equation 5.3). 
5.3 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 
Finally, I calculated an F-score, which is a harmonic mean between sensitivity and 
precision, and thus gives equal weight to both. As a result, it requires both values to 






Altogether, these performance measures can give us an idea of how good the tool is 
at correctly predicting positive instances of a term and thus concept (i.e. sensitivity) 
and the effectiveness of the tool in correctly not identifying those instances where no 
concept is to be associated (i.e. specificity). Finally, it gives an idea of how sure we 
can be that when a computer makes a positive call, it is a correct prediction (i.e. 




5.3.2 Design of Solution 
Here, I describe the overall structure and functional flow of data within the solution. 
The exact code can be found within the appendix of this document including 
annotations of the function of each line of the code (see Appendix III. Text mining 
tool: code used for program and list of expressions).  
5.3.2.1 Design features 
5.3.2.1.1 Platform solution 
The system was designed in a globalised manner through a web-based solution, 
with the thought that it could be incorporated into and hosted on existing web 
platforms. Here, once public access is given to the web page on a local or a global 
network, multiple users could use the application simultaneously. The advantage of 
this approach over a localised solution would be that data would be stored centrally 
on a server and individual user access would be controlled. This also allows for 
more frequent back-ups to be made centrally and thus keeping data safer, even 
when multiple people are working on the same project.  
5.3.2.1.2 Architecture of the system 
The architecture of the system was built in the architectural style of a 
Representational State Transfer Application Programming Interface (REST API). 
This is widely used for designing dynamic data driven web solutions. This 
technology allows the execution of required tasks within the program to be 
distributed (i.e. split up) between a front-end and a back-end. The back-end of the 
program performs all the core functions that can be automated such as tasks that 
require large calculations. The front-end takes input from the user that specifies 
instructions on how to execute back-end tasks and displays results of actions on a 
user-friendly interface. This sort of separation of tasks helps to improve performance 
of the tool. It also allows different browsers to be able to display a standardized user 




The two ends communicate with each other through standardized message 
structures (i.e. written in JSON, described in more detail below), which are sent back 
and forth between the two ends. These are in the form of GET and POST data, 
forms of AJAX HTTP requests (Asynchronous JavaScript and XML Hypertext 
Transfer Protocol), which are a set of rules used to transfer data between clients 
and servers. For example, GET is used to request data and POST is used to submit 
data. When the front-end instructs the back-end to do something it will prepare 
instructional statements in a standardized format that sends data to the back-end via 
a POST message. This way, the back-end knows what data to work with and it can 
carry out the appropriate calculations and actions. Once the back-end has carried 
out these actions, it then sends a performance report back to the front-end to say 
whether it has successfully carried out the specified instructions or if any errors 
occurred. 
 
Figure 5.3 The architecture of the program based on a REST API design that allows for 
complicated tasks to be separated out and performed “behind the scenes” by the 
back-end, while communicating only the relevant data with the front-end 
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5.3.2.2 Functional features 
5.3.2.2.1 Key stages of system behaviour 
The application is able to carry out three functionalities:  
1. Perform a search of a given set of .txt files using simple phrase expression, 
regular-expression or both 
2. Check size of given set of .txt files and compare these files with another set 
of .pdf files to highlight those .txt files of small size* and those which do not 
have a corresponding .pdf file 
Update a database (i.e. MS Access) using results obtained from the previous two 
steps. 
*File of a small size was defined as anything below 1KB. This equates to 1024 
bytes, which roughly equates to the same number of characters. One page of text is 
equal to about 3290 characters. This limit of file size was decided on from the 
observation that when comparing files before and after conversion from .pdf to .txt 
files, .txt files smaller than this were generally not converted properly and therefore 
did not contain any relevant and usable information for the text mining to be 
validated on. 
The program executes each of these actions so that it follows the overall 
communication system specified above. When the user prompts the program to do 
something: 
1. Front-end prepares an Update Statement containing instructions that is 
submitted to the back-end (i.e. search string to be processed and ran on 
files) 
2. Back-end receives this statement, it executes the statement accordingly, by 
looping through all relevant files (i.e. actual running of search) 
3. Back-end returns results of action to front-end, so it can be displayed to the 
client (i.e. results of search displayed to the user). 
This setup allows data to theoretically flow through the program to create a user-
friendly tool that is able to search publications using search expressions provided by 
the user and display results of this search back to the user, allowing them to update 











Figure 5.4 Detailed flowchart of how the search function of the tool works – including 
how front-end and back-end communicate 
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The file checker was a later addition to the application and functions in a similar 
flow, however, is independent of the search (Figure 5.5). 
 
5.3.2.2.2 Graphical appearance and functions 
 
The application is achieved through a single page application. This means that on 
initial loading of the page, the whole application is loaded into the browser. Due to 
the REST API architecture, however, only certain information is made visible to the 
user at any given stage of application use. This is controlled by the front-end 
process workflow, describing which components should be made visible to the user 
and which should be hidden from the user interface at different stages. 
Figure 5.5 Detailed flowchart of how the file check function of the tool works – note 
that the database update is the same as for the search function 
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5.3.2.2.2.1 Welcome page 
On loading the application the first ‘page’ that is visible is the Welcome Page of the 
tool (Figure 5.6). From here, the user has the following interactive possibilities: 
1. Perform a simple phrase expression search – this includes a free-text box 
where the user is able to enter their search phrases separated by a comma; 
and the actual “Search” button* 
2. Perform a regular expression-based search – this includes a free-text box 
where the user is able to enter their regular expressions in a specified 
format; and the same “Search” button as before* 
3. Check existence and size of files available in the specified folder – this 
function exists so user is able to check whether converted .txt files exist for 
each .pdf file in a given folder and whether these .txt files are of a size that 
are likely to contain valuable information 
*There is an option to execute both searches, by selecting the tick-box and entering 








Based on the user’s input, different workflows can be initiated - a simple expression 
search, a regular expression search, one where both are possible, and a file size 
check, the results of which can then all be used to update a database in the same 
way (Figure 5.7). 
 
5.3.2.2.2.2 Results of Search page 
Once the search has returned the results, these are displayed so that overall 
number of positive hits is shown as well as each publication where a hit has been 
identified is listed below with the corresponding piece of text identified within the file. 
At the top of the page, there is an option for the user to enter information relating to 
updating a database specified. This pilot project was designed to primarily update 
and tested on an MS Access database – a desktop relational database, but the 
application is designed to be able to work with other server-side relational databases 
as well (i.e. MSSQL, Oracle, MySQL). Here the user can specify the target table, the 
target column and the target value to be used for the Update Statement. The system 
by default will update all of the records that have come back with a positive result. 
The user is able to review and override this setting, by deselecting tick-boxes for 
records that they do not wish to include in the Update Statement ( 






Figure 5.7 Four main workflows that use four different functions initially, and then 




Figure 5.8 Appearance of the user interface when results of a single search are 
returned and displayed 
 
As mentioned before, it is also possible to run both searches simultaneously, where 
the data to be displayed is selected by the user based on which calculation they are 
interested in, in a similar format to described above (i.e. results of both searches or 
just a single one) (Figure 5.9). This was mainly useful for a quick comparison of the 
two search approaches in finding the information of interest within the given set of 
files. 
Figure 5.9 Appearance of the user interface when both searches are selected and 
executed simultaneously, and results are returned and displayed 
160 
 
5.3.2.2.2.3 Database update result page 
The results of the executed Update Statement are displayed to show the overall 
success of the update process, including number of errors encountered, if any, and 
a log of all the records that had been successfully updated (Figure 5.10). 
 
5.3.2.2.2.4 File overview page 
Upon executing the ‘File Overview’ function on the Welcome page, the page 
changes to display the results of the file checker function by showing the total 
number of files that are likely to be erroneous (i.e. be incomplete in terms of text) 
and then also each file one by one contained within the folder of interest. This is 
calculated by setting a cut-off limit for the size of each file, where anything smaller 
than this limit is highlighted by the program and given a “warning” label. The 
program also highlights where no corresponding .txt file exists for a .pdf file. This 
way it is possible to exclude these records from final text mining analysis. It is also 
possible for the user to save this information to a database in a similar way to the 
way the results of the search were updated to a database (Figure 5.11). 
 
Figure 5.10 User interface as it appears after the user has updated the database 
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5.3.2.3 Technology used to implement solution 
For this pilot project, a web server and a back-end framework were set up. To create 
the web server the freeware Apache was used and for the back-end framework PHP 
(Hypertext Preprocessor) was used. The application was developed on two separate 
local environments at the same time – one on Windows and one on Linux operating 
systems – in order to design a portable and widely applicable solution that is 
compatible with both operating systems. 
For front-end development, the following languages were used: 
HTML (HyperText Markup Language) – used for the overall structure of user 
interface; 
CSS (Cascading Style Sheets) – used for the styling and formatting of the HTML 
elements; 
JS (JavaScript) – used for specifying interactions for dynamic data handling; 
AngularJS – used to visualize dynamic data by simplifying the JavaScript code and 
HTML element visualizations; 
JQuery - helper class for Javascript to aid access of HTML element values and 
attributions;  
JQuery mobile – used to pre-define HTML elements in terms of styling to improve 
user experience. 
Figure 5.11 Results displayed on page in response to the program being prompted 
by the user to check files 
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A HTML document was used to specify the basic structural elements of the web 
page and thus define images, texts and inputs visible to the user. To support this, 
CSS was used, which is a HTML style sheet language essential in web design that 
allows the designer to specify the layout and the visual presentation of a web page 
by defining how HTML elements should be represented on screen. JavaScript, a 
dynamic scripting language was used for programming the behaviour of web pages. 
This was used to make the HTML document interactive. JavaScript is able to carry 
out simple functions and more specifically, we used JavaScript to generate various 
requests, for example, when a button is pressed, or when data are entered into 
fields, as well as for animation.  
PHP was used to develop the backbone of the program and manipulate the 
operation of the program. This is an easy to use and widely used, server-sided 
scripting language that is especially useful for interactive and dynamic web 
development, and thus allows for the automated calculation of heavy code parts to 
run by a webpage hosting server. This programming language was chosen over 
some other ones because it is a good beginner language that is free, open source 
and easy to learn for beginner coders like me. It also has a strong support 
community behind it, which means that any bugs can be resolved fast, making the 
development process easier and quicker. Moreover, it is a clear and easy to 
understand language that can be edited in simple text editing software packages. 
Using this language, dynamic websites are achievable that are fast operating and 
can call on JavaScript objects and run on various operating systems, meaning the 
final product can easily be transferred and adapted to a new system.  
As mentioned above, the front-end and the back-end communicated with each other 
through the posting of ‘messages’ written in JavaScript Object Notation (JSON) back 
and forth to each other. JSON is a data-interchange format, or in other words, 
syntax that is used to exchange and store data between the front-end and the back-
end. When exchanging data between the two, data is required to be in a text format. 
JavaScript objects can be converted into JSON from the front-end and sent to the 
back-end, and converted back into JavaScript objects when JSON is sent back from 
the back-end to the front-end.  
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5.3.3 Development of Search words 
5.3.3.1 Dictionary-based approach 
Creation of search terms based on this approach were simply a list of phrases 
commonly found within our animal literature to correctly describe the risk of bias 
item in question. Possible variables within a phrase (i.e. species of animal 
mentioned or term used to describe experimenter) and thus different variations and 
deviations in word orders of a phrase had to be accounted for and added into the list 
of phrases as separate entries to create alternative options for wording of the same 
concept.  
For randomisation, for example; 
“animals were randomised to group” 
would clearly not pick up on any of the following terms, despite being interpreted the 
same way by a reviewer: 
“rats were randomised to group” 
“mice were randomised to group” 
 
Equally for blinding, the example below; 
“investigators were blinded to treatment” 
 
Would not positively identify the following: 
“experimenters were blinded to treatment” 
“observer was blinded to treatment” 
 
Therefore, these options either had to be entered as separate items within my list, or 
as truncated expressions representing the shortest possible textual span that would 
identify as many correct phrases of interest as possible, while minimising 
identification of those that were not (i.e. “were blinded to treatment”). This latter 
approach could account for the high variability in syntax for the same basic concept. 
Of course, word order used between similar phrases limits this approach. In 
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addition, separate entries had to be considered for terms that might be affected by 
plurality, or letter case depending on whether phrase was at beginning or at the end 
of a sentence, and words, which might be in different forms of English (i.e. British 
English using “randomised” vs. American English using “randomized”).  
5.3.3.2 Rule based approach 
As this approach was rule based and specified a pattern, rather than exact phrases, 
it did not require entire phrases to be repeated for every single synonym or form of a 
word. Instead, ‘options’ could be added in for a certain phrase. 
For example, the positive phrases mentioned above for randomisation; 
“animals were randomised to group” 
“rats were randomised to group” 
“mice were randomised to group” 
 
Could be picked up by the use of alternation and the rule: 
 
(animals|rats|mice) were randomised to group 
 
Where “|” denotes the option “or” 
 
Similarly, where a letter might be different within a word (i.e. “s” vs. “z” in British or 
American English), this could be made into an option using regular expressions for 
character classes, where; 
“animals were randomi[sz]ed to group” 
Where [..] are used denote where character class might be one or the other within 
bracket 
Would match both: 
“animals were randomised to group” 
“animals were randomized to group” 
 
This provides a powerful option to account for the large variety in syntax and 
synonyms. In addition, regular expressions can be set to ignore the case of words, 
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by using a “/i” at the end of the list of expressions. This was another clear advantage 
over the previous approach, where cases of words would have to be accounted for 
using separate entries in our list of search phrases. 
5.3.4 Performance of Solution and Evaluation 
Overall success of the solution was measured by reassessing original objectives 
and seeing whether the system worked as intended.  
5.3.4.1 Achievement of Objective 1: Creation of a set of term identifiers 
The success of the prediction of reporting of measures taken to reduce the risk of 
bias through text mining was assessed by the calculation of specificity, sensitivity, 
precision and F-score. Scores could be interpreted so that when specificity is low it 
means that the computer falsely picks up on terms that would otherwise not be 
classed as an example of the reporting of the risk of bias item in question. In turn if 
sensitivity is low then the computer misses expressions that would otherwise be 
classed by a human as an example of the reporting of the risk of bias item in 
question. One would always indirectly influence the other and therefore the 
measurement of achievement would always involve a certain trade-off between the 
two values. Through discussions, we identified 80% as the minimum acceptable 
threshold value for specificity and sensitivity for the automation of risk of bias 
assessment, however, we also wanted a high sensitivity.  
Through the dictionary-based approach, the computer called 112 publications as 
reporting randomisation to group, 188 reporting blinded assessment of outcome, 
and 7 reporting a sample size calculation. The rule-based approach identified 152 
publications reporting randomisation, 187 reporting blinded assessment of outcome, 
and 37 reporting a sample size calculation. According to the human reviewers, 142 
publications had reported randomisation, 192 blinding, and 8 a sample size 
calculation. The confusion matrices created when computer predictions were 





Table 5.1 Confusion matrices showing number of publication when comparing 
predictions made by the computer and classifications made by the human reviewers 
 
5.3.4.1.1 Random allocation to group 
Calling of the reporting of random allocation to group by the computer produces 
similar results when comparing the dictionary- vs. rule-based approach (Table 5.2 
and Table 5.3). Sensitivity is low for both approaches, with dictionary terms resulting 
in 61% sensitivity and regular expressions performing slightly higher at 68%. 
Specificity on the other hand is very good for both, 97% for dictionary-based 
approach and 94% for rule-based approach. This means that for randomisation both 
approaches are good at ignoring papers that had not reported a risk of bias item 
within their experimental descriptions, but were less good at picking up on true 
examples of reporting. This is reiterated by the low value that we see for precision, 
and in turn the F-score. Precision of both approaches was similar at 77% for 
dictionary-based approach and 63% for rule-based approach. This means that the 
fraction of positives that were classified by the computer, over two-thirds were 
correct. 
Table 5.2 Calculated performance measures for the search expressions developed 




Yes No Yes No
Yes 86 26 Yes 96 56
No 56 966 No 46 936
Blinding Blinding
Yes No Yes No
Yes 170 18 Yes 170 17
No 22 924 No 22 925
Sample Size Calculation Sample Size Calculation
Yes No Yes No
Yes 4 3 Yes 7 30







Sensitivity/Recall Specificity Precision F-score
Randomisation 61% 97% 77% 0.68
Blinded assessment of 
outcome
89% 98% 90% 0.89




Table 5.3 Calculated performance measures for the search expressions developed 
using the rule-based approach 
5.3.4.1.2 Blinded assessment of outcome 
Automatic prediction of blinded assessment of outcome gives very good results 
across the board with both sensitivity and specificity returning percentages above 
80%. For both approaches the tool performs at 89% sensitivity and 98% specificity, 
and gives a precision of 90% and 91% for dictionary- and rule-based approaches 
respectively. This also means that we get a very high F-score of 0.89 and 0.9 for 
dictionary- and rule-based approaches respectively.  
5.3.4.1.3 Sample size calculation  
The classification of publications according to whether a SSC had been reported 
performed very differently between the two approaches. Using the dictionary-based 
approach sensitivity of the tool was calculated at 50% and specificity at 100%. This 
implies that using this approach the tool picks up on a number of False Negatives 
and therefore misses publications where reporting evidence exists. Looking at the 
raw numbers, this is the case for both False Positives and False Negatives, 
although few in number. The reason why False Positives make more of an impact 
and result in a less sensitive tool, although not a less specific tool, is because of the 
rarity at which this measure is reported at within the literature. Therefore, the 
number of False Positives makes less of an impact when it comes to calculating 
Specificity as the number of True Negatives is large. On the other hand because the 
total number of Positives to be identified is low (i.e. 8), the percentage of False 
Negatives is a large proportion out of all the possible Positives. Precision is equally 
affected by these low numbers and in turn causes the F-score to be low too. 
This also affects the rule-based approach, where even though the tool performs very 
well in terms of sensitivity and specificity, at 88% and 97%, respectively, precision is 
extremely low at 19%. This can again be explained by the low prevalence in the 
reporting of this methodological quality item. 
Sensitivity/Recall Specificity Precision F-score
Randomisation 68% 94% 63% 0.65
Blinded assessment of 
outcome
89% 98% 91% 0.90




5.3.4.2  Achievement of Objective 2: Creation of program to run and record 
results of term recognition 
The success of the solution was measured against the initial user specification 
criteria (Table 5.4). 
 
Overall, most of the points in my criteria were met to a standard where I, the primary 
user could use it for my research purposes. Limitations to the current solution would 
mainly arise if it were to be integrated into a web platform and used as a multi-user 
program.  
This limitation, despite the program being a web-based solution that runs in a 
browser, is due to it being hosted locally and thus only accessible on the computer 
that it was designed on. For it to be accessible through the internet by multiple 
users, it needs to be hosted on a webserver or integrated into our existing web 
Pre-specified Software Requirements
Simple to use and only contains key information
Limited guidance included on page about what display 
means - could be improved if used by additional users
Input is undefined and allows the entry of any string of 
search terms, thus not limiting risk of bias item to be 
searched
No option to select from pre-defined search terms, 
have to be entered manually
Program directed onto folder specified within code - 
any files within this folder will be searched
Folder to be searched is currently burnt into the code of 
the program and cannot be redirected without editing 
the code
Program updates MS Access folder, where table and 
column to be updated can be pre-specified
Can only currently update MySQL databases
As it is already designed as a webpage it can easily be 
moved to a web server and integrated into a web-based 
platform
Will need to adjust information about where program 
searches through files and what database it updates 
(i.e. database to be updated in future might also be web-
based therefore requiring minor adjustments to code)
Be possible to integrate into existing 
web-based platform
Software's satisfaction of this criteria
Allow the investigation of the 
reporting of risk of bias item of 
choice
User-friendly interface
Search a number of different files at 
once
Facilitate the storage of these 
results in a database, if necessary
Table 5.4 Table showing level of success for each requirement that was specified at 
the start of the project 
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platform (www.syrf.org.uk). For this to be then usable by anyone wishing to perform 
a risk of bias assessment of their dataset, some further developments would have to 
be made to the program. To fit in with the current platform the set of text files to be 
searched and their location would have to be redirected to the folder that contained 
them on our website. Furthermore, the database update process would need to be 
changed as the systematic review web platform uses a NoSQL database and will 
naturally store data slightly differently as the MS Access database that was used 
previously. 
Finally, in the implemented program, I would like to create the added option of using 
previously developed regular expressions for users that may be less familiar with the 
reporting of risk of bias items. This will allow for both those new to systematic 
reviews and those more experienced in performing these sorts of analyses to use 
the current solution. 
5.3.5 Critical analysis of results 
5.3.5.1 Objective 1 
My first objective was to develop a set of term identifiers that would pick up on a 
given set of phrases within a publication and automatically classify that publication 
according to reporting of risk of bias.  
When classifying according to randomisation to group using the regular expressions 
approach, the computer identifies more publications positively than it does using the 
normal dictionary-based approach. This signifies that regular expressions allow for 
more freedom in syntax and variations to the same expression. Using the dictionary-
based approach the computer identifies more false negatives, and using the regular 
based approach the computer identifies more false positives. Despite this difference, 
the two approaches still perform similarly because false positives have little impact, 
as the number of true negatives is so high. As a result, the proportion of false 
positives in relation to the total number of true negatives (i.e. used to calculate 
specificity) is very small and therefore specificity remains high. Therefore, while the 
dictionary-based approach here might be too strict in terms of only being able to 
identify a finite list of phrases, regular expressions can allow for too many options 
and pick up on examples that are very similar to those specified, but otherwise 
would not be included by a human investigator. 
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Classification of SSC worked well using the regular expression-based approach 
performing above our pre-specified success threshold for both specificity and 
sensitivity. It identified most possible examples of reporting of sample size 
calculation within the literature, but also identifying 30 more publications than the 
dictionary-based approach as reporting SSC. Therefore, it had a higher rate of false 
positives and thus very low precision. When using the dictionary-based approach, 
the sensitivity of the automated tool is low, and it misses a few instances of true 
reporting of SSC within the literature. On the other hand, specificity using this 
approach is very high. These dramatic differences in the observations in specificity 
and sensitivity measures  of SSC are likely explained by the fact that the prevalence 
of reporting of SSC within a given field of pre-clinical literature is usually around 1% 
or less (Sena et al., 2014). This makes it very difficult to develop reliable and 
uniform regular expressions for this methodological quality item. It also explains why 
we see such a high percentage of specificity, as this takes into account the number 
of true negatives, which is high for these rarely reported items. On the other hand, 
sensitivity will be more affected by the false classification of a single publication as 
the proportion of publications reporting SSC is few. In fact when tested in a set of 
publications reporting experiments of animal models of lacunar stroke and middle 
cerebral artery occlusion (MCAO), we see a similar pattern where the regular 
expressions perform above the threshold for MCAO, but only perform with 50% 
sensitivity and 100% specificity for Lacunar stroke (Bahor et al., 2017). 
When classifying publications according to blinded assessment of outcome, the tool 
performed above our target level of 80% for sensitivity and specificity in both 
dictionary and regular-expression approaches. It is likely that the classification of 
this risk of bias item by a computer had a better performance compared to 
randomisation and sample size calculation as blinded assessment of outcome, due 
to the fact that this is a more widely (Sena et al., 2014), and uniformly reported risk 
of bias item within the literature of many different pre-clinical fields.  
5.3.5.2 Objective 2 
The solution developed was able to speed up my work by both searching files, but 
also by being able to immediately update the desktop relational database Microsoft 
Access. The search of 1134 publications for the text relating to the reporting of a 
single risk of bias assessment took less than 2 minutes, and the updating of MS 
Access took a matter of seconds.  
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Having the program update a table in MS Access meant that I could immediately 
see and analyse the results of a search. This meant that using the tool I was able to 
get an overall prevalence of each risk of bias item in my validation dataset, as well 
as identify publications within this dataset where predictions made by the computer 
differed from human screener classifications. 
The major limiting factor in the smooth running of the program was the conversion of 
pdf files to a readable text file format. Despite using different pdf converters, none 
were effective in converting 100% of pdf files to text files. Moreover, some converted 
files appeared to be converted but on closer inspection contained no usable 
information. This meant that these files had to be excluded from our set before 
analysis was run as otherwise they would have given false negatives, where the 
computer would be unable to identify an otherwise positive piece of text due to 
unavailability of the overall text. This problem was solved by adding in a “File 
checker” that would alert the user to files where no pdf existed to begin with, where 
pdf existed, but no corresponding text file could be found and those files that were 
unusually small and therefore unlikely to contain all the relevant information of the 
original pdf file. 
5.3.6 Conclusions and Future Work 
The aim of this project was to design a program that would speed up and potentially 
automate the annotation of the reporting of measures taken to reduce the risk of 
bias and other methodological quality criteria.  
The tool created was successful from two aspects. First, it managed to reduce the 
time that it takes a human to score the reporting of measures taken to reduce the 
risk of bias. Classification by an experienced human reviewer is reduced from 5-10 
minutes per publication (depending on the complexity of a publication) to about two 
minutes by an automated tool like this for the classification of 1134 publications per 
methodological criteria item. This will likely save on not only time of reviewers, but 
also resources such as additional reviewers. There is an opportunity for the 
computer to act as a second screener and reduce the need for additional personnel 
needed for systematic reviews. This is also the second strength of this approach. It 
is able to provide a method of checking the work of a human reviewer and thus 
reduce any impact of human error that might arise, as well as issues with 
subjectivity between different reviewers. While we maintain manual reviewing in the 
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field as the “gold standard”, this approach is not always superior and is just as likely 
to be at risk of things like human error. This has been shown in the field of law 
(Grossman and Cormack, 2011), but also by previous work from CAMARADES 
demonstrating impact of the implementation of machine learning for the screening of 
publications in a systematic review (Bannach-Brown et al., 2018).  
While the solution is undoubtedly beneficial in many ways over a human reviewer, 
there are also some obvious limitations to replacing a human investigator with an 
automated system. Naturally, to decide the relevance of a particular document or a 
phrase within a piece of text human interpretation is required. There is often very 
little detail given about measures taken within an experiment to reduce the risk of 
bias, and it is not so straightforward what the correct interpretation of this evidence 
is. This makes it difficult to define specific rules and can lead to false positives and 
false negatives, where the algorithm given to the computer does not perfectly match 
that seen in the actual document. This is also the reason why the same tool might 
perform differently in some datasets when compared to others. At this stage, the tool 
is able to reliably automate the classification of publications for the reporting of 
blinded assessment of outcome. In some cases the classification of sample size 
calculation works well, but this along with the correct classification of reporting of 
randomisation to group needs more refinement before it can be confidently 
implemented in other reviews. It may be that there are differences between domains 
in the language that is used to describe risk of bias, and to make the tool applicable 
to a larger number of fields, this will need to be considered and refined in further 
iterations of the regular expressions used. 
Despite these shortcomings, text mining seems to be a feasible approach for the 
automation of the classification of studies according to methodological criteria. It 
would also likely make a valuable contribution to our work. For example, it has long 
been established in law that human reviewers will disagree about the relevance of a 
piece of information in a large number of cases, independent of their level of 
expertise or detail to attention (Grossman and Cormack, 2011). Similarly in the 
sciences we recognise that in a systematic review single data extraction produces 
very different and much less accurate results than when two reviewers look at the 
same data and have a third independent investigator review discrepancies (Buscemi 
et al., 2006). This makes it clear that incorporating text mining in the process of 
systematic reviews can potentially not only save time and resources, but might also 
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in future be equally as good or even superior to human, “gold standard” data 
extraction and interpretation. Perhaps a solution for now would be to help aid a 
systematic reviewer’s work by providing a second reviewer for smaller reviews. For 
larger reviews, it is arguable to say that underestimating the prevalence of the 
reporting of a risk of bias item by 10% of the total prevalence is exceeded by the 
considerable amount of work and time that is eliminated and saved by automation of 
this process.  
Here, I have only looked at three items off my methodological quality criteria list, but 
I believe with a bit more knowledge in the field, we can use text mining for other 
stages of the review process also. Mainly useful when it comes to categorization, 
but also potentially for some aspects of data extraction. 
5.3.6.1 Unsolved issues 
Some issues, which I was unable to account for during the development of this tool, 
included overcoming the issues with the conversion of pdf’s to text. While there are 
programs out there designed to perform this, they are all constrained by the nature 
of some of the pdf articles. For example, some pdf articles are ‘encrypted’, have 
restricted access for editing purposes, and therefore cannot be converted. Other 
articles might be scanned in copies, especially in the case of older articles and these 
cannot be “read” by a converter the same way as a modern pdf article. Moreover, a 
small proportion of articles would be converted using the tool, but would contain 
incomplete or disordered information from the source pdf (i.e. where text is 
displayed in multiple columns and sometimes these are not read in the right order 
during the conversion process). While the current tool attempts to exclude these 
files from the final analysis, these are all ongoing issues, which understandably limit 
the percentage of studies that can give a true estimate of the performance of the 
created tool.  
At the stage of text processing, issues arose with syntax and the structure of text 
presentation. I accounted for case sensitivity of search terms and spelling variants 
(i.e. American vs. British spelling) in the regular expressions, but it was much more 
difficult to account for things such as hyphens that would break up an expression 
and potentially stop the tool from recognising the sequence of terms specified. 
Moreover, special characters might not be recognised by the converter and could 
get in the way of language processing. As the regular expressions presented here 
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were written in English, they could in turn only be used for English publications. In 
addition, the current solution did not specify the location where an expression had to 
be identified within a publication. This means that if a phrase appears within a title of 
a referenced article, this would be falsely classed by the computer as reporting a 
risk of bias item. Moreover, the tool did not take into account any information that 
was in addition to the main publication, such as supplementary materials published 
in separate files, that may have contained information relevant to experimental 
methodology and risk of bias. Such supplementary files are not commonly obtained 
and downloaded during the initial search when PDF’s are collected for publications 
and therefore cannot be used to inform the final classification results. A quick search 
in the psychosis dataset shows that supplementary information is referred to in 
about 25% of the publications, included within the review and about 16% of 
publications in the test dataset refer to any form of supplementary information. 
Furthermore, the reporting of measures taken to reduce the risk of bias and other 
methodological criteria are recommended by reporting guidelines to be covered in 
the main text. 
Finally, concept drift might affect the effectiveness of the search terms developed at 
current, which means that as language evolves, terminology used to describe some 
methodological criteria might change over time and thus will require further human 
input to update search terms. 
5.3.6.2 Limitations to text mining as a tool for methodological criteria 
assessment 
Obviously, the effectiveness of the system is based on the knowledge that is fed to 
the computer in order to aid its decision-making. This, now, is purely based on the 
occurrence of pre-specified phrases and therefore will be limited if the computer 
comes across any phrases which deviate from this list of phrases. This can be 
improved by increasing the breadth of “knowledge” that is supplied to the computer 
in the form of the search phrases used by testing and validating in increasing 
amount of datasets. This increases our awareness of examples used to describe the 
same concept in the literature that search terms are based on. Therefore, the more 
data analysed, the more accurate the model will be. 
In addition, the number of publications which text mining can be applied to is limited 
by the above-mentioned limitations of issues with file conversion and language 
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restrictions. These drawbacks of text mining all limit the application of this process 
as well as the complete replacement of a human investigator. 
5.3.6.3 Further development plans 
Currently, the regular expressions I created through this project for the rule-based 
approach have been implemented into our systematic review platform SyRF (Figure 
5.12). It does not implement the program created, because SyRF currently has a 
different infrastructure and does not require the database update function. Perhaps 
other features of the program can be integrated into the platform, but at its current 
state, this is still under development.  
 
Figure 5.12 Screenshot of how automated assessment of measures taken to reduce 
the risk of bias is currently being implemented in the online platform SyRF 
(www.syrf.org.uk) – screenshot taken 22/08/2017 
 
Overall, the tool as it is, has been beneficial for my personal use and will continue to 
allow me to develop and test other search strings for other methodological criteria 
items as well as refine those that have already been designed. So for my own use, it 
would be interesting to take the program further and not just display phrases found, 
but have an option where the user can choose to look at the file of their choice and 
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be shown where the phrase has been identified. This can further be improved by 
allowing the user to manually edit the outcome for that publication and thus update 
the overall total. This might not be such a feasible option for large reviews but would 
create the optional opportunity for the user to check what the computer has done. 
Moreover, incorrect predictions by the computer could be accumulated to help 
further refinement of the expressions used for term recognition. Finally, an important 
limitation of the current tool is that it combines studies that explicitly said they did not 
take a measure to reduce risk of bias (i.e. did not randomise), with studies that might 
not have otherwise given enough information to determine whether they had or not. 
These were collectively labelled as no evidence of reporting of measures taken to 
reduce the risk of bias. This could potentially be further refined in future iterations of 
the program, to be classed as separate judgements. This would be in line with tools 
such as SYRCLE’s RoB tool, which makes this differentiation. In addition to “Yes” 
and “No” indications for low and high risk of bias, respectively, there is also an 
option to assign a judgement of “unclear” risk of bias to each item, where there is 





6 Methodological Quality in the Literature 
6.1 Introduction 
Research is informative and of high-quality, when experiments are well-designed in 
advance, they are rigorously carried out during, and results obtained are analysed 
correctly afterwards (Samuel et al., 2016). In line with methodological quality 
assessment is the consideration of the extent to which a study is at risk of bias 
within an experiment by looking at measures taken within studies to reduce these 
(Krauth et al., 2013). Risks of bias can lead to systematic errors (i.e. deviations from 
the “truth”) in the results that we see in studies. They can lead to overestimation or 
underestimation of a seen effect (Higgins and Green, 2008). The well-known study 
by Rosenthal and Fode in the 1960s demonstrated this concept very well, showing 
that experimenter bias in his students could in fact have a large impact on the 
differences in results, obtained in a study looking at the performance of the same 
groups of rats in a learning and memory paradigm (Rosenthal and Fode, 1963).  
While the importance of methodological quality (Chalmers et al., 1981) and quality of 
reporting of important methodological considerations, such as randomisation and 
blinded assessment of outcome (Begg et al., 1996), have long been established for 
clinical research, the animal research field seems to be lagging behind (Landis et 
al., 2012). In recent years it has become repeatedly clear that results from animal 
studies are affected by similar methodological criteria (Bebarta et al., 2003) and that 
the reporting of these measures within the literature of different fields of animal 
research is generally poor (Macleod et al., 2015). 
Internal validity in animal studies may be affected by four basic types of bias, which 
have the potential to introduce systematic differences between experimental groups 
within a study (van der Worp et al., 2010). These include 1) selection bias, when 
animals are allocated in a biased manner to a treatment group – overcome by 
randomisation and concealing allocation of animals to groups; 2) performance bias, 
when care and handling of animals differs between groups outside of intervention 
under investigation – overcome by blinded assessment of outcome; 3) detection 
bias, which is the systematic distortion of results as a result of investigator having 
knowledge of treatment assignment of animals – overcome by blinded assessment 
of outcome; and finally 4) attrition bias, when systematic differences arise between 
groups through the reporting of incomplete data as a result of omittance or exclusion 
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of animals from a study – overcome by blinded assessment of outcome and 
intention-to-treat analysis (van der Worp et al., 2010). Randomisation involves 
randomly allocating animals to an intervention group so that they have an equal 
chance of being allocated to either treatment or control group, while allocation 
concealment means concealing this group assignment sequence from those that will 
perform this allocation process (Higgins and Green, 2008; van der Worp et al., 
2010).  
In addition to bias, imprecision, which describes the likelihood of random error is 
also important and commonly tested for in systematic reviews (Higgins and Altman, 
2008). While these do not put a study at risk of bias per se, smaller studies are less 
precise and therefore could potentially falsely miss important biological effects that 
are otherwise present (Krauth et al., 2013; Landis et al., 2012). Moreover, selective 
reporting bias (discussed in greater detail in the next chapter, Chapter 7), is 
addressed by the good scientific practice of designing a protocol for a study before it 
is carried out, and subsequently making this available so that all analyses originally 
intended are performed and there is no cherry picking of data.  
Other factors to consider when evaluating the quality of a published study are 
certain reporting criteria, which can affect the outcomes within a study. These 
include the disclosure of any potential conflicts of interest and compliance with 
animal welfare regulations. In clinical studies, for example, it has been shown that if 
studies and investigators have financial ties, then research outcomes are usually 
supportive of funders (Lundh et al., 2017). Finally, animal welfare is not only 
recognised to be important in obtaining reliable results in the laboratory (Poole, 
1997). It has been shown that keeping high standards of animal welfare in 
laboratory experiments is important for the validity of animals as models, for the 
disorders in question and in order to make sure that studies are reproducible 
(Prescott and Lidster, 2017). 
While both lumped together here within this project under “internal validity”, it is 
important to differentiate between ‘quality’ and ‘risk of bias’. Performing a study to a 
high quality, does not necessarily mean that the study is free of risk of bias (Higgins 
and Altman, 2008). 
Ultimately, it has been suggested that poor methodological quality of animal 
experiments may impede the translation of results from this domain of research to 
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humans in a clinical setting (Hooijmans and Ritskes-Hoitinga, 2013). Therefore, it is 
of interest whether this could also be to blame for the difficulties in translation of 
animal research to new drug developments in the clinic within the psychotic 
disorders research field. For this reason, I was interested in looking at the 
prevalence of the reporting of certain study design criteria, including risk of bias, 
methodological and reporting criteria, in the pre-clinical literature of psychotic 
disorders. In this chapter I report on this overall prevalence in the literature, how it 
has changed over time and explore whether certain study characteristics might 
affect the reporting of these measures in published studies. 
6.2 Methods 
During the categorisation phase of the project (phase II) I looked at scoring 
publications against a pre-specified list of 8 study design criteria, which included 
items of risk of bias, methodological and reporting criteria. Some publications were 
manually categorised against these pre-specified criteria, and the rest of the 
publications were categorised for three of the items in the list using methods 
described in detail in the previous chapter, Chapter 5. These items were random 
allocation to group, blinded assessment of outcome and sample size calculation. 
To test for differences in reporting based on study design, I tested for equality of 
proportions of subgroups using the proportion test, calculated using the prop.test 
function in R, which uses the Chi-squared test for independence. As the chi-squared 
approximation is affected by small sample size, I performed Fisher’s exact test using 
the function fisher.test in R, as a sensitivity analysis. Due to the testing of 
associations between 8 risk of bias items and different methodological factors the 
critical value of p was adjusted to 0.006, using Holm-Bonferroni correction. 
When the chi-squared test proved to be significant for tests involving more than two 
samples, data were further investigated using all possible pairwise comparisons with 
Bonferroni corrections of p values (MacDonald and Gardner, 2000). This meant that 
for the 4-sample tests a corrected p value of 0.008 (i.e. 0.05/6 for 6 possible 





6.3.1 Overall reporting of risk of bias and other quality measures by studies 
in the literature 
During Phase II of the project, 3847 publications were included and categorised. I 
was able to categorise 2462 (64%) publications of this set manually for reporting of 
measures on my list of quality criteria, while 1387 publications were categorised 
using the text mining tool developed by me. The studies, which were manually 
categorised, were entirely random and there was no obvious difference in terms of 
study design or publication date between studies manually categorised and those 
categorised by the computer. 
Overall, of 2462 publications categorised manually, 573 (23%) reported randomising 
animals to group, 49 (2%) reported concealing allocation of these group 
assignments from investigators and 613 (24.9%) reported performing assessment of 
outcomes blinded (Table 6.1). Only 7 (0.3%) reported to have carried out a sample 
size calculation, and equally as few 5 (0.2%) publications reported the availability of 
a study protocol for their studies. In terms of reporting criteria, 1943 (79%) reported 
that their experiments were approved by and complied with animal welfare 
regulations, 726 (30%) included a statement of potential conflict of interest, including 
whether there was any to disclose or not. Overall, median score for number of items 
reported from the list of publications was 2/8.  
Table 6.1 Overall prevalence of the reporting of risk of bias items and other 





Total No. of publications categorised 2462 801
Number of publications reporting ... (Overall 
%)
Random allocation to group 573 (23.3%) 158(19.7%)
Allocation concealment 49 (2%) -
Blinded assessment of outcome 613 (24.9%) 162 (20.2%)
Sample size calculation 7 (0.3%) 27 (3.3%)
Compliance with Animal Welfare Regulations 1943 (78.9%) -
Statement of potential conflict of interest 726 (29.5%) -
Exclusion of animals pre-specified or explained 416 (16.9%) -
Availability of a study protocol 5 (0.2%) -




The text mining tool developed for randomisation, blinded assessment of outcome 
and sample size calculation was run on the rest of the publications that could not be 
manually categorised. Of 1387 publications, 801 publications could be converted for 
text mining utilising the text converter. Overall prevalence of reporting was equally 
as low here among publications. 158 (20%) of publications reported randomising 
animals to control or treatment groups, 162 (20%) of publications reported 
assessing outcomes in a blinded manner and 27 (3%) of publications reported the 
performance of a sample size calculation. 
Based on publications ascertained for these items manually, the tool performed at a 
sensitivity of 80% for randomisation, 83% for blinding and 100% for sample size 
calculation. Levels of specificity were calculated to be 95% for randomisation, 91% 
for blinding and 98% for sample size calculation in this dataset. This means that the 
tool seems to slightly underestimate the true prevalence of the reporting of random 
allocation to group, and blinded assessment of outcome in the literature, and 
overestimates the prevalence of the reporting of sample size calculations in the 
literature. This is also shown by the numbers in the manually categorised dataset 
and the dataset that has been categorised by the computer.  
Nevertheless, by aggregating the results from the two approaches I found that 
random allocation of animals to group is reported in about 22.4% of publications 
describing animal models of psychotic disorders, while blinded assessment of 
outcome is reported in about 23.8% of publications and sample size calculations is 







6.3.2 Change in prevalence of reporting of risk of bias and other quality 
measures as a result of different factors 
As I could only correctly ascertain all items on my methodological quality list for 
studies that had been manually categorised against the checklist, all further 
analyses were done using the manually categorised set of included studies (n = 
2462). 
6.3.2.1 Change in prevalence of reporting over time 
In recent years there has been increasing focus on the importance of better 
reporting of animal experiments including increasing transparency around measures 
taken to reduce risks of bias within animal studies and of the reporting  of other 
methodological criteria which might help increase predictive validity of these 
preclinical studies (Landis et al., 2012). 
In this context, I was interested in seeing whether the reporting of these risk of bias 
items and other methodological criteria had changed in the literature over time. 
Taking publications included and categorised in Phase II of the review I looked at 
the total prevalence of reporting of these measures over the years of publications of 
these studies. 
It appears that the reporting of these measures has increased over time especially 
since the early 1990s (Figure 6.1). The sharpest increase is seen in the reporting of 
compliance with animal welfare regulations and the inclusion of a statement of 
potential conflict of interest, whereas there doesn’t appear to be a significant 
increase in the reporting of a sample size calculation and availability of a study 
protocol among published studies. The reporting of allocation concealment appears 
to have very slightly increased in recent years. Across publications in the literature, 
the reporting of random allocation of animals to group, blinded assessment of 
outcome, and accounting for all animals through the reporting of exclusion of 







Nevertheless, it must also be taken into account that the number of publications 
published every year has also increased, which could make these observations 
slightly misleading. Figure 6.2. shows the true prevalence of reporting of these study 
design measures each year. 
 
Figure 6.1 Prevalence of reporting of risk of bias items and other methodological 
quality criteria in the field over time 
Figure 6.2 Prevalence of the reporting of risk of bias items and other methodological 
quality criteria as a percentage of total publications reported in the same year 
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This apparent increase in the overall prevalence of the reporting of risk of bias items 
such as random allocation of animals to group and blinded assessment of outcome 
has actually been very gradual if at all different compared to earlier years. It is also 
arguable based on this graph that the prevalence of reporting of these two 
measures in the literature has varied the least over the years. We still see a stark 
increase in the prevalence of the reporting of compliance with animal welfare 
regulations and the inclusion of a statement of any conflicts of interest. It is also 
apparent that the reporting of allocation concealment in the literature has not 
changed substantially since the late 1990’s. The reporting of animal exclusions 
looks to have decreased over the last decade and the availability of a study protocol 
and sample size calculations have continued to be poorly reported. 
6.3.2.2 Change in prevalence of reporting in types of studies 
In clinical trials for novel interventions, risks of bias and measures taken to reduce 
these are recognised to be an important factor in minimising the number of wrong 
conclusions that are reached about the efficacy of an intervention (Gluud, 2006). In 
this context, I was interested to see whether the type of study carried out affected 
the reporting of study design items and whether drug studies were more likely to 
report these measures as a direct result of clinical trial practice over model 
characterising studies. 
Manual categorization identified 1124 publications measuring the effect of an 
intervention in animal models of psychotic disorders that were administered in order 
to prevent or reverse effects of the model. The remaining 1338 publications were 
classed as model characterising studies comparing healthy or sham animals to 
animals that had an intervention to model an aspect of a psychotic disorder. 
Overall, dividing studies manually categorised for study quality showed very little 
difference on the prevalence of reporting of measures within the list of 
methodological criteria items (Figure 6.3). Only significant difference was seen in the 
reporting of a statement of potential conflict of interest, whereby the proportion of 
treatment exploring studies that reported a statement of potential conflict of interest 
was greater than the proportion of model characterising studies reporting it (χ12 = 











6.3.2.3 Change in prevalence of reporting across publications using different 
models 
As I have shown in Chapter 3, animal models of psychotic disorders can be largely 
grouped into 4 different methods of model induction. Manual categorization of 
included studies identified 1725 pharmacological (including substance studies), 352 
genetic, 692 developmental and 88 lesion studies. Naturally some publications can 
use more than one method to induce models, with many using these in combination. 
This factor could not be taken into account here but might mean numbers seen here 
for one method of induction were confounded by another method reported together 
with it in some publications. 
When looking at method of model induction individually, data shows that the 
proportion of studies reporting random allocation to group is significantly different 
depending on the method of model induction reported within a study (χ32 = 92.71, p 
= 2.2x10-16). The proportion of genetic studies reporting this item was significantly 
less than the proportion of all other studies reporting this risk of bias item (39/352, 
11% of publications reporting genetic models, Figure 6.4, p<2x10-5 for all pairwise 
comparisons between methods used). In contrast, this risk of bias item was 
significantly more widely reported in studies reporting lesion models (37/88,42% of 
publications reporting lesion models, proportion of lesion studies reporting 
randomisation significantly higher than proportion of genetic, p = 1.1x10-10, and 
pharmacological studies, p = 0.0002), and developmental models (240/692, 35% of 
publications reporting developmental models, proportion of developmental studies 
reporting randomisation significantly higher than proportion of genetic, p = 4.1x10-15, 
and pharmacological studies, p = 1.9x10-9). Reporting of allocation concealment was 
in general poor across all studies, but the proportion of studies reporting it was 
significantly different depending on the type of model used, despite small sample 
sizes (χ32 = 34.66, p = 1.4x10-7, significant results confirmed by sensitivity analysis 
using Fisher’s exact test). It was most prevalent among studies reporting 
developmental models (32/692, 5% of publications reporting developmental models, 
proportion of developmental studies reporting allocation concealment significantly 
higher than proportion of pharmacological studies, p = 1.5x10-7, no other significant 
differences between pairwise comparisons). Blinded assessment of outcome was 
reported significantly differently across different studies (χ32 = 27.46, p = 4.7x10-6). It 
was most widely reported by publications reporting genetic and developmental 
187 
 
models (127/352, 36% of publications and 184/692, 27% of publications, 
respectively). Interestingly pharmacological studies reported this item even less 
frequently than all studies combined did (399/1725, 23% of publications reporting 
pharmacological models compared to 25% of all studies, proportion of 
pharmacological studies reporting blinding significantly lower than proportion of 
genetic studies, p =3x10-6, no other significant differences between pairwise 
comparisons). The reporting of any exclusion of animals was highest in studies 
reporting lesion models (39/88, 44% of publications reporting lesion models, 
proportion of lesion studies reporting exclusion of animals significantly higher than 
proportions of all other types of studies, all pairwise comparisons p<9.2x10-6 for 
lesion studies). There was little difference in the prevalence of reporting between 
other studies of the same measure and the overall prevalence (17%). Sample size 
calculation was equally poorly reported among all studies irrespective of the method 
of model induction reported (no significant differences). Studies reporting genetic 
studies included a conflict of interest statement (168/352, 48% of publications 
reporting genetic models) significantly more commonly than studies using other 
methods of model induction (χ32 = 58.46, p = 1.25x10-12 overall, and p<9.6x10-5 for 
all pairwise comparisons for genetic studies). Genetic studies also reported 
compliance with animal welfare regulations (312/352, 89% of publications reporting 
genetic models) significantly more commonly than pharmacological studies (p = 
6.4x10-7). This item was also well reported in studies describing developmental 
models (604/692, 87% of publications reporting developmental models, proportion of 
developmental studies reporting compliance with animal welfare regulations 
significantly higher than proportion of pharmacological studies, p = 1.4x10-9, no 
other significant pairwise comparisons). And finally, the availability of a protocol for 
the study included in the review was rarely mentioned within studies, which was not 










6.3.2.4 Change in prevalence of reporting in publications reporting different 
outcome measure types 
During the categorization phase of the project, publications were classified 
according to the type of outcome measure that was reported. I differentiated 
between behavioural, anatomical, neurochemical and electrophysiological outcome 
measures. I wanted to see whether any of these outcome measures would influence 
the prevalence of publications that reported each item of interest on my list of 
methodological criteria. 
In total, 1837 publications were recorded as having measured behavioural 
outcomes, 288 as having measured anatomical outcomes, 1120 as measuring 
neurochemical outcomes and finally 273 publications as measuring 
electrophysiological outcomes. It is important to keep in mind that some studies 
measure more than one type of outcome measure and therefore, results for one 
type of outcome measure might be confounded by the effect of another outcome 
measure in publications that looked at more than one outcome. Overall, I found that 
prevalence of reporting of study quality measures was equally low across all studies, 
irrespective of type of outcome measured (Figure 6.5). Nevertheless, the proportion 
of studies reporting randomisation was significantly different based on the type of 
outcome measured (χ32 = 35.22, p = 1.1x10-7), whereby the reporting of this risk of 
bias item was least prevalent among studies measuring electrophysiological 
outcomes (29/273, 11% of publications measuring electrophysiological outcomes, 
proportion of electrophysiological studies reporting randomisation significantly lower 
than proportion of behavioural studies, p = 6.8x10-7, and neurochemical studies, p = 
0.0002). Allocation concealment was poorly reported across all studies, but was 
most widely reported in studies measuring electrophysiological and anatomical 
outcomes (both 4% of publications measuring each outcome measure compared to 
2% of all publications, no overall significant differences between outcome types). 
Blinded assessment of outcome was most widely reported in publications reporting 
measuring anatomical outcomes (140/288, 49% of publications measuring 
anatomical outcomes, proportion of anatomical studies reporting blinding 
significantly higher than proportion of all other outcome type studies, all pairwise 
comparisons p<4x10-12 for anatomical studies), and least commonly reported among 
studies measuring electrophysiological outcomes (53/273, 19% of publications 
measuring electrophysiological outcomes, only significantly different in comparison 
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to proportion of anatomical studies). The reporting of exclusion of animals differed 
significantly between type of outcome measure used (χ32 = 23.86, p = 2.7x10-5), 
whereby the proportion of neurochemical studies reporting this item was significantly 
lower than behavioural studies (p = 0.0001) and electrophysiological studies (p = 
0.0007). Sample size calculation was rarely found to be reported in any of the 
studies included in the dataset with no significant difference between studies 
reporting different outcome types. There was little variation in terms of publications 
including a conflict of interest statement or the reporting of compliance of 
experimental methods with animal welfare regulations, across publications 
measuring different outcome measure types (no significant differences between 
studies reporting different outcome types). Equally, the reporting of the availability of 
a study protocol was poor across all studies, with little effect of the type of outcome 
that was reported to be measured within studies (no significant differences between 










6.3.3 Does low quality of reporting affect outcome reported within 
publications? 
Using data extracted as part of a subset of studies within this review, which 
describes animal experiments of developmentally induced models of schizophrenia 
and is described in more detail in Chapter 4, I looked at how these trends in 
reporting affect the outcomes that are reported. None of the differences between 
studies reporting or not reporting measures taken to reduce the risk of bias were 
statistically significantly for model characterising studies (Figure 6.6). This included 
looking at the reporting of random allocation to group, allocation concealment, 
blinded assessment of outcome and exclusion of animals. I was unable to look at 
the difference between studies reporting or not reporting sample size calculations, 
despite this being of high interest, as data was insufficient for analysis for studies 






Figure 6.6 Model characterising studies reviewed here that do not report certain 
risk of bias items do not show statistically significantly different effects when 
compared to studies that do report these risk of bias items. 
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When looking at treatment testing studies, the reporting of random allocation to 
group significantly affected the efficacy of treatments reported within a study, 
whereby those that reported this risk of bias item also reported lower efficacy of 
treatments on model animals, compared to studies that did not report this risk of 
bias item (Figure 6.7). There was no significant difference seen in treatment effects 
between studies that reported blinded assessment of outcome and those that did 
not. Not enough treatment testing studies reported a sample size calculation, 
allocation concealment or animal exclusions in order to assess the impact of 
reporting these items in treatment testing studies. 
6.4 Discussion 
Overall data shows that the prevalence of reporting of measures taken to reduce the 
risk of bias, good methodological and other important reporting criteria are poorly 
reported in the pre-clinical literature of psychotic disorders. Most items are reported 
in fewer than 30% of publications in the literature, with allocation concealment, the 
Figure 6.7 Studies that do not report random allocation to group 
overestimate the efficacy of treatments compared to studies that do report 
it. In comparison, the effect of studies reporting or not reporting blinded 





performance of a sample size calculation and the availability of a study protocol 
most poorly reported among studies. The only item of study design criteria that 
showed high levels of prevalence for reporting in the literature, was the reporting of 
compliance with animal welfare regulations. This was reported in about 80% of 
studies published overall, and its prevalence of reporting has increased over time. 
Nevertheless, this number is still concerning considering that the legislation in 
modern societies demands that experimentation involving animals meets ethical 
guidelines (Kolar, 2006).  
Unfortunately, this observation is not exclusive to the psychosis research field and 
seems to follow the trend of results from similar reviews in other areas of pre-clinical 
neuroscience. Data from fields of experimental focal cerebral ischaemia (Macleod et 
al., 2008), experimental autoimmune encephalomyelitis (EAE) (Vesterinen et al., 
2010), pre-clinical Parkinson’s disease (Rooke et al., 2011) and pre-clinical bone 
cancer-induced pain (Currie et al., 2013) show on average about 20% of papers 
report randomization of animals to groups and 26% report blinding of outcome 
measurement across these fields. Some of these reviews have found on average 
that less than 2% of publications report the performance of an a priori sample size 
calculation. In the psychosis research field, I have found this to be reported in less 
than 1% of publications. This is an important aspect of a study as the probability of 
detecting a difference of a certain size between a control and treatment group of 
animals is based on the number of animals that are used in each group, the size of 
the difference and the variability in the outcome (Macleod et al., 2009). A meta-
analysis of EAE studies found that effect sizes reported were lower in studies using 
a larger number of animals in their experiments (Vesterinen et al., 2010). 
Furthermore, it is recognised that in an experiment the reliability of a conclusion of a 
causal relationship between treatment and outcome is dependent on the internal 
validity of an experiment and its statistical power (Sena et al., 2014). This poor 
prevalence of reporting of important methodological criteria in the literature calls for 
concern as many of these measures have been shown to influence overall 
outcomes. It is important to assess for these methodological criteria, as research 
shows that animal studies that do not report randomisation or blinded assessment of 
outcome and perform experiments with no evidence of a sample size calculation, 
can give inflated effect sizes as opposed to studies that do report having carried out 
these measures (Sena et al., 2014). This can lead to an overstatement in both the 
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severity of a model and the efficacy of a drug tested. For example, in systematic 
reviews looking at the effects of hypothermia in experimental stroke, studies that did 
not randomize, overstated the reduction in infarct volume by 27% (van der Worp et 
al., 2007). Similar observations have been made in reviews of other fields (Currie et 
al., 2013; Macleod et al., 2008; Rooke et al., 2011). 
From the data extracted in the context of publications describing developmentally-
induced animal models of psychotic disorders, only the reporting of random 
allocation to group in treatment testing studies significantly affected outcomes 
reported. Studies that did not report randomising overstated the efficacy of treatment 
drugs tested when compared to studies that did report randomising. There were no 
significant differences in the effect of reporting or not reporting other risk of bias 
items in both model characterising and treatment testing studies. Based on these 
results, we might conclude that the reporting of risk of bias items does not have an 
effect on outcomes reported within pre-clinical psychosis publications. Or perhaps 
we might see a different pattern if the number of studies reviewed was larger and 
thus more representative of the entire field, not just one group of models. Of course, 
there is also the possibility that reporting of these measures does not necessarily 
reflect the active performance of these measures to reduce the risk of bias within the 
studies reviewed here. Therefore, there might be some interference from studies 
which report, but do not correctly perform these measures, or vice versa, studies 
that do perform these measures, just simply do not report them within their 
publications. 
6.4.1 Change in reporting over time 
In light of these observations in recent years, there has been an increasing amount 
of focus placed on communicating the importance of taking measures to reduce the 
risk of bias within experimental work using animals and improving transparency of 
the reporting of this research (Landis et al., 2012). This led to the publication of The 
Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines (Kilkenny et 
al., 2010a) and the Gold Standard Publication Checklist (GSPC) (Hooijmans et al., 
2010a) in 2010. These guidelines took inspiration from established reporting 
guidelines for clinical trials (i.e. CONSORT Statement for randomised controlled 
clinical trials) and were written in a checklist format to provide guidance on how to 
report animal research. Since then, a number of journals have included the ARRIVE 
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guidelines in their guidance to authors when submitting research for publication 
(Baker et al., 2014).  
In the preclinical literature describing animal models of psychotic disorders, there 
seems to have been an increase in the prevalence of reporting criteria, such as the 
reporting of compliance with animal welfare regulation and a statement of potential 
conflict of interest since the publication of the ARRIVE guidelines. However, while 
there has been an increase in the number of publications reporting measures taken 
to reduce these risks of bias, this improvement is offset by the increase in the 
number of studies published each year. Moreover, none of these guidance materials 
have led to an increase in the reporting of the performance of a sample size 
calculation. Therefore, we find that in the psychosis research field at least, there has 
been little change in the prevalence of the reporting of measures taken to reduce 
important risk of bias items such as blinded assessment of outcome and random 
allocation to group. In fact, the data show that these are two items that have been 
reported since the 1970s and the 1980s, respectively, and their prevalence of 
reporting in the field has varied little since then. This tells us that these concepts are 
not new in the field of animal studies and that despite the increase in awareness of 
the importance of reporting these measures within animal experiments, still very few 
studies do. This suggests that perhaps there are reasons, other than a lack of 
knowledge of the importance of taking these measures, to blame for this poor 
prevalence in reporting of these measures. It might be explained by the argument 
that just because something is not reported within a publication, doesn’t mean it has 
not been done. It is true that we cannot ascertain the actual percentage of studies 
that have carried out certain study design measures, however, based on a review in 
experimental stroke, which found that there is little discrepancy between actual and 
reported levels of study quality (Samaranayake, 2006), this is unlikely to change 
overall results substantially. These unsatisfactory results in the prevalence of 
reporting of these study design measures might also be explained by the fact that 
while reporting guidelines are endorsed by many universities, journals and funding 
agencies, their completion is not mandatory for publication. This means that despite 
increased education on the matter and available forms of guidance, reporting 
standards have and are unlikely to improve in future unless further changes are 
made in the reporting process (Baker et al., 2014). 
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6.4.2 Differential reporting based on study design 
Another reason behind poor reporting standards might be that they are influenced 
by the type of studies that are being performed and whether investigators think that 
blinding assessment of outcome for example is important or not for their 
experimental design. 
When looking at whether different aspects of study design affected the reporting of 
methodological quality items, I observed that the inclusion of a conflict of interest 
statement for example was more prevalent among studies that tested the effect of a 
treatment drug in an animal model of psychosis compared to model characterising 
studies. This perhaps is a legacy of common practise in clinical trials and knowledge 
that financial ties of investigators positively influence the reported efficacy of drugs 
tested in support of these funders (Lundh et al., 2017).  
When looking at how using different models within experiments describing in vivo 
experiments of psychotic disorders, many of the trends we see from the data can be 
explained by common sense. I noticed that for example in genetic models, the 
prevalence of random allocation to group was lower than in studies using other 
methods of model induction. For studies where genetic models are bred over many 
generations the reporting of randomisation of these models and wildtype models to 
"intervention” and “control” groups in model characterising studies hardly makes 
sense, as these animals are already different and are not being chosen from the 
same pool of animals. In contrast for lesion and developmental studies, where the 
prevalence of reporting of this risk of bias item were the highest, this is easily done 
as the independent variable is the location of the lesion or the difference in rearing 
environment that animals are subjected to and not the animal population itself. 
Interestingly however, results also showed that blinded assessment of outcome, for 
example, was most widely reported in studies reporting using genetic models. 
Arguably, for some experiments using these models, this is perhaps more difficult to 
do in these studies as opposed to studies using other models, due to obvious 
phenotypic differences between animals of different genetic backgrounds. In 
addition, it was interesting to note that pharmacological studies seemed to report 
important measures to reduce the risk of bias most poorly out of all studies, despite 




Similarly, when looking at differences between studies measuring different 
outcomes in experiments describing in vivo experiments of psychotic disorders, 
many of the results are unsurprising. For example, random allocation to group was 
less likely to be reported in studies measuring electrophysiological outcomes 
compared to studies reporting behavioural and neurochemical outcomes. It is 
arguable that not allocating animals randomly to group has a more substantial 
impact on especially behavioural outcomes, as variation in behaviour will be much 
greater than variation seen in other outcomes like electrophysiological or anatomical 
outcomes among different animals. 
Blinded assessment of outcome was most widely reported in studies measuring 
anatomical outcomes and least commonly reported in studies measuring 
electrophysiological outcomes. Electrophysiological outcomes are measured using 
electrical recording techniques and therefore, outcomes of these experiments are 
less prone to subjectivity over other measures such as anatomical or behavioural 
measures. This will likely become more and more relevant for studies measuring 
behavioural outcomes as new, automated tools start to replace human scoring of 
behaviours. 
Overall, these differences between studies using different experimental designs are 
unlikely to explain the overall poor prevalence in reporting of study design criteria. 
They do however, provide an indication of where these problems are the greatest 
and where improvements in future might be made. It also highlights that some 
studies need to be evaluated on a different scale to the rest as their design does not 
fit and requires less of the classical methods of random allocation to group or 
blinded assessment of outcome perhaps. 
6.4.3 Limitations 
When reviewing the literature, it is only possible to analyse the reported quality of a 
study and there is no way of knowing the prevalence of the actual performance of 
some of these items within an experiment. 
Therefore, it is possible that some studies took measures to reduce the risk of bias 
but did not report these. While the two qualities should be considered as separate 
concepts, they also overlap in many ways, as good reporting means that 
methodological quality of a study is easier to assess (Samuel et al., 2016). If we are 
only able to derive reporting quality from a scientific publication, this will affect at 
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how accurately we can derive information from the literature perhaps (Samuel et al., 
2016). Therefore, while perhaps some might argue it is not appropriate to judge an 
experiment’s quality in a publication based on the reported quality of said 
experiment, appraising exact methodological quality without complete reporting is 
difficult to do especially in the animal literature.  
Alternatively, it may be that a failure to report measures to reduce the risk of bias is 
an indirect or surrogate measure of some other aspect of study design or conduct, 
which is responsible for the observed bias. Perhaps the lack of efficacy in blinded 
studies may be due to some other characteristic of those studies, such as the drug 
being tested, or the species used. There may also be other factors not looked at that 
could affect reporting of some methodological quality items in the literature, and thus 
confound the effects seen of variables assessed here. This could include things 
such as the nationality of authors and country where research was carried out in, 
where differences could arise perhaps from differing levels of emphasis based on 
the reporting of these measures in various countries, and institutions. 
The journal of publication might also affect how studies report their experimental 
methods and what key things they report in their publications, depending on what a 
journal requests or deems acceptable for publication. 
Identifying these differences would be important, because under those 
circumstances addressing the issue of blinding would not address the underlying 
bias.  
This also introduces the idea of covariance and that perhaps studies that do not 
report blinded assessment of outcome also don’t report randomising animals to 









7 Capturing all the Data of Relevance  
Systematic reviews can be extremely powerful in summarising a field quantitatively 
and highlighting areas where research may be lacking, or improvements can be 
made. These reviews and our knowledge based on them are strongly limited by the 
depth and breadth of research they are able to capture. Therefore, a review will be 
biased towards evidence that is made available in the literature and if this evidence 
is substantially different from that which is unpublished, this can affect conclusions 
drawn in these reviews. While systematic methods used aim to identify all sources 
of evidence out there, this step is still limited by the search strategy and terms used 
to identify relevant publications of data and how closely these reflect actual terms 
used in the literature. 
In this chapter, I explore the robustness of my systematic search of the literature 
and assess the extent to which these limitations might have affected my overall 
findings. I estimate the amount of publication bias that could be present in the 
literature describing animal models of psychotic disorders, look at the effect of 
updating a search a year after the original search and explore the impact of 
performing the search again, but this time using alternative keywords to answer the 
same research question. 
7.1 Missing data due to publication and reporting biases 
It is well established that positive and promising studies are more likely to be 
published in the literature than negative or neutral studies and naturally this skews 
the resulting conclusions drawn about biological truth represented by the literature 
(Rosenthal, 1979). This can lead to the wrongful estimation of the overall efficacy of 
a treatment drug or the effectiveness of a model in recapitulating a disorder. In 
clinical trials, this issue has long been recognised (Easterbrook et al., 1991) and has 
led to the introduction of registration systems for clinical trials allowing for more 
transparency in clinical research (De Angelis et al., 2004). In recent years, a number 
of studies have shown that the pre-clinical research field is not exempt from this 
problem either (Sena et al., 2010; ter Riet et al., 2012), and there has been a lot of 
discussion around the use of similar registries for pre-clinical studies (Wieschowski 
et al., 2016). 
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Reporting or not reporting of evidence depending on certain characteristics such as 
the directionality of findings also happens in the form of selective outcome reporting 
bias. This occurs when non-significant outcomes are omitted from the publication of 
a study despite having been evaluated in the study (Ioannidis et al., 2014b). 
Evidence for this concept is supported by observations that key findings cannot be 
replicated in many pre-clinical research fields (Begley and Ellis, 2012). 
Nevertheless, it is difficult to estimate the exact extent of this problem as few pre-
clinical studies publish protocols of their studies (as shown in Chapter 6). During 
categorization of included studies in this review, it became clear that many 
publications only reported data for outcome measures of significance or positive 
results. This selective reporting bias was very transparent in the sense that most 
studies reported having carried out the relevant behavioural measures, they just 
failed to report the actual data collected. 
7.1.1 Methods 
7.1.1.1 Source Data 
As publication bias requires a large amount of data, this concept was explored using 
data extracted and analysed in Chapter 4. This data described 974 model-
characterising experiments from 84 studies, and 143 treatment-testing experiments 
within 17 studies. I also briefly estimated the extent of selective outcome reporting 
bias within all identified studies in this systematic review.  
7.1.1.2 Analysis 
Methods used for meta-analysis are described in detail in Chapter 3. All data used 
for publication bias analyses were unnested and model-characterising comparisons 
were analysed separately to treatment-testing comparisons. Sensitivity analyses 
were performed by removing 5% of the most extreme data points and reanalysing 
results. For estimation of the extent of selective outcome reporting bias within 
published literature, all identified studies that could be analysed through text mining 





7.1.2.1 Prevalence of publication bias in a subset of the psychosis research 
field 
Visual inspection of funnel plots for model-characterising experiments and 
treatment-testing experiments suggested that there might be some evidence of 
publication bias for model-characterising experiments, but the graph was less clear 
for treatment-testing experiments (Figure 7.1).   
Figure 7.1 Funnel plot of model-characterising and treatment-testing experiments 
Funnel plots showing precision plotted against effect size. In the absence of 
publication bias these plots should be symmetrical around the global effect size (i.e. 
the dotted line). 
 
Egger regression suggested that there was significant asymmetry of model-
characterising experiments, but not drug testing experiments (Table 7.1).  
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Asymmetry was more apparent in model-characterising experiments using Egger 
regression than for treatment-testing experiments (Figure 7.2). 
 
Finally, trim-and-fill analysis in STATA confirmed results of Egger regression – that 
treatment-testing studies showed no significant asymmetry and that the model-
characterising dataset did show asymmetry.  
7.1.2.2 Impact of publication bias in the field 
Using trim-and-fill 458 experiments were estimated to be “missing” from the model-
characterising dataset, suggesting that these studies were conducted, but not 
reported in the literature. Trim-and-fill also imputed an overall estimate of effect size 
taking into account these potentially missing studies, giving an estimate of -2.236 
SD units (95% CI -2.594 - -1.879). This was 1.11 SD units below the original overall 
reported effect size and therefore suggested that the original reported effect size 
was an underestimation of the true effect. No studies were estimated to be missing 
in the treatment-testing dataset.  
7.1.2.3 Sensitivity analysis of results 
Due to obviously large outliers in the model-characterising dataset sensitivity 
analyses were run on both datasets. This 5% truncated mean analysis revealed no 
further evidence of potential publication bias for treatment-testing experiments, 
Figure 7.2 Egger regression plot of model-characterising and treatment-testing 
experiments 
Egger regression showing precision against standardized effect size. Publication bias 
is measured by how close to the origin the intercept of the regression line is.  
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however, overall reported effect size did reduce by 0.083 SD units (see Table 7.1 
above). Sensitivity analysis did however, affect earlier estimation of publication bias 
in model-characterising experiments. Overall, reported effect size was reduced from 
-1.126 SD units to -0.472 SD units and while Egger regression still suggested there 
was potential evidence for publication bias, trim-and-fill analysis did not suggest any 
asymmetry affecting the dataset. 
7.1.2.4 Selective outcome reporting bias 
Altogether, PDF documents of 5622 publications identified in my original search 
could be searched through the program PDF-Xchange Editor. The program 
identified 8579 entries of the phrase “data not shown” in 3806 documents (68% of 
publications searched). 
7.2 Missing data due to limitations across time and space 
Systematic reviews are used to provide current, up-to-date and comprehensive 
evidence on a particular research question. A major limitation of bigger reviews 
especially is the time that it takes to complete them. Another issue is the ability to 
capture all that is relevant when you are asking a broad research question about an 
otherwise uniquely human disorder. The totality and relevance of the evidence that 
is gathered and drawn conclusions from in a systematic review, is based almost 
entirely on the words and phrases used to search the literature to obtain this 
evidence in the first place. I wanted to explore the possible extent of both of these 
limitations and the impact these might have had on my overall conclusions using a 
model of substance-induced psychosis. 
7.2.1 Cocaine: a model of substance-induced psychosis 
We have seen that pharmacological models have continued to predominate the field 
of animal modelling of psychotic disorders and many of these substances are drugs 
of abuse in human populations. Drugs with psychotomimetic properties such as 
cannabis, cocaine, phencyclidine and amphetamines are able to produce psychotic 
symptoms similar to those seen in schizophrenia (Connell, 1990; Steeds et al., 
2015). Intoxication from substances can cause acute psychotic effects, but also a 
chronic abuse of these substances can lead an increased risk of developing more 
substantial psychotic outcomes which are independent of these temporary effects of 
drugs (Moore et al., 2007). Stimulants given to schizophrenic individuals can also 
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provoke a psychotic state which is almost identical to their own positive symptoms 
(Janowsky et al., 1973). According to the DSM-5, substance-induced psychotic 
disorders are characterized in the clinic by prominent delusions and/or hallucinations 
that an individual experiences during or shortly after substance intoxication and 
these symptoms can persist for weeks. As stimulant-induced psychotic symptoms 
usually subside within several days to a month after the end of substance abuse, the 
persistence of symptoms for more substantial periods of time might be better 
explained by a primary psychotic disorder (American Psychiatric Association, 2013; 
Sachdev and Keshavan, 2010).  
Cocaine is a substance of abuse, taken by about 18.2 million people throughout the 
world (United Nations Office on Drugs and Crime, 2016). In Europe, it is estimated 
that 4.1% of the population between the ages 15 and 64 have used cocaine at least 
once during their lifetime (European Monitoring Centre for Drugs and Drug 
Addiction, 2010). Its use is linked to psychiatric problems, with psychotic symptoms 
being most typical (Vergara-Moragues et al., 2014). Chronic use of the substance 
induces a paranoid psychotic state directly related to drug use and is almost 
indistinguishable from symptoms seen in acute paranoid schizophrenia (Brady et al., 
1991). It is thought that like with many other psychostimulants, once use of cocaine 
stops, hallucinations usually also end, but delusions can linger longer.  
Cocaine is an indirect dopamine agonist and in animals induces hyperlocomotion, 
consisting of ambulation and seeking behaviour. This is thought to occur through 
sensitization of the dopamine system (Ujike, 2002). Chronic administration 
experimental paradigms where animals are given repeated administrations of a 
substance induces a phenomenon called ’behavioural sensitization’, which has two 
distinct stages – ’development’ and ’expression’ (Richtand, 2006; Ujike, 2002). 
Sensitization is defined as a non-associate learning process where repeated 
exposures to a stimulus result in gradual augmentation of the behavioural effect 
(Weidenauer et al., 2017). This means that in these experimental paradigms 
locomotor activity gradually increases with repeated administration of the drug, a 
phase called the development of sensitization (Figure 7.3). This sensitized state also 
persists for a long time, evidence showing that in rats it remains a year after 
abstinence from substances such as amphetamine (Paulson et al., 1991). Once 
sensitization develops, challenging the animals after a period of abstinence and 
withdrawal from the drug with any subsequent doses of the drug will produce 
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intense stereotypy (Ujike, 2002). This is called the expression stage of sensitization. 
This enhanced activity is also observed in response to other stimulants as well as 
other types of drugs such as morphine, nicotine and cannabis and environmental or 
physiologic stressors (Ujike, 2002). The two phases – development and expression 
– of behavioural sensitization are thought to be different anatomically and 
neurochemically (Reeves et al., 2004).   
This sensitization also occurs in humans, where chronic, intermittent use of 
psychostimulants induces psychosis through the sensitization of dopaminergic 
systems (Figure 7.4). It is thought that initially chronic abuse of cocaine creates 
symptoms of euphoria, followed by dysphoria, and finally paranoid psychosis, 
increasing in severity with increasing dose of cocaine and increasing chronicity of 
cocaine use (Post, 1975). While withdrawing from the drug of abuse usually 
resolves psychotic symptoms within a short period of time, this psychotic state, 
resembling that of the initial symptoms can be induced again with few, or even a 
single exposure to the substance at lower doses than before (Sato et al., 1983). In 
addition, psychologic stressors and other drugs of abuse can have the same effect 
and these effects are seen even years or decades after abstinence (Ujike, 2002). 
Figure 7.3 Effects 
of chronic 
administration of a 
stimulant like 
cocaine to animals 
in the laboratory 
(Figure adapted 
from Ujike, 2002). 
Figure 7.4 Effects 
of chronic abuse 
of cocaine in 
humans 
(Figure adapted 
from Ujike, 2002). 
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Chronic paranoid schizophrenia is thought to share these mechanisms of underlying 
behavioural sensitization (Figure 7.5). Some individuals with schizophrenia exhibit 
activation and exacerbation of psychotic symptoms as a result of acute exposure to 
psychostimulants at doses otherwise not psychotogenic in healthy individuals 
(Curran et al., 2009; Lieberman et al., 1987). PET studies also show that dopamine 
release is increased in response to amphetamine, showing an exaggerated 
response in schizophrenic individuals (Breier et al., 1997). Since stimulant–induced 
increase in dopamine release characterizes sensitization, this has led to the concept 
of schizophrenia possibly representing a state of endogenous sensitization 
(Laruelle, 2000). Evidence shows that increased dopamine activity already occurs at 
prodromal stages of the disorder, which predates the onset of psychotic symptoms 
(Howes and Kapur, 2009). It is thought that here and during relapses, dopaminergic 
neurons are hyperresponsive to outside stressors such as environmental stimuli, 
stimulant use or discontinuance of medication (Laruelle, 2000; Ujike, 2002). This 
means that the pathologic process is thought to have already begun during the 
prodromal phase, and the disease and full-blown psychotic symptoms become fully 
manifested when the threshold is exceeded (Ujike, 2002).  
 
In the clinic, psychotic symptoms presenting with cocaine abuse can be diagnosed 
as cocaine intoxication, which is more of an acute state and disappears with 
abstinence; psychotic disorder induced by cocaine, where psychotic symptoms last 
longer and are usually more severe; or schizophrenia with cocaine abuse, where 









individuals would be diagnosed with the primary psychotic disorder but can 
experience acute psychotic symptoms induced by cocaine at the same time. These 
diagnoses mainly differ on the duration of their symptoms and therefore it is often 
difficult to give a distinguished diagnosis straight away (American Psychiatric 
Association, 2013; Vergara-Moragues et al., 2014). In the clinic, all three of these 
diagnoses are treated using the same pool of antipsychotic drugs. These dopamine 
receptor blocking agents have been shown to be able to block the development of 
sensitization when given during the induction of this sensitization and suppress the 
expression of sensitized behaviour when given before a psychostimulant challenge, 
however, have not been seen to be as effective in reversing the sensitized state 
(Meng et al., 1998; Shuto and Nishi, 2011). Therapeutic agents that are able to 
reverse this state of sensitization instead of just controlling it may have potential 
therapeutic value for schizophrenia.  Moreover, as substance abuse in 
schizophrenic individuals is common and can cause a relapse or worsening of 
symptoms, better treatment options are required for individuals with co-morbidities 
(Curran et al., 2009). 
7.2.2 Are we lagging behind in light of new data: the impact of updating a 
search 
My aim was to explore the extent to which updating my original search would 
change overall results. 
7.2.2.1 Methods 
This work was carried out as part of a BSc Biological Sciences Honours dissertation 
project and I would like to acknowledge Fala Cramond (FC) for her work on 
performing the update search, screening of studies for inclusion and exclusion and 
extracting data for included publications. Data were checked and meta-analyses 
were run by myself.  
7.2.2.2 Search strategy 
3847 publications identified to be of relevance in the current review as described in 
Chapter 3, were filtered by searching for “cocaine” in the title, abstract and 
keywords. This gave a subset of the data that will be hereon referred to in this 
chapter as the “Original search”. In addition to this, an update search of PubMed 
was completed in January 2015 using the same string of search terms as described 
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in Chapter 2 and restricted to studies published after January 2014. The same filter 
was applied to this dataset as the original dataset to give a subset of studies 
exploring the effects of cocaine in animals, labelled from hereon as the “Update 
Search”. Publications were screened independently by title and abstract in MS 
Access by two reviewers (FC and AS) and discrepancies were resolved by a third 
screener (myself).  
7.2.2.3 Inclusion criteria 
Initial methods used for screening were identical to those described in Chapter 2, 
with the addition of the following criteria: only experiments describing the effects of 
cocaine on locomotion were included. Studies specifically investigating the addictive 
effects of cocaine, those testing cocaine in transgenic mice and those that used 
animals with co-morbidities were also excluded. Experimental paradigms using both 
acute and chronic administration of cocaine were included, and this was not 
restricted to any particular route of delivery. The only outcome measure was 
horizontal locomotion and therefore other outcome measures, such as stereotyped 
behaviour, were not extracted. 
7.2.2.4 Data extraction 
From each study included, experimental comparisons describing the effects of acute 
or repeated administration of cocaine on locomotion and those exploring modulation 
of this effect through the administration of therapeutic agents were included. These 
comparisons were extracted and analysed separately. A single reviewer (FC) 
extracted study design, quality and outcome data for each included comparison as 
described in Chapter 2. For experiments describing acute effects of cocaine, where 
data were presented as total locomotion over a period, total movement and time 
period of assessment was extracted. Where locomotion was reported over a period 
through activity at multiple time points, the mean activity over that time was taken 
and time period of assessment was recorded as final time point of assessment. In 
experiments describing chronic cocaine administration paradigms, where the 
development of behavioural sensitization was measured by reporting locomotor 
activity on the first and last day of cocaine administration, the difference between 
these two measures was taken. For experiments measuring the expression of 
behavioural sensitization by reporting locomotor activity in response to a challenge 
dose of cocaine after withdrawal from the repeated administration paradigm, the first 
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withdrawal time point was taken. 15% of all data extracted were checked by me and 
any errors that were encountered within this set were changed. As no consistent 
errors were identified within this subset of the data, everything was taken ahead for 
further analysis. Overall, both raw data and analyses were also subject to a sense 
check and any data that appeared erroneous was double-checked within the 
publication.  
7.2.2.5 Analysis 
Meta-analysis methods are as described in Chapter 2. Acute cocaine-induced 
locomotor activity and chronic cocaine-induced sensitized locomotor activity were 
analysed separately. Moreover, for chronic cocaine administration paradigms, 
experiments measuring the development of behavioural sensitization and later 
measurements of expression of behavioural sensitization in response to a challenge 
dose of cocaine were also analysed separately. Where appropriate and data were 
sufficient (i.e. over 25 comparisons included in the meta-analysis), univariate meta-
regression was performed to investigate potential sources of heterogeneity. Meta-
regression was used to investigate possible sources of heterogeneity including 
components of study quality and methodological criteria checklist and study design 
characteristics, where a significance level of p<0.05 was set for each test. To correct 
for multiplicity of testing a Holm-Bonferroni adjusted critical p value was calculated 
to account for the number of variables tested within subgroup analyses, calculated 
separately for study quality and study design items. For study quality items and for 
study design items explored in experiments using chronic cocaine administration 
paradigms adjusted critical p value was set at p<0.006. For study design items 
explored in experiments using acute cocaine administration paradigms and 
characterising the model adjusted critical p value was set at p<0.009 and for those 
looking at the effect of a treatment on models of cocaine-induced psychosis it was 
set at p<0.007. 
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This included variables of study quality and study design characteristics. Criteria for 
study quality were as specified in Chapter 2. Study design characteristics for all 
studies were also as specified in Chapter 2, including (1) species of animal used, (2) 
strain of animal used, (3) sex of animal used, (4) dose of cocaine administered (i.e. 
whether acutely or repeatedly), (5) route of cocaine administration, (6) time of 
outcome assessment – measured as duration of assessment for acute locomotor 
activity and as last day of cocaine-induced locomotor activity assessment for chronic 
cocaine experiments. Furthermore, for experiments measuring locomotor activity 
after chronic exposures to cocaine, (7) number of cocaine administrations was 
tested, and for those measuring behaviour after withdrawal from this experimental 
paradigm (8) days of withdrawal between last cocaine administration and challenge 
dose of cocaine administration were also tested (Figure 7.6). For experiments 
testing the effect of a treatment drug (9) time of treatment administration and (10) 
treatment administered were also explored.  
Figure 7.6 Experimental design of acute and chronic administration paradigms of 




457 of the initially identified 14,721 publications identified in my main search 
included the word “cocaine” in their title, abstract or keywords. 153 were found to be 
potentially relevant to our research question at this stage and included. At full-text 
screening 61 publications of relevance were identified describing both model-
characterising and treatment-testing experiments. Updating the search a year later 
added another 12 publications of relevance.  
Overall, measures to reduce bias were reported in few publications (Table 7.2). In 
the original dataset the median number of study quality checklist items scored was 
one (interquartile range [IQR] 1-2). Random allocation of animals to group was 
reported in 5 publications (24.2%), blinded assessment of outcome in 6 (9.7%), 
reporting of animals excluded from analysis in 5 (8.1%), a statement of potential 
conflict of interest in 9 (14.5%), and compliance with animal welfare regulations in 
40 (64.5%). No publications reported having carried out a sample size calculation, 
the availability of a protocol for their study or having blinded the induction of model 
or administration of treatment. Improvements were only seen in the reporting of 
compliance with animal welfare regulations (increased to 70.3%) and potential 
conflict of interest statements (20.3%) when the search was updated to include the 
additional studies identified a year after the original search. In contrast to the original 
search, no studies in the updated search reported blinded assessment of outcome 












Table 7.2 A comparison of the reporting of methodological quality items and 
measures taken to reduce risks of bias in studies identified in our original search, in 
the updated search and with all the data pooled 






Total No. of publications identified 61 12 73 
     
Number of publications reporting 
... (Overall %)    
Random allocation to group  15 (25%) 2 (16.7%) 17 (23%) 
Allocation concealment  0 0 0 
Blinded assessment of outcome 6 (10%) 0 6 (8%) 
Sample size calculation  0 0 0 
Compliance with Animal Welfare 
Regulations 40 (66%) 12 (100%) 52 (71%) 
Statement of potential conflict of 
interest 9 (15%) 6 (50%) 15 (21%) 
Exclusion of animals pre-specified or 
explained  5 (8 %) 0 5 (7%) 
Availability of a study protocol 0 0 0 
 
Median quality (/8) 
(interquartile range) 1 (1-2) 2 (1-2) 1 (1-2) 
 
7.2.2.6.1 Acute cocaine-induced hyperactivity 
7.2.2.6.1.1 Results of the original search 
Acute locomotor activity was reported in 51 publications in the original dataset and 9 
in the updated dataset. Due to the small number of studies identified in the updated 
search, the data were insufficient to perform meta-regression on, but they were 
incorporated into an overall model that included both searches totalling data from 60 







Table 7.3 A comparison of the data extracted from studies reporting acute cocaine-
induced locomotor activity in the original search and in the updated search 
Negative values indicate a worsening in outcome and positive values indicate an 
improvement in the behavioural outcome of the animal. 
 
Overall, 66 experiments testing the effects of cocaine on locomotion (using 1234 
animals) were identified and extracted. 8 of these experiments were performed in 
gerbils (243 animals), 20 using mice (338 animals) and 38 using rats (653 animals).  
The most commonly used strain was Sprague Dawley (29 experiments, 566 
animals, representing 43% of all animals used and 87% of rats). There was much 
less consistency in the strain of mouse used, the most common being C57Bl/6 mice 
(6 experiments, 102 animals, representing 30% of mice). Most experiments used 
male animals (48 experiments, 875 animals), while 5 (131 animals) used female 
animals, 4 (51 animals) used both and 9 (177 animals) did not state the sex of 
animal used. Dose of cocaine used in the experiments varied from 0.04 mg/kg to 56 
mg/kg, with 58 experiments (88%) using 20mg/kg or less. Time of behaviour 





activity   
Original Search Overall 
No. of publications  51 60 
Animals/paper  46.3 43.69 
    
Naïve vs. Model 
Animals 
Effect size  
(95% CI) 
-1.0689 SD  
(-1.2688 - -
0.8689) 
-1.063 SD  
(-1.2496 -  -0.8765) 
 I² (%) 46.8 49 
 
No. of 
experiments 66 81 
 No. of animals 1234 1487 
    
Model vs. 
Treated Animals 
Effect size  
(95% CI) 
0.9293  
(0.6958 - 1.1629) 
0.9185 
(0.6912 - 1.1457) 
 I² (%) 52.2 51.2 
 
No. of 
experiments 91 93 
  No. of animals 1134 1163 
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Altogether, administration of cocaine increased locomotor activity by 1.0689 SD 
units (95% CI 0.8689 to 1.2688). This increase in locomotor activity is defined as a 
worsening in behavioural outcome, and therefore an increased efficacy of the model 
at showing signs of hyperactivity thought to model the psychotic symptoms seen in 
humans. The dataset also showed moderate heterogeneity (tau2 = 0.292, I² = 
46.8%), which was only significantly explained by the dose of cocaine used to 
induce the model (p = 0.0031, tau2 = 0.2201, I² = 41.88%, adj R2 = 24.62%, Figure 
7.7 Relationship between dose of cocaine used to induce the model and reported 
effect size in model-characterising studies (Figure 7.7). Heterogeneity was not 
explained by any of the other study characteristic variables investigated with 
univariate meta-regression, namely: animal, strain and sex of animals, dose of 
cocaine used to induce the model, method of cocaine administration and time of 
outcome assessment. 
 
Figure 7.7 Relationship between dose of cocaine used to induce the model and 
reported effect size in model-characterising studies 
 
For study quality, a greater increase in locomotion was observed and therefore 
worse behavioural outcome in studies that reported random allocation to group as 
opposed to studies that had not reported taking measures to reduce this risk of bias 
(p = 0.0053, tau2 = 0.2131, I² = 40.94%, adj R2 = 27.04%, Figure 7.8). No other 
potential sources of bias or other methodological quality accounted for a significant 
proportion of heterogeneity. 
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In this original search, an additional 91 experiments (using 1134 animals) were 
identified as testing the efficacy of interventions in moderating cocaine-induced 
hyperlocomotion. 
15 of these experiments were performed in gerbils (328 animals), 29 using mice 
(256 animals) and 47 using rats (550 animals). The most commonly used strains 
were Sprague Dawley (24 experiments, 328 animals, representing 29% of all 
animals used and 60% of rats) and Mongolian gerbils (15 experiments, 328 animals, 
representing 29% of all animals used and all of the gerbils used). The most common 
strain of mouse used was Swiss-Webster mice (15 experiments, 126 animals, 
representing 49% of mice). An overwhelming majority of experiments used male 
animals (88 experiments, 1094 animals), while the rest of the experiments did not 
state the sex of animal used (3 experiments, 40 animals). Dose of cocaine used in 
the experiments varied from 0.2 mg/kg to 40 mg/kg, with 89 experiments (99%) 
using 30mg/kg or less. Time of behaviour assessment ranged from 10 minutes to 2 
hours. Time of treatment administration varied from three days prior to and up to half 
an hour after cocaine administration.  
Considered together, drug treatments improved hyperlocomotion induced by acute 
cocaine by 0.929 SD units (95% CI 0.6958-1.1629), with again moderate 
Figure 7.8 Relationship between the reporting or not reporting of 






heterogeneity (tau2 = 0.5014, I² = 52.2%). The use of different drugs explained part 
of the heterogeneity observed (p = 0.0009, tau2 = 0.2071, I² = 28.79%, adj R2 = 
58.07%, Figure 3), however, many of these were only tested in one or two 
experiments. Nevertheless, I found that the two most effective drugs in reducing 
hyperlocomotion were amperozide, an atypical- (5.04 SD units, 95% CI 2.7673 - 
7.3105) and fluphenazine (5.00 SD units, 95% CI 2.9902 - 7.0093), a typical- 
antipsychotic. Drugs grouped by their mechanism of action did not contribute 
significantly to heterogeneity.  
7.2.2.6.1.2 Results from updating the search 
Updating the search identified an additional 17 experiments using 281 animals. 15 
experiments described model-characterising paradigms and 2 experiments looked 
at the effect of a treatment administered to modulate cocaine-induced locomotion. 
Both treatment exploring experiments were from the same study and used male, 
Sprague Dawley rats. Model-characterising studies used mice (7 experiments, 129 
animals) and rats (8 experiments, 124 animals) in about equal proportion. All rats 
were Sprague Dawley, while the most common strain of mice used was C57BL/6 (4 
experiments, 81 animals). As seen before the majority of experiments reported 
using male animals (9 experiments, 125 animals), while one experiment reported 
using females (14 animals) and five experiments did not specify the sex used (114 
animals). The dose of cocaine administered among different experiments to induce 
the model varied from 0.15 mg/kg to 20 mg/kg and time of outcome assessment 
ranged from 15 minutes to 3 hours. 
Both of these datasets were too small to perform univariate meta-regression on, but 
data were combined with those from original search to give an overall, pooled 
dataset. By pooling data from original search and those identified in the following 
year in the literature, effect sizes changed little. Administration of cocaine increased 
locomotor activity by 1.063 SD units (95% CI 0.8765 to 1.2496), with still moderate, 
albeit slightly more heterogeneity than seen in original dataset alone (tau2 = 0.32, I² 
= 49.0%). As before, part of the heterogeneity was significantly explained by dose of 
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cocaine administered (p = 0.0001, tau2 = 0.2113, I² = 40.37%, adj R2 = 33.96%, 
Figure 7.9), but not by any other variables assessed. 
 
Overall, drug treatments improved hyperlocomotion induced by cocaine by 0.919 SD 
units (95% CI 0.6912-1.1457), with again moderate, however, slightly less 
heterogeneity than seen in just the original dataset (tau2 = 0.4722, I² = 51.2%). This 
heterogeneity was like before, in part, only significantly explained by the type of drug 
administered as treatment (p = 0.0009, tau2 = 0.1969, I² = 27.80%, adj R2 = 
58.30%). The most effective drugs remained the same as before. No other variables 
of study characteristics or quality contributed significantly to heterogeneity.  
7.2.2.6.2 Chronic cocaine-induced locomotor activity 
Experimental paradigms involving a chronic drug administration schedule were 
identified in 22 publications through the original search. Both model-characterising 
and treatment exploring experiments using these paradigms measured either the 
development of sensitization over a period of time during which the animal was 
administered cocaine, as well as the expression of sensitization measured after 
abstinence from cocaine for a set period of time. These were analysed separately as 
we recognise them to be different in terms of measuring underlying biology. 
Individually, none of these separate meta-analyses were sufficient for univariate 
meta-regression, therefore heterogeneity could not be explored in detail. 
Figure 7.9 Relationship between the dose of cocaine used to induce model and 
reported effect size in model-characterising studies from the alternate search 
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From these 22 publications, 56 experiments using a repeated cocaine administration 
paradigm were identified. 18 reported measuring the development of behavioural 
sensitization. I define the development of behavioural sensitization here as the 
difference in locomotor activity induced by cocaine given on the first day of drug 
exposure compared to that induced by cocaine on the last day of the repeated drug 
administration paradigm. In addition, 38 experiments reported measuring the 
expression of sensitization. This is defined as an increase in locomotor activity in 
response to administration of a challenge dose of cocaine after a certain period of 
withdrawal from the original chronic drug abuse paradigm.  
7.2.2.6.2.1 Experiments characterising the model 
7.2.2.6.2.1.1 Results of the original search 
Out of the total 56 experiments, 10 experiments (using 208 animals), measured the 
behavioural effects of repeated cocaine administration on the development of 
behavioural sensitization. In addition, 14 experiments (using 283 animals) measured 
the expression of sensitization produced after a period of abstinence and a 
subsequent administration of a challenge dose of cocaine. Of these model-
characterising experiments, species used were mainly mice (15 experiments, 345 
animals), of the strains C57BL/6J (4 experiments, 92 animals) and Swiss-Webster 
(4 experiments, 100 animals), but also Balb/c (2 experiments, 46 animals), ICR (3 
experiment, 76 animals), CD-1 (1 experiment, 11 animals) and Swiss-Albino (1 
experiment, 20 animals). The only other species used were rats (8 experiments, 
animals), including strains Sprague Dawley (6 experiments, 123 animals), Lewis (1 
experiment, 9 animals) and Wistar (1 experiment, 14 animals). More of these 
animals used were male (14 experiments, 288 animals, 59% of all animals used), 
than females (1 experiment, 32 animals), while only 3 experiments used both (60 
animals) and 5 did not state gender of their experimental subjects (111 animals). 
Dose of cocaine administered repeatedly was either 7.5mg/kg (1 experiment), 10 
mg/kg (12 experiments), 15mg/kg (8 experiments) or 20 mg/kg (2 experiments). 
These repeated injections were mostly administered once a day, or twice a day for 1 
experiment, for the duration of either 5 (16 experiments), 7 (2 experiment), 8 (4 
experiments) or 20 (1 experiment) days, repeatedly. For those experiments 
measuring it, time of withdrawal allowed between the development of sensitization 
and measurement of expression of sensitization ranged from 2 days to 28 days after 
abstinence to cocaine. 
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Altogether, administration of cocaine over a prolonged period amplified locomotor 
activity by 3.4024 SD units (95% CI 2.2054 to 4.5993,  
Table 7.4) on the final day of administration compared to the first day of 
administration. This augmentation in locomotor activity is thought to indicate a 
development of sensitization to cocaine in these animals. Substantial heterogeneity 
was observed in the data (tau2 = 2.2523, I² = 83.5%), however, I could not explore 
this further using univariate meta-regression due to the small sample of data. When 
animals were tested after withdrawal from the chronic cocaine administration 
paradigm, a cocaine challenge increased locomotor activity by 1.3757 SD units 
(95% CI 0.7736 – 1.9778). This is thought to be a measure of cocaine-induced 
expression of behavioural sensitization, or in other words the effect of chronic 
cocaine abuse on the animals’ susceptibility to hyperlocomotion in response to 
subsequent uses of the substance. 
Table 7.4 A comparison of the data extracted from studies characterising chronic 




  Original Search 
Overall with 
Updated Search 






41.8 37     
Naïve vs. Model 
Animals 




Effect size  
(95% CI) 
-3.4024 SD  
(-4.5993 - -
2.2054) 
-2.7002 SD  
(-3.5240 - -1.8764) 
 














-1.3773 SD  
(-2.0218 - -0.7328) 
 




  No. of animals 283 348 
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7.2.2.6.2.1.2 Results from updating the search 
Updating the search by a year added an extra 9 publications. These included 8 
experiments describing the development phase of behavioural sensitization in 
response to chronic cocaine administration and 4 experiments measuring the 
expression of behavioural sensitization. All experiments that measured the 
development of behavioural sensitization were model-characterising experiments (8 
experiments, 123 animals) and looked at the effect of chronic cocaine administration 
on the amplification of locomotor activity. A further, 4 experiments (using 65 
animals) looked at characterising the model and measured outcome after withdrawal 
from the chronic drug administration paradigm.  
Altogether, model-characterising experiments used 188 animals in total, which were 
either rats (6 experiments, 101 animals) or mice (6 experiments, 88 animals). All of 
the rats used were Sprague Dawley rats, while the strain of mice used was much 
less consistent with 1 experiment using C57 (24 animals), 1 experiment using 
C57BL/6 (6 animals), 2 experiments using C57BL/6J (19 animals) and another two 
experiments using C57BL/6J x 129S1/SvlmJ mice (39 animals). Most experiments 
used male animals (7 experiments, 94 animals, 50% of all animals), 2 experiments 
used female animals (32 animals) and 3 experiments did not state the sex of 
animals used at all (63 animals). The dose of cocaine administered repeatedly over 
time to initiate behavioural sensitization ranged from 0.15 mg/kg to 20 mg/kg, 
administered once a day (10 experiments), every two days (1 experiment) or three 
times a day (1 experiment). Cocaine was administered in this manner over 5 (2 
experiments), 7 (5 experiments), 8 (2 experiments) or 10 days (3 experiments). The 
time between abstinence from this administration paradigm and measurement of 
sensitization taken in response to a challenge dose of cocaine was either one, 4, 14 
or 51 days.  
Once the original dataset was updated with data obtained from the update search, 
the effect of repeated cocaine administration on locomotion during the development 
of sensitization gave a pooled effect size of -2.7002 SD units (95% CI -3.5240 - -
1.8764), meaning cocaine administered worsened outcome by 2.7 SD units. 
Substantial heterogeneity was observed in the data (tau2 = 2.0491, I² = 79.2%), but 
unfortunately, even the updated dataset contained too few data points to be able to 
perform univariate metaregression. By pooling experiments that measured 
locomotor activity after withdrawal from a chronic abuse paradigm, a challenge dose 
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of cocaine had an effect of -1.3773 SD (95% CI -2.0218 - -0.7328) on locomotor 
activity. This meant that a challenge dose of cocaine worsened behavioural outcome 
by 1.38 SD units after withdrawal from a chronic drug administration paradigm. This 
dataset showed a substantial amount of heterogeneity (tau2 = 0.6372, I² = 71.1%) 
likely seen again due to the small sample size, which also meant univariate meta-
regression could not be performed due to low power. 
7.2.2.6.2.2 Experiments measuring the effect of a treatment drug 
7.2.2.6.2.2.1 Results of the original search 
8 experiments (using 142 animals), all from the same publication, measured the 
effect of a variety of possible therapeutics on the development of sensitization in 
animals initiated by a chronic cocaine administration paradigm. In comparison, 24 
experiments (using 287 animals) had measured the effect of possible therapeutic 
agents on the expression of behavioural sensitization, tested after withdrawal from a 
chronic cocaine administration paradigm. Together, all but one of these treatment 
exploring studies used rats (31 experiments, 409 animals), with 1 experiment using 
C57BL/6J mice (20 animals). Rats used were mostly Sprague Dawley rats (29 
experiments, 391 animals), with 2 experiments using Wistar rats (18 animals). All, 
but one of the experiments used male animals (409 animals), while the sex of the 
animals used was not specified in that one experiment (20 animals). Dose of 
repeated cocaine administrations before withdrawal from the drug ranged from 
10mg/kg – 30 mg/kg, with 30 mg/kg being the most prevalent dose given in these 
experiments (22 experiments). Cocaine was administered once daily either over 5 (3 
experiments), 7 (22 experiments), 10 (6 experiments) or 14 days (1 experiment). 
Measurements of locomotion were taken after administration of a challenge dose of 
cocaine after withdrawal periods of 5 (3 experiments), 10 (7 experiments), 21 (8 
experiments) or 22 days (6 experiments). Therapeutic agents were administered 
either once (9 experiments), 5 (2 experiments), 7 (7 experiments), 8 (8 experiments) 
or 10 (6 experiments) times during behavioural sensitization. Treatment was either 
given for the duration of the repeated administration of cocaine or just before the 
challenge cocaine dose was administered.  
The overall effect seen in studies measuring locomotion during the development of 
behavioural sensitization was that agents administered were not able to counteract 
the amplified locomotor activity produced by prolonged cocaine administration. 
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Overall, there was actually an increase in locomotor activity (i.e. worsening in 
behavioural outcome) by 1.0149 SD units (95% CI -3.1163 to 5.1460, Table 7.5). 
This, of course, is strongly affected by the fact that all the data came from a single 
study and overall amounted only to a small sample of experiments. The dataset also 
showed a substantial amount of heterogeneity (tau2 = 22.8659, I² = 94.4%), possibly 
due to the small sample size, which also meant that data were not sufficient to 
explore using univariate meta-regression. Therapeutic agents showed a small 
improvement in overall behaviour when locomotion was measured after withdrawal 
from the drug paradigm, and decrease in cocaine-induced hyperactivity by 0.2087 
SD units (95% CI -0.2646 - 0.6820) during the expression phase of behavioural 
sensitization. The dataset showed a moderate amount of heterogeneity (tau2 = 
0.4621, I² = 52.5%), but unfortunately, the sample of experiments was still too small 
to perform univariate meta-regression on.  
Table 7.5 A comparison of the data extracted from studies testing treatment drugs on 
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Effect size  
(95% CI) 
-1.0149 SD  
(-5.1460 - 
3.1163) 
-1.0149 SD  
(-5.1460 - 3.1163) 
 














0.2662 SD  
(-0.1573 - 0.6896) 
 









7.2.2.6.2.2.2 Results from updating the search 
Updating the search by a year added an extra 9 publications, which contributed only 
3 additional experiments looking at the effect of therapeutic agents on repeated 
administration of cocaine. The 3 experiments, reported in the same publication 
looked at the effect of fluoxetine, clozapine and haloperidol on the expression of 
behavioural sensitization in response to a challenge drug of cocaine following 
withdrawal from a chronic cocaine abuse paradigm. As they were from the same 
laboratory, they all used male, ICR mice. Experimental setup involved administration 
of 20mg/kg of cocaine over 5 days to the animal in order to initiate behavioural 
sensitization. Challenge dose of cocaine was administered and locomotor activity 
measured 19 days after abstinence from chronic cocaine administration paradigm. 
Therapeutic agents were administered 3 times, each starting 7 days before and 
finishing 3 days before challenge cocaine administration.  
When the effect of therapeutic agents was measured on this expression of 
sensitization induced by a challenge dose of cocaine, it was found that 
hyperlocomotion induced by cocaine could be reduced by 0.2662 SD units (95% CI -
0.1573 - 0.6896) with moderate heterogeneity (tau2 = 0.4287, I² = 50.7%). 
7.2.3 Are we capturing all the publications of relevance in our search: the 
impact of alternate search terms 
Next, I wanted to test the impact of search terms used on the results of my meta-
analysis for studies answering the same research question. I was interested in 
analysing the quality of my initial search words used to identify publications in this 
systematic review, as psychosis is a uniquely human and heterogeneous condition 
that is diagnosed in the clinic through self-reporting and manifests through a 
complex group of symptoms. Considering we can’t assess self-reporting in animals 
and it is expected that only a certain group of symptoms are being modelled by an 
animal instead of the full extent of the disorder (Nestler and Hyman, 2010), it is of 
interest to see how well we are able to identify relevant publications in the first place. 
The main aims were to assess if using more specific search terms to the animal 
experiments of interest instead of the human condition, would pick up on more and 
potentially different publications and ultimately whether missing these in my original 




This work was carried out as part of a BSc Biological Sciences Honours dissertation 
project and I would like to acknowledge Angus Sinclair (AS) for his work on 
performing the update search, screening of studies for inclusion and exclusion and 
extracting data for included publications. Data were checked, and meta-analyses 
were ran by myself.  
7.2.3.2 Search strategy 
Publications of relevance were identified from publications included and described in 
Chapter 3, by filtering using the word “cocaine” in title, abstract and key words of 
publications. This was pooled with a set of publications identified through an update 
search of PubMed, completed in January 2015, as described above in section 7.2.2. 
This pooled dataset will be hereon referred to as the “Original search”, as these 
publications were identified using the original search string specified in Chapter 2. 
To look at the effect of an alternate search strategy, an alternative search string was 
created, which was to identify cocaine-induced locomotor behaviours in animals 
using more specific search criteria. This alternative search used the following search 
criteria: 
[cocaine] AND [motor act* OR hyperact* OR hyperkinesis OR climbing OR rearing 
OR behavioural sensitisation OR head shak* OR head twitch* OR prepulse OR pre-
pulse OR acoustic startle OR acoustic reflex OR startle reflex OR auditory startle 
response OR latent inhibition OR social withdrawal OR motor inhibition OR catalep* 
OR nesting behaviour OR nest building OR stereotyp* OR sensory gating]  
Results were filtered using the same animal filter as mentioned in Chapter 2 
(Hooijmans et al., 2010b). The resulting dataset is hereon referred to as the 
“Alternate search”. All publications were screened independently by title and 
abstract in MS Access by two reviewers (FC and AS) and discrepancies were 
resolved by a third screener (myself).  
7.2.3.3 Inclusion criteria 
The only variable of interest was the effect of using an alternate set of search terms 
on the data obtained. Therefore, all methods used for inclusion were the same as 
described above in section 7.2.2 of this chapter. To reiterate, initial methods used 
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for screening for inclusion and exclusion were identical to those described in 
Chapter 2, with the addition of the following criteria: Only experiments describing the 
effects of cocaine on locomotion were included. Studies specifically investigating the 
addictive effects of cocaine, those testing cocaine in transgenic mice and those that 
used animals with co-morbidities were also excluded. Experimental paradigms using 
both acute and chronic administration of cocaine were included, and this was not 
restricted to any particular route of delivery. The only outcome measure was 
horizontal locomotion and therefore other outcome measures, such as stereotyped 
behaviour, were not extracted. 
7.2.3.4 Data extraction 
Data extraction was also identical to those described in section 7.2.2 of this chapter. 
From each study included, experimental comparisons describing the effects of acute 
or repeated administration of cocaine on locomotion and those exploring modulation 
of this effect through the administration of therapeutic agents were included. These 
comparisons were extracted and analysed separately. As before, a single reviewer 
(AS) extracted study design, quality and outcome data for each included comparison 
as described in Chapter 2. For experiments describing acute effects of cocaine, 
where data were presented as total locomotion over a period of time, total 
movement and time period of assessment were extracted. Where locomotion was 
reported over a period of time through activity at multiple time points, the mean 
activity over that time was taken and time period of assessment was recorded as 
final time point of assessment. In experiments describing chronic cocaine 
administration paradigms, where the development of behavioural sensitization was 
measured by reporting locomotor activity on first and last day of cocaine 
administration, the difference between these two measures was taken. For 
experiments measuring the expression of behavioural sensitization by reporting 
locomotor activity in response to a challenge of cocaine after withdrawal from the 
repeated administration paradigm, the first withdrawal time point was taken. 15% of 
all data extracted was checked by me and any errors that were encountered within 
this set were changed. As no consistent errors were identified within this subset of 
the data, everything was taken ahead for further analysis. Overall, both raw data 
and analyses were also subject to a sense check and any data that appeared 




Meta-analysis methods were as described in Chapter 2. Acute cocaine-induced 
locomotor activity and chronic cocaine-induced sensitized locomotor activity were 
analysed separately. Moreover, for chronic cocaine administration paradigms, 
experiments measuring the development of behavioural sensitization and later 
measurements of expression of behavioural sensitization in response to a challenge 
dose of cocaine, were also analysed separately. To correct for multiplicity of testing 
a Holm-Bonferroni adjusted critical p value was calculated to account for the number 
of variables tested within subgroup analyses, calculated separately for study quality 
and study design items. For study quality items and for study design items explored 
in experiments using chronic cocaine administration paradigms adjusted critical p 
value was set at p<0.006. For study design items explored in experiments using 
acute cocaine administration paradigms and characterising the model adjusted 
critical p value was set at p<0.009 and for those looking at the effect of a treatment 
on models of cocaine-induced psychosis it was set at p<0.007. This included 
variables of study quality and study design characteristics as described and 
explained above in section 7.2.2 of this chapter. 
7.2.3.6 Results  
In total, the alternate search for cocaine-induced locomotor activity identified 2831 
publications and screening of these results narrowed this down to 824 relevant 
publications. Unfortunately, due to time constraints and the large number of 
publications identified, data extraction was only possible for the most recent 
publications published up to and including 2010. This gave a final dataset of 85 
included publications. For this reason, in order to make the comparison between the 
data from the original search and the alternate search comparable, data obtained 
through data extraction from publications in our original search was also limited to 
the same publication date. This meant that the original search included data from 28 
publications, which were published in or after 2010. 
Reporting of measures taken to reduce bias and other methodological quality criteria 
within publications were more prevalent for some items than others (Table 7.6). In 
the original dataset the median number of study quality checklist items scored was 2 
(interquartile range [IQR] 1-2). Random allocation of animals to group was reported 
in 8 publications (29%), blinded assessment of outcome in 4 (14%), reporting of 
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animals excluded from analysis in 1 (4%), a statement of potential conflict of interest 
in 13 (46%), and compliance with animal welfare regulations in 26 (93%). No 
publications reported having carried out a sample size calculation, the availability of 
a protocol for their study or having blinded the induction of model or administration 
of treatment. Overall, the prevalence of reporting of these items assessed was very 
similar between the two different searches. A substantial difference between the two 
searches was only seen in the reporting of compliance with animal welfare 
regulations. 
 
Table 7.6 A comparison of the reporting of methodological quality items and 
measures taken to reduce risks of bias in studies identified in our original search, in 
the alternate search and with all the data pooled. 
 
7.2.3.6.1 Acute cocaine-induced locomotor activity 
7.2.3.6.1.1 Results from the original search 
In the original dataset 34 experiments reporting data for the effects of cocaine on 
locomotion (using 591 animals) were identified and extracted. 21 of these 
experiments were performed in rats (332 animals) and 13 using mice (259 animals). 





Total No. of publications identified 28 85 113 
     
Number of publications reporting ...  
(Overall %) 
   
Random allocation to 
group 
 
8 (29%) 22 (26%) 30 (27%) 
Allocation concealment 
 
0 0 0 
Blinded assessment of outcome 4 (14%) 11 (13%) 15 (13%) 
Sample size calculation 
 
0 0 0 
Compliance with Animal Welfare 
Regulations 
26 (93%) 85 (100%) 111 
(98%) 
Statement of potential conflict of 
interest 
13 (46%) 39 (46%) 52 (46%) 
Prespecified or explanation of 
exclusion of animals 
1 (4%) 2 (2%) 3 (3%) 
Availability of a study protocol 0 0 0 
Median quality (/8)(interquartile 
range) 
2 (1-2) 2 (1-2) 2 (1-2) 
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The most commonly used strain was Sprague Dawley (18 experiments, 302 
animals, representing 51% of all animals used and 91% of rats). There was much 
less consistency in the strain of mouse used, the most common being C57Bl/6 mice 
(5 experiments, 99 animals, representing 38% of mice). Most experiments used 
male animals (27 experiments, 438 animals), while one (16 animals) used female 
animals, and 6 (140 animals) did not state the sex of animal used. The dose of 
cocaine used in the experiments varied from 0.15 mg/kg to 30 mg/kg, with 26 
experiments (76%) using 15mg/kg or less.  
Altogether, administration of cocaine increased locomotor activity by 0.8165 SD 
units (95% CI 0.5003 to 1.1326, Table 7.7). As before, this is defined as a worsening 
in behavioural outcome, and therefore an increased efficacy of the model at showing 
signs of hyperactivity thought to model the psychotic symptoms seen in humans.  
Table 7.7 A comparison of the data extracted from studies reporting acute cocaine-
induced locomotor activity in the original search and in the alternate search. 
Negative values indicate a worsening in outcome and positive values indicate an 
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Naïve vs. 
Model Animals 














Effect size  0.8171 SD 0.4027 SD  
(95% CI) (-0.2139-1.8482) (0.1581-0.6474) 
 




  No. of animals 100 1207 
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The dataset also showed moderate heterogeneity (tau2 = 0.3867, I² = 53.1%), which 
was only significantly explained by the dose of cocaine used to induce the model (p 
= 0.0046, tau2 = 0.1864, I² = 35.92%, adj R2 = 51.79%, Figure 7.10). Heterogeneity 
was not explained by any of the other study characteristic variables investigated with 
univariate meta-regression, namely: animal, strain and sex of animals, dose of 
cocaine used to induce the model, method of cocaine administration and time of 
outcome assessment. 
 
Limiting studies according to publication date limit, unfortunately, excluded many 
previously included data from experiments testing the efficacy of interventions in 
moderating cocaine-induced hyperlocomotion. The comparison set included seven 
experiments from the original search dataset (using 100 animals). All of these 
experiments were performed in male rats, using Long-Evans (1 experiment, 15 
animals), Sprague Dawley (5 experiments, 73 animals) or Wistar (1 experiment, 12 
animals) rats. In four experiments animals were given 10mg/kg dose of cocaine to 
induce model, in two 15mg/kg, and in one experiment animals were administered 
20mg/kg to induce the model. Time of behaviour assessment ranged from 30 
minutes to 2 hours. Time of treatment administration was as early as a month before 
cocaine administration in some cases, but otherwise, it was usually administered 
alongside cocaine. Drugs tested as treatments included the typical antipsychotic 
flupenthixol, antidepressants, dopamine D3R agonists and an inhibitor of protein 
palmitoylation.  
Figure 7.10 Relationship between acute dose of cocaine used to induce the 
model and reported effect size in model-characterising experiments of the 
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Considered together, drug treatments improved hyperlocomotion induced by 
cocaine by 0.8171 SD units (95% CI -0.2139-1.8482), with again moderate 
heterogeneity (tau2 = 0.7989, I² = 65.4%). Due to the extremely small sample size, 
univariate meta-regression could not be performed. 
7.2.3.6.1.2 Results from the alternate search 
Data extraction from publications identified using the alternative search strategy 
established 71 publications exploring the effects of a single administration of 
cocaine on locomotor activity. From these publications, 99 experiments were 
established to be testing the ability of cocaine in increasing locomotor activity using 
1674 animals.  
52 of these experiments used mice as their animal model of choice (819 animals), 
45 experiments used rats (835 animals) and two used marmosets (20 animals). The 
most common strain used for mice was CD-1 (12 experiments, 170 animals, 21% of 
all strains of mice and 10% of all animals used), while the most common strain for 
rats was Sprague Dawley (25 experiments, 464 animals, 56% of rats used and 28% 
of all animals used). The majority of animals used, here as seen in the other 
datasets, was male (88 experiments, 1483 animals), while only 6 experiments used 
female animals (104 animals) and 4 experiments used both (77 animals). The dose 
of cocaine used to induce the model varied from 1.25 mg/kg to 66 mg/kg. Duration 
of behavioural assessment after cocaine administration varied from 5 minutes to 4 
hours and 20 minutes.  
Overall, these model-characterising experiments showed an overall increase in 
locomotion by 1.5891 SD units (95% CI 1.4138-1.7643) in animals in response to 
cocaine, with moderate heterogeneity (tau2 = 0.3590, I² = 48.2%). Variables that 
significantly accounted for a proportion of the heterogeneity included strain of animal 
used within experiments (p = 0.0034, tau2 = 0.2263, I² = 35.81%, adj R2 = 36.96%, 
Figure 1) and dose of cocaine used to induce the model (p = 0.0007, tau2 = 0.2939, 
I² = 44.18%, adj R2 = 18.15%, Figure 7.11). No other variables of internal validity or 
study characteristics significantly accounted for heterogeneity seen in the dataset. 
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Figure 7.11 Relationship between acute dose of cocaine used to induce the model and 
reported effect size in model-characterising studies from the alternate search. 
86 experiments also tested the efficacy of interventions in moderating cocaine-
induced hyperlocomotion (1207 animals). The two most commonly used animals in 
these experiments were mice (45 experiments, 641 animals), and rats (40 
experiments, 556 animals), in addition to one experiment using marmosets (10 
animals). Experiments using mice used 8 different species to create the models, but 
most common models were Swiss-Webster (13 experiments, 137 animals, 21% of 
all mice used and 11% of all animals used) and CD-1 (10 experiments, 137 animals, 
again, 21% of all mice used and 11% of all animals used). For rats, the most 
common strain used was Sprague Dawley (22 experiments, 370 animals, 67% of all 
rats used and 31% of all animals used). In terms of sex used, the same pattern was 
seen as before. The majority of experiments used male animals (83 experiments, 
1161 animals, 96% of all animals), while one used both (10 animals) and 2 did not 
specify the sex of the animals at all (36 animals). The dose of cocaine used to 
induce the model varied from 5 mg/kg to 66 mg/kg, with the majority of experiments 
administering 20 mg/kg or lower doses to animals (79% of all experiments). Duration 
of behavioural assessment after cocaine administration varied from 10 minutes to 4 
hours and 20 minutes. Time of treatment administration varied from over two 
months before model induction, to administration at the same time as cocaine. 
Overall treatment drug studies improved cocaine-induced hyperactivity by 0.4027 
SD units (95% CI 0.1581-0.6474) with slightly more observed heterogeneity than 
seen in the data identified in the original search, however, still only moderate (tau2 = 
0.5700, I² = 61.4%). None of the variables assessed in univariate meta-regression 
significantly accounted for any of this heterogeneity.  
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7.2.3.6.2 Chronic cocaine administration schedule 
7.2.3.6.2.1 Experiments characterising the model 
7.2.3.6.2.1.1 Results of the original search 
When limiting the original search results on cocaine studies to publications 
published in or after 2010, 32 experiments using 219 animals reported 
measurements of locomotor activity after chronic cocaine administration.12 
experiments measured the development of behavioural sensitization through 
repeated cocaine administration (219 animals). An additional 11 experiments (using 
245 animals) reported the effect of a challenge dose of cocaine on locomotion in 
animals who had previously been sensitized to the drug through a chronic drug 
administration paradigm.  
In total these experiments used 464 animals, most of which were mice (15 
experiments, 324 animals), while 8 experiments reported outcomes in rats (141 
animals). The most commonly used strain of mouse was C57BL/6J (6 experiments, 
111 animals, 34% of all mouse strains used, 24% of all animals used). All rats in the 
dataset were Sprague Dawley rats. The majority of these animals were male (15 
experiments, 296 animals), with two experiments using female animals (32 animals), 
one experiment using both sexes (22 animals), and 5 experiments not stating the 
sex of animals used at all (115 animals). Dose of cocaine administered repeatedly 
ranged from 0.15 mg/kg to 20 mg/kg, with most experiments using a chronic dosage 
paradigm of 10 mg/kg (7 experiments) or 15 mg/kg (12 experiments) doses given 
repeatedly. These doses were either given every two days (1 experiment), once a 
day (21 experiments) or three times a day (1 experiment) over 5 (9 experiments), 7 
(5 experiments), 8 (6 experiments), or 10 days (3 experiments). Expression of 
behavioural sensitization measured in the 11 experiments by assessing locomotor 
activity in response to a challenge dose of cocaine, was measured after a 
withdrawal period ranging between 1-51 days after the last day of the chronic drug 
paradigm. 
Overall these studies indicate that chronic cocaine administration amplifies the 
hyperlocomotor response to cocaine by 2.2028 SD units (95% CI 1.2898-3.1157, 
Table 7.8), implying the development of behavioural sensitization. Substantial 
heterogeneity was observed in the data (tau2 = 1.4818, I² = 76.4%). Administration 
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of a challenge dose of cocaine after previous chronic exposure to the drug 
increased locomotor activity by 1.3654 SD units (95% CI 0.6969 – 2.0338) 
compared to healthy, control animals when taking these experiments together. 
Substantial heterogeneity was observed in the data (tau2 = 0.6918, I² = 70.2%), 
however, neither of the datasets was sufficiently big enough to perform univariate 
meta-regression. 
Table 7.8 A comparison of the data extracted from studies reporting chronic cocaine-
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7.2.3.6.2.1.2 Results from the alternate search 
Performing the search using a set of alternate search words identified an additional 
84 experiments reporting experimental paradigms using chronic cocaine 
administration to measure both the development and expression of behavioural 
sensitization in response to the drug. 24 of these experiments (using 351 animals) 
measured cocaine-induced locomotor activity at the end of the development phase 
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of behavioural sensitization initiated by chronic cocaine administration, and 22 
experiments (using 340 animals) measured locomotion after withdrawal from this 
administration paradigm in response to a challenge dose of cocaine. 
Overall, animals used (658 in total) were mainly mice (19 experiments, 306 animals) 
and rats (24 experiments, 357 animals), but also three experiments reported using 
marmosets (28 animals). The most common strain of mouse used was C57BL/6J 
mice (7 experiments, 115 animals, 38% of all mice used), and for rats Sprague 
Dawley was the most prevalent strain of choice in this dataset (18 experiments, 263 
animals, 74% of all rats used). Most of the animals used were male (37 
experiments, 566 animals, 82% of all animals used), with 4 experiments reporting 
locomotion in female animals (54 animals) and 3 reporting using animals of both sex 
(51 animals), with the remaining two experiments not specifying sex of animals used 
(20 animals). Development of behavioural sensitization was initiated using doses of 
cocaine ranging from 5 mg/kg to 30 mg/kg, repeatedly administered either once, 
three times a day, or every other day. Duration of chronic cocaine administration 
ranged from 3 – 21 days between different experiments. Most experiments 
administered 10 mg/kg (11 experiments) or 15 mg/kg (24 experiments) of cocaine 
using a once a day paradigm (36 experiments, 78% of all experiments) for 5 (13 
experiments) or 7 days (16 experiments). For experiments measuring withdrawal 
from this chronic cocaine paradigm, challenge dose and subsequent measurement 
of locomotion was performed 1 to 42 days after last cocaine administration.  
Overall experiments measuring locomotor activity at first and last day of chronic 
cocaine administration schedule showed that cocaine administered after behavioural 
sensitization had been initiated locomotor activity was increased by 2.1571 SD units 
(95% CI 1.2243 – 3.0900). Heterogeneity was quantified to be substantial (tau2 = 
3.3068, I² = 82.3%). Experiments that measured locomotor activity after a period of 
withdrawal show that locomotor activity increased in response to a challenge dose 
of cocaine by 1.465 SD units (95% CI 0.9465 – 1.9836) compared to animals that 
had not been previously administered cocaine. Heterogeneity was only moderate for 
this subset of studies (tau2 = 0.6377, I² = 60.9%). Due to low sample of experiments 
contributing to both meta-analyses, heterogeneity could not be explored further in 
either datasets using meta-regression. 
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7.2.3.6.2.2 Experiments measuring the effect of a treatment drug 
7.2.3.6.2.2.1 Results of the original search 
No experiment measured the ability of therapeutic drugs to modulate the 
development of behavioural sensitization. 9 experiments looked at the reversal of 
the expression of behavioural sensitization through the administration of therapeutic 
drugs and their ability to modulate exaggerated hyperactivity in response to a 
challenge dose of cocaine following a previous chronic administration paradigm of 
the drug. These experiments used again mice (3 experiments, 36 animals, ICR 
strain) or rats (6 experiments, 52 animals, Sprague Dawley strain) in their 
experimental designs. All animals reported were male. Cocaine administered 
repeatedly to induce development of behavioural sensitization was either given at a 
dose of 20 mg/kg (3 experiments) or 30 mg/kg (6 experiments), once a day over 5 (3 
experiments) or 7 days (6 experiments). Expression of this behavioural sensitization 
and ability of therapeutic agents to reverse this was measured after withdrawal for 
19 or 22 days from this paradigm. Therapeutic drugs were administered either once 
2 hours before challenge dose of cocaine was given or three times starting 7 days 
before to 20 hours before challenge cocaine administration. 
These agents overall were able to reduce the exaggerated hyperactivity induced by 
a challenge dose of cocaine after previous chronic administration to the drug by 
1.2658 SD units (95% CI 0.5041 - 2.0276, Table 7.9) with very little heterogeneity 









Table 7.9 A comparison of the data extracted from studies reporting treatment effects 











Total no. of 
publications 
 
2 21 23 
Animals/paper 
 
44 26 27 









Effect size  - 1.0198 SD  1.0198 SD  




I² (%) - 87.3 87.3  
No. of 
experiments 




- 327 327 




Effect size  1.2658 SD 0.9569 SD 1.0937 SD  






I² (%) 21.9 71 63.9  
No. of 
experiments 
9 15 24 
  No. of 
animals 
88 217 305 
 
7.2.3.6.2.2.2 Results from the alternate search 
Through the alternate search a further 39 experiments (using 544 animals) were 
identified to be exploring the effect of potential therapeutic agents on chronic 
administration paradigms of cocaine. 24 experiments looked at the effect of these 
compounds on the development of behavioural sensitization (327 animals) or tried 
to reverse its expression (15 experiments, 217 animals). These experiments 
similarly to model-characterising studies used either rats (20 experiments, 290 
animals), mice (18 experiments, 246 animals) or marmosets (1 experiment, 8 
animals). The most common rat strain used was Sprague Dawley rats (12 
experiments, 162 animals, 56% of all rats, 30% of all animals used) and the most 
common strains of mouse used were C57BL/6 and C57BL/6J (5 experiments, 82 
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animals, 33% of all mice, each). Marmosets were all common marmosets. Sex of 
animals used was overwhelmingly male (34 experiments, 464 animals, 85% of all 
animals), with one experiment reporting the use of both male and female animals in 
their experimental groups (8 animals), and 4 experiments not stating the sex of 
animals used (72 animals). Dose of cocaine repeatedly administered to create the 
model ranged from 5 mg/kg to 20 mg/kg, with most experiments administering 10 
mg/kg (13 experiments) or 15 mg/kg (19 experiments). These doses were 
administered mostly once a day (29 experiments), but also some experimental 
paradigms administered cocaine repeatedly three times a day, every 2 or every 3 
days, over a period of 3 – 14 days. Most commonly cocaine was administered over 
a course of either 5 days (10 experiments) or 7 days (14 experiments). For 
experiments that measured locomotor activity after withdrawal from this chronic 
administration paradigm, challenge dose of cocaine was given and measurement 
was taken after abstinence from the drug ranging from 1 – 20 days.  
Therapeutic agents were able to reduce the increase in locomotor activity seen in 
animals as a result of chronic administration of cocaine during the development 
phase of behavioural sensitization by 1.0198 SD units (95% CI 0.0090 – 2.0306), 
with substantial heterogeneity observed in the data (tau2 = 4.3302, I² = 87.3%). 
Treatment compounds tested dampened the hyperactivity induced by administration 
of a challenge dose of cocaine after withdrawal from the chronic cocaine 
administration paradigm by 0.9569 SD units (95% CI 0.2609 - 1.6529), with again, 
substantial heterogeneity observed in the data (tau2 = 1.0599, I² = 71.0%). 
Unfortunately, like before, the low sample of experiments contributing to both meta-
analyses meant that heterogeneity could not be explored further in either datasets 
using meta-regression. 
7.2.3.6.2.3 Results from pooling all the data 
Overall effect sizes for data stratified by search criteria (original search or alternate 
search were similar. By pooling data from both searches, chronic cocaine 
administration showed an overall increase in locomotor activity after the 
development of sensitization by 2.1619 SD units (95% CI 1.5090 – 2.8149) which 
was not considerably different from the effect seen by only including data identified 
through the original search in the meta-analysis (2.2028 SD units with 95% CI 
1.2898-3.1157). Pooling the two datasets however, did increase the amount of 
statistical heterogeneity observed in the overall dataset (tau2 = 2.4790, I² = 80.2%), 
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when compared to the original dataset (tau2 = 1.4818, I² = 76.4%). While the original 
dataset was insufficient to perform meta-regression using all variables of interest, I 
was able to use univariate meta-regression on the pooled dataset. Strain of animal 
used was the only variable to contribute significantly to heterogeneity (p = 0.001, 
tau2 = 0.7918, I² = 58.96%, adj R2 = 68.06%,  
Figure 7.12).  
 
Figure 7.12 Relationship between the strain of animal used and reported effect size in 
chronic model-characterising studies from both original and alternate searches 
 
Pooling data for experiments that had measured locomotor activity after withdrawal 
from the chronic cocaine administration paradigm, showed that a challenge dose of 
cocaine worsened behavioural response by 1.4231 SD units (95% CI 1.0373 - 
1.8089). This was a small increase in the effectiveness of the model from that seen 
in the meta-analysis of only data from the original search (worsening in behaviour by 
1.3654 SD with 95% CI 0.6969 - 2.0338). Pooling the two datasets decreased the 
amount of statistical heterogeneity observed in the overall dataset (tau2 = 0.6139, I² 
= 63.5%), when compared to the original dataset (tau2 = 0.6918, I² = 70.2%). Strain 
of animal used within each experiment did not make a significant contribution to 
heterogeneity in this dataset.  
Other variables that did not contribute significantly to heterogeneity in either of the 
analyses included: reporting of random allocation of animals to groups, allocation 
concealment, blinded assessment of outcome, specified inclusion or exclusion of 
animals, a conflict of interest statement, compliance with animal welfare regulations, 
availability of a study protocol and sample size calculation, species, strain or sex of 
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animals used, dose of cocaine repeatedly administered, total number of 
administrations, day of last administration and number of days of abstinence from 
cocaine for experiments which measured locomotor activity after withdrawal.    
No data were identified through the original search describing the effects of 
treatment compounds on the development of sensitization. Exploring the 
administration of therapeutic agents on the expression of behavioural sensitization, 
measured after withdrawal from the model showed an improvement in behavioural 
outcome by 1.0937 SD units (95% CI 0.5744 - 1.6131). This was a decrease from 
the effect seen just using data from the original search (1.2658 SD with 95% CI 
0.5041 - 2.0276). The amount of statistical heterogeneity observed was more (tau2 = 
0.8149, I² = 63.9%) than found in the original search dataset (tau2 = <0.0001, I² = 
21.9%). None of these datasets were sufficient to perform univariate meta-
regression and therefore heterogeneity could not be explored further.  
7.3 Discussion 
In this chapter, I have shown that capturing all the data relevant to a specific 
research question can be difficult. While reporting bias is not as substantial in the 
subset of the field reviewed as expected, identification of additional studies through 
updating a search and performing an alternate search show that some relevant 
publications might have been missed through my systematic review.  
7.3.1 Publication bias and selective reporting bias 
Data collected in the context of experiments reporting developmentally induced 
animal models of schizophrenia failed to show substantial evidence for possible 
publication bias in the field for both model-characterising and treatment-testing 
experiments. On analysis of the entire dataset of model-characterising experiments 
calculations suggested that a potential 458 experiments were missing from the 
literature and that the overall reported effect of model induction on behaviour was 
being underestimated. Removing outliers in data during sensitivity analysis, still 
suggested some extent of publication bias using Egger’s regression, however, no 
asymmetry was detected using trim-and-fill. These disparities in outcome before and 
after sensitivity analyses suggest that extreme values in the dataset associated with 
small sample sizes used within these experiments, show why sometimes animal 
studies can be unreliable and imprecise when based on groups of small sizes. It is 
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suggested that when the size of a sample is small the variance of this sample will be 
further from the underlying population variance, which introduces a measurement 
error and thus may weaken the SMD approach to calculation of effect sizes. In fact a 
recent study shows that the statistical power of SMD for calculating effect sizes for 
animal experiments using small sample sizes is not as high as it is for calculating 
this using the NMD approach (Wang et al., 2018). Perhaps a review of the entire 
field might yield different results in future, but it appears that in the context of the 
dataset reviewed here there is no substantial evidence for the presence of 
publication bias. 
This is very interesting of course as other pre-clinical fields show that publication 
bias is a substantial issue (Sena et al., 2010). However, a recent analysis of 
publication bias assessment in animal studies shows that publication bias may have 
been overestimated in some previous preclinical studies. This is due to their use of 
standard error-based precision estimates in assessment of publication bias instead 
of the sample size-based precision estimates used here, which recent research 
suggests causes distortion of funnel plots and can lead to false-positive results 
(Zwetsloot et al., 2017). This distortion has been found to be largest for experiments 
of small sample sizes and therefore relevant for all assessments looking at 
preclinical studies. If there is in fact no publication bias in the psychosis research 
field, perhaps this can be explained by the fact that our understanding of the 
disorder is still very limited and the need for new treatment drugs is great. This might 
mean that more studies are published in this field of research compared to others, 
regardless of overall directionality of outcomes.  
Assessment of selective reporting bias on the other hand in the field shows that this 
problem seems to be extensive. The method used here to estimate the extent of this 
problem is arguably a crude way of estimating the extent of selective outcome 
reporting bias. Therefore, it is likely that this is only an underestimation of the true 
extent of this issue as we cannot tell how many outcomes were changed, omitted or 
introduced at later stages of experiments. 
Estimations in clinical trials imply that about 40-62% of all data collected in clinical 
trials is at risk of this bias (Dwan et al., 2008). The exact extent of this in other pre-
clinical research fields is unknown, but evidence shows that publications reporting 
neurological diseases show an excess of significant studies, likely explained by 
publication bias and other reporting biases in these research fields (Tsilidis et al., 
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2013). In order to get the entirety of a biological picture that is robust and true, we 
must be able to see and have all the pieces of knowledge available to interpret. An 
improvement in initiatives such as pre-registering of studies to overcome publication 
bias and selective outcome reporting play an integral role in this.  
7.3.2 Out-of-date search 
Updating the current review, a year after the initial search was performed identified 
an additional 12 publications describing animals given cocaine to induce 
hyperactivity. The overall trend seen in the reporting of measures taken to reduce 
the risk of bias and other methodological quality criteria showed little change upon 
the update of the dataset. The only differences seen were in the prevalence of the 
reporting of compliance with animal welfare regulations (100% in the update search, 
compared to 66% in the original search, raising prevalence to 71% in pooled 
dataset), and in the reporting of any potential conflicts of interest (15% in the original 
search, 50% in the update search, raising prevalence to a total of 21% in the overall 
dataset). Interestingly, the reporting of other measures such as blinded assessment 
of outcome and descriptions of any animal exclusions, were not reported in 
publications of the update search at all, despite having been described as two of 
four core items of reporting standards (Landis et al., 2012). This is somewhat 
surprising considering that the impact of these items in pre-clinical research has 
gained a lot of attention in recent years (Macleod et al., 2015) and that the ARRIVE 
guidelines were published in 2010 (Kilkenny et al., 2010b), almost a whole 4 years 
before any of the publications in the update search. On the other hand, it has been 
shown by other research that the impact of these guidelines appears to be slow and 
even an assessment of its impact in the year of which the original search was 
performed showed that it was not well implemented (Baker et al., 2014). 
Improvements in light of these guidelines seems to advance slowly in other fields 
also (Bahor et al., 2017; Gulin et al., 2015). Implementing changes in editorial policy 
in order to increase the completeness of reporting of study design has potential to 
show greater improvements in future reporting of these measures (Macleod, 2017).  
The number of animals used per publication did not seem to change a great deal 
between the original and the updated search. Overall the number of experiments 
using acute administration paradigms was much more common than those using 
repeated exposure paradigms in the original search (157 acute cocaine experiments 
and 56 chronic experiments). In the update search, the number of publications 
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reporting experiments using acute cocaine administration and chronic cocaine 
administration to model psychosis were similar (17 acute experiments and 15 
chronic cocaine experiments). There seems to be somewhat of a disagreement in 
the field as to which dosage regimen in animals is likely to have most validity for the 
clinical condition of psychosis. In humans, it is widely believed that psychotic 
symptoms are related to chronic consumption of cocaine (Roncero et al., 2013), 
where a ’binge’ often involves short periods of heavy use with periods of little or no 
use (Myers et al., 1995). The chronic administration paradigm induces a persistent 
state of sensitization, which is thought to be a better model of the clinical condition 
(Featherstone et al., 2007). Especially as schizophrenia has been described as a 
state of endogenous sensitization and this is only induced after a repeated 
experimental paradigm (Weidenauer et al., 2017). Nevertheless, a review of the 
clinical literature shows that even acute exposure to psychostimulants is able to 
elicit psychotic symptoms thus arguing that acute administration models have more 
predictive validity (Segal et al., 1981). Perhaps the validity of the dosage regimen 
lies in the actual dosage of cocaine administered. Early research shows that large 
doses of a single administration of psychostimulants can produce acute psychotic 
symptoms (Bell, 1973). When used at lower doses, psychotic symptoms only appear 
in a subset of abusers and do so after repeated use of these drugs (Bramness et al., 
2012). In experiments from both the original and update search reviewed here, the 
dose of cocaine administered did not differ substantially between acute or chronic 
administration paradigms. In the original search, the dose of cocaine administered 
acutely ranged from 0.04 mg/kg to 65 mg/kg for all experiments extracted with 88% 
of experiments using doses of less than 20 mg/kg in model-characterising studies 
and 99% of experiments using doses of less than 30 mg/kg for treatment exploring 
experiments. This did not substantially change in experiments extracted as part of 
the update search, where acute dose of cocaine ranged from 0.15mg/kg to 20 
mg/kg. In experiments administering cocaine as part of a repeated experimental 
setup, doses of cocaine administered fell between similar ranges. Doses ranged 
from 7.5 mg/kg to 30 mg/kg in all experiments included in the original search, and 
0.15 mg/kg to 20 mg/kg in experiments extracted as part of the update search. This 
seems to model the human pattern of abuse where it has been shown that 
individuals who are sensitized to the effects of cocaine after chronic use, showed 
longer regular use of cocaine and less dose escalation over time (Bartlett et al., 
1997). Dose did not seem to explain a substantial proportion of the heterogeneity 
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seen in studies where cocaine was administered chronically, whereas there was a 
significant relationship between dose of cocaine and outcome measure in acute 
dosage paradigms. The duration of cocaine administration also differed widely 
between experiments, but overall, experiments identified through the original search 
and those identified through the update search showed similar patterns of this 
experimental setup (repeated cocaine administration ranged from 5-20 days of 
administration in original search and 5-10 days in update search). In the clinic, the 
development of psychotic symptoms in individuals who abuse cocaine is positively 
correlated with the amount and duration of use (Brady et al., 1991). Any significance 
of differences in duration of cocaine administration or length of withdrawal from drug 
could not be established on reported outcome in the current analysis. 
In terms of the experimental subjects used, this did not change with time. For 
example, strain of animals used seems to influence effects in behaviour in response 
to cocaine. Experiments included here from both original and update searches, used 
Sprague Dawley rats consistently, whereas mouse strains used were more varied. It 
is clearly established that genetic factors have a strong impact on differences in 
locomotion seen between different strains in response to both acute and chronic 
psychoactive drug administration (Ruth et al., 1988; Zombeck et al., 2010). And in 
fact pre-clinical studies show that locomotor activity in response to the same 
experimental setup can be very different across different strains (Thomsen and 
Caine, 2011), showing that central nervous system sensitivity to cocaine is 
genetically determined (Ruth et al., 1988). This means that in order to get robust 
results, future studies should validate effects of treatments in multiple strains. 
Further to this, the sex of animals used in studies identified both in the original and 
update searches were overwhelmingly just male animals. In fact, all of the 
experiments looking at the effects of therapeutic agents on both acute and chronic 
cocaine induced behaviours used male animals. Clinical data show that males are 
significantly more likely to develop psychosis than females in response to cocaine 
(Brady et al., 1991), and dopamine release has been shown to be greater after a 
single administration of a psychostimulant in males as opposed to females (Munro 
et al., 2006). However, studies also show that the behavioural effects of 
sensitization as a result of chronic psychostimulant administration are stronger in 
females (Becker et al., 2001). Nevertheless it is interesting to note that this trend in 
the use of animals used has not changed in more recent experiments despite more 
focus on these issues in preclinical research (Check Hayden, 2010). 
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Overall, the pooled effect of both model-characterising and treatment exploring 
experiments changed very little by updating the search. This could be due to the 
small sample size of publications that the update search added to the overall 
dataset, therefore having little impact on the overall outcome. There was also little 
difference in observed heterogeneity of the different datasets reviewed. The 
reporting or not reporting of randomisation was the only variable of interest that 
seemed to explain part of the observed heterogeneity in acute cocaine experiments 
before, but not after the addition of the update search. 
In clinical systematic reviews, quantitative signals such as changes in statistical 
significance or relative change in effect magnitude of at least 50% has been used to 
warrant the need for updating a systematic review (Shojania et al., 2007). In this 
chapter, we see that by missing data published in the literature a year after the 
original search has little effect on the overall effect observable. Nevertheless, it can 
also be argued that additional studies published in subsequent years might add 
further to not only our overall knowledge, but perhaps also to our confidence in 
findings already in the literature. For example, knowing that something works or 
doesn’t work in a variety of different experimental paradigms using different species, 
strains, and sex of animals, or doses of drug administered at various times of 
treatment administration, is likely to increase the chance of successful translation of 
information into clinical understanding and practice (Hånell and Marklund, 2014). As 
the data show there are a large number of drugs, which have been tested in this one 
model of stimulant-induced psychosis and the relative paucity of evidence for 
individual drugs suggests that a more systematic approach to drug development 
may be helpful in future.  
7.3.3 Using alternative search methods 
Performing the search using alternate search words, more specific to the research 
question of cocaine’s effects on locomotor activity in animals, identified an additional 
85 publications. Compared to the 28 publications identified within the same 
timeframe through the original search, this was a considerable corpus of 
publications that were missed as part of the original search. The original study used 
broad search terms related to psychosis, schizophrenia and other psychotic 
disorders, and it was not specific to induction method nor outcome measure, unlike 
the alternate search. Therefore, it is likely that additional studies were missed 
because they were not labelled as being of relevance to psychosis. In fact, many of 
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these publications claimed to be exploring the addictive properties of cocaine in 
these animals. As mentioned in Chapter 3, the validity of locomotor activity as a 
measure of the clinical state of psychosis is debatable. In the clinic humans are not 
normally hyperactive, however, can often display stereotyped behaviours (Geyer 
and Moghaddam, 2002).  
Moreover, locomotion is a non-specific behaviour in animals and can be interpreted 
to in many different ways (Pratt et al., 2012). In the context of addiction, acute drug-
induced locomotor activity is a measure of an animal’s sensitivity to a substance and 
chronic drug-induced locomotor activity is a measure of incentive-sensitization 
model of drug craving (Eisener-Dorman et al., 2011). However, locomotor activity in 
response to psychotomimetic drugs such as cocaine is also widely considered to be 
a marker of stereotyped behaviours in the clinic such as psychotic agitation (Powell 
and Miyakawa, 2006), and is used as a robust and consistent measure of the 
positive symptoms of psychosis (Marcotte et al., 2001) 
Despite differences in how studies were labelled and the context they were 
described in, overall study designs did not differ substantially. Both sets of data used 
a mixture of mice and rats, with the alternate search also identifying some 
experiments describing the effects of cocaine in marmosets. The strains of these 
animals used were also fairly uniform across experiments in the two datasets, 
whereby most rats used were mainly Sprague Dawley rats, whereas mice were 
tested in a larger variety of strains. The use of male animals also predominated in 
both datasets, with female animals being used only in a handful of experiments. To 
find this pattern among studies that are supposedly modelling addiction in animals is 
interesting as clinical studies show that there are some striking differences between 
the sexes in drug abuse (Becker and Hu, 2008). Nevertheless, this shows that the 
misbalance in reporting of animals of both sexes is an issue in all areas of preclinical 
research.  
Overall the alternate search identified a large number of additional experiments 
looking at the effects of acute cocaine administration (99 model-characterising and 
86 treatment exploring experiments identified in the alternate search compared to 
only 34 model-characterising and 7 treatment exploring experiments in the original 
search). Chronic experimental paradigms were less common and described in about 
equal amount of experiments in the alternate search as the original search. As 
mentioned already, dependence on a drug tends to develop after repeated, heavier 
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use, implying that these studies not identified in the initial search do not seem to 
show any more validity for the clinical abuse patterns seen in the clinic leading to 
psychosis. Dosage administered was also comparable between the original dataset 
and the alternate dataset. Within both datasets, experiments characterising the 
model were more frequently reported than experiments where therapeutic drugs 
were administered. 
In the original dataset, the effect of chronic cocaine administration was more often 
measured during the withdrawal phase, compared to the alternate dataset where 
more studies measured the effect of chronic cocaine administration during the 
development phase of behavioural sensitization. These differences show that by not 
capturing the data identified by the alternate search, we are missing a number of 
studies, which may be very similar in their setup, but are measuring different 
underlying biological concepts, perhaps of benefit to translation of results in future.  
Evaluating the impact of missing these studies showed that overall effect of acute 
cocaine administration on locomotor activity was greater in data collected as part of 
the alternate search, when compared to data from the original search. In contrast, 
therapeutic agents administered seemed to be much more effective at improving 
behavioural outcome in data identified through the original search as opposed to the 
alternate search. Statistical heterogeneity observed in each of these two datasets 
was similar within acute studies. 
For repeated cocaine paradigms there was less of a difference between overall 
effect sizes for data from the two different datasets, meaning the pooled effect size 
was not substantially different from that observed just from experiments identified in 
the original search. In terms of observed heterogeneity, in studies measuring 
behaviours after withdrawal from these chronic drug paradigms there was a 
reduction in heterogeneity seen in the alternate dataset compared to that seen in the 
original search dataset. When therapeutic agents were tested on the reversal of this 
behaviour, there was an opposite effect where observed statistical heterogeneity 
was much more substantial in the alternate search dataset, compared to that 
observed in the original search dataset.   
Identifying these additional studies alongside those identified in my initial search, 
would have given me a larger sample of data leading to tighter confidence intervals 
and thus a smaller margin of error. Moreover, when looking at the effect of 
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therapeutic agents, more data means that any significant results that are seen can 
be considered more robust if repeated or generalized in different animal models 
using different animals, strains, sexes. Arguably, broad reviews such as this current 
one are at a threat from this kind of variability in reporting and labelling of studies. 
Moreover, studies using animal models of uniquely human disorders like psychiatric 
disorders, where any links between the model population and the human population 
with the disorder are mainly subjective, are also likely affected by difficulties in 
identifying all the data that is of relevance in the preclinical research field. For 
example, where the same outcome measure such as locomotor activity is used to 
describe a model for many different human behaviours in many different disease 
models, it can be argued that we might miss results that would be of value to a 
research question perhaps phrased differently to the original investigators. 
7.3.4 Limitations 
As mentioned resources only allowed for single data extraction. Depending on the 
error rate of data extractors this could mean that overall estimates of effect are 
prone to slight errors, however, any mistakes at this level are unlikely to have a 
substantial impact on the overall conclusions that are drawn. Data extractors were 
given continuous guidance throughout the extraction process with any issues 
discussed with a second investigator (myself). All data extractors followed a pre-
defined protocol and 15% of both datasets were checked in detail by myself as the 
second screener. No substantial and recurring errors were encountered during this 
process and therefore the data were deemed robust. Unfortunately, due to time 
constraints the rest of the data extracted was only put to a sense check during 
analysis, where any missing data or any obvious outliers were double-checked and 
re-extracted if necessary. Clearly, issues like this call for more robust quality control, 
and advocate for double-data extraction. Of course, if time allowed in future, all 
datasets used for analyses above would ideally be double-screened to increase 
robustness of results. 
We must also remember that conclusions based on data presented here are 
affected by the small sample of experiments, which affected my ability to perform 
multivariable meta-regression and assess for any co-linearity of variables. This 
could have also affected the overall estimation of publication bias. Moreover, studies 
collected as part of the original search were performed using a broad search and 
those identified in the alternate search were based on very narrow search criteria. It 
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has been shown by previous literature that results identified as part of a broad 
search and a more specific search can vary substantially, with the recommendation 
that both should be included in a systematic review (Egan et al., 2012). Finally, I 
only looked at the effect of updating the review of the field by a single year. For 
clinical systematic reviews there is a policy for relevance assessments every two 
years (Higgins and Green, 2008), however, there are no such guidance or criteria in 
place for animal studies and therefore it is unclear how often preclinical systematic 
reviews should be updated. It is difficult to say when these reviews become out of 
date as the rate of publication for animal studies seems much faster than for clinical 
studies, yet it is difficult to estimate differences in impact of new studies on overall 
conclusions. Finally, all of these analyses have been done on a subset of the 
literature identified during my initial systematic search and therefore might not be 






“Our field might become inundated with undigested data that 
collectively do not make sense" 
(Tandon, 1999) 
In 1999, a group of experts in the field suggested that perhaps part of our lack of 
understanding underlying schizophrenia was a result of the overwhelming amount of 
data that had been amassed in an effort to improve our knowledge of its biology in 
humans and how we might treat the disorder. The aetiology and the 
pathophysiology of the disorder were still elusive at the time and treatments 
available for those affected only provided moderate efficacy for managing the 
disorder, despite the vast amount of research in the field even then.  
Arguably, little has changed in almost 20 years. Despite decades of research 
progress, our understanding of the disorder is still very limited, managing the 
disorder in the clinic still poses a challenge to psychiatry and developing entirely 
novel treatments have been largely unsuccessful. The drugs that have been 
developed in recent years build on similar mechanisms as more established 
antipsychotics, and include D2 receptor partial agonists like aripiprazole, 
brexpiprazole and cariprazine. These are sometimes called third generation 
antipsychotics, or dopamine system stabilizers (Mailman and Murthy, 2010) due to 
their novel and alternate mechanism of action compared to previously developed 
antipsychotics. Cariprazine has even been shown to be effective for negative 
symptoms (Debelle et al., 2015), and aripiprazole and brexpiprazole are approved 
as an adjunctive medication in the management of depression Unfortunately, when 
placed in context with other existing antipsychotics evidence suggests that 
aripiprazole is not superior to other antipsychotics (Khanna et al., 2013) and scores 
only 9th on a list of fifteen antipsychotic drugs in terms of efficacy in schizophrenia 
(Leucht et al., 2013). Moreover, while these drugs have less metabolic and weight 
gain effects than other antipsychotics (Khanna et al., 2013), they are not without 
adverse side effects and a number of individuals do discontinue use due to these 
reasons (Frankel and Schwartz, 2017). A COCHRANE review of the efficacy of 
aripiprazole vs placebo in the treatment of schizophrenia, found that the while 
aripiprazole has efficacy for schizophrenia, the data that shows this in clinical trials 
is of low or certainly questionable quality (Belgamwar and El-Sayeh, 2012).  
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This suggests that perhaps even these antipsychotics add little to the already long 
list of other antipsychotics being used in the clinic, and therefore research efforts 
into novel drugs of therapeutic value in schizophrenia continue. 
A classic, coherent approach to development of novel treatments is challenging as 
our understanding of the aetiology of schizophrenia and the molecular mechanisms 
of action of current antipsychotics remains incomplete. Most therapeutic compounds 
approved for schizophrenia have been developed using hypotheses based on 
observations made from existing treatments. For example, aripiprazole was 
discovered using phenotypic screening of established targets to identify alternate 
molecular mechanisms of action for the reduction of dopaminergic overactivity 
(Swinney and Anthony, 2011). As a result, many therapeutic compounds are not 
entirely “novel” in this sense, but can offer perhaps improved solutions to issues 
seen in earlier drugs, such as a less severe side effect profile (Khanna et al., 2013)  
The use of animal models for the study of schizophrenia and other related psychotic 
disorders has remained widespread, however, little of this information has been 
translated forward into clinical research (Moore, 2010). This arguably is somewhat 
of a far-removed domain of research especially for a uniquely human disorder such 
as schizophrenia and with the disorder being an undoubtedly complex one. It seems 
that we have something to gain from these experimental models; however, it is not 
always clear how much of this will have the power to ‘predict’ new and effective 
treatments for schizophrenia as well as other psychotic disorders. While some 
model paradigms are well established and discussed in the field as part of a number 
of excellent reviews (Jones et al., 2011; Marcotte et al., 2001), others are not as 
commonly described in the context of schizophrenia.  
In the context of the large collection of research that has been published in the 
literature, it has become increasingly difficult to make sense of, perhaps for lack of a 
better word, ‘true’ models of psychotic disorders and understand the exact role they 
are able to play in improving our understanding of these disorders and their efficient 
management. In the context of these questions, my aim was to look at what could 
be affecting the translation of knowledge from the animal research field to 




In order to solve a problem, we first need to understand the problem, and therefore 
the aim of this project was to get a better understanding of the current state of the 
literature and quantitatively attempt to summarise aspects of this field through a 
systematic review and meta-analysis. 
Of course, there are a number of general issues with summarising research, which 
also pertains to the schizophrenia research field. It can be difficult to summarise a 
field where there are a large number of studies all reporting discrete findings, which 
are rarely replicated. While some findings are corroborated by subsequent studies, 
the context in which to place new findings is often not clear. 
In this review, I have shown in fact, that the literature available on this topic is vast, 
having identified and categorized almost 4000 studies of relevance. In order to 
better understand the preclinical field and its relevance to the human conditions it 
aims to model, I explored four main themes that I believe are building blocks of good 
pre-clinical research practice and thus are essential in informing subsequent 
research domains like clinical research (Figure 8.1). I argue that if compromised 
these components could explain failures in this information translation process. In 
this chapter, I review my main findings on what issues in the preclinical literature 
might be limiting translation and what considerations in future research could help to 
minimise these issues. 
Figure 8.1 Research in basic science needs to be able to satisfy 4 key qualities of 
robust and reliable research in order to effectively support subsequent clinical 
research and practice 
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8.1 Models most often reported in the literature have limited 
relevance to psychotic disorders in the clinic 
A resource compiled in 2014 recognised 149 different animal models used for 
research in schizophrenia, most models being genetic models (Koenig, 2014). 
Having performed a broad and shallow systematic review of the literature, here I 
have shown that this number is proportionally higher, in total having captured over 
800 ways of inducing psychotic or schizophrenic-like behaviours in animals.  
Clearly, the definition of an animal model of “schizophrenia” is subjective, however, 
all these publications claimed to have been looking at their research in relation to 
psychosis or more specifically schizophrenia in one way or another, or would have 
induced a model using methods otherwise regarded as a model in other 
publications. Some also claimed to have relevance to other psychiatric disorders, 
which makes it even more difficult to label an experimental setup in an animal as an 
‘animal model of schizophrenia’. 
A summary of the pre-clinical field of psychotic disorders shows that by large, animal 
models created using pharmacological interventions have continuously dominated 
the field. These models have been back-translated from clinical observations and 
have increased our knowledge substantially of underlying biology, by indicating 
dopaminergic, serotonergic, glutamatergic and other mechanisms in the 
psychopathology of schizophrenia (Moore, 2010).  
For those publications claiming to model schizophrenia, the weaknesses of using 
drugs to induce a model, is their limited face validity and their lack of ability to 
recapitulate the neurodevelopmental nature of schizophrenia (Mattei et al., 2015), as 
well as their lack of validity in modelling aspects such as negative symptoms and 
cognitive deficits of schizophrenia (Jones et al., 2011). Schizophrenia in the clinic is 
chronic and episodic with different symptom domains appearing at different stages 
of the disorder (Steeds et al., 2015). It is also well established that there are likely to 
be multiple biological pathways at play as part of an integrative circuitry in the 
manifestation of the disorder (Benes, 2009). As most animal experimental 
paradigms using these pharmacological methods to induce their models involve 
acute administrations of these drugs and considering that these agents tend to be 
specific to single neurotransmitter systems, the ability of these models to present a 
complete picture of the clinical disorder is limited. Importantly, any treatment 
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compounds discovered through the reversal of the effects of these psychotic 
pharmacological agents, are constrained by the pharmacology of these agents to 
the specific mechanisms they are acting on (Moore, 2010), therefore limiting their 
utility in finding treatments with novel routes of action and treatments for negative 
and cognitive deficits. 
In addition to a large number of pharmacological methods used to induce animal 
models, data collected here show that in the past couple of years there has also 
been a surge in the use of genetic models to study schizophrenia. Genetic models 
target a wide range of different genes to create so-called “risk factor models” 
(Moore, 2010). It is now well established that the genetic liability of schizophrenia is 
polygenic and genetic risk is conferred by a large number of alleles that exist in 
many different genes (Rees et al., 2015). As schizophrenia is associated with a 
large number of common genetic variants, all of which are rare and only contribute 
small effects of risk for the disorder (Nestler and Hyman, 2010), it is questionable 
how useful genetic models with single mutations can be. While GWAS studies have 
identified some drug targets such as genes involved in calcium channel signalling 
(Purcell et al., 2014), many of these common genetic variants have also been 
implicated in other psychiatric disorders. As a result, any models created using 
genetic manipulation of these targets would not only not be specific to 
schizophrenia, but would also not provide selective treatments for schizophrenia 
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). If genetic 
models continue to be used these should mainly address highly penetrant mutations 
(Nestler and Hyman, 2010). It is unarguable that in the clinic, the heterogeneity of 
the genetic makeup of different individuals is high. This implies that a treatment 
developed in a single gene knockout model is unlikely to help the entire patient 
population diagnosed with schizophrenia. This further limits the translatability of any 







Biological pathways and affected genes might be studied in more reliable ways that 
do not require genetic manipulations or acute pharmacological interventions. For 
example, data presented here show that in recent years there has also been an 
increase in the reporting of developmentally induced animal models of 
schizophrenia. These models are based on human epidemiological observations 
and it is possible that environmental challenges during development in these models 
might initiate cell responses via epigenetic mechanisms as part of the animal’s 
adaptation to a shift in external conditions which can induce similar effects as those 
seen in genetic models (Mattei et al., 2015). This is seen in animals born to mothers 
infected with Poly I:C during gestation that show naturally low levels of reelin 
expression, observed in schizophrenic patients, and the same effect as seen in 
animal models of schizophrenia where reelin is knocked out (Mattei et al., 2015).  
8.2 Assessment of animal models in the field is disordered and 
inconsistent 
As animals are not naturally psychotic or schizophrenic for that matter, both model 
and outcome measure used to characterize models need to be of relevance to 
provide an animal model of high fidelity for psychiatric conditions (Geyer, 2008). In 
total, I recorded 336 different behavioural outcome measures reported in the 
literature. These tests measured behaviours in animals that corresponded to about 
34 different human symptoms or changes in natural behaviours. This clearly 
demonstrates that in the pre-clinical research field of psychotic disorders there is a 
substantial heterogeneity in the assessments used to measure behaviours in animal 
models by. Some tests in animals can be used to measure different behavioural 
domains and therefore sometimes the same test would be used to refer to measures 
of different behaviours.  
At current, there are no strict rules for behavioural assessment in these animal 
models and the extent of their relevance to behaviours in schizophrenia. Some 
behavioural measures, however, can be tested in both rodents and humans such as 
pre-pulse inhibition of the startle response and cognitive tests defined as part of the 
Cambridge neuropsychological test automated battery (CANTAB) that can lead to 
robust associations between animal models and schizophrenic individuals (Geyer, 
2008). Unfortunately, even pre-pulse inhibition can be modulated by various brain 
regions in animals and therefore its relevance to human schizophrenia can be 
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argued if it is entirely based on the argument that it involves the same brain regions 
in animals as it does in humans (Powell and Miyakawa, 2006). 
Some obvious arguments against simple behavioural measurements in animals 
being representative of schizophrenic symptoms in humans are that they are too 
reductive and are measuring the use of brain structures that are too evolutionarily 
distant from complex human phenotypes. For this reason, especially, it is important 
that multiple tests are used to ascertain any one type of behavioural dimension 
(Powell and Miyakawa, 2006). There is no single behavioural task that captures the 
full clinical spectrum of schizophrenia that is diagnostic evidence in humans or is 
uniquely relevant to the disorder. Therefore, quantification of animals needs to 
employ a battery of tests, but the description of these tests I believe should also be 
as consistent as possible across different studies and different laboratories so 
meaningful comparisons can be made between them. This change would make it 
easier for novel research to build on previous knowledge. It is thought that 
adherence to established and common standards, for example when outcomes are 
universally agreed and are straightforward about what exactly they are measuring, is 
more likely to lead to true and meaningful findings (Ioannidis, 2005). 
8.3 Lack of repetition to increase the robustness of results of 
individual studies 
Ultimately, the data presented in this review shows that the literature is extremely 
broad in terms of exact methods used to induce a model, treatments tested and 
measures used to assess these models and treatments.  
Not only is the field highly fragmented, making summarising it and putting new 
research into the context of others’ difficult, but also studies are rarely replicated and 
therefore theories are not always corroborated. We see from this review that while a 
large number of potential treatment compounds have been tested across the 
literature many of these have only been considered in one or two studies. In fact, 
results in this review show that about 60% of treatments reported in the literature 
were only assessed in one study. It is possible that some of these compounds were 
not further explored due to lack of initially promising results, however, unsurprisingly 
many studies came to the conclusion that while their study showed important 
evidence for a phenomenon in our understanding of psychosis and schizophrenia, 
further research was needed to support their theory and take their data further. 
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While I did not assess the connection between different studies, it seems to me that 
there is little follow-up research leading on from previous research for some of the 
studies reviewed here. Replicability is imperative if we are to amass a collection of 
data reliable enough to drive and underpin theories towards better understanding 
and treatment of a disorder in the clinic and therefore I would suggest that the 
studies that are not used as building blocks for subsequent studies are wasteful. I 
believe a more systematic approach to research across different centres around the 
world would help to overcome this problem and maximise the potential of all 
findings. 
In the clinic as mentioned above, multiple biological pathways are believed to be 
dysfunctional as part of an integrative circuitry and it is thought that any treatments 
that selectively only target one pathway are not likely to meet all the therapeutic 
needs of the disorder (Li et al., 2016). Many of the treatments assessed here were 
only explored in terms of their interactions with a single pathway. Different avenues 
of schizophrenia research have led to candidate drugs of more diverse mechanisms 
of action being tested in Phase II and III clinical trials (Geerts, 2016). Unfortunately, 
there has also been a high rate of false positives, as many drugs have shown 
efficacy in animal models, but have failed in clinical trials (Moore, 2010). Studying 
biological pathways in isolation can lead to novel insights into their working, but 
ultimately, we need more use of models and treatments in these models, which are 
able to interact with multiple pathways. Evidence shows that patient-reported quality 
of life is higher in schizophrenic individuals taking second-generation antipsychotics 
over those taking first-generation antipsychotics (Gründer et al., 2016), and it is 
thought that this superiority in some cases might be due to second-generation 
antipsychotics interacting with serotonin 5-HT2A receptors as well as dopaminergic 
D2 receptors (Mauri et al., 2014).   
While involvement of more than a single pathway might yield treatments that are 
able to manage more complicated symptoms such as negative symptoms and 
cognitive deficits (Li et al., 2016), future studies need to have an important balance 
between the extent to which different pharmacological targets are engaged as it can 
lead to adverse side-effects. It has been suggested that by constraining animal 
models through etiological and pathogenic theories of schizophrenia based on 
clinical observations, we will also be able to reduce the number of false positive 
drugs being developed for treatment in humans (Moore, 2010). 
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8.4 Limitations in external validity of experiments 
Animal models are used so that results collected in this sample can then be 
generalized to the target population of human sufferers of the disorder – the 
robustness of this causal relation and the extent to which this can be done is a 
measure of external validity (Belzung and Lemoine, 2011).  
One of the most obvious and least surprising observations from this review was that 
most experiments measured behaviours of mostly male animals. The significance of 
this bias in the pre-clinical research field of psychotic disorders is that there are 
substantial differences between the sexes in both human schizophrenic individuals 
and animals, and in their basic response to experimental manipulations and 
measurements. Differences in humans include differences in incidence and the 
course of the disorder (Hayes et al., 2012), symptom severity (Ochoa et al., 2012), 
and differential response to antipsychotic treatment (Smith, 2010). Animals on the 
other hand show differential sensitivity to interventions used to induce models and 
perform differently in certain behavioural tests (Kokras and Dalla, 2014). While 
females are often omitted from studies for fear of hormonal cycles affecting the 
homogeneity of results and confusing the direct effects of experimental interventions 
(Beery and Zucker, 2011), this is the very reason why I think more research should 
focus on creating female animal models of schizophrenia and psychosis in general. 
Schizophrenia among other psychoses is thought to have a hormonal aetiological 
component (Hayes et al., 2012) and epidemiological data indicate that oestrogen 
may be protective in women (Riecher-Rössler, 2002). Women pre-menopause show 
a more benign course of schizophrenia, which changes after due to falling levels of 
oestrogen during menopause, and in turn, begins to require more severe treatment. 
As mentioned in Chapter 3 few studies focused their research specifically on 
puerperal psychosis and psychosis associated with the onset of menopause. For 
those affected by these conditions, this is a very real and debilitating problem (Crow, 
2016; Robling et al., 2000) which unfortunately does not get enough distinct 
recognition in current classification systems (Rai et al., 2015). Research using 
female animals would increase our understanding of how to differentially treat 
schizophrenia in women, but also how to treat those women who suffer from 




Second, there is little variability in species of animals most widely reported to be 
used in the literature. Mice used are most often C57BL/6 mice and rats used are 
mainly Sprague Dawley or Wistar rats. It is difficult to argue that results gained from 
a study that reports on the behaviour of an animal model measured in a single 
strain, which is then not replicated in any other strains, is generalizable to humans. 
In research, the argument for not using various strains is similar to that for not using 
both sexes: it is thought to introduce too much variability into behavioural results 
(Chadman et al., 2009). While it is argued in the literature that this genetic variability 
will reduce the likelihood of detecting a behavioural phenotype in relation to the 
manipulation of interest (Kannan et al., 2013), I would argue that variability can also 
be beneficial and essential in many cases. For example, genotype-phenotype 
relationships don’t even necessarily generalize across different outbred strains of 
mice as shown by a study systematically looking at the phenotype of 30 inbred 
laboratory strains genetically mutated to model brain abnormalities showing 
differential and sometimes opposing responses (Sittig et al., 2016). Therefore, by 
studying a single genetic background, we are unlikely to make direct inferences, 
which are robust enough to generalize to humans. Perhaps one way to better model 
the genetic heterogeneity that we see in the clinic is to create and evaluate the 
same models as well as novel treatments tested using them, in various animal 
strains. This would maximise the spectrum of possible observations and thus 
increase the generalizability of results in this field of research to a larger proportion 
of those diagnosed with schizophrenia. Moreover, treatments that are shown to work 
in some strains, but not others, might also reduce the number of false positive drugs 
taken forward to clinical trials that end up failing to show efficacy in humans. 
As schizophrenia is a neurodevelopmental disorder, the age at which models are 
investigated, especially developmental models, is an important variable that can 
affect the generalizability of preclinical findings to treatment regimens used in the 
clinic. In the clinic, psychotic symptoms in schizophrenia normally manifest 
themselves in adolescence and early adulthood in men and in slightly later in 
women. Developmental models allow for the unique opportunity to study disease 
progression over the developmental period in animals, potentially using models for 
the study of pre-clinical applications of preventative treatments that might be able to 
halt disease progression in humans. Data collected here shows that models were 
largely studied at adult stages of life and almost all treatments reported in 
experiments analysed were also tested in adult animals. It should be remembered, 
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however, when making inferences at these stages of life, different species show 
differences in the timing of key maturation events (Semple et al., 2013). 
Nevertheless, in recent years, there has been a lot of interest in the prevention of 
psychiatric illnesses through treatment during the prodromal phase of schizophrenia 
and in so-called “high-risk” individuals who have subtle symptoms, and some of 
whom later go on to develop full-blown schizophrenia (Mokhtari and Rajarethinam, 
2013). While intervention at these early stages is still a controversial topic due to 
concerns over how much predictive validity criteria to identify these individuals 
actually have, research suggests that early intervention can potentially delay or 
prevent transition to psychotic disorders (Stafford et al., 2013). In order to improve 
our understanding of the feasibility of these treatment options and to increase our 
general understanding of the development of the disorder and its underlying biology, 
future animal studies of schizophrenia should consider animals at all stages of life. 
Finally, in this review, I used a standardized measure to categorize time of 
assessment of animals into specific stages of life in order to summarize studies 
easier. I did notice, however, that many studies reported fairly arbitrary age 
categories within their publications. In the literature, a recent study has highlighted 
that categories of rodent age can vary substantially between different laboratories, 
with animal researchers referring to rodents as an “adult” when aged anywhere 
between 6 to 20 weeks (Jackson et al., 2017). This lack of consistency in reporting 
can further hinder translatability of data collected in animal models and should be 
improved. 
8.5 Limitations in face validity of developmental animal models 
Face validity of animal models is a measure of phenomenological similarity between 
the model and the human condition, and the assessment of this concept is therefore 
complicated by exact definitions of the human condition. For example, according to 
one of the earlier descriptions of face validity, an animal model should not only 
resemble its clinical equivalent behaviourally, but these features should also be 
specific to the condition being modelled, co-exist in a subgroup of individuals 
diagnosed with the disorder and should not include features that are otherwise not 
seen in the clinic (Willner, 1984). Of course, these latter two restrictions make it 
difficult for any animal model to have strong face validity for schizophrenia.  
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This is not only because symptoms in the clinic are not necessarily specific to the 
disorder, but also the analogous behaviours of schizophrenia measured in 
preclinical research are widely used in the context of other disease models to 
measure sometimes different aspects of behaviour.  
As the quality of predictions from animal models to humans depend heavily on the 
agreement between measures taken in animals in the laboratory and measures 
taken in humans in the clinic, animal models with high face validity for a clinical 
disorder should measure behaviours with a good degree of homology to measures 
used in clinical research (Geyer et al., 2012). If measures in animal models are not 
what is subsequently assessed in clinical trials then the extent to which these 
models are able to predict efficacy of drugs will be limited (Markou et al., 2009). It is 
clear from this review that some of the most commonly reported behavioural 
endpoints measured in the literature are of relevance to positive symptoms. While in 
animals, it is easy to perform these analogues of positive symptoms, it is arguable 
that the face validity of these models is weak. For example, the validity of locomotor 
activity as a measure of the clinical state of psychosis should be considered. 
Primarily, it is a non-specific behaviour in animals and can be interpreted in many 
different ways in the context of animal models of different disorders (Pratt et al., 
2012). Secondly, in the clinic humans are not normally hyperactive, however, can 
often display stereotyped behaviours (Geyer and Moghaddam, 2002), but increased 
activity levels are more often seen as a core feature of bipolar disorder as opposed 
to schizophrenia (Perry et al., 2010). Thirdly, it is thought that an increase in 
locomotion in animals is a result of increased dopaminergic activity in mesolimbic 
and nigrostriatal dopamine pathways (van den Buuse, 2010) and therefore is widely 
used in the pre-clinical literature as a marker of stereotyped behaviours in the clinic 
such as psychotic agitation. However, in the clinic individuals affected by 
schizophrenia as well as those categorized as “high risk” individuals, show 
increased presynaptic dopamine functions in the associative striatum as opposed to 
the limbic striatum as we had previously thought. This misalignment in anatomy 
based on clinical evidence shows that back-translation of clinical findings has been 
slow to animal model studies (Kesby et al., 2018). Therefore, as our understanding 
of the underlying biology of psychosis increases, it becomes increasingly clear that 
some existing methods used to measure models might require some fine-tuning or 
that we need to look to measure models using alternative, perhaps more effective 
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translational approaches that are in line with neuroanatomical and biological 
features in schizophrenia.   
Future experiments could improve translatability of outcome measures by either 
using tests in experimental animals which are as close to those used in humans 
(Eagle and Robbins, 2003) or measuring tests in humans which have more similarity 
to those measured in rodents (Shipman and Astur, 2008). They also might focus 
more on behavioural tests, which assess negative and cognitive deficits in animal 
models. Recent research shows that severe negative symptoms and cognitive 
deficits all correlate with poorer quality of life in schizophrenic individuals (Karow et 
al., 2014), and behavioural analogues of these symptoms might have more face 
validity than behaviours for positive symptoms (Kesby et al., 2018). As shown from 
this review, analogues of these human symptoms are much less widely reported in 
the literature than those thought to be of relevance to positive symptoms. This is 
limiting the introduction of novel drugs in schizophrenia, which currently do not exist 
for negative and cognitive deficits. Unfortunately, negative symptoms and cognitive 
deficits are not specific to schizophrenia and therefore measuring these behaviours 
in animal models of schizophrenia challenges classic definitions of face validity. Of 
course, it will be always difficult to claim an animal is only specific to schizophrenia if 
we are to do this, as clinically schizophrenia is a polythetic definition, whereby the 
same diagnosis can be made for patients with a different set of symptoms of 
differing severity, course and showing a variety of different outcomes (Owen, 2014). 
This substantially confounds the extent to which an animal experimental paradigm 
can be said to have an adequate level of face validity for schizophrenia as seen in 
the clinic.  
As it has been suggested that each symptom domain should be addressed 
separately in schizophrenic individuals, future preclinical studies should consider 
testing their animal models of schizophrenia using comprehensive battery tests to 
maintain high face validity for schizophrenia, especially when assessing the efficacy 
of new treatments. In the clinic, functional outcome is measured through composite 
scores calculated from performance on questionnaires or test batteries 
(Goetghebeur and Swartz, 2016). Obviously, we are unable to model questionnaires 
in animals, but by matching this multi-criteria testing approach through test batteries, 
we could increase the reliability at which we could detect important biological 
changes in a sample and then generalize these findings to the target population.   
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8.6 Limitations in construct validity of developmental animal 
models 
Construct validity measures the extent to which underlying pathological mechanisms 
in animal models and in humans diagnosed with the clinical condition are 
homologous (Wilson et al., 2010). Despite the fact that some animal models like 
developmentally induced animal models have strong face validity, true construct 
validity is hard to ascertain, as animal models of psychiatric disorders will always be 
limited to some extent on the premise that the clinical picture of these disorders is 
not entirely straightforward. Firstly, the related symptomology is categorised with a 
high degree of subjectivity (Geyer and Markou, 2000). Secondly, diagnostic 
categories are continuously being revised and do little for improving problems with 
the unreliability of psychiatric diagnoses (Aboraya et al., 2006). But most 
importantly, the construct validity of clinical diagnostic criteria themselves, defined 
as “the degree to which a diagnostic construct delineates a group of cases that 
share common underlying etiological and/or pathogenic processes” is arguably low 
for major psychiatric disorders (Owen et al., 2016). There is a lack of construct 
validity of current syndromic diagnostic approaches because our exact 
understanding of the aetiology and underlying pathogenic processes of these 
disorders is still very much limited. 
Analysis of the literature herein accentuates some limitations in construct validity of 
developmentally induced animal models including that experimental design is highly 
heterogeneous even in studies using the same method of model induction, as most 
notable within this review for animal models created using prenatal infection. 
Variables differed across studies in terms of time of infection administration, the 
dose of substance administered and number of administrations. Perhaps this 
variability in preclinical methods stems from our uncertainty of the role these 
variables play in schizophrenia in the clinic, making our ability to judge the construct 
validity of each of these different approaches difficult. In the clinic maternal infection 
during pregnancy has been linked to adult schizophrenia, however, our 
understanding of whether there is a ‘sensitive period’ of development in the womb 
remains unclear (Khandaker et al., 2013). Some studies have implicated the first 
and second trimesters of pregnancy as critical periods of vulnerability to various 
infections (Selemon and Zecevic, 2015), however, it is not clear how these clinical 
data translate back down to animal studies mimicking these experimental 
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paradigms. Data presented here show that infections were administered to mothers 
at all stages of gestation. Translation between the two species is further complicated 
by the simple fact that in rodents, brain development carries on after birth while in 
humans this is done in utero, making inferences about the correct stages of 
development between the two species difficult (Mattei et al., 2015). A solution 
proposed for this in the literature is the use of mice of the spiny strain, which show 
complete brain development at birth (Ratnayake et al., 2012). None of the studies 
included and reviewed here reported using this strain of mice, but future studies 
could consider using strains such as this one, which closer models human brain 
development in utero for models where disruptions to early development are at the 
core of the model. While variation in experimental design is able to increase external 
validity (Maier et al., 2010), a lack of replication of experiments reporting different 
variables to existing experiments can also add further uncertainties to the field if 
these differences are not adequately highlighted. In this review, for example, it was 
difficult to draw conclusions about the impact of this variability in studies, as many 
experimental characteristics were not reported to be further replicated in the 
literature. Therefore I reiterate here my argument for an increased level of 
consistency in the performance and reporting of experiments. Any type of variability 
in the literature pertaining to experimental design needs to be more consistently and 
comprehensively described as well as replicated in ensuing experiments to allow 
conclusions to be meaningful. For this, use of existing guidelines such as the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 
2010b), Gold Standard Publication Checklist (Hooijmans et al., 2010a) and Landis 
(Landis et al., 2012) guidelines should be more widely used by researchers. 
Moreover, their use and full disclosure should be mandated more thoroughly by 
funders and journals to encourage scientists in the field. In addition to this, 
registration of preclinical experiments in a centralized database similar to those used 
for clinical trials will aid replication and transparency of experimental design used in 
studies. A more systematic approach like this can identify gaps in our knowledge 
based on where research has been done and where more research is required so 
that we can increase the chance of successful translation of preclinical research 
data into clinical research. Furthermore, research should aim to carry out tests using 
standardized procedures across different laboratories, to minimise the effects of 
unknown confounding factors. Evidence shows that data collected in experiments of 
a seemingly identical nature across different laboratories can yield very different 
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results (Wahlsten et al., 2003). A comprehensive reporting of the exact methodology 
used can reduce the impact of unknown confounding variables affecting results 
between studies in different laboratories. Limitations like this can also be a strong 
argument for the performance of more multicentre animal studies in future 
(www.multi-PART.org). 
Ultimately, to improve translation in this field, there must be a bidirectional feedback 
loop between animal research and clinical research (Kesby et al., 2018). In the 
context that schizophrenia is a disorder characterized by gene-environment 
interactions, combined models perhaps have stronger construct validity for 
schizophrenia in the sense that they allow us to more closely mimic the predicted 
aetiology of this disorder as well as other psychotic disorders by looking at the effect 
of at least two disruptive “hits” (Karl and Arnold, 2014). Only 20% of the overall 
literature reviewed here explored the use of combination models, and only 12% of 
experiments testing the effects of a treatment in developmental animal models 
involved a second hit. While these models are still not able to model the entirety and 
the complexity of the disorder we see in humans, they are useful basic multifactorial 
models, which can help improve our understanding of the complexity of the 
interactions and mechanisms that underlie the disorder (Karl and Arnold, 2014). 
Moreover, some of these combined models might be of relevance to schizophrenic 
individuals with psychiatric comorbidities (Buckley et al., 2009).  
8.7 Limitations in predictive validity of developmental animal 
models 
Predictive validity is a measure of the similarity at which an animal model responds 
to medication used to treat the disorder in question when compared to how humans 
in the clinic respond to the same medication. The literature reviewed here shows 
that a similar hierarchy of treatment efficacy was seen in animal models as we 
observe in the clinic among patients (i.e. clozapine is superior to rest of treatments 
in terms of efficacy).  
As most experiments involved looking at the effect of drugs already clinically 
established in developmentally-induced animal models, full predictive validity of 
these models remains to be established as so far no entirely novel clinically 
approved therapeutics have been developed using these models (Geyer et al., 
2012). Unfortunately, it seems that quite a few novel drugs are compared to these 
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more established drugs. While it can be useful to compare the efficacy of a new 
treatment to a known treatment that already shows some efficacy in patients, 
models that are developed and validated through known treatment drugs, leave little 
room for the discovery of drugs of alternate chemical structures and mechanisms of 
action. Therefore, if our ultimate goal is to develop novel treatment options that treat 
symptoms that are not effectively addressed by current drugs then this is a limited 
approach (Geyer and Markou, 2000). What we are really lacking in the field today, 
and therefore something future studies could focus more on, is models with good 
predictive validity for cognitive deficits seen in schizophrenia as current 
antipsychotics do not seem to have a great efficacy on this cluster of symptoms in 
the clinic. 
Ascertainment of the true predictive validity of developmentally induced animal 
models is difficult as there are many differences between how human patients 
usually utilise and respond during the course of treatment and how novel treatments 
of potential efficacy are assessed in animals. Firstly, in the clinic maintenance 
treatment of variable lengths is recommended for individuals experiencing psychotic 
episodes and usually, the treatment course is long term especially for those with 
more severe symptoms (Lally and MacCabe, 2015). Analysis of evidence presented 
in this review shows that often antipsychotics are administered acutely, which does 
not allow for long-term analysis of efficacy and therefore has limited relevance for 
clinical applications of the same drug. Moreover, evidence from the literature shows 
that treatment drugs are often tested in preclinical animal models at doses that are 
not representative of the clinical condition being modelled (Kapur et al., 2003). For 
example, single injections of haloperidol have been shown to create a different 
pharmacokinetic profile as the same regimen in humans does (Kapur et al., 2000). 
This suggests that any potential new treatment options need to be tested more 
systematically, using treatment regimens that more closely represent clinical 
therapeutic regimens. It is suggested that full dose-response relationship studies are 
still needed for potential treatment drugs in order to allow for appropriate inferences 
to be made between animal models and humans (Goetghebeur and Swartz, 2016). 
One way to better represent clinical treatment regimens in future preclinical studies 
could be through the use of receptor occupancy studies in rodents similar to those in 
positron emission tomography (PET) studies of humans. These could help to 
translate dose-response relationships in animals into a clinical context, however, will 
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also come with the limitations that results will be specific for species, strain, method 
of administration and type of drug used (Kapur et al., 2003). 
Further to this, in the clinic, about 30% of those diagnosed with schizophrenia do not 
respond to currently available treatment options (Lally and MacCabe, 2015). In 
studies reviewed here only 15% of experiments in developmental animal models 
reported a negative effect of clinically established antipsychotics. Until we 
understand more about the heterogeneity of the clinical disorder it might be difficult 
to create animal models of translational value for all individuals who need treatment 
for a psychotic disorder. Future studies should increase some of the focus on animal 
models specific for antipsychotic drug-resistant schizophrenia. In the clinic clozapine 
is the first-line medication for individuals who don’t respond to two or more other 
dopaminergic drugs (Lally et al., 2016).  Therefore animal models that show 
improvement in response to clozapine, but not other antipsychotics in certain 
behavioural domains (Mouri et al., 2013) might be of relevance when developing 
new compounds of potential therapeutic value for treatment-resistant individuals. 
These limitations could partly explain why many drugs which work in animals, do not 
work in humans. By overcoming some of these limitations in preclinical experiments 
their relevance and their ability to predict clinical outcomes could potentially be 
increased.  
Lastly, it is not only positive effects of treatments that should be explored in animal 
models but also any negative impact a therapeutic drug may have on other 
behavioural domains. There are a significant number of side effects associated with 
both typical and atypical antipsychotics (Lally and MacCabe, 2015). In the preclinical 
research field few measures of these side effects exist (i.e. catalepsy and vacuous 
chewing) (Gobira et al., 2013), and evidence collected here shows that they are 
rarely reported in the literature. This lack of information in the preclinical research 
means that we cannot ascertain for sure that animals do in fact respond to existing 
antipsychotics with enough homology as humans do. Moreover, in humans, side 
effects take time to manifest and therefore animal models might increase predictive 
validity by assessing novel therapeutic drugs and any behaviours indicative of 
potential side effects over a longer period of time than currently measured. 
Ultimately, treatment of these disorders will always seem to require more than just 
pharmacological treatment in order to raise these patients’ quality of life (Savilla et 
al., 2008). In the clinic, effective management of psychotic disorders often involves 
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some aspect of psychotherapy and social support (Owen et al., 2016). Pre-clinical 
tests looking at the effects of natural contextual changes like environmental 
enrichment could help us understand more about how non-pharmacological 
treatments might be able to support and possibly potentiate the effects of 
pharmaceutical treatments to give patients a more complete relief from the disorder. 
8.8 Overall reporting of risk of bias and other methodological 
quality criteria is low 
A failure in seeing drugs that show efficacy in animals then also showing efficacy in 
human clinical trials may also be in part attributed to inadequate design, conduct 
and reporting of animal experiments distorting overall results (Macleod et al., 2009). 
The reliability of results obtained in preclinical studies is highly dependent on the 
rigour at which an experiment is designed and carried out (Macleod et al., 2015). 
Systematic reviews of clinical trials show that inadequate methodological 
approaches are associated with bias (Jüni et al., 2001). Similarly, flaws in the quality 
and reporting of the methodology of animal studies can lead to systematic bias in an 
experiment and result in wrongful conclusions (van der Worp et al., 2010).   
Based on the literature reviewed it is obvious that the reporting of aspects of 
experimental approach which might reduce the risk of bias and thus the likelihood of 
introduction of systematic errors into an experiment, is generally low across the 
psychotic disorders preclinical literature. These include a low percentage of 
reporting of random allocation of animals to group, blinded conduct of experiment 
and blinded assessment of outcome as well as a pre-defined explanation of 
inclusion and exclusion of animals. Additionally, one of the most poorly reported 
items is the reporting of the performance of sample size calculations. This overall 
was only reported in about 1% of the literature, which is concerning as we know that 
not performing a sample size calculation can lead to imprecision (Krauth et al., 
2013). As animal studies often use very small group sizes in their experiments, 
unless these numbers are based on valid sample size calculations, they will be less 
precise, giving less accurate estimates of a true effect and will add very little to the 
research field (Button et al., 2013), arguably wasting resources and unnecessarily 
causing animal suffering in some cases. These findings are similar to those seen in 
other preclinical neuroscience domains (Macleod et al., 2015) and affect both 
independent study conclusions, and meaningful interpretations of evidence collected 
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in a field relating to a particular question. Moreover, the literature reviewed here and 
other fields of preclinical research (Hirst et al., 2014) reiterate the importance of 
future studies performing and reporting these experimental steps. They show that 
studies, which do not report randomisation, allocation concealment or blinded 
assessment of outcome report larger estimates of effect than those studies that do 
report these items. At its worst, this can lead to overestimation of the efficacy of a 
therapeutic drug in animals, which is then taken forward to and subsequently fails in 
clinical trials. To a lesser extent, this can mean that those studies, which are thus 
deemed unreliable, will have essentially been wasteful of resources used.  
Study quality has been studied a lot more extensively in clinical trials compared to 
animal studies and therefore recommendations of good study quality for animal 
studies are largely based on the clinical CONsolidated Standards of Reporting Trials 
(CONSORT) statement (Altman et al., 2001). Arguably, however, different measures 
might be relevant for animal studies. Research collected here shows that the 
prevalence in reporting of these measures varies across the field depending on 
experimental design variables such as methods used to induce the model or 
measure outcome of the model in question. While in some cases it may not be 
appropriate to report these measures, it could also imply in other cases that 
investigators consider the impact of these measures to be less relevant for some 
experiments over others. As we move towards more advanced technological tools to 
measure behavioural and electrophysiological outcomes especially, some of these 
methodological considerations will no longer be relevant. For example, blinded 
assessment of outcome, in my opinion, is perhaps less relevant in studies where 
behaviour is measured using automated tools, such as beam breaks that record 
locomotion of animals to a computer. I would argue blinded assessment of outcome 
and the reporting of this concept becomes redundant in this scenario. Nevertheless, 
other important methodological criteria might come to the forefront in these cases, 
which we currently do not widely assess for (Krauth et al., 2013). Rosenthal’s 
original study on experimenter bias, for example, also showed that an investigator’s 
bias towards a group of animals affected the way they handled the animals – rats 
that were expected to perform better were handled with more care and friendliness 
(Rosenthal and Fode, 1963). Handling of animals is very rarely reported in the 
literature (Avey et al., 2016) as it is difficult to generalize not just between different 
institutions, but also individuals. Clearly, this is of less relevance in clinical trials and 
of more relevance to animal studies, where it is strongly argued that environmental 
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changes in laboratory environments can affect the behaviour of animals and thus 
have adverse effects on research data (Bailey, 2017; Gerdin et al., 2012). 
Considering schizophrenia has an established environmental nature and based on 
discussions with other animal researchers I believe that this is an important 
measure, which deserves more consideration and more detailed reporting in the 
methodology section of animal studies, especially those conducted in the context of 
psychotic disorders. Currently this and other confounding factors differing across 
different laboratories such as housing and husbandry (Avey et al., 2016), as well as 
factors more specific to experimental setup such as details about measuring 
apparatus used and exact timeline of experiments, are either rarely or inconsistently 
reported in the literature according to previous research (Egan et al., 2016). This 
makes the attention that we give to these factors, their standardization and 
subsequent reporting such an important concept. Unfortunately, things such as 
handling of animals is a vague concept in many ways, limiting the introduction of 
specific evaluation criteria for this measure, however, other aspects of methodology 
can and should be standardized in order to increase consistency and comparability 
of data collected from multiple sources.  
My findings here support the hypothesis that efforts to develop new treatments for 
psychosis may have been hampered by the quality of supporting animal research. 
To improve the future field of pre-clinical psychosis research not only must the 
quality of studies improve, but reporting of this quality must also improve. Arguments 
for incomplete reporting because of limitations due to a lack of space are less valid 
for modern publications as many journals now allow for online publication of 
supplemental data. It is suggested that with risk of bias assessments becoming 
more prevalent in animal studies reporting of animal research will likely improve 








While many of the studies identified here predate publication of the ARRIVE 
(Kilkenny et al., 2010b), Gold Standard Publication Checklist (Hooijmans et al., 
2010a) and Landis (Landis et al., 2012) reporting guidelines these are cardinal 
aspects of good experimental design. Their importance (Fisher, 1937; Rosenthal 
and Fode, 1963), as well as lack of reporting has been recognised for many years 
and therefore this low prevalence in reporting is concerning. Perhaps even more 
concerning is the fact that data collected here shows that reporting of many of these 
items has improved little since these reporting guidelines have come into publication 
shown both by data collected here and elsewhere in the literature (Baker et al., 
2014; Gulin et al., 2015).  
It is clear that a shift in practice and comprehensive reporting of methodology will 
require more than just authors to change their practice. Reviewers, funders and 
journals will play a big role if we are to improve the quality for reporting of animal 
studies (Landis et al., 2012). For example, I have shown here that reporting criteria 
thought to affect the reported efficacy of therapeutic compounds especially (Hart et 
al., 2012), such as a statement of potential conflict of interest, were also infrequently 
reported in the literature. This and the reporting of compliance with animal welfare 
regulations, however, were the only two measures to have substantially improved in 
recent years, likely as a result of more stringent demands from journals. This shows 
that journals play a big role in the improvement of comprehensive reporting of 
methodology including methodological quality criteria. A recent study shows that a 
change in editorial policy by journals through mandating the completion of a 
checklist at the point of manuscript revision can improve the reporting of risks of bias 
for in vivo research (Macleod and The NPQIP Collaborative group, 2017). While the 
study also shows that there is further room for improvement, novel initiatives trying 
to tackle the problems of reproducibility and translatability of animal studies by 
attempting to minimise these issues early on in the experimental process might help. 
Through the introduction of guidelines aimed at helping investigators plan their 
experiments, such as PREPARE (Smith et al., 2017) or the Experimental Design 
Assistant commissioned by the NC3Rs (Percie du Sert et al., 2017), animal 




8.9 Incomplete reporting of collected data 
Reproducibility and translation of findings in preclinical research are not only 
confounded by incomplete reporting of methods, but also of incomplete reporting of 
results. Poor or no reporting of preclinical data, when carried out, is detrimental to 
the design of future studies as well as hindering these studies’ ability to inform 
research in the clinical domain. An interesting perspective in the literature highlights 
just how important publishing of all studies and of all results is in the drug 
developmental process. Markou et al. (2009) suggest that there is a strong feed-
forward loop in drug development, which always favours the forward progression of 
test compounds from preclinical studies to increasing phases of clinical trials in the 
presence of positive findings of efficacy. This feed-forward loop overlooks all other 
data that is otherwise negative or neutral and even when results of a compound are 
mixed in animal models, the predicted consensus will be that the compound is 
efficacious. This only becomes a real problem at later stages of the drug 
developmental process when a compound fails during clinical trials (Markou et al., 
2009). This problem is clearly exacerbated by problems with publication bias and 
selective outcome reporting.   
Publication bias has been shown in many other fields of pre-clinical research (Sena 
et al., 2010). Based on the subset of data used here for the estimation of publication 
bias in the literature, there is no significant evidence to show that animal studies of 
developmentally induced animal studies might be missing from the literature. This, 
however, could be a bigger problem if looking at the entire literature of animal 
models of psychotic disorders. Nevertheless, the data does show that there is 
substantial selective outcome reporting in the entire field, with almost 70% of 
publications analysed reporting some form of omittance of result data. Incomplete 
reporting of results or favouring those of significance and positive results could lead 
to a skewed image of how good we think a model is at recapitulating symptoms of 
schizophrenia in animals and how efficacious a treatment compound is at 
attenuating effects in these animal models. Therefore, data collected here does 
imply that we are in fact getting a distorted image of all the data that has been 
collected to improve our understanding of schizophrenia. This problem is not unique 
to this field (Tsilidis et al., 2013) and suggests that universal changes could make a 
difference in multiple preclinical research fields. Ultimately, studies and individual 
experimental outcomes where model animals do not show significant deficits in 
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behaviour or where therapeutic drugs do not show efficacy in attenuating 
behavioural or other outcomes in model animals, need to be made available. This is 
so that we do not overestimate the overall efficacy of a therapeutic drug in pre-
clinical studies and then have these candidate drugs fail later in clinical trials. For 
model characterising studies it is essential in improving the validity of a model and 
our understanding of its relevance to the clinical picture. 
Moreover, as replicability of studies is not as common as arguably it should be, it is 
important that we have access to all raw data that has been collected through 
research so that this can be built upon by any subsequent research. Unfortunately, 
raw data are not something that are often disclosed or shared making post hoc 
calculations and comparisons by other scientists difficult when replicating studies or 
using data for meta-analyses for example. This affects not only the robustness of 
any conclusions that are drawn in such a way, but also makes an analysis of 
publications time-consuming. Novel initiatives encouraging the pre-registration of 
animal study protocols on www.preclinicaltrials.eu, similar to initiatives that have 
been used for almost two decades now in clinical trials will help reduce duplicates 
and overcome the risk of reporting bias. As shown by data collected here the 
reporting of an available protocol for a study is at current rare practice in the 
preclinical research field. This makes it difficult to tell whether published results of a 
completed study were part of the original protocol and if there were any that were 
not reported in the final study. Further to this, transparent publishing sites such as 
www.F1000research.com, allowing null results and other research outputs such as 
posters and slides to be published and for work to be openly reviewed by others in 
the field, have the potential to increase transparency in the field and allow for faster 
publication of all the data that has been collected. Open access to data is also being 
made more available through the use of data repositories, which should increasingly 
be used to publish all raw data collected that makes it citable and shareable and will 
overcome any issues with lack of space in a manuscript for reporting of all data 
(Hooijmans and Ritskes-Hoitinga, 2013). All of these platforms will hopefully be the 
beginning of a shift in this field of research towards more transparency in all fields of 
preclinical science and future studies reporting on animal models of psychosis 
should consider interacting more with these platforms. In order to increase the 
efficacy and robustness at which evidence can be summarised using meta-analyses 
to then inform further research and decisions, I would like to see more accurate and 
complete raw data being reported in the field. This would mean these analyses can 
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be more precise, leaving less room for over- or underestimations of biological 
phenomena, conclusions can be reached much faster without having to email 
authors, and automated tools could be developed to analyse data that is more 
structured. 
8.10 Lack of consistency in reporting of studies which further 
complicates timely review of data 
It is not only publication bias that can lead to an incomplete picture of a research 
field. The time that it takes to review studies will also inevitably mean that the 
snapshot of the available research evidence gained will be incomplete. Difficulty in 
identifying preclinical studies of relevance can also mean some publications are 
missed. I show here for example that by using alternate search words we can 
identify a comparable amount of additional studies also of relevance to a specific 
research question. While perhaps less of an issue in other research fields, I believe 
that especially in the field of complex and uniquely human disorders such as those 
seen in psychiatry (i.e. Where classification between symptoms and underlying 
pathophysiology are blurred even in the clinic), it can be difficult to capture all of the 
animal data that is of relevance to the clinical disorder whether reported to be of 
relevance to it or not. While it is useful to refer to relevant human disorders to a 
certain extent, this can also be less useful when we are looking at an experimental 
paradigm that is applicable to many different disorders and thus will not be captured 
as part of a search for a single disease entity. Recent literature suggests that there 
are no categorical distinctions in psychiatry and that in order to improve clinical 
outcomes we need to consider biologically similar subtypes that are not bound by 
phenotypic diagnosis according to current psychiatric nosology (Kapur et al., 2012). 
Moreover, it is thought by some researchers that psychosis should be seen more 
from the perspective of a spectrum model that is phenomenologically and temporally 
continuous and its expression is transdiagnostic and bi-directional with other mental 
health disorders (Guloksuz and van Os, 2018; McGrath et al., 2016). The debate 
over the validity of this view is not of importance here, however, it shows that studies 
reporting on animal models could take a similar approach. Studies could instead of 
defining their models by categorising them into separate entities based on a single 
or number of disorders they were modelling, instead report on phenotypes they were 
focusing on. This could lead to a more logical and comprehensive structure of the 
pre-clinical research field of psychosis. And I believe that this would make the 
276 
 
identification of patterns in the evidence collected easier to identify and could lead to 
a more straightforward picture of how preclinical data can be translated into clinical 
research. New initiatives such as the introduction of the endophenotype-oriented 
Research Domain Criteria (RDoC) system are being proposed as a new framework 
for defining animal models (i.e. according to endophenotypes instead of the old 
approach of complex diseases) (Anderzhanova et al., 2017). The fact that more 
recently developed antipsychotic medication such as aripiprazole, brexpiprazole and 
cariprazine are also approved for the treatment of other psychiatric disorders, such 
as bipolar disorder and major depressive disorder (Frankel and Schwartz, 2017), 
supports this idea. Perhaps focusing on doing research by looking at phenotypes 
that are of relevance to multiple psychiatric disorders would help in the discovery of 
‘novel’ compounds to those already being used for schizophrenia.  
In addition to this, I think there is also a more general issue with the contents of 
publications. More specifically, I think the detail of reporting of titles and abstracts for 
example as well as indexing of studies could be vastly improved. I observed during 
this review that some studies would fail to mention important aspects of 
experimental setup such as a full list of treatments tested or behavioural outcome 
measures used, for example. Difficulties with identifying studies of relevance has 
been widely described for qualitative research (Barroso et al., 2003), but I would 
argue this is not limited to only these types of research. Understandably, most 
abstracts are limited by word counts, as well as by their purpose to summarise a 
study in a way that is concise and interesting to the reader and will make them want 
to read the article further (Grant, 2013). Nevertheless, a lack of uniformity in 
reporting of and publishing of all data that has been collected through pre-clinical 
studies can affect those trying to summarise the literature relating to a specific area 
of interest and therefore these limitations in reporting can affect these reviews. For 
example, many systematic reviews perform electronic searches by searching titles 
and abstracts of studies in electronic databases (Sampson et al., 2006). To 
maximise the number of publications to be found of relevance especially during the 
performance of a broad search, which has been shown to yield results different to 
more specific searches shown both by evidence presented here and elsewhere in 
the literature (Egan et al., 2012), where possible, authors should list all interventions 
and treatments tested. This is not only in an effort to increase replicability, but also 
so that where experiments are similar despite being investigated and reported in 
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different research contexts, we may also learn from looking at research avenues 
that are directly parallel to ours. 
For example, it is entirely likely that drugs of therapeutic value for some symptoms 
of complex disorders like schizophrenia already exist, but are being used in other 
lines of medicine. And in fact, the more our understanding grows of schizophrenia, 
the more it becomes apparent that not only the dopamine system is involved. Thus 
in order to treat other symptoms in schizophrenia like cognitive deficits, researchers 
have begun to repurpose drugs that have already been approved, which affect other 
systems (Yang et al., 2017). Cognitive enhancers spanning multiple targets, 
including ones that affect glutamatergic or cholinergic pathways, anti-dementia or 
anti-inflammatory agents, or even hormones like oxytocin and other compounds 
such as omega-3 fatty acids have all been tested for schizophrenia (Yang et al., 
2017). Unfortunately, despite these compounds showing positive results in other 
conditions such as attention deficit disorders, schizotypal personality disorder, 
results are mixed and often inconclusive about the effectiveness of these drugs in 
schizophrenia (Harvey, 2009). It has been suggested that this could partly be due to 
the fact that most of the clinical trials assessing the efficacy of these compounds 
have done so in chronic schizophrenic individuals instead of focusing on individuals 
who are at an earlier phase of their disorder, when cognitive deficits begin to appear 
(Vreeker et al., 2015). In fact research shows that cognitive remediation is more 
effective for adults who are at earlier stages of their disorder (Corbera et al., 2017). 
Perhaps focusing on individuals who have increased vulnerability for the disorder 
might yield different results for cognitive enhancers (Vreeker et al., 2015). From a 
pharmacological aspect, the efficacy of these add-on cognitive enhancers in 
schizophrenic individuals might also be affected by the interference of simultaneous 
use of antipsychotic medications, exacerbated by our lack of understanding of the 
full spectrum of effects of current antipsychotics (Harvey and Bowie, 2012). 
Moreover, it is not clear if the same accepted doses for use in other conditions 
should be used in the treatment of cognitive deficits in schizophrenia and therefore 
dosing of these add-on treatments is likely to be an important variable. The 
interference from antipsychotic medication may especially affect dose-dependent 
side effects (Harvey and Bowie, 2012). In order to understand these interactions, 
when developing dosing standards using pre-clinical exploratory studies for 
cognitive enhancers, experimental setups should reflect this common clinical picture 
of simultaneous use of antipsychotics and cognitive enhancers (Harvey, 2009). 
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Nevertheless, by using research from other branches of science we might increase 
our pool of knowledge of compounds that might help alleviate these deficits in 
schizophrenia, which are otherwise also seen in a multitude of other psychiatric 
conditions. 
Identifying all potential sources of relevant data also introduces another problem, of 
course. In the context of the large amounts of data that continue to be published in 
relation to specific areas of research, it becomes increasingly difficult to understand 
and process all of this data in a timely manner. This is important so that reliable 
decisions can be made for future studies and higher research domains can be 
reliably informed based on all the evidence that exists. As the research field is so 
broad-ranging within the psychosis field, it is hard to imagine how human 
investigators might keep up to date with all the research that is continuously going 
on. While systematic reviews can help, they are also limited by the time that it takes 
for reviewers to screen and process data and therefore can often lead to reviews 
which are considered to be out-of-date (Beller et al., 2013). I have shown here 
through updating a specific subset of the literature that overall conclusions may 
survive for a period of time even if the search does not include most recent data. 
Nevertheless, it is difficult to tell how long it would take for evidence published after 
a search to change results significantly in a broader sense of the field (Shojania et 
al., 2007). I believe I have also shown in Chapter 5 that there is potential in using 
computer-assisted techniques such as text mining to help with the processing of 
these data by automating a simple data extraction stage of the review process. The 
use of this tool and its expansion to the extraction of other types of data are limited 
by the format that this information is in and the variability of wording used to explain 
the same concept across different research fields (Bahor et al., 2017). This, as 
before, warrants a desire for standardization of reporting of publications. Machine 
learning is currently being fine-tuned and utilised for screening of publications for 
relevance (Bannach-Brown et al., 2018), however, we are still struggling with the 
extraction of certain types of data from these publications, which arguably is one of 
the most time-consuming and least reliable stages of the process (Jelicic Kadic et 
al., 2016). While this search was done prior to the availability of machine learning 
tools for citation screening, the manual screening results of this review are currently 
being used in the testing and validation of such systems for future reviews. Tools 
such as this would allow for faster initial screening of abstracts especially for larger 
projects like this review. If initiatives mentioned above were enforced and there was 
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an improvement in preclinical research publication in terms of consistency and 
completeness of reporting of methods and of results, then systematic reviews could 
be further automated.   
8.11 Limitations 
Firstly, this work is essentially observational and not experimental and should be 
considered as hypothesis generating only. Secondly, much of the data used for 
analyses was extracted by a single person, whereas to ascertain maximum reliability 
in results double data extraction would be the gold standard. Moreover, many of the 
analyses presented here as part of this project could only be done for part of the 
literature due to time constraints. While conclusions are thought to be representative 
of the entire dataset, data from studies not extracted might yield differential results. 
Here, I have demonstrated the use of an automated tool that could both reduce the 
time that it takes to perform a systematic review as well as provide a second 
screener for when resources do not allow for this. Clearly, this approach requires 
further development and ideally future research will build on this as well as other 
tools currently in development so that they can be adapted to systematic reviews of 
other fields of preclinical research and can thus be of use to many researchers.  
The studies reviewed here were identified a number of years ago now and an 
update of the search might reveal new or different findings, the impact of which is 
likely to be minimal, however, not clear. Manually screened data from this project is 
being used for the development of machine learning techniques for the screening 
phase of the systematic review process, potentially making future updates of the 
project quicker. Categorization of studies could also be automated in future updates 
of the project, by using the lists of categories for model induction methods, 
behavioural outcome measures and treatments tested, put together here. These 
could be used to generate a string of regular expressions to be used in text mining 
of novel publications. 
Moreover, I have shown here that the methodological quality of studies has some 
serious limitations and inadequacies and therefore conclusions based on this data 
might affect the precision and reliability of overall estimates of effect. The inclusion 
of only high-quality studies in this review of animal data, as suggested in clinical 
systematic reviews, was not appropriate at this stage due to the overwhelming 
number of animal studies, which do not report important methodological criteria. 
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Exploring the extent of limitations in reporting of these measures and looking at the 
impact of this in the literature to be able to make recommendations in future, was 
recognised to be a much more appropriate approach for this review.  
Other general limitations of all systematic reviews possibly affecting results include 
the fact that I was only able to review the evidence and its impact as it was reported 
in publications, irrespective of what might have actually been done in the laboratory. 
Differences in reporting may have been confounded by unaccountable things such 
as differences in what different journals ask for to be reported, as well as restrictions 
on word counts (McCann et al., 2017). For reporting of closely related items such as 
measures taken to reduce risks of bias, it is also difficult to account for co-linearity. 
Unfortunately, due to small sample sizes, I was unable to use multi-variable meta-
regression to investigate this further. In addition to this, I have also shown that the 
heterogeneity in the field is high and therefore in my meta-analysis I grouped studies 
together with sometimes vastly different characteristics as well as outcomes 
measured in different ways. This limits the usefulness of calculated overall estimates 
of effect, however, exploration of this heterogeneity, as done here where appropriate 
and possible, can help to understand any differences in efficacy that do exist 
between groups (McCann et al., 2017). Unfortunately, for many analyses reported 
here while heterogeneity could be detected and quantified, it was not always 
possible to look at the exact sources of this.  
Finally, it is important to highlight that all research is susceptible to bias, including 
that of my own. For now, current assessment of risks of bias in preclinical 
systematic reviews and thus their quality is assessed using expert opinion instead of 
any reliable evidence-based methods (Mueller et al., 2014).  
8.12 Conclusion 
It is clear that there is a failure of translation from preclinical research to clinical 
research in the field of psychotic disorders. The aim of this project was to improve our 
understanding of current and past preclinical uses of animal models in the psychotic 
disorders research field. Here I have reviewed a number of potential underlying issues 
that could be having a negative effect on the effective translation of results, although 
it is most likely that all of these factors contribute to some extent to the problem.  
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At the moment, we are largely presented with information in the literature but have 
little knowledge of what came before the study including what the original design of it 
was, shown by a low 0.2% of studies that reported having a protocol available for their 
work. Due to incomplete reporting, we are also not always clear on what exactly 
happened during the study, evidenced by a lack of reporting of measures taken to 
reduce the risk of bias and incomplete descriptions of animals used including details 
about cohort, time of model induction and time of assessment to name a few. 
Moreover, heterogeneity in all aspects of experimental design and reporting in the 
literature is great, with minimal consistency across different studies. Variability should 
be encouraged in terms of animals used in research, including their sex, strain and 
age, as this increases the external validity of data collected. Variability in experimental 
design, however, needs to be more consistently and comprehensively described. 
Lastly, we are not always aware of what happens after a study has been performed. 
Selective outcome reporting is an obvious issue and data collection is further limited 
by that findings are very rarely reported as raw data. When these building blocks that 
make up good quality preclinical research are compromised, then how can we expect 
to effectively build on this structure (Figure 8.2)? All of the limitations mentioned here 
in the field are also frequently mentioned for clinical trials (Correll et al., 2011), so why 
are we measuring animal studies by a different scale?  
Figure 8.2 Translation of knowledge from basic science to clinical research and 
practice is clearly limited by four main issues, improvement of which might in turn 
also improve translation 
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It is important that future animal studies not only consider better experimental quality 
but also better reporting of said experimentation, including publishing of all data 
collected. Unless we are presented with a full and comprehensive picture, it is difficult 
to identify patterns in the literature, studies cannot be replicated and thus they lose 
their validity and reliability in informing subsequent domains of research. Reporting of 
all measures should be routinely done whether authors think that it might have a 
confounding effect on results or not. If a study is missing important information about 
experimental design then this also makes it difficult to compare and put into context 
with other studies. When we can’t place animal work in the context of other work in 
the literature, has that piece of work added to our knowledge or has it been a waste 
of resources? I believe these are strong arguments for demanding a change in the 
pre-clinical research field of psychotic disorders.  
It is also imperative that our methods of getting to important conclusions about the 
data are as fast as they can be, as reliable as they can be and as least wasteful or 
damaging to our resources as they can be. Undoubtedly collaboration is essential and 
that’s why international consortiums such as Novel Methods leading to New 
Medications in Depression and Schizophrenia (NEWMEDS), a collaborative project 
between researchers in academia and industry for the development of new drugs in 
schizophrenia and depression, will be vital in agreeing on standardized methods in 
preclinical research that will be analogous to clinical research (NEWMEDS-
europe.com). The price of pre-clinical research is high, but the price of testing drugs 
in clinical trials, which then go onto fail, is even higher. While there are a number of 
promising drug candidates in final stages of clinical trials at the moment (Fellner, 
2017), whether they will make it into clinical use and how they will be received remains 
to be seen. In the meantime, animal models should continue to be a unique tool used 
in improving our understanding of complex psychiatric conditions such as psychosis 
spectrum disorders. The extent of their ability to inform clinical knowledge is not 
known, and will only become clear once we start doing and reporting research 
properly and thoroughly. The only thing that is certain is that there is a need for better 
treatment options for individuals who battle with psychotic disorders, and this certainly 
warrants the use and further development of tools, which might increase our 
knowledge of how to reach these end goals. I believe that in order to overcome the 
issue of having the research field of psychotic disorders “become inundated with 
undigested data that collectively do not make sense" (Tandon, 1999), improve 
translation of evidence between pre-clinical and clinical studies, and thus propel 
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preclinical psychosis research in the right direction, we must have a transparent, 
replicable and systematic approach to future research. Only by learning from and 
building on previous research in this way through systematic reviews will we truly be 
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Appendix I. Search strategy expanded 
Full expansion of search terms described in Chapter 2 
(((((((((((((((((((((((psychot[All Fields] OR psychot'erapie[All Fields] OR psychotactile[All 
Fields] OR psychotainment[All Fields] OR psychotaxonomy[All Fields] OR 
psychote'erapeutique[All Fields] OR psychotechnic[All Fields] OR psychotechnical[All Fields] 
OR psychotechnicians[All Fields] OR psychotechnicien[All Fields] OR psychotechniciens[All 
Fields] OR psychotechnics[All Fields] OR psychotechnie[All Fields] OR psychotechnik[All 
Fields] OR psychotechniken[All Fields] OR psychotechnique[All Fields] OR 
psychotechniques[All Fields] OR psychotechnisch[All Fields] OR psychotechnische[All 
Fields] OR psychotechnischen[All Fields] OR psychotechnischer[All Fields] OR 
psychotechnological[All Fields] OR psychotechnologies[All Fields] OR 
psychotechnologies'[All Fields] OR psychotechnologists[All Fields] OR psychotechnology[All 
Fields] OR psychotehnic[All Fields] OR psychotehrapies[All Fields] OR psychotemporal[All 
Fields] OR psychoten[All Fields] OR psychoterapei[All Fields] OR psychoterapeuta[All 
Fields] OR psychoterapeutic[All Fields] OR psychoterapeutick[All Fields] OR 
psychoterapeutick'e[All Fields] OR psychoterapeutick'y[All Fields] OR psychoterapeuticka[All 
Fields] OR psychoterapeuticke[All Fields] OR psychoterapeutickeho[All Fields] OR 
psychoterapeutickej[All Fields] OR psychoterapeutickem[All Fields] OR 
psychoterapeutickom[All Fields] OR psychoterapeuticky[All Fields] OR 
psychoterapeutickych[All Fields] OR psychoterapeutische[All Fields] OR 
psychoterapeutom[All Fields] OR psychoterapeutova[All Fields] OR psychoterapeuty[All 
Fields] OR psychoterapeutyczne[All Fields] OR psychoterapeutycznego[All Fields] OR 
psychoterapeutycznej[All Fields] OR psychoterapeutycznych[All Fields] OR psychoteraph[All 
Fields] OR psychoteraphy[All Fields] OR psychoteraphy'[All Fields] OR psychoterapia[All 
Fields] OR psychoterapic[All Fields] OR psychoterapie[All Fields] OR psychoterapii[All 
Fields] OR psychoterapique[All Fields] OR psychoterapist[All Fields] OR psychoterapists[All 
Fields] OR psychoterapli[All Fields] OR psychoterappi[All Fields] OR psychoterapy[All Fields] 
OR psychoteratogenesis[All Fields] OR psychoteratogenic[All Fields] OR 
psychoteratogenicity[All Fields] OR psychoteratology[All Fields] OR psychoterminal[All 
Fields] OR psychoterminalny[All Fields] OR psychoterror[All Fields] OR psychotest[All Fields] 
OR psychotestings[All Fields] OR psychotestu[All Fields] OR psychotetramine[All Fields] OR 
psychoth[All Fields] OR psychoth'erapeutique[All Fields] OR psychoth'erapie[All Fields] OR 
psychoth'erapies[All Fields] OR psychoth'erapique[All Fields] OR psychoth'erapiques[All 
Fields] OR psychoth6rapeute[All Fields] OR psychotheapeutic[All Fields] OR 
psychotheapy[All Fields] OR psychotheeapy[All Fields] OR psychothematics[All Fields] OR 
psychothematik[All Fields] OR psychotheological[All Fields] OR psychotheoretical[All Fields] 
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OR psychother[All Fields] OR psychothera[All Fields] OR psychotheraeuten[All Fields] OR 
psychotheraia[All Fields] OR psychotheraoeutische[All Fields] OR psychotherap[All Fields] 
OR psychotherapei[All Fields] OR psychotherapeia[All Fields] OR 
psychotherapeieresultaten[All Fields] OR psychotherapeifallen[All Fields] OR 
psychotherapetic[All Fields] OR psychotherapeut[All Fields] OR psychotherapeute[All Fields] 
OR psychotherapeuten[All Fields] OR psychotherapeutenausbildung[All Fields] OR 
psychotherapeutengesetz[All Fields] OR psychotherapeutengesetzes[All Fields] OR 
psychotherapeutenverhaltens[All Fields] OR psychotherapeutes[All Fields] OR 
psychotherapeutic[All Fields] OR psychotherapeutic'[All Fields] OR psychotherapeutical[All 
Fields] OR psychotherapeutically[All Fields] OR psychotherapeuticapproach[All Fields] OR 
psychotherapeutiche[All Fields] OR psychotherapeutickeho[All Fields] OR 
psychotherapeutics[All Fields] OR psychotherapeuties[All Fields] OR psychotherapeutik[All 
Fields] OR psychotherapeutikum[All Fields] OR psychotherapeutin[All Fields] OR 
psychotherapeutinnen[All Fields] OR psychotherapeutinuniversitatsklinik[All Fields] OR 
psychotherapeutique[All Fields] OR psychotherapeutiques[All Fields] OR 
psychotherapeutis[All Fields] OR psychotherapeutisch[All Fields] OR 
psychotherapeutische[All Fields] OR psychotherapeutischem[All Fields] OR 
psychotherapeutischen[All Fields] OR psychotherapeutischer[All Fields] OR 
psychotherapeutisches[All Fields] OR psychotherapeutist[All Fields] OR 
psychotherapeutists[All Fields] OR psychotherapeutization[All Fields] OR 
psychotherapeuts[All Fields] OR psychotherapeuty[All Fields] OR psychotheraphie[All Fields] 
OR psychotheraphobia[All Fields] OR psychotheraphy[All Fields] OR psychotherapi[All 
Fields] OR psychotherapi'aj'anak[All Fields] OR psychotherapia[All Fields] OR 
psychotherapiaban[All Fields] OR psychotherapias[All Fields] OR psychotherapic[All Fields] 
OR psychotherapicabteilung[All Fields] OR psychotherapie[All Fields] OR 
psychotherapieabteilung[All Fields] OR psychotherapieakzeptanz[All Fields] OR 
psychotherapiealternative[All Fields] OR psychotherapieangebots[All Fields] OR 
psychotherapieaschaffenburg[All Fields] OR psychotherapieassistenten[All Fields] OR 
psychotherapieauffassung[All Fields] OR psychotherapieausbildung[All Fields] OR 
psychotherapiebedurfnis[All Fields] OR psychotherapiebedurftiger[All Fields] OR 
psychotherapiebedurftigkeit[All Fields] OR psychotherapiebegleitende[All Fields] OR 
psychotherapiedokumentation[All Fields] OR psychotherapieeffekte[All Fields] OR 
psychotherapieempfehlungen[All Fields] OR psychotherapieerfolg[All Fields] OR 
psychotherapieerfolges[All Fields] OR psychotherapieergebnissen[All Fields] OR 
psychotherapieform[All Fields] OR psychotherapieformen[All Fields] OR 
psychotherapieforscher[All Fields] OR psychotherapieforschung[All Fields] OR 
psychotherapiegruppen[All Fields] OR psychotherapieindikation[All Fields] OR 
psychotherapieinduzierter[All Fields] OR psychotherapieinstitution[All Fields] OR 
psychotherapieklinik[All Fields] OR psychotherapiekongress[All Fields] OR 
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psychotherapiekontrolle[All Fields] OR psychotherapiekonzept[All Fields] OR 
psychotherapiemethoden[All Fields] OR psychotherapiemotivation[All Fields] OR 
psychotherapien[All Fields] OR psychotherapiepatienten[All Fields] OR 
psychotherapiepatientinnen[All Fields] OR psychotherapieplanung[All Fields] OR 
psychotherapieplatz[All Fields] OR psychotherapiepraxis[All Fields] OR 
psychotherapieprinzip[All Fields] OR psychotherapieprogramme[All Fields] OR 
psychotherapieprozessforschung[All Fields] OR psychotherapierelevanten[All Fields] OR 
psychotherapierichtlinien[All Fields] OR psychotherapies[All Fields] OR psychotherapies'[All 
Fields] OR psychotherapieschulen[All Fields] OR psychotherapiestation[All Fields] OR 
psychotherapiestationen[All Fields] OR psychotherapiestudie[All Fields] OR 
psychotherapiestudien[All Fields] OR psychotherapieverfahren[All Fields] OR 
psychotherapieverlauf[All Fields] OR psychotherapieverlaufe[All Fields] OR 
psychotherapieverlaufsforschung[All Fields] OR psychotherapieversuch[All Fields] OR 
psychotherapiewoche[All Fields] OR psychotherapii[All Fields] OR psychotherapiqe[All 
Fields] OR psychotherapique[All Fields] OR psychotherapiques[All Fields] OR 
psychotherapist[All Fields] OR psychotherapist'[All Fields] OR psychotherapist's[All Fields] 
OR psychotherapiste[All Fields] OR psychotherapists[All Fields] OR psychotherapists'[All 
Fields] OR psychotherapits[All Fields] OR psychotherapty[All Fields] OR 
psychotherapuetic[All Fields] OR psychotheraputic[All Fields] OR psychotherapy[All Fields] 
OR psychotherapy'[All Fields] OR psychotherapy's[All Fields] OR psychotherapy1[All Fields] 
OR psychotherapygenetics[All Fields] OR psychotherapyuniversity[All Fields] OR 
psychotherapyw2[All Fields] OR psychotheratpie[All Fields] OR psychotheray[All Fields] OR 
psychotherayp[All Fields] OR psychothereutic[All Fields] OR psychotheroapy[All Fields] OR 
psychotherories[All Fields] OR psychotherpay[All Fields] OR psychotherpeutic[All Fields] OR 
psychotherpie[All Fields] OR psychotherpiemotivation[All Fields] OR psychotherpists[All 
Fields] OR psychotherpy[All Fields] OR psychotherrapeutic[All Fields] OR psychotherspy[All 
Fields] OR psychothrapeutic[All Fields] OR psychothraphy[All Fields] OR psychothrapie[All 
Fields] OR psychothropic[All Fields] OR psychothymic[All Fields] OR psychotic[All Fields] 
OR psychotic'[All Fields] OR psychotic's[All Fields] OR psychotica[All Fields] OR 
psychotical[All Fields] OR psychotically[All Fields] OR psychoticbody[All Fields] OR 
psychotici[All Fields] OR psychoticism[All Fields] OR psychoticism'[All Fields] OR 
psychoticismu[All Fields] OR psychoticity[All Fields] OR psychoticity'[All Fields] OR 
psychoticizm[All Fields] OR psychotick'y[All Fields] OR psychotick'ym[All Fields] OR 
psychoticka[All Fields] OR psychoticke[All Fields] OR psychotickeho[All Fields] OR 
psychoticky[All Fields] OR psychotickych[All Fields] OR psychoticlike[All Fields] OR 
psychoticng[All Fields] OR psychotics[All Fields] OR psychotics'[All Fields] OR 
psychoticum[All Fields] OR psychotiform[All Fields] OR psychotiform'[All Fields] OR 
psychotigues[All Fields] OR psychotiker[All Fields] OR psychotikern[All Fields] OR 
psychotikmi[All Fields] OR psychotiku[All Fields] OR psychotikum[All Fields] OR 
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psychotikus[All Fields] OR psychotikusokon[All Fields] OR psychotiky[All Fields] OR 
psychotique[All Fields] OR psychotiques[All Fields] OR psychotisation[All Fields] OR 
psychotisch[All Fields] OR psychotische[All Fields] OR psychotische'[All Fields] OR 
psychotischem[All Fields] OR psychotischen[All Fields] OR psychotischer[All Fields] OR 
psychotisches[All Fields] OR psychotisicm[All Fields] OR psychotism[All Fields] OR 
psychotizing[All Fields] OR psychotizismus[All Fields] OR psychoto[All Fields] OR 
psychotocism[All Fields] OR psychotoform[All Fields] OR psychotogen[All Fields] OR 
psychotogenesis[All Fields] OR psychotogenic[All Fields] OR psychotogenicity[All Fields] OR 
psychotogens[All Fields] OR psychotogique[All Fields] OR psychotogiques[All Fields] OR 
psychotoid[All Fields] OR psychotoid'[All Fields] OR psychotoksykologii[All Fields] OR 
psychotolysis[All Fields] OR psychotolytic[All Fields] OR psychotomimesis[All Fields] OR 
psychotomimetic[All Fields] OR psychotomimetic'[All Fields] OR psychotomimetically[All 
Fields] OR psychotomimetics[All Fields] OR psychotomimeticumok[All Fields] OR 
psychotomimetika[All Fields] OR psychotomimetique[All Fields] OR psychotomimetiques[All 
Fields] OR psychotomimetische[All Fields] OR psychotomimetric[All Fields] OR 
psychotomimmetic[All Fields] OR psychotomorphic[All Fields] OR psychotomymetic[All 
Fields] OR psychoton[All Fields] OR psychotone[All Fields] OR psychotonic[All Fields] OR 
psychotonica[All Fields] OR psychotonics[All Fields] OR psychotonicumok[All Fields] OR 
psychotonika[All Fields] OR psychotonikum[All Fields] OR psychotonikums[All Fields] OR 
psychotonin[All Fields] OR psychotonique[All Fields] OR psychotoniques[All Fields] OR 
psychotonisierender[All Fields] OR psychotonovy[All Fields] OR psychotonu[All Fields] OR 
psychotop[All Fields] OR psychotopes[All Fields] OR psychotopic[All Fields] OR 
psychotopics[All Fields] OR psychotorpnijch[All Fields] OR psychototmimetic[All Fields] OR 
psychotoxic[All Fields] OR psychotoxical[All Fields] OR psychotoxicity[All Fields] OR 
psychotoxicologic[All Fields] OR psychotoxicological[All Fields] OR psychotoxicology[All 
Fields] OR psychotoxikologie[All Fields] OR psychotoxikologische[All Fields] OR 
psychotoxin[All Fields] OR psychotoxins[All Fields] OR psychotoxischen[All Fields] OR 
psychotraining[All Fields] OR psychotramide[All Fields] OR psychotrauma[All Fields] OR 
psychotrauma's[All Fields] OR psychotraumagroep[All Fields] OR psychotraumas[All Fields] 
OR psychotraumas'[All Fields] OR psychotraumata[All Fields] OR psychotraumatic[All Fields] 
OR psychotraumatique[All Fields] OR psychotraumatiques[All Fields] OR 
psychotraumatischen[All Fields] OR psychotraumatised[All Fields] OR psychotraumatism[All 
Fields] OR psychotraumatisme[All Fields] OR psychotraumatismes[All Fields] OR 
psychotraumatitisierter[All Fields] OR psychotraumatizace[All Fields] OR 
psychotraumatization[All Fields] OR psychotraumatized[All Fields] OR 
psychotraumatizing[All Fields] OR psychotraumatol[All Fields] OR psychotraumatologi[All 
Fields] OR psychotraumatological[All Fields] OR psychotraumatologie[All Fields] OR 
psychotraumatologische[All Fields] OR psychotraumatologischen[All Fields] OR 
psychotraumatologischer[All Fields] OR psychotraumatology[All Fields] OR psychotria[All 
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Fields] OR psychotriae[All Fields] OR psychotrianoside[All Fields] OR psychotrianosides[All 
Fields] OR psychotrichological[All Fields] OR psychotrichology[All Fields] OR 
psychotridine[All Fields] OR psychotrieae[All Fields] OR psychotriifolia[All Fields] OR 
psychotrimine[All Fields] OR psychotrine[All Fields] OR psychotripine[All Fields] OR 
psychotroic[All Fields] OR psychotronic[All Fields] OR psychotronice[All Fields] OR 
psychotronics[All Fields] OR psychotronika[All Fields] OR psychotrop[All Fields] OR 
psychotropa[All Fields] OR psychotrope[All Fields] OR psychotropen[All Fields] OR 
psychotroper[All Fields] OR psychotropes[All Fields] OR psychotroph[All Fields] OR 
psychotrophes[All Fields] OR psychotrophic[All Fields] OR psychotrophics[All Fields] OR 
psychotrophie[All Fields] OR psychotrophs[All Fields] OR psychotropia[All Fields] OR 
psychotropic[All Fields] OR psychotropic'[All Fields] OR psychotropic's[All Fields] OR 
psychotropica[All Fields] OR psychotropical[All Fields] OR psychotropically[All Fields] OR 
psychotropicity[All Fields] OR psychotropicmedication[All Fields] OR psychotropics[All 
Fields] OR psychotropics'[All Fields] OR psychotropid[All Fields] OR psychotropism[All 
Fields] OR psychotropn'ich[All Fields] OR psychotropne[All Fields] OR psychotropneho[All 
Fields] OR psychotropni[All Fields] OR psychotropnich[All Fields] OR psychotropnimi[All 
Fields] OR psychotropowe[All Fields] OR psychotropowego[All Fields] OR 
psychotropowych[All Fields] OR psychotropowym[All Fields] OR psychotropowymi[All Fields] 
OR psychotrops[All Fields] OR psychotropy[All Fields] OR psychotroropes[All Fields] OR 
psychotrpic[All Fields] OR psychotuberculosis[All Fields] OR psychotychznych[All Fields] OR 
psychotyczna[All Fields] OR psychotyczne[All Fields] OR psychotycznego[All Fields] OR 
psychotycznej[All Fields] OR psychotyczny[All Fields] OR psychotycznych[All Fields] OR 
psychotycznym[All Fields] OR psychotycznymi[All Fields] OR psychotyczych[All Fields] OR 
psychotype[All Fields] OR psychotypes[All Fields] OR psychotypical[All Fields] OR 
psychotypological[All Fields] OR psychotypology[All Fields] OR psychotyzcznymi[All Fields] 
OR psychotyzm[All Fields]) OR ("psychotic disorders"[MeSH Terms] OR ("psychotic"[All 
Fields] AND "disorders"[All Fields]) OR "psychotic disorders"[All Fields] OR "psychosis"[All 
Fields])) OR ("psychotic disorders"[MeSH Terms] OR ("psychotic"[All Fields] AND 
"disorders"[All Fields]) OR "psychotic disorders"[All Fields] OR "psychoses"[All Fields])) OR 
("paranoid disorders"[MeSH Terms] OR ("paranoid"[All Fields] AND "disorders"[All Fields]) 
OR "paranoid disorders"[All Fields] OR "paranoia"[All Fields])) OR paraphrenia[All Fields]) 
OR (sensitive[All Fields] AND beziehungswahn[All Fields])) OR (involutional[All Fields] AND 
paranoid[All Fields] AND state[All Fields])) OR ("shared paranoid disorder"[MeSH Terms] OR 
("shared"[All Fields] AND "paranoid"[All Fields] AND "disorder"[All Fields]) OR "shared 
paranoid disorder"[All Fields] OR ("folie"[All Fields] AND "deux"[All Fields]) OR "folie 
deux"[All Fields])) OR (catatonia[All Fields] OR catatonia'[All Fields] OR catatonialike[All 
Fields] OR catatonias[All Fields] OR catatonic[All Fields] OR catatonica[All Fields] OR 
catatonical[All Fields] OR catatoniche[All Fields] OR catatonici[All Fields] OR catatoniclike[All 
Fields] OR catatonico[All Fields] OR catatonicocatalettiche[All Fields] OR catatonicos[All 
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Fields] OR catatonics[All Fields] OR catatonie[All Fields] OR catatonies[All Fields] OR 
catatoniform[All Fields] OR catatoniformpsychomotor[All Fields] OR catatonig'ene[All Fields] 
OR catatonigene[All Fields] OR catatonigenes[All Fields] OR catatonigenic[All Fields] OR 
catatonin[All Fields] OR catatonine[All Fields] OR catatonique[All Fields] OR catatoniques[All 
Fields] OR catatonis[All Fields] OR catatonizante[All Fields] OR catatonizzati[All Fields] OR 
catatono[All Fields] OR catatonogenic[All Fields] OR catatonoid[All Fields] OR catatony[All 
Fields])) OR (delusion[All Fields] OR delusion'[All Fields] OR delusion's[All Fields] OR 
delusional[All Fields] OR delusional'[All Fields] OR delusionalilty[All Fields] OR 
delusionalism[All Fields] OR delusionality[All Fields] OR delusionally[All Fields] OR 
delusionals[All Fields] OR delusionary[All Fields] OR delusione[All Fields] OR delusiones[All 
Fields] OR delusioni[All Fields] OR delusionlike[All Fields] OR delusionnal[All Fields] OR 
delusions[All Fields] OR delusions'[All Fields])) OR (hallucinate[All Fields] OR 
hallucinated[All Fields] OR hallucinates[All Fields] OR hallucinatic[All Fields] OR 
hallucinatie[All Fields] OR hallucinaties[All Fields] OR hallucinatiion[All Fields] OR 
hallucinatiions[All Fields] OR hallucinating[All Fields] OR hallucination[All Fields] OR 
hallucination'[All Fields] OR hallucinational[All Fields] OR hallucinationen[All Fields] OR 
hallucinationer[All Fields] OR hallucinationes[All Fields] OR hallucinations[All Fields] OR 
hallucinations'[All Fields] OR hallucinations'than[All Fields] OR hallucinatire[All Fields] OR 
hallucinative[All Fields] OR hallucinatoire[All Fields] OR hallucinatoire'[All Fields] OR 
hallucinatoires[All Fields] OR hallucinatoiresaigues[All Fields] OR hallucinator[All Fields] OR 
hallucinatoria[All Fields] OR hallucinatoric[All Fields] OR hallucinatornih[All Fields] OR 
hallucinators[All Fields] OR hallucinators'[All Fields] OR hallucinatory[All Fields] OR 
hallucinatory'[All Fields] OR hallucinatroy[All Fields])) OR (schizotypai[All Fields] OR 
schizotypal[All Fields] OR schizotypal'[All Fields] OR schizotypal''[All Fields] OR 
schizotypality[All Fields] OR schizotypals[All Fields] OR schizotype[All Fields] OR 
schizotype's[All Fields] OR schizotypes[All Fields] OR schizotypes'[All Fields] OR 
schizotypia[All Fields] OR schizotypic[All Fields] OR schizotypical[All Fields] OR 
schizotypics[All Fields] OR schizotypie[All Fields] OR schizotypies[All Fields] OR 
schizotypique[All Fields] OR schizotypische[All Fields] OR schizotypischen[All Fields] OR 
schizotypital[All Fields] OR schizotypy[All Fields] OR schizotypy'[All Fields] OR 
schizotypyal[All Fields] OR schizotypys[All Fields])) OR psychoactive[All Fields]) OR 
oneirophrenia[All Fields]) OR (psychogen[All Fields] OR psychogender[All Fields] OR 
psychogene[All Fields] OR psychogeneic[All Fields] OR psychogenem[All Fields] OR 
psychogenen[All Fields] OR psychogenenic[All Fields] OR psychogeneous[All Fields] OR 
psychogener[All Fields] OR psychogenes[All Fields] OR psychogenese[All Fields] OR 
psychogenesis[All Fields] OR psychogenetic[All Fields] OR psychogenetical[All Fields] OR 
psychogenetically[All Fields] OR psychogenetics[All Fields] OR psychogenetique[All Fields] 
OR psychogenetiques[All Fields] OR psychogenetische[All Fields] OR 
psychogenetycznym[All Fields] OR psychogenia[All Fields] OR psychogenias[All Fields] OR 
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psychogeniatrie[All Fields] OR psychogeniatrie'[All Fields] OR psychogenic[All Fields] OR 
psychogenic'[All Fields] OR psychogenica[All Fields] OR psychogenical[All Fields] OR 
psychogenically[All Fields] OR psychogenicity[All Fields] OR psychogenicor[All Fields] OR 
psychogenics[All Fields] OR psychogenie[All Fields] OR psychogeniecharakterliche[All 
Fields] OR psychogenien[All Fields] OR psychogenies[All Fields] OR psychogenique[All 
Fields] OR psychogeniques[All Fields] OR psychogenitat[All Fields] OR psychogenitically[All 
Fields] OR psychogenna[All Fields] OR psychogenne[All Fields] OR psychogennego[All 
Fields] OR psychogenneho[All Fields] OR psychogennej[All Fields] OR psychogenni[All 
Fields] OR psychogennich[All Fields] OR psychogennie[All Fields] OR psychogenniho[All 
Fields] OR psychogennim[All Fields] OR psychogennimi[All Fields] OR psychogenny[All 
Fields] OR psychogennych[All Fields] OR psychogennym[All Fields] OR psychogennymi[All 
Fields] OR psychogenomic[All Fields] OR psychogenomics[All Fields] OR psychogenous[All 
Fields] OR psychogenously[All Fields] OR psychogenuously[All Fields] OR psychogeny[All 
Fields])) OR (bouffee[All Fields] AND delirante[All Fields])) OR ("schizophrenia, 
disorganized"[MeSH Terms] OR ("schizophrenia"[All Fields] AND "disorganized"[All Fields]) 
OR "disorganized schizophrenia"[All Fields] OR "hebephrenia"[All Fields])) OR 
(schizophren[All Fields] OR schizophrena[All Fields] OR schizophrenc[All Fields] OR 
schizophrenci[All Fields] OR schizophrencis[All Fields] OR schizophrencs[All Fields] OR 
schizophrene[All Fields] OR schizophrene's[All Fields] OR schizophrenek[All Fields] OR 
schizophrenem[All Fields] OR schizophrenen[All Fields] OR schizophrenengruppe[All Fields] 
OR schizophrenenproblem[All Fields] OR schizophrener[All Fields] OR schizophrenes[All 
Fields] OR schizophrenese[All Fields] OR schizophreni[All Fields] OR schizophreni'as[All 
Fields] OR schizophrenia[All Fields] OR schizophrenia'[All Fields] OR schizophrenia's[All 
Fields] OR schizophrenia1[All Fields] OR schizophreniaban[All Fields] OR schizophreniac[All 
Fields] OR schizophreniaclinicaltrials[All Fields] OR schizophreniacs[All Fields] OR 
schizophreniaes[All Fields] OR schizophreniaforum[All Fields] OR schizophreniagene[All 
Fields] OR schizophreniagroup[All Fields] OR schizophreniai[All Fields] OR 
schizophreniak[All Fields] OR schizophrenial[All Fields] OR schizophrenialike[All Fields] OR 
schizophreniaor[All Fields] OR schizophreniara[All Fields] OR schizophreniaresearch[All 
Fields] OR schizophreniaresearchforum[All Fields] OR schizophreniarol[All Fields] OR 
schizophrenias[All Fields] OR schizophrenias'[All Fields] OR schizophreniaspectrum[All 
Fields] OR schizophreniay[All Fields] OR schizophrenic[All Fields] OR schizophrenic'[All 
Fields] OR schizophrenic's[All Fields] OR schizophrenical[All Fields] OR schizophrenically[All 
Fields] OR schizophrenices[All Fields] OR schizophrenicity[All Fields] OR 
schizophreniclike[All Fields] OR schizophrenicpatients[All Fields] OR schizophrenics[All 
Fields] OR schizophrenics'[All Fields] OR schizophrenicss[All Fields] OR schizophrenie[All 
Fields] OR schizophrenie'[All Fields] OR schizophrenieaehnlichen[All Fields] OR 
schizophrenieahnliche[All Fields] OR schizophrenieahnlichen[All Fields] OR 
schizophrenieahnlicher[All Fields] OR schizophrenieartige[All Fields] OR 
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schizophrenieartigen[All Fields] OR schizophrenieartiger[All Fields] OR 
schizophreniebeggriffs[All Fields] OR schizophreniebegriff[All Fields] OR 
schizophreniebegriffes[All Fields] OR schizophreniebegriffs[All Fields] OR 
schizophreniebehandlung[All Fields] OR schizophreniebehandlungen[All Fields] OR 
schizophreniediagnose[All Fields] OR schizophrenieerkrankten[All Fields] OR 
schizophrenieerkrankter[All Fields] OR schizophreniefalle[All Fields] OR 
schizophreniefallen[All Fields] OR schizophrenieform[All Fields] OR schizophrenieforme[All 
Fields] OR schizophrenieformen[All Fields] OR schizophrenieformer[All Fields] OR 
schizophrenieforschung[All Fields] OR schizophreniefrage[All Fields] OR 
schizophreniegenese[All Fields] OR schizophreniekonzepte[All Fields] OR 
schizophreniekonzepten[All Fields] OR schizophreniekranke[All Fields] OR 
schizophreniekranken[All Fields] OR schizophreniekranker[All Fields] OR 
schizophreniekreises[All Fields] OR schizophrenielehre[All Fields] OR schizophrenien[All 
Fields] OR schizophrenienahe[All Fields] OR schizophreniepatienten[All Fields] OR 
schizophreniepatientinnen[All Fields] OR schizophrenieproblem[All Fields] OR 
schizophrenieproblems[All Fields] OR schizophrenierisiko[All Fields] OR 
schizophrenieritoriality[All Fields] OR schizophrenies[All Fields] OR 
schizophreniespektrums[All Fields] OR schizophreniespezifitat[All Fields] OR 
schizophreniestudie[All Fields] OR schizophreniesymptomen[All Fields] OR 
schizophrenietheorie[All Fields] OR schizophrenietherapie[All Fields] OR 
schizophrenietypologie[All Fields] OR schizophrenieverlauf[All Fields] OR 
schizophrenieverlaufe[All Fields] OR schizophrenieverlaufs[All Fields] OR 
schizophrenieverstandnis[All Fields] OR schizophrenifallen[All Fields] OR 
schizophreniforems[All Fields] OR schizophreniform[All Fields] OR schizophreniform'[All 
Fields] OR schizophreniforme[All Fields] OR schizophreniformen[All Fields] OR 
schizophreniformes[All Fields] OR schizophreniformic[All Fields] OR schizophreniforms[All 
Fields] OR schizophrenigenesis[All Fields] OR schizophreniics[All Fields] OR 
schizophrenikern[All Fields] OR schizophrenine[All Fields] OR schizophreniologists[All 
Fields] OR schizophreniphorm[All Fields] OR schizophrenique[All Fields] OR 
schizophreniques[All Fields] OR schizophrenis[All Fields] OR schizophrenisation[All Fields] 
OR schizophrenism[All Fields] OR schizophreniucs[All Fields] OR schizophrenix[All Fields] 
OR schizophrenix's[All Fields] OR schizophreniz[All Fields] OR schizophrenization[All Fields] 
OR schizophrenized[All Fields] OR schizophrenjeforschung[All Fields] OR schizophrenlcs[All 
Fields] OR schizophrenle[All Fields] OR schizophreno[All Fields] OR schizophrenoform[All 
Fields] OR schizophrenogenesis[All Fields] OR schizophrenogenic[All Fields] OR 
schizophrenoid[All Fields] OR schizophrenomimetic[All Fields] OR schizophrenomimetics[All 
Fields] OR schizophrenosimilar[All Fields] OR schizophrens[All Fields] OR schizophrenuc[All 
Fields] OR schizophreny[All Fields])) OR (schizoaffectieve[All Fields] OR schizoaffectif[All 
Fields] OR schizoaffectifs[All Fields] OR schizoaffective[All Fields] OR schizoaffective'[All 
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Fields] OR schizoaffectively[All Fields] OR schizoaffectives[All Fields] OR 
schizoaffectives'[All Fields] OR schizoaffectivity[All Fields])) OR (("bipolar disorder"[MeSH 
Terms] OR ("bipolar"[All Fields] AND "disorder"[All Fields]) OR "bipolar disorder"[All Fields] 
OR "manic"[All Fields]) AND ("stupor"[MeSH Terms] OR "stupor"[All Fields]))) NOT 
comment[Publication Type]) NOT case reports[Publication Type]) NOT letter[Publication 


























Appendix II. Results of categorisation of the literature: Complete list of model 
induction methods used, behavioural outcomes measured, and treatment 
compounds tested 
 
Results of phases I and II of the project including screening and categorization of 
entire dataset identified in the search can be viewed here:  
Bahor, Zsanett. (2018). Systematic Review of Animal Models of Psychotic Disorders 
(Version Version I) [Data set]. Zenodo. Accessible at: 
https://doi.org/10.5281/zenodo.1209832. 
Overall frequency lists of methods of model induction, behavioural outcome 





















Appendix III. Text mining tool: code used for program and list of expressions 
Code 
Code for program developed is available here: 
https://drive.google.com/open?id=1hMAJboVD8WAGrt_8iRiPs2rkGdzoO_La 
Please use the password TextMiner2018 when unzipping the file.  
Simple word phrases 
Random allocation to group 
randomly assigned, Randomly assigned, assigned randomly, randomly divided, 
divided randomly, randomly treated, randomly split, randomly determined, random 
assignment, randomly received, were randomised, were randomized, randomly 
allocated, allocated randomly, treated in a randomized manner, treated in a 
randomised manner, randomly selected groups received, randomised to, 
randomised into, randomised in, randomized to, randomized into, randomized in, 
random assignment, randomization to, randomisation to, randomly categor, 
categorised randomly, categorized randomly, randomly subdivided, subdivided 
randomly, randomly divided, divided randomly 
Blinded assessment of outcome 
blind to, blindly performed, blinded, blindly, blind manner, blind evaluation, 
performed blind, blind condition, ‘blind’, “blind”, blind as to, counted blind, blind 
observer , blind investigator, blind rater, blind experimenter, blind researcher, blind 
tester, blind quantification, conducted blind, genotype blind, blind coded, blind with 
respect to, blind method, blind analysis, was unaware, was not aware of, observer 
unaware of, observer not aware of, observers unaware of, observers not aware of, 
experimenter unaware of, experimenter not aware of, experimenters unaware of, 
experimenters not aware of, researcher unaware of, researcher not aware of, 
researchers unaware of, researchers not aware of, tester unaware of, tester not 
aware of, testers unaware of, testers not aware of, rater unaware of, rater not aware 
of, raters unaware of, raters not aware of, person not aware of, person unaware of, 
investigator unaware of, investigator not aware of, investigators unaware of, 
investigators not aware of, operator unaware of, operator not aware of, operators 
unaware of, operators not aware of, were unaware of, were not aware of, without 
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awareness of, unaware of treatment, unaware of the treatment, unaware of the 
pretreatment, not aware of treatment, not aware of the treatment, was kept unaware, 
unaware of genotype, unaware of the genotype, not aware of genotype, not aware 
of the genotype, kept unaware of, unaware of group, not aware of group, unaware of 
the group, not aware of the group, unaware of drug, not aware of drug, unaware of 
the drug, not aware of the drug, unaware of experimental condition, not aware of 
experimental condition, unaware of the experimental condition, not aware of the 
experimental condition, naive to the identity of 
Sample size calculation 
minimum number required to give, required to give statistically valid results, Through 
a priori calculation, through a priori calculation, minimum sample size, Minimum 
sample size, planned sample size, calculated a sample size of, Target sample size, 
target sample size, Sample size of at least, Sample size calculation, Sample size 
determination, Sample size estimation, Sample size was calculated, Sample size 
estimate, Sample size consideration, Sample size would be sufficient, sample size 
of at least, sample size calculation, sample size determination, sample size 
estimation, sample size was calculated, sample size estimate, sample size 
consideration, sample size would be sufficient, Power calculation, Power analysis, 
Power estimation, Power of at least, Power of the study was, power calculation, 
power analysis, power estimation, power of at least, power of the study was, 
adequate to detect a, To detect differences of, To detect the treatment effect, To 
detect a treatment effect, To detect a treatment interaction, To detect statistical 
differences, To detect the expected difference, To detect the predetermined effect, 
To detect a mean difference, To detect a difference, To detect a similar treatment 
effect, To detect a significant change, to detect differences of, to detect the 
treatment effect, to detect a treatment effect, to detect a treatment interaction, to 
detect statistical differences, to detect the expected difference, to detect the 
predetermined effect, to detect a mean difference, to detect a difference, to detect a 
similar treatment effect, to detect a significant change, A power of, a power of, To 
insure sufficient power, to insure sufficient power, Sufficient statistical power, 
sufficient statistical power, would be needed if the null hypothesis, to achieve 
statistical significance, To achieve statistical significance, to estimate the sample 










Blinded assessment of outcome 






aware( of)?))|((not aware of|unaware of|without awareness of).(the 
)?((pre)?treatment|genotyp|group|drug|experimental condition)|without awareness 
of|naive to the identity of)/i 
Sample size calculation 
/((minimum|planned|target|calculated a) sample size( of)?)|(sample sizes? ((of|for) 
the study )?(of at least|calculation|determination|estimation|was 
calculated|estimate|consideration|would be sufficient|was determined according 
to|was estimated based on|was based on|for group assignment were made a 
priori|and outcome measurements|and statistical evaluation|was devised))|(power 
(calculation|analysis|estimation|of at least|of the study was|of .?[0-9]{1,3}(.[0-
9]{1,3})?\%?)|(?<!not )adequate to detect|(to detect (a |the )?(differences? 
(of)?|treatment effect|treatment interaction|statistical differences|expected 
difference|predetermined effect|mean difference|(.?[0-9]{1,3}(.[0-9]{1,3})?\%?) 
(improvement|increase|decrease)|similar treatment effect|significant change))|to 
insure sufficient power|would be needed if the null hypothesis|(to estimate the|used 
to determine the|based on these assumptions a) sample size|(the study|gave 
appropriate|increase the|descrease the|\%|the planned|statistical) power|a power 
of|(?<!failed to )achieve statistical significance|was powered at|minimum number of 
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(mice|rats|animals|subjects|patients) were used|\% chance of|\% to detect 
a|minimum clinically worthwhile effect|power of more than|\% to reject the null 
hypothesis|effectively powered|power and statistical analysis|are required per 
group|per group were required|minimum number required to give|required to give 
statistically valid results|through a priori calculation)/i 
 
